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Abstract 
Background 
Previous studies have demonstrated suboptimal management of care for osteoarthritis (OA). The 
objectives of this study were to (i) identify indicators of quality of care for OA in general practice, 
(ii) measure quality of care using routine general practice records and through an enhanced 
recording template (iii) estimate the effect of the template introduction on quality of care, and 
(iv) assess the feasibility of quality indicators as trial outcome measures. 
Methods 
A systematic review and narrative synthesis of quality indicators was undertaken. An iterative 
process of development resulted in an electronic template to record management of OA in 
consultations, based on identified quality indicators. This was triggered by a case definition of 
clinical OA derived through consensus. An assessment of coding, diagnostic misclassification using 
consultation narrative, and baseline recorded quality of care before template installation in eight 
practices was undertaken. Measurement after template installation facilitated a before-and-after 
comparison of care. The indicators were used as secondary outcomes in a cluster-randomised trial 
of a model OA consultation. 
Results 
There were fifteen valid, feasible quality indicators. Consultation prevalence of clinical OA was 
comparable to other estimates but up to one-third of cases may not represent true OA. Prescribing 
and referral data were well-captured in the routine record; assessment and core treatment 
indicators (such as education and advice) were not and so were included in the recording template. 
The template had small-to-moderate effects on weight recording, and paracetamol and topical anti-
inflammatory prescription. 
 vi 
Assessment of the effect of the model consultation was limited by high baseline quality 
achievement and variation between trial arms, practices and clinicians. 
Conclusion 
Assessment of quality of care for OA in general practice through quality indicators is feasible but 
comprehensive assessment requires enhanced recording approaches. Inter-clinician variability 
requires further understanding and reduction, and triangulation with patient-experienced quality 
is needed.  
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Chapter One: Introduction and background literature 
1.1 Introduction 
This thesis will describe the identification, synthesis, and implementation of quality 
indicators for the primary care of peripheral joint (hand, hip, knee, foot) osteoarthritis (OA). 
To investigate how these might be implemented in practice and in clinical trials to improve 
adherence to the National Institute for Health & Care Excellence* (NICE) OA management 
guidelines, a case definition for clinical OA in primary care records was developed and tested. 
Using this definition, the feasibility of assessment of quality of care for OA through the 
routine general practice medical record was investigated; the overcoming of important 
identified recording deficiencies through an enhanced recording methodology is described, 
with the resulting level of recorded quality of care outlined as well as an estimate of the 
effect of the change in record quality after implementation of the enhanced recording 
approach. Finally, the implementation of the quality indicators as outcome measures in the 
clinical trial is reported and overall conclusions presented. 
For context, this chapter identifies an appropriate definition of OA and its recognition for 
clinical and research purposes. The impacts that OA has on populations and its clinical 
management as applied to general practice in England are described. The previously-
reported quality of care for OA is outlined, with a description of the methods of assessment 
of quality, and a summary of methods for improving care for OA in general practice. The 
thesis aims and objectives are set out and the outline of the thesis including the programme 
of studies within which the research for this thesis was conducted is briefly described.  
 
*NICE is constituted to provide guidance to England only, though some products are also supplied to 
the other UK home nations https://www.nice.org.uk/about/who-we-are [Accessed 21/09/2016] 
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1.2 Definitions of osteoarthritis 
OA does not have an established, single, generally accepted definition. It has been variously 
defined in terms of pathological changes that occur in joints,2 radiographic changes,3 and  
symptoms.4  
The broad concept of osteoarthritis that was proposed by NICE is used as the foundation of 
much of the work in this thesis. This states that: 
“Osteoarthritis is defined not as a disease or a single condition but as a 
common complex disorder with multiple risk factors.” (NICE 2008, p. 35) 
For practical clinical purposes, the concept of OA has to be converted into a clinically 
recognisable and relevant working definition. This could be based on findings from 
radiographs, clinical history and examination, or on histopathology, only the first two of 
which are applicable to general practice. The means of recognising OA in a patient is not 
always straightforward: one systematic review identified 25 different classification criteria 
(clinical, radiological, or combined) for knee OA alone.6  
 Radiographic OA 
Plain film radiography has historically been the principal imaging modality used to identify 
OA. Classification systems and score such as the Kellgren-Lawrence scale3 and minimal joint 
space7 have been used extensively to define OA in research studies. However, the use of plain 
radiography to define OA, especially of the knee, has been increasingly criticised. The finding 
of radiographic features of OA is sensitive to positioning8 and the number of views taken.9 
Plain X-rays also do not image the soft tissues associated with joints, which are known to 
contribute to OA symptomatology.10 The European League Against Rheumatism (EULAR) 
recommendations for diagnosis of knee OA suggest multiple views of both knees as the gold 
standard for morphological assessment of knee OA through plain radiography and also 
suggest that further imaging modalities are not usually required for a diagnosis of OA.11  
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The contemporary role of X-rays in general practice management of OA is not clearly 
understood. Although NICE argue4 that radiographic investigation is not needed for 
diagnosis, and that the need for onward referral is poorly correlated with radiographic 
findings, Bedson et al. have previously found that general practitioners’ (GPs’) decisions 
about management of knee pain are associated with a decision to request an X-ray; the 
decision to X-ray was thought to be a clinician characteristic rather than the result of the 
clinical presentation.12 Radiographic OA has been suggested to be more likely to be reported 
if it had been raised as a clinical diagnosis by the clinician requesting the X-ray.13 There is also 
evidence that the link between joint pain and radiological findings of OA are not consistent: 
for example, one study of hip pain in Framingham study participants identified a sensitivity 
of only 16.5% for radiological OA in patients with hip pain localised to the groin.14 Knee pain 
symptoms and radiographic OA have also been found to be only weakly associated.15  
The EULAR recommendations for the diagnosis of knee OA indicate that a clinical diagnosis 
of OA can be made even in the absence of radiographic changes if symptoms (activity-related 
pain, no more than short-lived early morning stiffness, and functional limitation) and at least 
one examination finding (crepitus, painful or restricted movement, bony enlargement, and 
no more than a modest joint effusion) are present.11 Guidance in England also argues that X-
rays do not have an important role in the diagnosis and management of OA in primary care, 
and so a clinical definition of OA that is not dependent upon radiological investigations should 
be used.4  
 Clinically apparent OA 
As the pathological processes involved in OA are not highly correlated with clinical syndrome 
of pain and disability,16 from a clinician’s perspective an alternative approach to the definition 
and recognition of the clinical syndrome of OA is required. The 2008 National Collaborating 
Centre for Chronic Conditions OA guidelines recommended the use of the following clinical 
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working diagnosis of OA, assuming that non-OA inflammatory arthritis and connective tissue 
disease had been excluded:4 
“The [Guideline Development Group] considered the following to 
represent a clinician’s working diagnosis of peripheral joint osteoarthritis: 
● persistent joint pain that is worse with use ● age 45 years old and over 
● morning stiffness lasting no more than half an hour.” (p. 9) 
Such an approach has the advantage that the diagnosis is not dependent upon further 
investigations. However, the definition is more open to interpretation than some other 
primary care diagnoses, which may be recorded on the basis of a laboratory or near-patient 
test, or specialist assessment. Based on this, there is the potential for substantial variability 
between (and possibly within) clinicians in the making and recording of a diagnosis of OA. In 
an analysis of influences on the decision to record an OA diagnosis, Jordan et al. concluded 
that some cases of recorded joint pain (which in the UK is a much more commonly recorded 
diagnostic term than OA) represented early OA, with some cases fitting the clinical and 
radiographic criteria for diagnosis.17 This again suggests that GPs are not consistent in coding 
OA as such but that some cases may rather be recorded as joint pain. It is unclear if GPs 
manage patients on the basis of a working diagnosis of OA even where it is not formally 
recorded as such. 
There has been an attempt to reconcile the pathological/radiological and clinical approaches, 
by a joint OARSI – Food and Drug Administration (FDA) initiative, which used OA ‘disease’ to 
mean the structural changes that occur within a osteoarthritic joint, and OA ‘illness’ to refer 
to the clinical symptoms experienced by patients with OA.18 Under this definition, the work 
presented in this thesis is more concerned with the latter.  
 5 
1.3 The population burden of OA 
 Epidemiology of OA 
Estimates of the prevalence of OA in population surveys vary widely and depend on the case 
definition used.19 A series of population surveys undertaken between 2002 and 2005 in North 
Staffordshire estimated the prevalence of OA in the hand, hip, knee or foot (the joints 
applicable to the Management of OSteoArthritis In ConsultationS (MOSAICS) studies, 
described in section 1.7, below). The overall estimate for OA affecting at least one joint was 
532 per 10,000 people aged 50 and over, with 219 per 10,000 having disabling OA (equivalent 
to 714 per 10,000 in the general population).20 
For research based in general practice consulters, such as the MOSAICS studies,1 estimates 
of the proportion of the registered population consulting for OA during a defined period of 
time (‘consultation prevalence’) are particularly relevant. The main sources of such estimates 
in the UK are general practice medical record databases. Jordan et al.21 compared rates of 
recorded OA between four primary care datasets. The recorded annual consultation 
prevalence of OA was estimated as 164 to 426 per 10,000 people aged 15 and over; joint pain 
was estimated at 273 to 433 per 10,000. In a second study, which used data from a local 
network of general practices in North Staffordshire (the Consultations in Primary Care 
Archives [CiPCA]21,22), the one-year consultation prevalence for diagnosed OA was estimated 
at 447 per 10,000 people aged 45 years and over.23 Using a wider definition of OA (including 
certain joint pain codes, further discussed in Chapter Three, section 3.5), the annual 
consultation prevalence estimates in people aged 45 and over increased to 1192 per 10,000; 
when a seven-year period was used, the consultation prevalence estimate was 3483 per 
10,000. 
It is difficult to estimate with accuracy the expected proportion of people registered with a 
GP who would be expected to have clinical OA (the ‘illness’ as described by the OARSI-FDA 
initiative) but it might be as high as 35% of adults aged 45 and over as suggested by the 7-
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year period consultation prevalence reported by Jordan et al.23; only around one-third of 
these would be expected to consult in a one-year period. This estimate may be inflated, 
especially in relatively young patients, by people consulting with symptoms that cause little 
(or temporary) disability. By comparison, estimates from the North Staffordshire 
Osteoarthritis Project (NorStOP) suggested a 22% prevalence of knee pain associated with 
some disability in people aged 50 and over.20 
 Assessment of OA burden of disease 
There are limitations in the assessment of the population burden of OA that flow from the 
differences in case definitions of OA, referred to above. The Global Burden of Disease study24 
based estimates on a systematic review of hip and knee OA prevalence (which itself used 
estimates of prevalence from radiographic OA with or without symptoms).25 It estimated the 
number of years lived with disability (YLD) due to OA at 197 per 100,000 population (95% 
confidence interval [CI] 134–279) in 1999 and 249 per 100,000 (95% CI 172–352) in 2010, a 
26.2% increase.26 In the UK, OA was ranked as the 11th most common cause of YLDs; there 
were an estimated 351 per 100,000 (95% CI 221–520) disability-adjusted life-years (DALY).27  
Costs associated with OA are substantial. The 2008 NICE guidelines reported hip and knee 
joint replacement costs at £405 million in the year 2000 and wider societal costs at £3.2 
billion in lost production (due to working days lost) plus £43 million in community services 
and £215 million on social services.4 In the 2012 OA Nation report, Arthritis Care estimated 
that at a patient level, additional OA-related costs were in the order of £480 per patient, or 
£2.6 billion annually across the country.28 Overall, societal costs (in higher-income countries) 
have been estimated as 0.25-0.50% of gross domestic product.29 
OA should therefore be regarded as a common condition with a substantial associated 
degree of ill-health and high healthcare and wider societal costs. As such, it is an important 
condition for primary health care services to treat as effectively as possible to reduce the 
burden of disease. 
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1.4 Clinical management of OA 
Some risks for OA may be ameliorated through promotion of maintenance of a healthy 
weight and avoidance of trauma30 but beyond these, there are no clearly-established 
preventative actions to be implemented at an individual level. The majority of clinical 
interventions attempt to treat symptoms once OA is established.  
 Summary of recommended care for OA in general practice 
There are various international guidelines, including those from EULAR,11,31-34 OARSI,35-37 and 
the American College of Rheumatology (ACR),38 but identification and treatment of OA in 
general practice in England has been guided by the recommendations made by NICE 2008,5 
updated in 2014.39 Guidance for the management of OA has diverged in some respects, 
notably regarding the use of SYmptomatic Slow-Acting Drugs in OsteoArthritis (SYSADOA), as 
well as in the detail of oral NSAID use and gastroprotection. In general, however, there is not 
much heterogeneity between different sources of guidance on the management of OA. 
NICE (2008) recommended a holistic assessment, core interventions of education, exercise 
advice and weight loss advice where relevant, followed by relatively safe pharmacological 
pain management options (paracetamol, topical non-steroidal anti-inflammatory drugs 
[NSAIDs]) and then adjuvant pharmacological (analgesics) options, non-pharmacological 
management (e.g. ambulatory or non-ambulatory assistive devices, orthotics, 
thermotherapy, manual therapy), and joint arthroplasty.5 NICE also recommended against 
certain processes of care, notably topical rubefacients, glucosamine, and arthroscopic 
debridement and washout.  
The principles of quality measurement are described below, with a summary of the general 
practice delivery of OA care and the extent to which clinicians actually adhere to 
management guidelines.  
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 Measurement of quality of care 
Structures, processes, outcomes, and the concept of case mix 
The quality of care delivered by health services may be assessed in a number of ways. 
Donabedian divided quality assessment into the domains of structures (such as the premises 
from which healthcare is provided, equipment, or staffing levels), processes (the care 
delivered to patients, including diagnosis and treatments) and outcomes (the end points 
most relevant to patients such as health status or quality of life).40,41 Patient experience has 
been added to these assessment domains, with evidence that patient experience is linked to 
the quality of care delivered (clinical effectiveness and patient safety).42 Maxwell proposed 
extending Donabedian’s assessment framework through six ‘dimensions’ of healthcare 
quality: access, relevance, effectiveness, equity, acceptability, and efficiency.43 
Assessment of structures is regarded as the weakest method for assessment of quality of 
healthcare as there is not typically any established link between structures and clinical 
outcomes.44 Assessment of outcomes is a necessary part of monitoring health services but is 
not always clearly linked to the quality of care delivered.44 Adverse outcomes would not be 
expected to arise each time the delivery of care was not of a required standard.45,46 Equally, 
adverse outcomes may appear to be more frequent in settings even where care is of high-
quality. For example, a surgeon who treats patients at high risk of complications may appear 
to have worse outcomes than another surgeon who treats only low-risk cases. Adjustment 
for this case mix is usually complex and may be only partially effective due for example to 
differences in measurement of variables used in the adjustment process.47 Mant argued that, 
for successful implementation of outcome indicators, improved (and standardized) data 
collection was needed, with validated case mix adjustment methods. He argued that this was 
only appropriate in situations where there was likely to be sufficient variation in healthcare 
provision that there might be clinically important variation in outcomes that occurred with 
sufficient frequency to be identifiable.47 In general, use of process measures to identify and 
monitor quality of care has been preferred due to various factors including (i) reduced 
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complexity compared to outcome measures, (ii) measurable from routine sources; (iii) speed 
of implementation, and (iv) relevance to healthcare providers.48 Conversely they can be hard 
for patients to interpret or identify with, and are not easily aggregated into a useful summary 
measure.48 Process measures are only appropriate and relevant where there is high-quality 
evidence that links the process to improved patient outcomes.44 For the same reasons as for 
outcomes, it has been suggested that case mix adjustment also be used in the assessment of 
care processes such as prescribing49 and referral.50,51 
Quality improvement cycles 
In general, quality improvement projects require repeated measurements to determine 
changes in quality over time. This is part of the methodology used in health care quality 
improvement strategies such as the Plan-Do-Study-Act (PDSA) cycle,52 which evolved from 
the original full-cycle medical audit approach.53 Identification of a need for quality 
improvement, usually based on some measurement of at least one of the quality domains, 
would be followed by an improvement intervention and evaluation of its level of success with 
further measurement of the quality domain(s).  
Quality indicators  
Some aspects of quality may be assessed through measurement of indicators, an indicator 
having being defined as  
“a measurable element of practice performance for which there is 
evidence or consensus that it can be used to assess the quality, and hence 
change in the quality, of care provided” (Lawrence and Olesen 1997 
p.10454).  
There is a sizeable body of research on the development and implementation of quality 
indicators. Campbell et al. identified in 2002 that, although many quality indicators had been 
developed for use in hospitals, there was an increasing use in primary care.55 Indicators may 
be based upon clinical practice guidelines, or derived de novo from primary or synthesised 
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evidence. Indicators themselves should reflect a potentially measurable aspect of practice – 
such as structures, processes of care, or outcomes (which may be a true clinical endpoint, an 
intermediate or surrogate clinical endpoint, or patient-reported other outcome such as 
satisfaction).40,43,55-58 The development of clinical quality indicators typically rests on a 
foundation of evidence relevant to clinical practice, sometimes with the use of consensus 
exercises to determine the relative importance, validity, and feasibility of candidate 
indicators.55,59,60 Although some authorities specify the need for feasibility in data collection 
for measurement of the indicators,61 this is not a universal feature of indicator development.  
Much work has been done on indicators of quality of care based on the domains of structure, 
process, and, to an extent, outcome. Studies developing or implementing quality indicators 
for OA are described fully in Chapter Two. 
 Primary care services delivery of care for OA 
There is some evidence that GPs do not prioritise OA in the context of a consultation, making 
assumptions that patients do not consider it a priority.62 A narrative review of comparison of 
patient experience with GP beliefs about, and attitudes to, OA identified that some GPs do 
not regard OA as a disease but rather an inevitable consequence of aging,63 despite the fact 
that the NICE guidelines state otherwise.5 Although no evidence was found that an 
association between GP beliefs about or attitudes towards OA and the diagnosis or care 
processes received by patients has been identified, it seems plausible that such an 
association may exist; this would be consistent with behavioural theory such as the theory of 
planned behaviour.64,65 
In general, it is well-established that the recorded quality of primary care for OA has been 
shown to have deficiencies. Porcheret et al. identified through a population survey that 
recommended core non-pharmacological interventions (exercise, weight loss, written 
information provision) were used by a minority of survey participants and often on the advice 
of a friend or relative rather than a health professional.66 Quality of care for OA has also been 
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described through the use of studies that included a review of the narrative component of 
medical records (whether electronic or paper-based), such as by Kirk et al.,67 Steel et al.,68 
and Broadbent et al.69 Although this approach is very thorough and captures all the recorded 
quality of care, it is cumbersome compared to assessments based on electronic retrieval of 
specific codes and therefore less likely to be used in quality improvement cycles.53 Previous 
studies have tended to use a tightly-defined denominator for quality assessment (formally 
recorded diagnoses of OA) rather than a wider clinical interpretation of persistent joint pain 
as representing clinical OA.5 Steel et al. 70 used patient self-report of indicators to measure 
quality of care and this approach was also used in the population survey element of the 
MOSAICS study.1 No studies examining quality of care for OA solely through use of the 
electronic, coded health record were identified.  
Broadbent et al. reported achievement of assessment indicators of between 27% (pain) and 
43% (function), information achievement rates of 17% (NSAID risks) and 30% (education), 
and treatment provision achievement of 48% (paracetamol), 59% (oral NSAIDs), and 90% 
(referral to orthopædics for arthroplasty consideration where conservative measures had 
failed).69 Steel et al. used patient self-report of quality indicators to identify adjusted (for 
weights and clustering) achievement rates of 24.8% (exercise), 17.7% (education), 41.1% 
(paracetamol), and 35.8% (orthopædic referral); 77.8% of eligible respondents reported that 
a clinician had discussed the purpose of treatment in arthritis.70 Multiple studies in the USA 
have demonstrated suboptimal quality of care for OA.71-79 Li et al. also identified suboptimal 
non-pharmacological care for OA in Canada.80 In Australia, Runciman et al. reported that 43% 
of clinical encounters delivered appropriate care for OA.81 Østerås et al. used self-reported 
measures in a Norwegian survey to identify a median 27% pass rate for individual indicators 
(interquartile range 12-50%).82  
Where guideline adherence has been examined, over-use of radiological investigation has 
been identified,83 with under-use of non-pharmacological management approaches.83-85 One 
study identified better self-reported recommended use of non-pharmacological therapy by 
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clinicians, in up to 76% of patients (weight reduction).86 Clinician self-reported adherence to 
the EULAR knee OA management recommendations was identified as 74.8% for non-
pharmacological management and 73.6% for pharmacological, but only 54.2% for the two 
approaches combined.87 Variation in practice between clinicians has been identified, with 
clinicians who have been in practice for less than 20 years less likely to request tests and 
more likely to recommend exercise and prescribe oral NSAIDs than those in practice for 20 
years or over.88  
Overall, the quality of care for OA as assessed within the UK and internationally has 
demonstrated significant shortcomings. Although many of the recommended interventions 
for OA have only small to medium benefits,4 given the prevalence of OA, the cumulative 
population effects of deficits in OA management seem likely to be substantial. Previous 
studies have used either analysis of the whole medical record or patient self-report; this 
study adds to those through examination of coded information, which is more feasible to use 
for continuous quality improvement through audit and feedback. Additionally, this study 
adds to the relatively small amount of evidence examining associations between patient and 
clinician factors and quality of care for OA. 
1.5 Improving quality of care for OA in general practice 
Given that there are established, evidence-based, national and international guidelines for 
the management of OA, there is potential for general practice, and primary care more 
generally, to deliver high quality care to people with OA. Although there is considerable 
concern about the application of multiple single-disease guidelines to patients who have 
multiple morbidities, the core interventions for OA have considerable overlap with 
recommendations for other long term conditions, such as weight management and exercise 
for vascular disease and diabetes, and exercise for chronic obstructive pulmonary disease. 
The principles of the core interventions for OA management should therefore be very familiar 
to clinicians, as well as to many patients with relevant comorbidities, and given the capacity 
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to benefit from such interventions across a range of conditions, one might expect that their 
implementation should not be unduly onerous. In this section, the possible approaches to 
quality improvement for OA are outlined. 
The Centre for Reviews and Dissemination concluded in 1999 that improvement strategies 
employing multiple approaches were more likely to be effective than those using only one, 
and that most interventions were effective under some circumstances but none under all.89 
Educational outreach was found to be generally effective in North America but further work 
was needed to determine its effectiveness in the UK. Reminder systems were identified to 
be “generally effective for a range of behaviours” (p. 7). Audit and feedback, use of opinion 
leaders, and other interventions were identified as having mixed effects with a 
recommendation that they be used “selectively”. Reminder systems are discussed in more 
detail in the development of the enhanced recording template in Chapter Three, section 3.3. 
In terms of the implementation of complex interventions in primary care, a recent (2015) 
systematic review of reviews concluded that despite an extensive body of literature, it 
remains unclear which implementation strategies are most effective.90 Features that seemed 
to be associated with more successful implementation included use of printed educational 
materials; educational strategies; educational outreach, audit and feedback; practice 
facilitation; financial incentives; and multidisciplinary opinion leaders.  
The optimum method for improving the primary care of OA specifically has not been 
established. Brand et al. concluded, in a systematic review, that reported effectiveness of 
complex OA management interventions varied but there was some evidence to support the 
use of primary care collaborative care models or multidisciplinary case management; where 
a positive impact had been observed, this tended to be small to moderate.91 The review 
identified a lack of information systems to assist OA disease identification and monitoring 
within populations. The studies reported in this thesis aim to further the development of 
systems to facilitate this identification and monitoring of OA in general practice populations.  
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1.6 Thesis aims and objectives 
 Aim 
The aim of the thesis is to identify quality indicators for the primary care of OA and assess 
the feasibility of their measurement within primary care in England. 
 Objectives 
(i) To review the existing evidence for quality indicators for OA, applicable to general 
practice (Chapter Two) 
(ii) To identify how the quality indicators may be assessed through information 
routinely recorded in general practice medical records and develop a mechanism 
for enhanced recording where necessary (Chapter Three) 
(iii) To describe patterns of clinical OA in primary care and the possible extent of 
misclassification of a peripheral joint pain record as OA within a definition of clinical 
OA (Chapter Four) 
(iv) To describe the routinely-recorded quality of care for clinical OA in general practice 
(Chapter Five) 
(v) To describe the quality of care for OA as captured by the enhanced recording 
mechanism (Chapter Six) 
(vi) To estimate the effect of the enhanced recording mechanism on routinely recorded 
quality of care (Chapter Seven) 
(vii) To investigate the feasibility of use of quality indicators in assessment of a cluster-
randomised controlled clinical trial of a complex intervention to improve care for 
OA (Chapter Eight) 
1.7 Outline of thesis 
The aim and objectives of the thesis were addressed through research undertaken as part of 
the MOSAICS studies research programme. MOSAICS was a programme composed of various 
studies, chief amongst which was a cluster-randomised controlled clinical trial of a complex 
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intervention to improve uptake of NICE-recommended core treatments for OA. The research 
undertaken for, and reported in, this thesis formed a part of the MOSAICS programme. 
Although the candidate was involved in the design of the MOSACIS trial, as reported in the 
full study protocol,1 the purpose of this thesis is not primarily to report on the design, 
conduct, or outcomes of the trial. As the MOSAICS trial is reported in a style consistent with 
the CONSORT trial reporting recommendations92 in Chapter Eight, only a brief outline is 
presented here, to provide orientation to the study as referred to throughout the thesis.  
This thesis uses the same definition of clinical OA as that in the MOSAICS study protocol.1 
Peripheral joint sites (hip, knee, and small joints of the limbs) for OA were chosen as these 
are the most common sites for OA to be manifest.5 Therefore, OA at the shoulder, elbow, 
and axial skeleton were excluded from this study. Shoulder pain may represent a wide range 
of alternative conditions including referred pain or soft tissue disease;93-95 the elbow is also 
commonly affected by other soft tissue conditions or may be involved in a regional pain 
syndrome.95 Although no studies investigating the positive predictive value (PPV) of pain at 
these sites as a marker of OA were identified, the PPV would be likely to be lowered by the 
baseline prevalence of OA at these sites as well as the wide range of differential diagnoses. 
Spinal OA was also excluded as the management of axial pain has developed into an academic 
and clinical specialism of its own, with back pain management supported by a separate NICE 
guideline.96  
MOSAICS was designed to assess the utility of a model OA consultation (MOAC), which was 
a complex intervention to increase the adherence to the NICE OA management guidance and 
in particular uptake of its core management interventions. The complex intervention 
consisted of clinician training (GPs, nurses, and allied health professionals), additional 
resources for nurse follow-up clinic appointments, and a patient OA guidebook; practices 
were paid for participation to reflect additional service costs rather than as an incentive to 
promote guideline adherence.  
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Practices were selected for the MOSAICS study on the basis of willingness to participate. To 
be eligible to participate, practices had to (i) use the EMIS clinical computer system, (ii) have 
at least two general practice nurses (to allow for cross-cover in service provision during 
periods of leave), (iii) have been willing to have the OA consultation recording template 
installed, and (iv) willing to undertake the clinician training. The CRN research facilitation staff 
approached 10 practices to seek participation; eight consented. Reasons given by the two 
non-consenting practices were (i) involvement in another research study and (ii) recent 
commitment to teaching medical students.  
Table 1-1: MOSAICS practice characteristics 
Trial 
arm Practice ID 
Practice 
population 
% 
female 
% 
aged ≥ 
45 
years 
IMD 
2010 
score 
IMD 2010 
rank 
In
te
rv
en
ti
o
n
 1 23,868 50.7 47.4 3.4 31,573 
2 5,810 47.7 35.9 58.9 921 
7 7,206 50.5 48.2 22.4 12,310 
8 4,077 50.3 48.2 11.7 21,868 
C
o
n
tr
o
l 
3 8,170 51.0 53.7 13.2 20,182 
4 8,461 51.4 58.0 3.2 31,702 
5 7,324 50.7 47.7 28.1 9,085 
6 3,978 47.8 52.8 45.7 3,067 
Overall  Mean 8,612 50.4 49.0 - - 
England [Source: ONS97] 6,891 
(estimated 
2012 
average98) 
50.297 58.297 - Range 1 = 
most 
deprived to 
32482 = 
least 
deprived 
 
The eight practices who participated in MOSAICS together form a representative sample of 
general practice in England. There was a spread of practice size, though with one very large 
practice that was three times the English mean practice size. The sex structure of the 
practices was broadly reflective of that of England as a whole. The age structure for the 
practices was generally younger than that of England as a whole, which would be expected 
to reduce the number of people consulting with clinical OA. There was also a spread of 
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deprivation, as estimated by the deprivation score and rank for the practice location 
(individual patient-level deprivation information was not available). None of the eight 
MOSAICS practices were included in the CiPCA database at any point.  
Before the trial period to test the intervention, there were two preceding phases – one to 
establish a baseline level of care recorded during the six months immediately prior to cluster 
randomisation of the practices to the trial, and a further phase for 12 months before that to 
assess recorded care that was naturally-occurring before any meaningful study engagement 
with the practices.  
The primary aim of the MOSAICS trial was to “determine the clinical and cost effectiveness of 
the MOAC intervention in patients with OA.” [protocol, p.31] 
The secondary study aims were to: 
1. “Describe the [patient self-reported] uptake of core NICE OA recommendations [the 
assessment of a person with OA and the central management strategies of education, 
exercise, weight-loss support where appropriate, and first-line analgesic medication from the 
NICE guidance management diagram (NICE 2008, p85)] in participants aged 45 years and over 
with joint pain” 
2. “Test the feasibility of deriving ‘quality markers’ of OA management [from electronic 
health records] using a new consultation template and medical record review”  
3. “Develop and evaluate a training package for management of OA by general practitioners 
(GPs) and practice nurses” 
4. “Investigate the impact, feasibility and acceptability of the MOAC intervention.” 
This thesis addresses the second of these subsidiary aims. Quality markers (indicators of 
quality of care) were first identified by the candidate through a systematic review of quality 
indicators, with a narrative synthesis of indicators considered feasible for use in primary care. 
Identification of the capability of the routine electronic health record (EHR) to measure the 
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identified indicators was conducted in a local routine database of primary care consultations 
(CiPCA). As a result, an enhanced consultation recording mechanism (the template) and its 
trigger codes for OA and peripheral joint pain likely to represent OA in older adults (which 
formed the Read-code definition of clinical OA) was designed, developed and implemented 
by the candidate.  
The assessment of baseline coding of clinical OA (defining the denominator population for 
the routinely-recorded quality indicators) was developed and implemented by the candidate, 
with an estimate of diagnostic misclassification. The template was installed in all the 
MOSAICS practices for a six-month period before the clinical trial randomisation. The quality 
of care for OA was estimated by the candidate both before and after template installation. 
The estimate of the effect of the template on routinely recorded quality of care was then 
undertaken by the candidate based upon an analysis by Professor Jordan for the associated 
publication99 as shown in Appendix B (for which the candidate was first author, leading the 
study design and interpretation), though using an extended set of covariates compared to 
that used in the associated publication.  
The feasibility of quality indicators as trial outcomes was assessed through their use as 
secondary outcome measures in the MOSAICS cluster-randomised controlled clinical trial 
(during which all practices continued to use the template), including an estimate of the effect 
of the model consultation. This used a similar approach to the analysis undertaken for the 
associated publication (Jordan KP et al., in submission), co-designed by the candidate with 
Professor Jordan; once again the candidate used a broader set of outcomes and covariates 
for the analysis reported in this thesis, as well as undertaking sensitivity analyses, which 
extended the analysis submitted for publication. The primary purpose of the associated 
publication was to assess the effect of the intervention on quality of care rather than the 
objective here of assessing feasibility of using quality indicators as outcomes. 
The MOSAICS study timeline is shown in Figure 1-1. 
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The discussion (Chapter Nine) summarises the main findings of the thesis, linked to the 
objectives, and draws conclusions from the work overall. The next Chapter describes a 
systematic review and narrative synthesis of existing quality indicators relevant to the 
primary care of OA.  
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Figure 1-1: MOSAICS study timeline 
01/06/2008 - 31/05/2010
Comorbidity download
01/06/2011 - 30/11/2011
Phase 2 - template only
30/11/2011
Randomization &
Intervention training
01/06/2010 - 31/05/2011
Phase 1 - baseline
01/03/2012 - 28/02/2013
Phase 3 - intervention vs control
Period 1- template 
calendar control 
01/06/2010 to 
30/11/2010
Period 2 - 
01.12.2012 to 
31.05.2011
Period 4 – 
intervention vs. 
control, main 
outcome
Period 5 – 
intervention vs. 
control, extended 
analysis
Period 3 -
 template only, all 8 
practices
01/06/2011 - 30/11/2011
Phase 2 - template only
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Chapter Two: Systematic review of quality indicators for 
osteoarthritis 
2.1 Introduction 
As discussed in Chapter One, osteoarthritis (OA) is a condition that is not consistently well-managed 
in primary care. As it is such a frequently-occurring condition with important consequences for 
patients, health services, and funders, the improvement of condition management for OA is 
important, and primary care, as the predominant provider of non-surgical care for OA in England, 
is best-placed to deliver improvements.  
Baker highlighted that primary care in general had a shortage of “accessible, valid, complete, and 
relevant” data in 2000 (p. 83).100 Although there has been some improvement in data capture in 
general practice since the advent of computerisation (from the 1990s) and, more recently, the 
Information Management and Technology (IM&T) Directed Enhanced Service (DES),101 there is no 
current nationally mandated structured method to record data regarding OA care. Consequently, 
quality of care for OA cannot routinely be monitored from general practice data due to a lack of 
routinely recorded and coded information on the structures, processes of care, and outcomes for 
OA. Although OA is not unique in this respect, many other long term conditions such as asthma, 
diabetes, and ischaemic heart disease have been included in the Quality and Outcomes Framework 
(QOF)102 and consequently have various general practice processes-of-care or outcomes 
measurements associated with them. The inclusion of such conditions in the QOF necessitated the 
development of QOF indicators (essentially quality indicators, covering the four domains of clinical 
standards, organisational standards, patient experience, and “additional services” agreed-upon by 
NHS Employers and the BMA103). The indicators were then tested with the development of, 
sometimes complex, business rules to measure the indicators by (see for example the osteoporosis: 
secondary prevention of fragility fractures ruleset104). These business rules have often required the 
adoption of new coding practices within primary care to ensure that the numerator (people whose 
care achieves the indicator) and denominator (those eligible to achieve the indicator) can be 
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correctly identified.59 New coding practices therefore have an established track record in the 
implementation of quality measures in general practice in England.  
The systematic review reported in this chapter aimed to identify all published studies of the 
development or implementation of quality indicators for OA care relevant to primary care and to 
undertake a narrative synthesis to identify the indicators most appropriate for use in general 
practice in England. This review adds to two previous reviews on quality indicators for OA, by 
Hochberg,105 published in 2007, and Strömbeck et al.,106 in 2013, by identifying indictors applicable 
to and feasible to measure in primary care and synthesising the disparate indicators within each 
quality domain into an overarching single indicator, with proposals for implementation in general 
practice in England.  
The review reported here has been published in a peer-reviewed journal (Edwards et al., 2013107), 
reproduced in Appendix A. 
2.2 Methods 
The methodology used was designed to align with that set out by the National Institute for Health 
Research (NIHR) Centre for Reviews and Dissemination at the University of York.108 The candidate 
led the review, working with two additional reviewers (a second experienced GP and an academic 
physiotherapist). The methods developed by the candidate were refined following comments from 
the Research Information Manager and the systematic review team within the Research Institute 
for Primary Care and Health Sciences (RIPCHS). 
 Search strategy 
The search strategy was developed for use with the NHS Evidence portal.109 This provided access to 
the main bibliographic databases, including CINAHL, EMBASE, HMIC, Medline, and PsychINFO. An 
initial scoping exercise, using a range of OA terms combined with quality indicator terms, was 
undertaken and identified published articles used to refine the development of the search strategy 
through use of their medical subject headings (MeSH terms).110 The scoping exercise also identified 
repositories of healthcare quality indicators (the Agency for Healthcare Research and Quality 
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[AHRQ]111) which were searched in addition to the bibliographic databases. Included articles had 
reference lists checked for relevant articles not already included. The search was last updated in 
August 2013.  
Box 2-1: Example search strategy for use in Medline 
An example of the search strategy (for Medline) is shown in Box 2-1. The specific terms used were 
adjusted for the other databases listed above, to account for the differences in controlled 
vocabulary between databases. 
 Inclusion and exclusion criteria 
Inclusion criteria: 
All articles had to refer to patients with OA.  
There had to be a focus on either the development or implementation of quality indicators relevant 
to OA. Such indicators may have been developed through a range of methodologies, but for the 
1.  MEDLINE; (qualit* AND (outcome* OR indicat*)).ti,ab 
2.  MEDLINE; exp "OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)"/ 
3.  MEDLINE; exp QUALITY ASSURANCE, HEALTH CARE/ 
4.  MEDLINE; exp QUALITY INDICATORS, HEALTH CARE/ 
5.  MEDLINE; 1 OR 2 OR 3 OR 4 
6.  MEDLINE; exp *OSTEOARTHRITIS/ 
7.  MEDLINE; 5 AND 6 
8.  MEDLINE; *ORTHOPEDICS/ 
9.  MEDLINE; *ORTHOPEDIC PROCEDURES/ 
10.  MEDLINE; 8 OR 9 
11.  MEDLINE; 7 NOT 10 
12.  MEDLINE; 11 [Limit to: Publication Year 2000-2013 and English Language] 
 24 
purpose of inclusion, any articles self-identifying or appearing to the reviewers as having 
undertaken quality indicator development or implementation were eligible.  
Articles had to be applicable to a general practice context in England, further described in section 
2.2.5. This last criterion was necessarily subjective and was determined by either of the GP 
reviewers on the basis of professional judgment.  
Exclusion criteria: 
Articles were excluded if they fell into one of the following categories: 
 Any articles not dealing with human subjects 
 Any non-English language articles (as no translation facilities were available for this project) 
 Articles published prior to 2000 (as the majority of OA management guidance has been 
published since that time and quality indicators were likely to have been based on 
treatment guidelines) 
 Unpublished articles (‘grey literature’) with the exception of information from identified 
quality indicator repositories 
 Articles describing the testing of treatment effectiveness and efficacy 
 Radiological and surgical techniques, reports, follow-ups (as these were not considered 
applicable to primary care) 
 Basic science articles (not applicable to primary care) 
 Case series reports; economic analyses; cost-effectiveness articles; assessment scales; 
scoring tool development and validation; letters; commentaries; professional development 
articles; trial protocols (as these were not considered to reflect quality indicator 
development and implementation) 
 Complementary medicine, with the exception of glucosamine and chondroitin, and 
acupuncture. 
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 Selection of articles 
All articles identified through the search strategy above were downloaded to a citation 
management database (RefWorks112). The deduplication facility within this database was used to 
identify and remove duplicate articles. All titles after deduplication were subject to an initial 
screening by a single reviewer (the candidate). Articles deemed to be clearly not relevant or eligible 
according to the inclusion and exclusion criteria were removed from further consideration.  
The abstracts of the remaining articles (or, where abstracts were not available, the full-text article) 
were assessed by the two GP reviewers, including the candidate. Where both reviewers agreed 
after independent assessment that an article was not relevant or eligible, it was excluded from 
further consideration.  
The final determination of inclusion for articles used full-text information. Each was subject to dual 
review (by the candidate and one other reviewer). In the case of disagreement, a third opinion was 
sought from the remaining reviewer. Articles remaining at the end of this process were included in 
the quality assessment and narrative synthesis phases. 
 Data extraction 
In order to assess the articles which developed or implemented quality indicators, a proforma for 
data extraction was created and refined after testing by all three reviewers. This structured and 
standardised the data extraction process, and gathered information relevant to the quality 
assessment process, including the hierarchy of evidence113 and consensus method114 (described in 
section 2.2.5). Due to differences in the assessment process between development and 
implementation articles, a separate extraction proforma was developed for each. To improve 
reliability, each included article was subject to data extraction by two reviewers. Where differences 
in extraction occurred, these were resolved by consensus and reference back to the original article. 
Any remaining disagreement was resolved by discussion with the third reviewer, with a third data 
extraction to be undertaken by the third reviewer if required. The data extraction proformas are 
shown in Appendix D. 
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Where information was considered unclear or insufficient, the corresponding authors of the 
included papers were contacted if necessary for clarification.  
 Quality assessment process 
Although assessment of systematic reviews, randomised controlled trials and ecological studies has 
developed into a well-defined science, there was no similarly well-established method identified 
for assessment of quality indicator development and implementation. The assessment process 
used for this review was based on the Outcome Measures in Rheumatology (OMERACT) filter of 
truth, discrimination, and feasibility.115 This tool was originally used to assess clinical trials in 
rheumatoid disease but its structure was transferrable to other studies, including for example use 
in the development of quality indicators, guidelines and outcomes in scleroderma.116  
The quality assessment process occurred at two levels – (i) that of the whole study (or group of 
studies, where a number of studies were based on the same foundation work), to provide 
information about the evidence base used to identify the indicator content, the consensus exercise 
to develop the indicators, target population, method of measurement, implementation, and 
assessment of reliability; and (ii) that of the individual indicator (to determine its feasibility, for 
example).  
Sometimes, studies did not report the whole development of indicators but rather referred to other 
articles. Here, the evidence for the group of studies was considered as a whole corpus rather than 
for each report separately; where derivative indicator sets were developed, any supplementary 
evidence or consensus building was considered and reported within the review.  
The assessment tool was based on a methodology for assessment of clinical performance measures 
by Geraedts et al.117 This was the most suitable instrument identified from a literature search for 
assessment methodologies appropriate to quality indicator development and was also broadly 
consistent with the COSMIN checklist118 for assessment studies of methodological quality of health 
status measurement instruments. Additional literature supporting the assessment methodology is 
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cited below for each assessment domain. The extraction tools used an approach consistent with 
the OMERACT filter, with various measures for each OMERACT domain. 
Assessment at the level of the study or study group 
Articles, or groups of articles if produced by the same development group, were assessed against 
the following criteria: 
 Conflict of interest in the development or implementation processes was assessed from 
any statements of conflict of interest in the article; if no statement was made, the 
reviewers’ judgment was used to assess whether it was likely any conflict of interest would 
have affected the study. [OMERACT domain: truth] 
 Current relevance: In order to be considered ‘current’, included indicators should have 
been developed since the NICE OA guidance publication in 2008 or, if developed earlier, 
the reviewers had to determine whether it was still relevant to best practice. Evidence of a 
mechanism for keeping the indicator set up-to-date with new evidence was sought. 
[OMERACT domain: truth] 
 Content validity (i): Method of evidence collection and synthesis for the indicator 
development (where a systematic review was best and expert opinion was least robust, as 
set by the University of Oxford Centre for Evidence-based Medicine113). This was especially 
relevant to interventions offered to patients such as drugs or devices, where robust 
evidence of potential benefits and risks was necessary for good clinical care. [OMERACT 
domain: truth] 
 Content validity (ii): Consensus was defined in the first Assessing Care Of Vulnerable Elders 
(ACOVE-1) indicator set119 as “adequate scientific evidence or professional consensus 
supported a link between the process specified by the indicator and a health benefit to the 
patient” (p.649). The method of consensus development of the indicators was identified 
(the modified RAND process was regarded as the optimum method, followed by the Delphi 
method114). [OMERACT domain: truth] 
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 Field testing (feasibility): Articles were considered to offer a higher standard of indicator if 
there was evidence that the indicators had been tested or implemented in practice. 
[OMERACT domain: feasibility] 
 Test-retest reliability: this was assessed through implementation studies to see whether 
multiple data extractions of quality indicator results from the same dataset gave the same 
results. [OMERACT domain: truth] 
Assessment of individual indicators 
 External validity: (defined by Geraedts et al.117 for clinical performance measures as “The 
measurement activity and subsequent orientation of the care process measured towards 
established performance thresholds actually should lead to an improvement of medical care 
delivery and/or of the outcomes of care” [p.81]) was assessed by examination of 
implementation studies for evidence of quality improvement in populations in which the 
indicator had been used.117 [OMERACT domain: truth] 
 Responsiveness: (the identification of quality improvement over time in a population 
independently known to have sustained such an improvement) was assessed through 
evidence from implementation studies. [OMERACT domain: discrimination] 
 Feasibility: (including identification of the applicable population and method of 
measurement) was assessed through any recommendation regarding the method for 
implementation in the development studies, or through implementation studies, and 
whether such methods were judged compatible with routine general practice in England 
(which required that the indicator be consistent with the NICE OA management 
guidelines5). This domain was deemed to include aspects of practice such as the clinical or 
administrative burden, additional cost, and likely acceptability to clinicians and patients. 
This component was judged by either of the GP raters through clinical practice expertise 
rather than by comparison with identified empirical evidence, though factors such as 
methods of prior implementation and data sources were important components in this 
decision (data needed in principle to be retrievable from primary care clinical information 
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systems, with or without some degree of modification to current practice). [OMERACT 
domain: feasibility] 
 Reproducibility: assessed by identification of similar indicators independently created from 
more than one study. [OMERACT domain: truth] 
 Narrative synthesis 
Identified indicators were collated in themes derived from the NICE OA guidance5 such as patient 
assessment, non-pharmacological management, pharmacological management, and specialist 
assessment. All indicators were arrayed within themes, divided into subthemes by their specific 
focus (such as assessment of pain or assessment of function).  
On the basis of this array, an exemplar indicator was selected from those identified, determined by 
the robustness of its development, implementation, and applicability to general practice in England. 
Differences of opinion between the reviewers was resolved by consensus.  
Each subtheme was synthesised into an indicator which, in the reviewers’ opinion, was suitable for 
direct implementation. This entailed the clear articulation of a quality criterion, numerator, and 
denominator, as is customary for quality indicator development.120 This final indicator was based 
upon the exemplar but was also intended to overcome any heterogeneity between the published 
indicators that were deemed valid for inclusion (such as timeframes for assessment), be consistent 
with the NICE guidance,5 and be suitable for implementation with only modest modification to 
usual practice (i.e. feasible).  
2.3 Results 
The stages of analysis are shown in the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow chart121 From the original search strategy after deduplication, 10,853 
articles were identified. (Figure 2-1). The final inclusion set numbered 32,67-80,82,111,119,122-136 with 14 
development articles and 18 implementation articles resulting in 10 indicator groups. Two 
corresponding authors were contacted for clarification of issues, one of whom responded.  
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 Quality indicators: assessment  
The 32 included articles were put into ten groups, allocated on the basis of their original 
development or modification. The flow of information from studies to indicators is illustrated in 
Figure 2-2 and the ten indicator development groups are shown in Table 2-1 as well as Table 2 of 
the associated publication [Appendix A]. Many aspects of the quality of the indicators themselves 
were assessed at group level: method of evidence synthesis; consensus methodology used; target 
population; method of measurement of the indicator; any testing or implementation of the 
indicators. Reliability assessments for data extraction in implementation studies, where reported, 
were given at the level of the study as a whole rather than the individual indicator. Some elements 
of feasibility assessment were also reported at this level, such as any methods used to test or 
implement the indicators. 
Figure 2-1: PRISMA reporting flowchart for stages of the systematic review 
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Figure 2-2: Sankey diagram of flows from included studies to synthesised indicators 
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Conclusions on some aspects of quality assessment were common across all indicators and so 
are not separately reported. These were: 
 Conflict of interest: Although an absence of conflict of interest was not explicitly stated for 
every article, the reviewers considered that there was no significant likelihood of resulting 
bias in the results 
 Current relevance: no studies identified a method of ensuring updates of indicators in the 
light of new evidence, though the ACOVE-1 indicators were subsequently updated in 
ACOVE-3 
 External validity and responsiveness: these aspects had not been demonstrated in any of 
the indicator development or implementation studies 
No articles were excluded from the final set as the result of the quality assessment process. 
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Table 2-1: Quality indicators grouped by developer, with quality assessment 
Indicator/group 
development 
Author & Date 
Truth 
Target population Method of measurement 
Test-retest 
reliability 
Feasibility 
Content 
validity (i): 
Evidence 
synthesis 
Content validity 
(ii): Consensus 
method 
Indicator testing or 
implementation 
1. RAND Quality of Care 
Assessment Tools (RAND QA) 
Moore 2000135 
  Not specified. Medical record review.   
2. Assessing Care of 
Vulnerable Elders (ACOVE) -1 
MacLean 2001119,134, 
  Vulnerable elders Not specified.   
3. ACOVE-1 adapted for the 
English Longitudinal Study of 
Ageing (ELSA) 
Steel 2004124 
  Older patients (≥65y) in the UK  
Interviews for the English 
Longitudinal Study of Aging. 
  
4. ACOVE-1 adapted for 
Nursing Home (NH) 
implementation 
(ACOVE/NH) 
Saliba 2005133 
  Long-stay NH residents ≥65y. Not specified.   
5. ACOVE-1 adapted for the 
Home-based Primary Care 
Quality Initiative (HPCQI) 
Smith 2007123 
  
Patients ≥60y who are 
homebound. 
Not specified. x x 
6. ACOVE-3  
ACOVE investigators 
2007122,126,132 
  
Community-dwelling individuals 
aged ≥65y who are at greater risk 
of death or functional decline over 
a 2-year period. 
Medical records and/or 
administrative data, patient or 
proxy interview. 
  
(con’t) 
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Indicator/group 
development 
Author & Date 
Truth 
Target population Method of measurement 
Test-retest 
reliability 
Feasibility 
Content 
validity (i): 
Evidence 
synthesis 
Content validity 
(ii): Consensus 
method 
Indicator testing or 
implementation 
7. Quality Indicators for 
General Practice 
(QIGP) 
Underwood 2002131 
 x Not specified. Not specified.   
8. Arthritis Foundation 
Arthritis Foundation 
2004127,128 
  Patients with OA. Not specified. x  
9. PCPI 
Physician Consortium for 
Performance Improvement 
(PCPI) 2006129 
x x 
All patients aged ≥21y with a 
diagnosis of OA. 
Medical record data extraction 
(detailed numerator and 
denominator information 
provided) 
x x 
10. EUMUSC.net 2012125 
x x 
All adult patients with OA of hand, 
hip or knee. 
Varies. Examples include 
patient record or survey. 
Numerator and denominator 
clearly identified. 
x x 
Key - : optimal methodology; : acceptable methodology; x: either inadequate evidence of method used or inadequate methodology 
(Adapted from Edwards et al. 2015107).
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Of the ten groups, five were found to be based upon the ACOVE indicator series. These indicators 
were found most closely to fulfil the indicator quality specifications noted under 2.2.5 Quality 
assessment process, above. The strengths of the ACOVE indicators were particularly in their robust 
evidence collation and synthesis, the consensus methodology used in the indicator development, 
field testing in implementation studies (ACOVE-1 and 3), and in their update cycle in ACOVE-3. 
Relatively minor modifications to ACOVE-1 were made for several other study groups: the English 
Longitudinal Study of Aging,124 assessment of care quality in nursing homes,133 and for home-based 
primary care.123 Such modifications included those to the target population and to the timeframe 
for recommended processes of care. Although the degree to which the modifications were the 
result of further empirical study and consensus was variable, the identified modifications were 
judged to be compatible with the original parent indicators. Some heterogeneity was noted 
regarding the use of oral NSAIDs and gastroprotection agents, with respect to the particular drugs 
recommended or the target population.  
The remaining indicator groups were less well matched to the quality assessment criteria. The 
RAND indicators,135 the earliest identified, were based upon a literature review but this was not 
identified as a systematic review, although the consensus exercise was high-quality. The Arthritis 
Foundation indicators127,,128 were based upon a “comprehensive” (rather than systematic) literature 
review and a high-quality consensus process; one implementation of a non-pharmacological 
Arthritis Foundation indicator (weight loss) was identified. The remaining indicator groups used 
either a less rigorous evidence base or consensus exercise, or did not specify how the indicators 
were derived. Some had no evidence of any testing or implementation (HBPCQI123, PCPI129 and 
EUMUSC.net125), though the EUMUSC.net indicators had only recently been published at the time 
of the review.  
All identified indicators predominantly used processes of care. The EUMUSC.net125 indicator set 
also included three outcome measures, relating to a proposed 20% improvement in pain and 
function on patient-reported outcome measures within three months of commencing treatment, 
and workforce participation.  
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The studies from the full-text assessment that did not meet the inclusion criteria for the narrative 
synthesis are listed in Appendix D.3. 
 Quality indicators: narrative synthesis 
The indicator themes are listed, with a chosen exemplar indicator, evidence of an indicator’s 
reproducibility in other studies, all identified instances of implementation, and an assessment of 
feasibility, in Table 2-2. A full breakdown of all identified indicators within holistic assessment is 
shown in Appendix D.4, to demonstrate the way in which the original indicators were brought 
together under each unifying proposed indicator for implementation. The themes are discussed 
further below, with the conclusions from the review process. The final proposed indicators are 
shown in Table 2-3. 
Holistic assessment 
There were 28 instances of indicators relating to holistic assessment in 17 studies (nine 
development and eight implementation studies), as identified in Table 2-2. Indicators relating to 
assessment of pain and function occurred relatively frequently and were considered valid and 
feasible. The ACOVE-3 examples were considered most closely to fulfil the assessment criteria (due 
to the systematic review evidence collection methodology, modified RAND appropriateness 
consensus method, and field testing with a high level of feasibility for implementation with only 
small modification to usual practice) and form the exemplar indicators for the pain and function 
sub-themes. The proposed final indicator wording107 was the percentage of patients with a working 
diagnosis of OA with evidence of pain assessment within the previous 12 months, and the 
percentage of patients with a working diagnosis of OA with evidence of function assessment within 
the previous 12 months. 
Indicators for joint examination and aspiration were identified, though less frequently. Although 
these too were the outcome of studies with high-quality evidence synthesis and consensus 
development, they had not been successfully implemented and were considered less feasible for 
use in general practice in England.  
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The indicators for holistic assessment are shown in Appendix D.4, with the thematic extractions and 
resulting indicators proposed for implementation as an example of the synthesis output. 
Education and information 
Indicators within this theme occurred 18 times in 10 studies (four development and six 
implementation studies). The Arthritis Foundation indicator was selected as the exemplar, being 
based upon a high-quality evidence synthesis and consensus exercise as well as being consistent 
with the similar ACOVE-1 indicator (but more recent). It was also considered to be consistent with 
the EUMUSC.net education indicator. The ACOVE-3 OA indicator set did not include an education 
indicator, though the medication use and pain management sets did include such indicators.137,,138 
These medication use and pain management indicator sets from ACOVE-3 did not meet the 
inclusion criteria for this review as they were not stated specifically to refer to OA but rather were 
generic medication use and pain management indicators; the five indicators in the medication use 
set that were simultaneously included in the ACOVE-3 OA indicator set were included in this 
review.132  
Within the theme, some variability was noted relating to the recommended timeframe specified 
for OA education processes to occur within. For example, the ACOVE-1 set specified slightly 
different indicators for patients with incident OA (education to be offered within six months of 
diagnosis) and prevalent disease (a record of education should be present for people who have had 
symptomatic OA for 12 months).134 The Arthritis Foundation set did not differentiate between 
incident and prevalent disease, specifying that education should be provided or recommended at 
least once for people with a diagnosis of symptomatic OA for at least three months.127 Other 
indicators did not include a timeframe.82,,124  
Most indicators referred to the need for education about the natural history, treatment, and self-
management of the disease. The EUMUSC.net indicator referred to continuous access to education 
on important preventive and therapeutic strategies in the management of OA, and some 
implementation indicators were less specific: “Has any doctor or nurse ever talked to you about 
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what the specific purpose of the treatment for your arthritis or joint pain is?” (Steel 2008,70 
additional Table A). Østerås82 (p1046) used five education indicators – “Have you been given 
information about how the disease usually develops over time?”, “Have you been given information 
about different treatment alternatives?”, “Have you been given information about how you can live 
with the disease?”, “Have you been given information about how you can change your lifestyle?”, 
and “Have you been given information about the importance of physical activity and exercise?” 
There was some variation in the requirement for education to be “given” or “recommended”. The 
method for collecting the information required to assess indicator achievement was generally not 
clear. In one implementation study, the patient was interviewed by telephone: “Has any doctor or 
nurse ever talked to you about: (1). What your arthritis or joint pain will be like as time goes on, or 
the natural history of arthritis?, (2). How to keep your arthritis or joint pain from getting worse?, 
(3). How your arthritis can be treated?”74 The indicator in this study was considered achieved if 
there was at least one positive response. The reviewers rated this indicator as less feasible for 
implementation (as it would require either a detailed set of education indicator records or a series 
of patient self-report indicators). The reviewers proposed a more general education indicator: the 
percentage of patients with a working diagnosis of OA with evidence of education or advice since 
diagnosis. 
The EUMUSC.net indicator set125 also included an indicator for clinician education. This was not 
considered eligible for inclusion in the systematic review as it was not patient-focussed. 
Exercise and physiotherapy 
Twenty-two instances of indicators recommending or prescribing exercise or physiotherapy were 
identified in 18 studies (nine development and nine implementation). One related to patients with 
“symptomatic OA,” 125 one to patients with hand, hip or knee OA,82 six to patients with hip or knee 
OA 71,77,80,128,132,135 and the remainder to patients with knee OA. 
There was variation in the forcefulness of the indicator. Some recommended only that exercise be 
“recommended” or “considered”, while others required it to be “prescribed”. These terms were 
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somewhat open to interpretation. When considering feasibility, it seemed likely that the different 
terms would result in different clinical behaviours were the indicators to be implemented. There 
would also be different implications for data capture: use of “recommended” or “considered” may 
risk becoming a ‘tick-box’ requirement, whilst “prescribed” may require evidence of prescription 
(possibly written instructions or a referral to an exercise programme or physiotherapist).  
The type of exercise referred to by the indicators was also noted to be variable: specific exercise 
programmes, general aerobic exercise, or referral to a physiotherapist. The criterion for success in 
one study was a record of prescription for lower extremity strengthening or ambulation with a 
physical therapist or restorative nursing assistant after OA diagnosis.72 Others used special data 
sources such as patient interview and sometimes the assessment method was not specified. From 
implementation studies, the reviewers concluded that feasible indicators for primary care relate to 
the offer of exercise advice or referral to a physiotherapist, and review of current exercise activity. 
It was considered feasible to separate two elements of the ACOVE-3 exemplar indicator into a 
proposed indicator for advice, recommendation, or prescription of exercise (the percentage of 
patients with a working diagnosis of OA in the hip or knee with evidence of exercise advice or 
physiotherapy referral since diagnosis), and a proposed indicator of annual review of activity (the 
percentage of patients with a working diagnosis of OA with evidence of an activity review within the 
previous 12 months).107 
Weight loss 
Weight loss indicators for overweight patients occurred eight times in five studies (three 
development, two implementation). Six instances related to patients with established OA and two 
(from the Arthritis Foundation, ACOVE-3) to primary prevention of OA. 
Variability was noted in the BMI threshold for intervention (“overweight” not further defined, BMI 
≥27 kgm-2, or BMI ≥30 kgm-2). As with exercise and physiotherapy, there was variation in the type 
of intervention contained within the indicator, from advice only to referral to a formal weight loss 
programme. Two implementation studies between them implemented weight loss indicators three 
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times. Li et al.80 implemented the Arthritis Foundation indicator for weight loss in symptomatic OA, 
chosen here as the exemplar indicator, by using entry to a weight loss programme or having a 
dietetics appointment as criteria for success. Østerås et al.82 used patient self-report of either 
advice to lose weight or referral for help with weight loss as success criteria.  
The reviewers considered that a record of advice to lose weight would be a feasible indicator. An 
indicator regarding referral to a weight loss programme for patients with OA who had been 
overweight for three years or more, such as in the second Arthritis Foundation weight loss indicator, 
would be less feasible to implement due to difficulty in identification of the denominator 
population. The indicators proposed for implementation are the percentage of patients with a 
working diagnosis of OA with a BMI ≥25 kgm-2 who have a record of weight loss advice within the 
previous 12 months and, for primary prevention of OA, the percentage of patients with a BMI ≥30 
kgm-2 who have a record of weight loss advice within the previous 12 months.107 
Assistive devices 
Indicators for the assessment of need of ambulatory or non-ambulatory assistive devices occurred 
nine times in five studies (three development, two implementation studies). No interventions 
resulting from the assessment of need were included in the indicator. The ACOVE-3 indicators were 
chosen as exemplars; implementation of the Arthritis Foundation indicators (which were consistent 
with the ACOVE-3 indicators) was considered to provide evidence of feasibility. Li et al.80 used a 
physiotherapy or occupational therapy (OT) consultation within the previous year as criteria for 
success for ambulatory or non-ambulatory devices respectively; Østerås et al.82 used patient self-
report of assessment for assistive devices. 
General indicators for the assessment of, or referral to physiotherapy/OT, seem feasible for use in 
primary care. The proposed implementation wording for the ambulatory and non-ambulatory 
assistive device indicators is the percentage of patients with a working diagnosis of OA with 
evidence of functional impairment who are recorded as receiving a referral or assessment for 
ambulatory assistive devices within the previous 12 months and the percentage of patients with a 
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working diagnosis of OA with evidence of functional impairment who are recorded as receiving a 
referral or assessment for assistive devices within the previous 12 months.107 
Analgesics 
Indicators regarding analgesics were the most frequently occurring, with 53 instances in 22 studies 
(11 development, 11 implementation). Topics included assessment of current use of analgesics, 
consideration of analgesics, use of appropriate first-line agents (paracetamol), and risk assessment 
and communication. Exemplar indicators were generally derived from high-quality evidence 
synthesis and consensus methods (although the PCPI NSAID risk assessment indicator129 had a less 
clear evidence and consensus basis, it was consistent with a similar indicator from ACOVE-1). 
Variability in the indicators regarding the use of oral NSAIDs use was noted, particularly in terms of 
the drugs recommended: some did not specify which NSAIDs should be used, others recommended 
ibuprofen,131 or ibuprofen or a COX-2 inhibitor.68,69 There was a similar variation in recommendation 
about risk assessment and advice.  
Four indicators relating to use of paracetamol or oral NSAIDs were considered feasible for 
implementation:  
- the percentage of patients with a working diagnosis of OA with evidence of paracetamol as the 
first oral analgesic prescribed or advised since diagnosis 
- the percentage of patients with a working diagnosis of OA taking oral analgesics or NSAIDs with 
evidence that a suitable maximal dose of paracetamol was tried beforehand 
- the percentage of patients with a working diagnosis of OA with evidence of a standard NSAID or 
COX-2 inhibitor as the first oral NSAID prescribed or advised since diagnosis 
- the percentage of patients with a working diagnosis of OA taking an oral NSAID with a documented 
risk assessment prior to first prescription.  
No indicator for the use of topical NSAIDs was identified. Indicators for the assessment of existing 
use of, and consideration of further treatment with, analgesics,129 and another implemented 
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indicator for stronger analgesia82 were not selected due to an unspecified evidence base and 
consensus approach, although their face validity was acknowledged by the reviewers. Indicators 
relating to risk communication were not selected as feasible due to difficulties in implementation 
in the electronic medical record as these were considered to require free-text record analysis, as 
they would not otherwise be easily and meaningfully recorded. 
Gastroprotection 
There were 13 occurrences of gastroprotection indicators in 12 studies (four development, eight 
implementation). There was substantial variation in the triggers specified for gastroprotection use 
as well as in the choice of agent to be used. The most general indicator was developed in a study 
which cited a meta-analysis to support the use of gastroprotection agents in reducing the incidence 
of adverse events in people taking oral NSAIDs.129 This was consistent with the conclusion of the 
NICE guidelines5 that all patients with OA over the age of 45 years should be co-prescribed a proton 
pump inhibitor (PPI) when also prescribed an oral NSAID.  
Where indicators have been implemented, the denominator (eligible) population was frequently 
determined by reference to past medical history (e.g. history of peptic ulcer disease) or co-therapy 
(aspirin, warfarin).  
The PCPI indicator129 was considered the most relevant and feasible (“Percentage of patient visits 
for patients aged 21 years and older with a diagnosis of OA during which GI prophylaxis was 
considered”), with some changes for the final proposed indicator to reflect the NICE guidelines that 
a PPI should routinely be used with an oral NSAID for adults with OA: the percentage of patients 
with a working diagnosis of OA taking an oral NSAID who are also prescribed a PPI or alternative 
gastroprotective agent. The inclusion of alternative gastroprotective agents was made to reflect 
the clinical reality that PPIs are not always suitable or tolerated. 
X-rays, joint injections, specialist assessment, and joint replacement 
Sixteen indicator occurrences in 14 studies (six development, eight implementation) were 
identified. These 16 indicators mainly related to consideration of X-ray use and more specialist 
 43 
interventions (specialist referral, joint injection) where symptoms were not controlled by other 
means.  
As NICE guidance for OA did not recommend routine use of X-rays, none of the identified X-ray 
indicators were considered relevant or feasible for primary care in England.  
A number of indicators referred to the use of failure of conservative treatment as a prerequisite for 
onward specialist referral, though the term ‘failure’ was not clearly defined. One implementation 
study asked patients if they had pain and functional impairment, and had been offered a joint 
replacement or orthopædic assessment.74 Another used a patient self-report to identify failure of 
conservative treatment leading to referral.82 
An indicator, based on the exemplar ACOVE-3 indicator, mandating that all other indicators must 
have been recorded as appropriately met prior to referral was considered to be feasible for primary 
care in England: the percentage of patients with a record of achievement of all other applicable 
indicators prior to specialist referral. 
Outcome indicators 
The EUMUSC.net indicator set 125 included three outcome measures: 
 a 20% functional improvement within three months of a treatment initiation or change 
 a 20% reduction in pain within three months of a treatment initiation or change 
 enablement of workforce participation for people of working age 
Whilst acknowledging the desirability of outcome measures in addition to process-of-care 
measures, the reviewers considered these to be less feasible for use in general practice in England 
due to difficulties in accounting for comorbidities and case mix, as well as the fact that the required 
patient-reported outcome measures were not in established use in general practice. 
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Table 2-2: Narrative synthesis of exemplar indicators and their feasibility for use in primary care 
Overarching 
theme 
[guidance source] Exemplar indicator 
Reproducibility (studies 
also developing similar 
indicators) 
References for identified 
implementation studies Feasibility assessment 
Holistic 
Assessment: Pain 
[EULAR (hand, hip, 
knee), NICE] 
“IF a vulnerable elder has symptomatic OA of the 
knee or hip, THEN pain should be assessed when 
new to a primary care or musculoskeletal disease 
practice and annually…” [ACOVE-3]122,126,132 
RAND QA135, ACOVE-1119,,134, 
and as adapted (ELSA124, 
HPCQI123), Arthritis 
Foundation127,,128, PCPI129, 
EUMUSC.net125 
Asch71 Broadbent69 Chodosh73 
Ganz74 McGlynn77 Osteras82 
Steel 200768 Wenger78  
Feasible: Requires change in 
routine coding to improve 
capture of this information. 
Holistic 
Assessment: 
Function  
[ACR (hand), 
EULAR (hand, hip, 
knee), NICE] 
“IF a vulnerable elder has symptomatic OA of the 
knee or hip, THEN functional status should be 
assessed when new to a primary care or 
musculoskeletal disease practice and annually…” 
[ACOVE-3]122,126,132 
RAND QA135, ACOVE-1119,,134, 
and as adapted (ELSA124, 
HPCQI123), Arthritis 
Foundation127,,128, PCPI129 
Asch71 Broadbent69 Chodosh73 
Ganz74 McGlynn77 Osteras82 
Steel 200768 
Feasible: Requires change in 
routine coding to improve 
capture of this information. 
Holistic 
Assessment: 
Examination  
[NICE, EULAR 
(hand, hip, knee)] 
“IF a patient is begun on a drug treatment for “joint 
pain,” “arthritis,” or “arthralgia,” THEN evidence 
that the affected joint was examined should be 
documented.” [Arthritis Foundation]127,,128 
ACOVE/NH133 (2 indicators, 
one relating to new 
residents, one to residents 
prescribed a drug to treat 
new joint pain), PCPI129 
This indicator had not been 
implemented in any identified 
studies 
Not suitable: This indicator was 
not considered feasible for 
implementation due to 
limitations in recording 
examination findings in format 
suitable for easy audit– could 
only be implemented with 
substantial change to coding 
behaviour. 
    (con’t) 
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Overarching 
theme 
[guidance source] Exemplar indicator 
Reproducibility (studies 
also developing similar 
indicators) 
References for identified 
implementation studies Feasibility assessment 
Holistic 
Assessment: Joint 
aspiration 
[None] 
“IF a vulnerable elder has monoarticular joint pain 
associated with redness, warmth, or swelling AND 
the patient also has an oral temperature greater 
than 38.0°C and does not have a previously 
established diagnosis of pseudogout or gout, THEN 
a diagnostic aspiration of the painfully swollen red 
joint should be performed that day…” [ACOVE-
1]119,,134 
ACOVE/NH 133, HPCQI 123 Although implemented in one 
identified study78, no patients 
were eligible for this process of 
care (numerator/denominator 
of zero) 
Not suitable: This indicator was 
not considered feasible for 
implementation due to 
limitations in recording 
differential diagnoses, and 
because such patients are likely 
to be referred to secondary care 
as an emergency; denominator 
hard to define. 
Education  
[EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“IF a patient has had a diagnosis of symptomatic 
osteoarthritis of the knee or hip for > 3 months, 
THEN education about the natural history, 
treatment, and self-management of osteoarthritis 
should have been given or recommended at least 
once…” [ Arthritis Foundation]127,,128 
ACOVE-1 (2 variations – 
new and pre-existing 
disease)119,,134, and as 
adapted (ELSA124), 
EUMUSC.net125 
Broadbent69 Ganz74 Osteras82 
Steel 200768 Steel 200870 
Wenger78 
Feasible: Requires change in 
routine coding to improve 
capture of this information. 
Exercise 1 & 2 
(ACR (hip, knee), 
EULAR (hand, hip, 
knee), NICE, OARSI 
“IF an ambulatory vulnerable elder has 
symptomatic OA of the knee or hip for longer than 
3 months and is able to exercise, THEN a directed or 
supervised muscle strengthening or aerobic 
exercise program should be recommended and 
activity reviewed annually…” [ACOVE-3]122,126,132 
Initial recommendation 
RAND QA 135, ACOVE-1 
(indicators for new and pre-
existing disease)119,,134, and 
as adapted (ELSA124, 
ACOVE/NH133, HPCQI123), 
Arthritis Foundation127,,128, 
PCPI129, EUMUSC.net125 
Annual review 
RAND QA135, ACOVE-1119,,134 
Initial recommendation 
Asch71 Cadogan72 Ganz74 Higashi 
2005136 Li80 McGlynn77 Osteras82 
Steel 200870 Wenger78  
 
Annual review 
Li80 
Feasible: Requires change in 
routine coding to improve 
capture of this information. 
    (con’t) 
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Overarching 
theme 
[guidance source] Exemplar indicator 
Reproducibility (studies 
also developing similar 
indicators) 
References for identified 
implementation studies Feasibility assessment 
Weight loss 1  
[ACR (hip, knee), 
NICE, OARSI 
“IF a vulnerable elder is obese (body mass index 
(BMI) ≥30 kgm-2), THEN he or she should be 
advised annually to lose weight…” [ACOVE-
3]122,126,132 
Arthritis Foundation127,,128 No implementation studies 
identified for this indicator. 
Feasible: Should be captured 
from existing weight and health 
promotion records. 
Weight loss 2  
[ACR (hip, knee), 
NICE, OARSI 
“IF a patient has symptomatic osteoarthritis of the 
knee or hip and is overweight (as defined by body 
mass index of ≥27 kgm-2), THEN the patient should 
be advised to lose weight at least annually AND the 
benefit of weight loss on the symptoms of 
osteoarthritis should be explained to the patient…” 
[Arthritis Foundation]127,,128 
EUMUSC.net125 Li80 Osteras82 Feasible: Consider a lower BMI 
threshold of 25 kgm-2 for 
consistency with the usual 
definition of ‘overweight’. Should 
be captured from existing weight 
and health promotion records. 
Weight loss 3 
[ACR (hip, knee), 
NICE, OARSI] 
“IF a patient has symptomatic osteoarthritis of the 
knee or hip and has been overweight (as defined by 
body mass index of ≥27 kgm-2) for 3 years, THEN 
the patient should receive referral to a weight loss 
program…” [Arthritis Foundation]127,,128 
No other variations Osteras82 Not suitable: This indicator was 
considered less feasible for 
implementation in primary care 
using routine data sources. 
Aids and devices 1 
[ACR (hip, knee), 
EULAR (hip, knee), 
NICE, OARSI] 
“IF a vulnerable elder has symptomatic OA of the 
hip or knee and has difficulty walking that makes 
activities of daily living difficult for longer than 3 
months, THEN the need for ambulatory assistive 
devices should be assessed…”[ACOVE-3]122,126,132 
Arthritis Foundation127,,128, 
EUMUSC.net125 
Li80 Osteras82 Feasible Requires change in 
routine coding to improve 
capture of this information. 
Aids and devices 2 
[ACR (hand), NICE] 
“IF a vulnerable elder has symptomatic OA and has 
difficulty with non-ambulatory activities of daily 
living (ADL), THEN the need for ADL assistive 
devices should be assessed…”[ACOVE-3]122,126,132 
Arthritis Foundation127,,128, 
EUMUSC.net125 
Li80 Osteras82 Feasible Requires change in 
routine coding to improve 
capture of this information. 
    (con’t) 
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Overarching 
theme 
[guidance source] Exemplar indicator 
Reproducibility (studies 
also developing similar 
indicators) 
References for identified 
implementation studies Feasibility assessment 
Paracetamol 1 
[ACR (hip, knee), 
EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“IF a vulnerable elder is started on pharmacological 
therapy to treat OA, THEN acetaminophen should 
be tried first…”[ACOVE-3]122,126,132 
RAND QA135, ACOVE-1119,,134, 
and as adapted (ELSA124, 
ACOVE/NH133, HPCQI123), 
QIGP131, Arthritis 
Foundation127,,128,  
Asch71 Broadbent69 Cadogan72 
Ganz74 Higashi 200475 Higashi 
2005136 Kirk67 McGlynn77 
Osteras82 Steel 200768 Steel 
200870 Wenger78 
Feasible: Requires change in 
routine coding to capture over-
the-counter drug use. 
Paracetamol 2 
[ACR (hip, knee), 
EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“IF oral pharmacologic therapy for osteoarthritis is 
changed from acetaminophen to a different oral 
agent, THEN there should be evidence that the 
patient has had a trial of maximum dose 
acetaminophen (suitable for age/ 
comorbidities)….”[Arthritis Foundation]127,,128 
ACOVE-1119,134,and as 
adapted (ELSA119,,134, 
ACOVE/NH124, HPCQI133) 
Broadbent69 Cadogan72 Higashi 
200475 Steel 200768 Wenger78  
Feasible: Requires change in 
routine coding to capture over-
the-counter drug use. 
Paracetamol 3 
[ACR (hip, knee), 
EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“Percentage of patient visits for patients aged 21 
years and older with a diagnosis of OA with an 
assessment for use of anti-inflammatory or 
analgesic OTC medications”[PCPI]68,,69,,72,75,,78, 
No other variations This indicator had not been 
implemented in any identified 
studies 
Not suitable: not considered to 
have been through the same 
degree of development and 
testing as most other indicators. 
Paracetamol 4 
[ACR (hip, knee), 
EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“Percentage of patient visits for patients aged 21 
years and older with a diagnosis of OA during which 
an anti-inflammatory agent or analgesic was 
considered”[PCPI] 82 
No other variations This indicator had not been 
implemented in any identified 
studies 
Not suitable: not considered to 
have been through the same 
degree of development and 
testing as most other indicators. 
Paracetamol 5 
[ACR (hip, knee), 
EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“IF a vulnerable elder is prescribed chronic high-
dose acetaminophen (≥3 g/d) or a VE with liver 
disease is prescribed chronic acetaminophen, THEN 
he or she should be advised of the risk of liver 
toxicity…”[ACOVE-3]129 
No other variations This indicator had not been 
implemented in any identified 
studies 
Not suitable: considered less 
feasible to measure from 
routinely coded data sources – 
could be implemented with 
substantial change to coding 
behaviour.  (con’t) 
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Overarching 
theme 
[guidance source] Exemplar indicator 
Reproducibility (studies 
also developing similar 
indicators) 
References for identified 
implementation studies Feasibility assessment 
Oral NSAIDs 1 
[all] 
“If NSAIDs are considered, ibuprofen should be 
considered for first-line treatment unless 
contraindicated or intolerant.†” [QIGP]122,126,132 
Modifications exist in two 
implementation studies 
(Steel131, Broadbent68) to 
include use of COX-2 
selective drugs 
Broadbent69 Kirk67 Steel 200768  Feasible: Requires change in 
routine coding to capture over-
the-counter drug use. 
Oral NSAIDs 2 
[all] 
“Percentage of patients aged 21 years and older 
with a diagnosis of OA on prescribed or OTC NSAIDs 
who were assessed for GI and renal risk factors.” 
[PCPI]67,68,,69, 
Two indicators from ACOVE-
3 state that risks from 
NSAIDs and aspirin should 
be “discussed and 
documented,”129 
EUMUSC.net122,126,132 
Broadbent69 Steel 200768 Feasible: Requires change in 
routine coding to capture over-
the-counter drug use. 
Oral NSAIDs 3 
[all] 
“Percentage of patient visits for patients aged 21 
years and older with a diagnosis of OA with an 
assessment for use of anti-inflammatory or 
analgesic OTC medications” [PCPI]68,,69 
No other variations This indicator had not been 
implemented in any identified 
studies 
Not suitable: not considered to 
have been through the same 
degree of development and 
testing as most other indicators 
Oral NSAIDs 4 
[all] 
“Percentage of patient visits for patients aged 21 
years and older with a diagnosis of OA during which 
an anti-inflammatory agent or analgesic was 
considered” [PCPI]82 
No other variations This indicator had not been 
implemented in any identified 
studies 
Not suitable: not considered to 
have been through the same 
degree of development and 
testing as most other indicators 
 
† Different sources of guidance offer varying recommendations about the use of specific NSAIDs. In the UK, NICE recommend a standard NSAID or COX-2 inhibitor (other than 
etoricoxib 60mg) to be co-prescribed with a PPI  
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Overarching 
theme 
[guidance source] Exemplar indicator 
Reproducibility (studies 
also developing similar 
indicators) 
References for identified 
implementation studies Feasibility assessment 
Oral NSAIDs 5 
[all] 
“IF a VE is prescribed an NSAID (nonselective or 
selective), THEN GI bleeding risks should be 
discussed and documented…” [ACOVE-3]129 
ACOVE-1 122,126,132], HPCQI 
119,134, 
Broadbent69 Ganz74 Higashi 
2005136 Steel 200768 
Not suitable: Indicator was 
considered less feasible to 
measure from routinely coded 
data sources. Could only be 
implemented with substantial 
revision to coding practices.  
Gastroprotection 
[EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“IF a vulnerable elder with a risk factor for GI 
bleeding (aged ≥75, peptic ulcer disease, history of 
GI bleeding, warfarin use, chronic glucocorticoid 
use) is treated with a nonselective NSAID, THEN he 
or she should be treated concomitantly with 
misoprostol or a PPI.” [ACOVE-3]68,69,74,75,78,82,136 
ACOVE-1122,126,132, ACOVE-
3119,134, (NSAIDs, and 
aspirin), QIGP122,126,132, 
PCPI131 
Chodosh73 Ganz74 Higashi 
200475 Higashi 2005136 Kirk67 
Maclean76 Wenger78 
Zingmond79 
Feasible: Should be captured 
from existing electronic 
prescribing records. 
Specialist 
Assessment: X-ray 
[None] 
“IF a patient has hip or knee osteoarthritis AND has 
worsening complaints accompanied by a 
progressive decrease in activities AND no previous 
radiograph during the preceding 3 months, THEN a 
knee or hip radiograph should be performed within 
3 months…”[Arthritis Foundation]67,73-75,76,,78,79,,136 
No other variations This indicator had not been 
implemented in any identified 
studies 
Not suitable: Indicator was not 
considered appropriate for 
implementation since 
denominator hard to define; NICE 
do not recommend routine use of 
X-rays for diagnosis or referral 
decisions.  
Specialist 
Assessment: 
Referral 
[EULAR (hand, hip, 
knee), NICE, 
OARSI] 
“IF a VE has severe symptomatic OA of the knee or 
hip despite nonsurgical therapy, THEN a referral to 
an orthopædic surgeon should be made, BECAUSE 
joint surgery may reduce pain and improve 
functional status and quality of life.”[ACOVE-
3]127,,128 
RAND QA 122,126,132, ACOVE-1 
135, and as adapted (ELSA 
119,134,), Arthritis 
Foundation124, QIGP 127,,128, 
EUMUSC.net 131 
Broadbent69 Ganz74 Higashi 
2005136 Kirk67 Osteras82 Steel 
200768 Steel 200870 
Feasible: It would be feasible to 
capture the presence of non-
surgical therapy indicators in the 
record, routine data sources 
cannot be used reliably to assess 
the need for a surgical opinion. 
(adapted from Edwards et al. 2013107) 
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Table 2-3: Quality indicators for OA - proposals for primary care implementation 
Theme Proposal for primary care implementation 
Holistic Assessment: 
Pain 
Numerator: patients with evidence of pain assessment within the previous 12 
months 
Denominator: all patients with clinical OA 
Holistic Assessment: 
Function  
Numerator: patients with evidence of function assessment within the previous 
12 months 
Denominator: all patients with clinical OA 
Education  
Numerator: patients with evidence of education or advice since diagnosis 
Denominator: all patients with clinical OA 
Exercise 1  
Numerator: patients with evidence of exercise advice or physiotherapy referral 
since diagnosis 
Denominator: all patients with clinical OA in the hip or knee 
Exercise 2  
Numerator: patients with evidence of an activity review within the previous 12 
months 
Denominator: all patients with clinical OA 
Weight loss 1  
Numerator: patients who have a record of weight loss advice within the previous 
12 months 
Denominator: all registered patients with a BMI ≥30 kgm-2 
Weight loss 2  
Numerator: patients who have a record of weight loss advice within the previous 
12 months 
Denominator: patients with clinical OA with a BMI ≥25 kgm-2 
Aids and devices 1 
Numerator: patients who are recorded as receiving a referral or assessment for 
ambulatory assistive devices within the previous 12 months 
Denominator: patients with clinical OA with evidence of functional impairment 
Aids and devices 2 
Numerator: patients who are recorded as receiving a referral or assessment for 
assistive devices within the previous 12 months 
Denominator: patients with clinical OA with evidence of functional impairment 
Paracetamol 1 
Numerator: patients with evidence of paracetamol as the first oral analgesic 
prescribed or advised since diagnosis 
Denominator: patients with clinical OA with evidence of pain 
Paracetamol 2 
Numerator: patients with evidence that a suitable maximal dose of paracetamol 
was tried first 
Denominator: patients with clinical OA prescribed oral analgesics or NSAIDs 
Oral NSAIDs 1 
Numerator: patients with evidence of a standard NSAID or COX-2 inhibitor as 
the first oral NSAID prescribed or advised since diagnosis 
Denominator: patients with clinical OA prescribed an oral NSAID 
Oral NSAIDs 2 
Numerator: patients taking an oral NSAID with a documented risk assessment 
prior to first prescription 
Denominator: patients with clinical OA prescribed an oral NSAID 
Gastroprotection 
Numerator: patients prescribed a PPI or alternative gastro-protective agent 
Denominator: patients with clinical OA prescribed an oral NSAID  
Specialist assessment 
Numerator: patients who have a record of achievement of all other applicable 
indicators‡ 
Denominator: patients with clinical OA referred for a specialist opinion 
 
‡i.e. the other 14 indicators above, depending on applicability of weight and therapy indicators to individual patients  
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Proposed indicator set for general practice in  
Fifteen indicators were therefore considered to be consistent with the NICE OA guidelines and 
feasible for implementation in primary care in England. These are shown in the format of definitions 
of numerator (patients fulfilling the quality criterion) and denominator (patients eligible for the 
criterion) in Table 2-3. All numerator and denominator statements imply application to patients 
with a working diagnosis of OA. 
The remaining indicators were considered to be less valid (on the basis of the evidence used or 
consensus approach), inconsistent with NICE guidance (such as the use of X-rays), or less feasible 
for implementation. The reasons are listed in Table 2-2. 
2.4 Discussion 
 Summary and comparison with previous literature 
This review provides an overview of the published quality indicators for the management of OA 
relevant to primary care in England. It adds to previous work by Hochberg105 and Strömbeck et al.106 
through identification and appraisal of the indicators within related groups, including use of 
implementation evidence. A novel aspect to this review was the determination of feasibility for 
primary care application of the indicators.  
The indicators selected in this review were broadly applicable across the different course of 
guidance on OA management guidance referred to in section 1.4.1. Clinical practice guidelines do 
not always reflect the state of the art, and quality indicator sets are likewise at risk of becoming 
superseded by developments in evidence (for example, in relation to concerns about paracetamol 
use being less safe than previously thought,139 or the heightened concerns about COX-2 and other 
oral NSAID use140) after the development of indicators. None of the indicator sets were found to 
have a mechanism to ensure revision in light of emerging evidence. The use of Quality Standards 
by NICE,141 which have included OA since June 2015, goes some way towards addressing this issue 
through use of an annual review of those quality standards to determine whether or not an update 
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is required. The range of standards for OA mandated by NICE was less broad than the indicators 
identified by this review.  
There were various aspects of guidance which were not clearly reflected by existing quality 
indicators. Most notably, topical agents have not been the subject of previous indicator 
development, despite both topical NSAIDs and capsaicin being recommended for hand and knee 
OA in the NICE guidance.106 There were many other areas which also have either no indicator or 
which were not distinctively identified within the existing indicators. These included (i) holistic 
review – all aspects except pain and function assessment, notably a periodic review, a jointly agreed 
management plan, and the effect of comorbidities; (ii) education and self-management: the 
development of a self-management plan, and thermotherapy; (iii) non-pharmacological 
management: manipulation and stretching, electrotherapy, bracing, joint supports, footwear and 
insoles; (iv) pharmacological management: topical NSAIDs and capsaicin, and intra-articular 
injections. In principle, these subject areas were considered suitable for indicator development. As 
well as a lack of some relevant indicators regarding recommended processes of care, no evidence 
of any indicators regarding aspects of care that were recommended not to take place (‘do not do’ 
indicators) was found. Such indicators might be considered for such aspects of NICE guidance as 
prescription of topical rubefacients or nutraceuticals, intra-articular hyaluronic acid injections, and 
referral for electro-acupuncture or arthroscopic lavage.  
No evidence of external validity was found for any indicator, so it is unclear whether the use of 
quality indicators can directly result in quality improvement. Evidence of responsiveness (sensitivity 
to change) was also not identified so, although an indicator’s ability to discriminate between care 
of a higher or lower quality is assumed, this has not been demonstrated in the literature. Both 
aspects merit further development: an increased use of patient-reported process measures such as 
those used by Østerås et al.82 would be one means of such development, especially if such 
indicators could be entered directly into the primary medical record to enable routine use in audit.  
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Implementation of the recommended indicators would generally require some modification to data 
capture. Prescriptions were a notable exception, since the bulk of prescriptions tend to be 
electronically generated and the information systems could identify with relative ease the nature 
of the prescription. This has been successfully used in the QOF102 for various prescription 
monitoring indicators such as the use of antiplatelet agents in vascular disease. Many of the 
remaining indicators were reliant on clinicians taking time to record the full content of the 
consultation. With appropriate modification to coding behaviour, the selected indicators were 
considered to be generalisable to general practice across the UK and to international practice where 
medical records are computerised. 
The proposed indicators were designed to be compatible with an episodic review of care for people 
with OA (such as would occur for long-term condition reviews facilitated by the QOF), so indicators 
such as the annual assessments for pain and function, an annual review of physical activity and 
weight advice (where relevant), and an aids and devices needs assessment would need to be 
sufficiently succinct that they do not trigger clinical disengagement from the process.  
It should be noted that the indicators may be most appropriate at a population level:142 in a 
population of patients with OA, there could be patients in whom individual indicators would be less 
appropriate (for example, people who have already been actively self-managing may not need to 
be referred to an exercise programme, and some patients may present with such advanced disease 
that an early referral is warranted without necessarily going through the other processes of care 
beforehand). Population-level thresholds for achievement have not been established. 
 Strengths and limitations 
This review used a sensitive search strategy to identify the available literature on quality indicators. 
A system of dual-review of abstracts and full-text articles, with dual extraction of data for the 
included articles and subsequent narrative synthesis, improved the reliability of the review. 
Alignment to the NICE guidelines and interpretation of feasibility for a primary care context by two 
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experienced GPs, has improved the applicability of the final indicator set to general practice in 
England.  
There were some limitations in this review. There may be indicators not captured by the search 
strategy (such as any prior to 2000, and all non-English language indicators). So-called ‘grey’ 
literature was also not eligible for inclusion in this review. Given that a number of the identified 
indicator sets were based upon a thorough evidence synthesis, it seems unlikely that any major 
themes will have been omitted, though it was possible that some variability within themes may not 
have been captured. Additional information was sought from the authors of two included articles 
but the majority of the assessments were made solely on the basis of published information. Quality 
assessment of quality indicators is not a highly-developed science and skill. The methodological 
assessment used in this review was a pragmatic approach based on accepted methods of indicator 
development and a peer-reviewed clinical performance measures checklist.117 This could be 
enhanced by establishment of a consensus on quality indicator assessment methodology similar to 
the COSMIN checklist,118 such as the Quality Indicator Critical Appraisal (QICA) checklist proposed 
in 2014 by Jones et al.143 The subjective nature of some of the assessments made in the review, 
particularly in relation to feasibility, was a limitation, though it was not considered achievable to 
create a robust, transparent and reproducible method for making judgments about feasibility and 
relevance to primary care in England. This could have been strengthened by use of a group of GPs 
to undertake a formal consensus exercise such as that used by Marshall et al.144 Acceptability of the 
indicators to a wider group of GPs was not assessed; an exercise to determine clinical acceptability 
similar to that undertaken by Marshall et al. would be a potential method of achieving this. The 
review identifies that some indicators require additional data collection to make routine 
assessments possible. It could be argued that the proposed extension to routine coding of data 
should include additional detail. Determination of data collection requirements could again be 
strengthened through use of a consensus panel. In recommending the synthesised OA primary care 
indicators, the precision of some of the original indicators has been somewhat diluted to overcome 
within-group heterogeneity, to maintain concordance with NICE guidance, and to maximise the 
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feasibility of the indicator implementation. This approach both strengthens the probability of 
implementation in UK general practice and to an extent undermines the science behind the 
originally developed indicators. However, the approach taken was in a similar vein to other 
adaptations of original indicators that have taken place without recourse to further evidence 
synthesis and consensus development (for example, the inclusion of compound analgesics by Steel 
et al.,144 or the interpretation of success criteria by Li et al.68).  
An additional limitation to the application of the review was the potential difficulty in determining 
the population to whom the indicators should be applied. Whilst they were applicable to people 
with a formal OA diagnosis, this would be likely to represent only a part of the population who 
actually have clinical OA as defined by NICE (section 1.2, Definitions of osteoarthritis). The issue of 
a practical definition of clinical OA is discussed further in Chapter Three, section 3.5.  
 Conclusion 
In conclusion, a set of 15 indicators considered valid and feasible for implementation in general 
practice in England have been identified. Structured implementation was considered necessary to 
achieve uptake of many of these in primary care, given the information capture limitations noted. 
In Chapter Three, the way in which these indicators might be used within the MOSAICS study is 
developed and discussed, with their use in assessing quality of care for OA reported in Chapter Five 
to Chapter Eight.  
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Chapter Three: Development of an osteoarthritis consultation 
recording template 
3.1 Introduction 
Much of the general practice medical record in the UK is computerised. This has been increasing 
since the early days of general practice computerisation in the late 1980s, encouraged by policies 
such as the IM&T DES of the General Medical Services contract 2004.101 However, the electronic 
medical record structure retains some similarity with previous paper records, in that only part of 
the electronic record is coded and therefore easily searchable with automatically retrievable 
information.22,,145 Some elements of a consultation would be expected to be recorded in an easily 
retrievable manner whereas others would tend to require a full analysis of a patient’s whole record 
including the narrative (free-text). Typically, a consultation record would consist of at least one item 
coded using the Read code system.146 This could be a symptom, procedure, or process-of-care code, 
or a disease diagnostic code; the associated narrative rubric is generally of lower utility for routine 
analysis. Other coded elements may include investigations or referrals. Prescriptions are typically 
electronically generated and consequently prescribing records can be retrieved relatively 
straightforwardly. Even if hand-written, a prescription entry should additionally be made in the 
electronic record.147 Test results tend to be recorded electronically, though may either result from 
manual entry of a paper copy of the result or through automated electronic delivery of the result 
from its originator.  
Of the quality indicator outputs from the systematic review107 (Chapter Two), some could be 
assessed though use of the medical record as used in standard practice, notably the prescribing 
indicators. However, standard methods of consultation recording were not considered likely to be 
adequate to examine other aspects of recorded quality of care for osteoarthritis in the MOSAICS 
study, as outlined in Table 2-2. Indicators identified as likely to need a change in recording practice 
were pain and function assessment recording, education provision, exercise advice, aids and 
devices referrals, and use of (over–the–counter) paracetamol and oral NSAIDs. In order to enhance 
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the reliability of data collected within the MOSAICS study, it was decided to use an electronic 
consultation recording template within the study practices. The objective of this chapter is to 
describe the evidence for such templates in influencing clinical behaviour and show, through a 
series of developmental studies, the way in which the MOSAICS template was developed, tested, 
and implemented. 
In this chapter, the evidence for the effects of templates on delivery and recording of clinical care, 
and evidence for the best methods of template development and implementation in primary care 
are examined. The need for, and development and implementation of, a template for OA in the 
MOSAICS study is explained. The development and implementation work is presented as a series 
of developmental studies, outlined in Figure 3-1. 
Figure 3-1: Outline of the structure for Chapter Three.  
 
The developmental studies took place over a period of 18 months and, rather than being conducted 
in a linear sequence, overlapped as determined by the needs of the MOSAICS study timeline. The 
studies used a mixture of methods and at times a minimal formal evaluation was used. The methods 
Introduction 
•The need for enhanced data collection in the MOSAICS study
Background
•Feasibility and effects of reminder systems
Evidence for computerised templates in primary care clinical management
•The development of the OA consultation recording e-template
E-template development study
•Read code triggers for the e-template in consultations
Triggers for the e-template
•Assesssment of the Clinical OA burden using the trigger terms to define OA
Assessment of population OA disease burden
•Implementing the e-template in the MOSAICS study practices
E-template implementation study
Conclusion
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and results for each component study are discussed individually, with discussion and critical 
reflection on the potential impact on the content and performance of the template. 
3.2 Background: the need for enhanced data collection in the MOSAICS study 
The outputs from the systematic review were used to assist the identification of those indicators 
not identifiable in routinely recorded primary care data and therefore necessary for inclusion in the 
template.  
No published evaluation of the utility of the general practice EHR in the UK at capturing information 
other than morbidity codes, prescriptions, and referrals was identified. A preliminary scoping 
exercise was undertaken using the Read code browser148 and the CiPCA database. CiPCA is a 
database of primary care consultations from twelve (as at 2007) North Staffordshire general 
practices trained in, and assessed upon, the quality of recording of consultations and so should 
represent best practice in recording.21,22 This exercise demonstrated that some aspects of care were 
routinely recorded (predominantly, prescribing); referrals were also potentially identifiable from a 
related database of referrals. However, many aspects of OA care could not be, or were not, 
recorded. There were no available codes identified for recording assessment of, or advice to use, 
over-the-counter topical NSAIDs. Only limited codes were identified for pain and function 
assessment, information provision regarding OA, or paracetamol and oral NSAID use assessment 
and advice. Even the information that could be recorded through the use of the available codes for 
pain, function, exercise assessment and advice was not consistently well-recorded; for example, 
advice regarding weight loss appeared not consistently to have been coded as recorded rates were 
implausibly low. Physiotherapy referral within consultations was also rarely recorded, implying that 
although a formal referral may be captured through specific referral data (not interrogated for this 
aspect of the investigation), other advice to contact physiotherapy (such as private therapy, or 
physiotherapy triage) was not routinely coded. Some of this information may have been present in 
the uncoded narrative associated with Read codes but this lacked practicality as an alternative data 
source due to the lack of sufficiently sophisticated natural language processing software to extract 
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the relevant information.149 The alternatives for data collection within MOSAICS were therefore 
either to undertake an in-depth analysis of each patient’s full-text record, or to create a mechanism 
for improved data recording. Full-text record analysis was not considered to be a feasible method 
of data extraction for the purposes of comparing intervention and control arms on recorded 
achievement of quality of care for two reasons; (i) the size of the dataset in MOSAICS (projected 
eligible study population 30,000 people aged 45 years and over1), and (ii) for study practicability, 
only a small subset of the practice population (those included in the main trial) were to be 
approached for consent to view their identifiable medical record through a population survey of 
joint pain with medical record linkage.1  
To improve the utility of the medical record for the purposes of the MOSAICS study, a computer 
template was created. This was conceived as a means to improve the routine recording of 
consultations with patients seeing a clinician due to OA. The template was intended to provide a 
straightforward means of coding assessments that existing Read codes could not have facilitated 
(either due to a complete absence of codes or lack of precision) and to prompt the recording of 
aspects not well-captured even if codes were available (such as for exercise advice).  
3.3 Evidence for computerised templates in primary care: feasibility and 
effects 
 Background 
Although computer templates in primary care have become commonplace, and are routinely used 
for data capture and structuring of consultations (for example, in the QOF102), their use is 
controversial. For example, Swinglehurst et al.,150 in a case study of two general practices in 
England, highlighted a risk of compartmentalisation of the complexities of clinical care into 
templates, and of framing quality of care through such a potentially reductionist approach. An 
examination of evidence about e-Health interventions151 in a wide sense (including data storage, 
management and transmission; decision support; and remote healthcare) concluded that there was 
a lack of high-quality evidence to support many of the policy assertions made about some of these 
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interventions in changing care and expressed specific relevant concerns relating to the time spent 
documenting patient data as well as the computer becoming a “third person” in a consultation. 
The aim of this initial developmental study was to identify what evidence existed about the effects 
of templates on clinical behaviours, with particular regard to the recording of data, to inform the 
creation of a recording template for the MOSAICS study. The potential that such a template could 
act as an additional intervention within the study was recognised at the study inception by the 
candidate and also by the trial steering committee. In light of this, evidence for templates as a 
healthcare intervention was also sought, with a view to assessment of the likelihood and degree of 
any effect on planned trial outcome measures. 
 Method 
A MEDLINE scoping search (without restriction by clinical condition or geographical location) was 
conducted using NHS Evidence.§ No systematic reviews specific to the effect of primary care 
computer templates on consultation recording or clinical management were identified. The search 
strategy was therefore broadened to consider reminder systems in general, on the basis that 
templates essentially act as reminders to clinicians to record information or conduct a particular 
process of care. This identified a relatively recent relevant Cochrane systematic review (Shojania  et 
al. 2009152) on the effects of computer reminders on clinical care. This review was used as the basis 
for identification of the evidence for the feasibility of use and effects on care (processes or 
outcomes) of the template with any additional evidence published since the review identified 
through implementation of part of the same search strategy as used by Shojania in MEDLINE. The 
objective was not to undertake a fresh systematic review or meta-analysis but rather to use a 
systematic search strategy to identify additional new and potentially important information.  
The MEDLINE search strategy used by Shojania et al. and set out comprehensively in their review152 
(Appendix 1, p.64) was used in the NHS Evidence MEDLINE search portal with a publication date 
 
§NHS Evidence is a portal through which various bibliographic databases may be searched. 
https://www.evidence.nhs.uk/ [Accessed 24/09/2016] 
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restriction from July 2008 (when the previous review search was undertaken) onwards. The 
resulting citations were downloaded to a citation manager tool (EndNote® X7). The same inclusion 
criteria as set out in the review were used. The candidate alone determined the relevance of the 
studies through an assessment, hierarchically, of the title, abstract, and full-text of the identified 
articles. The search was last updated on 02/09/2015. 
Only some results were considered to be of interest. These related to the effects of templates in 
general, and on the following outcomes: 
- Data capture 
- Process adherence 
- Prescribing 
- Test ordering 
- Referral to other healthcare providers including therapy professions and secondary care 
medical professionals 
The results are presented in Table 3-1 with the selected relevant conclusions from the Shojania 
review and additional studies identified subsequent to the evidence search date in that review. 
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 Results 
Table 3-1: Evidence for the feasibility and outcomes of reminder systems in clinical practice 
STUDY TYPE INTERVENTION DOMAIN SUMMARY RESULTS NOTES 
Shojania et 
al.,152 2009 
Systematic 
review 
Reminder systems – 28 included articles 
with 32 comparisons. Nineteen based in 
the USA, 24 outpatient-based.  
 Median absolute improvement (IQR)  
(Using median 
outcome from each 
study) 
(Using best outcome 
from each study) 
All process 
domains 
4.2% 
(0.8% to 18.8%) 
5.6% 
(2.0% to 19.2%) 
Due to multiple studies not 
reporting a primary outcome, the 
results were presented as the 
median outcome with interquartile 
range and also using the best 
outcome with IQR to give a range of 
potential effects on the process-of-
care domains.  
It was unclear if one USA hospital, 
from where a number of studies 
had been undertaken, had greater-
than-average success rates due to 
reminder system features or other 
institutional/cultural factors. 
Overall, small-to-moderate effects 
of reminders were seen in the 
context of considerable 
heterogeneity between studies 
(including in the method of 
reporting) and reminder systems.  
Clinical process 
(prescription of 
medication) 
3.3% 
(0.5% to 10.6%) 
6.2% 
(3.0% to 28.0%) 
Test ordering  3.8% 
(0.4% to 16.3%) 
9.6% 
(0.6% to 24.0%) 
Process measures 
(documentation 
elements)  
0.0% 
(-1.0% to 1.3%) 
2.0% 
(2.0% to 4.0%) 
Process measures 
(other)  
1.0% 
(0.8% to 8.5%) 
4.0% 
(0.8%to 8.5%) 
Clinical outcomes 
(dichotomous) 
2.5% (1.3% to 4.2%) n/a 
      (con’t) 
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STUDY TYPE INTERVENTION DOMAIN SUMMARY RESULTS NOTES 
Lecumberri 
et al.,153 
2008 
Before-
and-after 
study 
Automated electronic alerts based on a 
hospital clinical record database to reduce 
venous thromboembolism (VTE) risk 
Clinical outcome 
(dichotomous) 
No significant effect was seen in year 1 nor 
for surgical patients or the population overall. 
Odds for VTE in medical patients was lower by 
year 2 (OR 0.36, 95% CI 0.12,0.98). 
Secondary outcomes were the total number 
of electronic alerts sent (significant in both 
medical [1.9% increase] and surgical [2.5% 
decrease] subgroups but not the population 
overall) and the percentage of alerted 
patients who received appropriate 
thromboprophylaxis (significant 15.2% 
improvement in medical patients but not 
significant in surgical patients (1.2% decrease) 
or the population overall (0.3% increase)) 
 
Tamblyn et 
al.,154 2008 
Cluster RCT Automated vs. on-demand customizable 
computerised decision support for 
prescribing. 
Process measure 
(prescribing) 
No significant effect on the prevalence of 
prescribing problems (primary outcome) 
except for reduced therapeutic duplication 
errors (secondary outcome, OR 0.55, 95% CI 
0.33,0.90). 
 
Process measure 
(prompts) 
Increase in prompts viewed (secondary 
outcome: 10.3% of total problems viewed in 
the automated group vs. 0.9%) 
 
Lo et al.,155 
2009 
Cluster RCT Non-interruptive alerts for test ordering 
relevant to prescribing behaviours 
Process measure 
(test ordering) 
No significant difference in recommended 
test ordering rates (39% of patients in the 
control group had baseline tests requested, 
41% in the intervention group) 
 
     (con’t) 
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STUDY TYPE INTERVENTION DOMAIN SUMMARY RESULTS NOTES 
Sundaram 
et al.,156 
2009 
RCT Clinician-level randomisation to education 
plus one of two electronic reminder types, 
with controls receiving education only.  
Process measure 
(screening) 
No significant difference in the primary 
outcome of HIV screening in primary care: 
control group testing increased from 1% to 
1.4% and the intervention group 1.8% to 
1.9%.  
Relevant secondary outcomes included 
guideline-concordance of testing and 
reminder adherence. Reminder adherence 
was stated to be significantly better in the 
intervention group (11% vs. 5%, p<0.01) but it 
was not apparent that this adjusted for 
baseline achievement 
 
Walker et 
al.,157 2010 
Cluster RCT Control practices received education only; 
intervention received this plus a simple 
pop-up reminder in all 16 to 24 years old 
women in Australia, embedded in the EHR.  
Process measure 
(screening) 
Improvements in chlamydia testing were seen 
in the intervention group more than the 
control (OR 1.3, 95% CI 1.1,1.4) 
 
Holt et 
al.,158 2012 
Systematic 
review 
A review of the effects of patient-specific 
reminders available in consultations. 42 
papers (44 comparisons) included with high 
heterogeneity. Computer-generated paper-
based reminders were included. 
Composite of 
process-of-care 
measures and 
clinical outcomes 
Summary odds ratio (OR) of 1.79 (95% C 
1.56,2.05) favouring reminders was derived 
from a composite meta-analysis of 44 
comparisons (process-of-care measures and 
clinical outcomes, including screening and 
vaccination rates, diagnostic tests, blood 
pressure control, rate of VTE, measures of 
prescribing quality). 
There was high heterogeneity 
(χ2=1530.40, I2=97%) and specific 
features of computer generated 
reminder tools that determine the 
effectiveness were regarded as 
unclear.  
     (con’t) 
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STUDY TYPE INTERVENTION DOMAIN SUMMARY RESULTS NOTES 
Robbins et 
al.,159 2012 
RCT Clinical decision support system for HIV 
management in the USA. Healthcare 
providers received interactive alerts (which 
facilitated care) for half their patients and 
static alerts for the other half. 
Clinical 
intermediate 
outcome 
(continuous 
measure) 
The primary outcome of CD4 count increases 
was statistically significantly better in the 
intervention arm (mean difference 2.0 
cells/mm3/month, 95% CI 0.1,4.0). 
 
Process measure  Secondary outcomes of rate of 6-month 
suboptimal follow up 20.6 versus 30.1 events 
per 100 patient-years (p=0.022) and, after a 
suboptimal follow-up or toxicity alert, time to 
next appointment (1.71 versus 3.48 months; 
p<0.001) were better in the intervention 
group. 
 
Were et 
al.,160 2013 
RCT Reminders for overdue clinical tasks were 
integrated into a hospital electronic health 
record in Kenya. Applied to paediatric HIV 
care over 6 clinic visits.  
 
Composite process 
measures 
Primary outcome of interest was the number 
of visits (inclusive) before a recommended 
action had been fulfilled and documented. In 
the intervention group, mean time to 
completion was 77 days (SE 2.4 days), 
compared to 104 days (SE 1.2 days) for the 
control group (P<0.001 
Results varied by type of care 
recommended by the reminder, 
with reported statistical significance 
for test requests (HIV ELISA test, 
chest X-ray, and some other tests 
including blood chemistry and 
blood counts) and for referral due 
to malnutrition 
Higher rates for commencing 
antiretroviral therapy in the 
intervention group did not achieve 
statistical significance. 
There was a fourfold increase in the 
completion of overdue clinical tasks in 
intervention arm (68% intervention vs 18% 
control, P<0.001). 
     (con’t) 
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STUDY TYPE INTERVENTION DOMAIN SUMMARY RESULTS NOTES 
Kortteisto 
et al.,161 
2014 
Patient-
level RCT 
Primary care RCT of 154 reminder rules in 
the electronic health record in Finland. 
Intervention patient records received a 
system for patient-specific reminders to be 
displayed on opening and closing the 
patient record; control records were 
treated according to normal practice – 
reminders were not displayed but stored in 
a log file to facilitate comparison with 
intervention records.  
Composite process 
measures 
(screening, test 
ordering, 
prescribing) 
The primary outcome (reminder incidence 
rate ratio, a composite of change in numbers 
of reminders in groups over 12 months) 
showed no significant difference between 
groups. [incidence rate ratio 1.002 (95% CI 
0.995 – 1.009)] 
In a subgroup analysis, for patients followed 
up for only 6 months, the number of 
reminders increased less in the intervention 
group once confounding factors were 
adjusted for [incidence rate ratio 0.989 (95% 
CI 0.978 – 0.9997)].  
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 Discussion 
Since publication of the Shojania review,152 Cheung et al.162 (2012) published an overview of 
systematic reviews of the effects of computer reminders. None of the reviews included in the 
Cheung overview had a literature search date later than the Shojania review, however. The authors 
concluded that reminders can have modest beneficial effects on clinical behaviour but that the 
quality of the review literature on the subject was generally poor.162  
The studies identified in Table 3-1 suggested that the effects of reminder systems on various 
process and outcome measures were diverse and not consistently statistically significant. Due to 
the identified statistical (and methodological) heterogeneity of studies, and the use of composite 
and secondary outcome measures, it was difficult to draw robust conclusions about the feasibility 
and impact of reminder systems on clinical practice.  
Although there is a growing body of literature regarding template and reminder systems, such 
systems have been very heterogeneous in their approaches. Some reported systems were more 
akin to computerised decision support systems, which have not been discussed here. Some were 
less complex but nevertheless more than simple reminders. A few were just isolated pop-ups, 
prompting the clinician to act on one specific point. 
No evidence was found to indicate how long the benefits of reminders identified in the literature 
persisted for, though follow-up in some of the studies included in the Cochrane review was 18 
months or more. It was, however, notable that in the study by Kortteisto et al.,161 the primary 
outcome at 12 months was not statistically significant whereas the secondary outcome at six 
months follow-up was significant, suggesting that there may be a waning of the initial impact of 
reminders in practice.  
It was not possible to draw firm conclusions from the literature about which aspects of templates 
and reminder systems have the greatest effect, except that the Cochrane review and other studies 
agree that computerised systems are better than paper-based, and that systems requiring an active 
response seem more effective than those which do not, though the latter was confounded by 
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healthcare provider type. Some aspects of recording, process measures, and prescribing, were seen 
to improve by modest amounts.  
 Implications 
Given the heterogeneity of the reminder interventions, and variable but generally small to modest 
effects on clinical behaviour, there was no clear model identified to be followed in the development 
of the MOSAICS template. The two features identified in the Shojania review as having greater 
effect sizes (computerisation and active responses) were noted and included in the development 
model for the MOSAICS template.  
It was not clear from the literature how well the template might be expected to function in 
encouraging data capture, as the Cochrane review showed no statistically significant effect on 
recording (when using the median of study outcomes), nor was there any definitive evidence about 
the duration of benefit of the template or any effect of time in reducing template or reminder use. 
Although any effects of reminder systems on clinical practice seemed to be small-to-moderate only, 
it was clear that the MOSAICS study would have to assess the effect of the template itself on quality 
of care and that it could not be regarded as an entirely neutral intervention. This is addressed in 
Chapter Seven. It was not considered feasible to avoid a consultation recording template altogether 
due to the need to capture data from the medical records for all consulters to reduce the risk of 
recruitment bias in the cluster trial.163 
3.4 Template development study 
 Introduction 
The RIPCHS has a considerable collective experience in the design and use of templates, arising 
from the clinical experience of the primary care clinicians who work in the RIPCHS (including the 
candidate), and from experience in template use in clinical trials, predominantly for trial 
recruitment purposes.  
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Given the absence of a template model that could be derived from empirical evidence, the RIPCHS 
experience was used as a basis for the template development methodology.  
For MOSAICS, a recording template was planned to record aspects of care not well-captured by the 
routine medical record and thus to facilitate recording patterns in three periods (i) prior to the 
study, (ii) during the template-only phase of the study (prior to randomisation), and (iii) during the 
MOAC cluster trial phase.  
The potential clinical opportunity cost associated with coding items in the EHR was weighted heavily 
in considerations about the template length. It has been estimated149 that it can take 30-40 seconds 
per item coded in the EHR and, although this might be an over-estimate for a structured template 
such as the one proposed, it would nonetheless represent an unacceptable intrusion into a 
standard general practice consultation were this to be accurate.  
The aim of this developmental study was to design a consultation recording template for the 
MOSAICS study that would facilitate capture of information within consultations for OA whilst 
retaining acceptable simplicity and brevity so that clinicians would continue to use it for at least the 
duration of the study.  
 Method 
Initially, it was necessary to identify which quality indicators could be assessed through data 
captured routinely by the general practice EHR and which would need to be included in the 
consultation recording template. No previous defined set of Read codes to determine achievement 
of OA assessment quality indicators was identified. Therefore, the candidate used the Read 
browser148 to determine the codes that mapped to the quality indicators (see Appendix E.1). A 
search through relevant sections (assessment, processes of care) of the Read hierarchy and of key 
text words, supplemented by clinical knowledge, was used to identify codes associated with the 
process-of-care concepts. All codes were searched for through use of keywords or word stems (such 
as, for the pain and function domains, “pain”, “function”, “ability”, “gait”, “mobility”, “aid”) and 
inspection of the Read hierarchy for relevant terms. These were investigated in the CiPCA 
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database22 for the year 2008 to determine which codes had actually been used in general practice. 
These were compared with evidence from prior assessments of the quality of OA care in general 
practice68-70 to judge the apparent completeness of recording of quality measures through Read 
codes. This judgment was used to determine which aspects of the quality indicators could be 
measured by use of Read-coded data without further intervention. From this, a list of aspects of 
care that were not routinely captured was created. A sample template was developed which was 
taken through an iterative process of development within the MOSAICS team and other experts-
by-experience within the RIPCHS until the MOSAICS team (predominantly, the candidate and his 
supervisory team, the Chief Investigator, the MOAC intervention lead GP, and the Comprehensive 
Research Network (CRN) health informatics staff) considered the template to represent the best 
balance between information inclusiveness, technical feasibility, and clinical acceptability. The way 
in which the EMIS clinical system presented a template, with a 10-item limit per page, was relevant 
to the acceptability discussions: the experience of others has been that clinicians dislike using 
guidelines that do not fit on a single screen.164 
Once the domains to be included in the template had been agreed, a set of potential response 
options was agreed following an iterative process of development, discussion, and refinement 
through the MOSAICS team, including assessment of potential responses through pre-existing Read 
codes. To maintain homogeneity of responses within the trial, it was agreed within the MOSAICS 
team that the template responses should be determined from a short pick-list of options, except 
where a continuous response was required (weight measurement). The homogeneity was 
considered necessary to allow rule-based dichotomisation into achievement or non-achievement 
of the quality indicators. This approach maintained the need for the clinician to provide an active 
response to the template, consistent with the conclusions of the Cochrane Review152 that point-of-
care reminder templates had the greatest effect where an active response was required.  
The resulting template was tested using an alternative clinical system (INPS Vision) in the 
candidate’s own practice and in the (EMIS-using) practice of the lead GP for the MOAC intervention. 
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Although the system in the candidate’s practice had some interface differences, key elements 
(triggering and feasibility of completion) could still be assessed.  
Once agreed, the CRN health informatics staff created the template within the EMIS clinical system, 
which was the system used by all trial practices (as a prerequisite for MOSAICS study participation). 
This used the flexibility of the EMIS system to create bespoke Read codes for use within the study 
practices, meaning that all template responses could be tagged with a retrievable code.  
 Results 
Prior routine code use 
The total registered population of CiPCA-contributing practices was 104,965. Table 3-2 shows the 
number of patients in whom information relevant to the template domains was recorded. Very low 
frequencies of recording of information in all domains were identified. It is not known what 
proportion of patients actually have these care processes performed (rather than recorded) in a 
year and therefore it is not clear how well the records reflect the care delivered. Referral 
information was considered likely to have been available in MOSAICS (not captured by the CiPCA 
database). For the purposes of the MOSAICS study, the levels of recording of information about 
quality of care other than referrals seen here were considered inadequate to allow comparison of 
quality indicator achievement between trial arms. The template development therefore continued 
with decisions about which domains to include.  
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Table 3-2: Frequency of Read codes relevant to selected OA process-of-care measures 
Domain 
OA patients in whom relevant 
consultation Read code recorded n (%) 
Pain assessment 7 (0.2) 
Functional assessment 16 (0.3) 
Information provision/education 1 (<0.1) 
Weighta 14 (0.4) 
Weight loss advice or referral 1 (<0.1) 
Exercise grading 1 (<0.1) 
Exercise advice/referralb 2 (<0.1) 
Physiotherapy referralb 3 (0.1) 
Occupational therapy referralb 0 (0) 
Specialist assessmentb 0 (0) 
athis was likely substantially to underrepresent the total frequency of weight measurement due to the 
way CiPCA data is extracted from the clinical system; bthese domains examined only Read-coded 
referrals in consultations: a separate CiPCA-like referrals archive was not interrogated and so the 
referrals estimate here is considered likely to be a substantial under-estimate. 
The quality domains considered necessary for inclusion in the MOSAICS study are shown in 
Table 3-3. These addressed the most essential holistic assessment and core management for OA as 
recommended in the NICE guidelines (2008) as well as the recommended first-line pharmacological 
management strategies. The planned data source is shown (following review of the CiPCA analysis 
shown in Table 3-2).  
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Table 3-3: Quality indicator domains for template-derived recorded management of OA 
Quality indicator Indicator origin Assessment data source(s) 
Assessment of pain Systematic review Template 
Assessment of function Systematic review Template 
Weight/BMI record 
[Prerequisite for weight loss 
advice indicator] 
Routinely recorded or 
template 
Assessment or advice about 
paracetamol use Systematic review Template 
Prescription for paracetamol Systematic review 
Routinely recorded 
prescriptions 
Assessment or advice about 
topical NSAID use NICE guidance Template 
Prescription for topical 
NSAIDs NICE guidance 
Routinely recorded 
prescriptions 
Evidence of education or 
advice for OA Systematic review Template 
Weight loss advice for people 
with peripheral joint clinical 
OA and a BMI ≥25kgm-2  Systematic review Template 
Consideration of 
physiotherapy referral Systematic review Template 
Exercise or physiotherapy 
referral Systematic review Routinely recorded codes 
Assessment or referral for 
assistive devices (ambulatory 
or non-ambulatory) – 
intended for people with 
functional impairment Systematic review 
Routinely recorded codes or 
template 
Co-prescription of 
gastroprotection (for people 
prescribed oral NSAIDs) Systematic review Routinely recorded codes 
Completion of all template 
indicators above for people 
receiving specialist referral Systematic review Template 
Template domains 
An initial draft template (Appendix E.2), based on the quality indicators identified from Chapter 
Two included all the proposed indicators from the systematic review with the exception of the 
prescribing indicators, which were considered possible to derive from the prescriptions records. 
This draft was put forward for discussion amongst the wider trial team and health informatics 
specialists.  
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A pragmatic decision to limit the template to a single page was taken, after discussion between the 
candidate, his primary supervisor, and the CRN informatics staff, due to concern that a template 
which extended beyond one page would be less clinically acceptable, especially to the GP staff. The 
template needed to capture the core aspects of management listed in the NICE OA guidelines.5 
These were considered to represent selected aspects of holistic assessment (pain, function), and 
the core interventions of advice and education, exercise, and weight loss where relevant.  
In addition to the indicators from the systematic review, an indicator regarding the use of topical 
NSAIDs as a relatively safe pharmacological option was included to be consistent with the NICE 
guidelines for initial analgesic use. The final template recording domains selected were: 
1. Pain assessment 
2. Function assessment 
3. Weight 
4. [System automatic calculation of body mass index, using last height record carried forward] 
5. Record of prior use of or recommendation for paracetamol use 
6. Record of prior use of or recommendation for topical NSAID use 
7. Information provision 
8. Advice regarding weight [for people who are overweight: BMI ≥25 kgm-2] 
9. Advice regarding exercise 
10. Advice regarding physiotherapy referral 
The order in which the domains appeared was agreed between the candidate and the academic GP 
leading the model OA consultation (MOAC) intervention for the MOSAICS study.1 The order above 
was considered to be the best fit with the MOAC structure.  
The restriction to 10 items inevitably meant that some aspects of care, which might have been 
desirable to collect in order to understand the primary care of OA better, were not included in the 
final design. Those not considered to be priorities for individual inclusion in the template were: 
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 Assessment of mobility 
 Assessment of current exercise activity 
 Risk assessment (oral NSAIDs) 
 MED3 incapacity for work or fit note certification 
 Over-the-counter drug use 
 Specific contra-indications to drug therapies (paracetamol, NSAIDs in particular) 
 Referral to dietician** 
 Referral to weight management programme** 
 Referral to exercise programme** (other than physiotherapy) 
 Referral to occupational therapy** 
 Referral to podiatry** 
 Referral to orthotist** 
 Referral to secondary care** (rheumatology, orthopædics, pain clinic) 
Template response options 
A clinician could complete all, some or none of the domains either during or after a consultation. It 
was possible to press ‘escape’ to bypass the template. It was also possible to move between fields 
without entering data and file an incomplete template response to the medical record, in line with 
its use as a recording aid rather than a minimum data set. In all cases, a bespoke code was designed 
to be written to the record indicating that the template had successfully been triggered, whether 
or not template data had been entered by the clinician.  
A quality indicator needed to be achieved only once in a time period rather than each time the 
template was triggered, along similar lines to the responses to templates used in the QOF. 
 
**Actual referrals (rather than consideration) could be measured through the referrals data 
collection rather than the template  
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i. Pain and function 
The potential for use of a numerical rating scale (NRS) for pain and function assessment was 
considered and discussed. However, since the use of such a scale in primary care has known 
deficiencies,165,166 and the template could be completed after a consultation rather than strictly 
contemporaneously, it was considered that the use of a NRS may give a spurious sense of accuracy 
regarding pain assessment. Whilst this would not have had a significant impact upon the research 
project (since the medical record was not being used to track patients’ pain over time), it may have 
leant an unwarranted apparent validity to the information in the medical record. This decision is 
consistent with subsequent evidence that there is only moderate agreement between the EHR 
information about pain and that actually reported by patients in a survey.167 
Therefore pain and function was recorded using a simple ordinal scale: 
 Pain: None, mild, moderate, or severe 
 Function impact: Not limited, mild limitation, moderate limitation, severe limitation 
Any of these responses were considered to meet the quality indicators for assessment of pain and 
function. If the responses were not considered appropriate, or the pain or function status was 
unknown, the whole domain(s) could be skipped with no data entry, in which case the quality 
indicator would not have been met on that occasion.  
ii. Weight and BMI 
A weight record needed to be added to the template for an updated BMI calculation to be made. If 
no weight record was made, the last weight and BMI record in the system would be displayed in 
the template. For brevity, it was assumed that a height record would be present already and that it 
would not have changed. 
iii. Paracetamol and topical NSAID use 
As this template was intended for use in both prevalent and incident cases of osteoarthritis, the 
responses to the assessment of paracetamol and topical NSAIDs needed to account for the fact that 
patients may have previously tried these agents, or that their pain may have become too severe for 
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it to be considered clinically sensible to revert to plain paracetamol or topical NSAIDs. It also needed 
to capture patients’ independent use of such drugs, for example on an over-the-counter basis. Thus, 
this domain was distinct from the indicator assessment through analysis of electronic prescription 
records. For each of these two pharmacological domains, the following possible responses were 
included: 
1. Tried full dose [i.e. at some point the patient has tried a clinically appropriate maximum 
dose of the agent] 
2. Advised full dose [i.e. the clinician recommends this, either to be obtained over the counter 
or supplied through prescription] 
3. Declined full dose [i.e. the patient declines to try the recommended treatment] 
4. Not appropriate [i.e. it was not considered clinically appropriate, for example due to the 
ongoing use of much more potent agents, or comorbidities causing concern about the 
appropriateness of such drugs] 
5. Unknown [i.e. the clinician entering the information does not know about paracetamol use 
– for example, when the consultation was over and the patient has left] 
The first four of these were considered to demonstrate achievement of the quality indicator.  
iv. OA information given 
This intention of this domain was to capture the use of the OA guidebook, an integral part of the 
MOAC. However, since the template needed to be identical for the intervention and control arms 
of the MOSAICS study, a generic OA information domain was created. Since GPs give information 
to patients in different ways, both verbal and written methods were considered possible, though 
for the sake of simplicity, it was assumed that written information would only be given in 
conjunction with some verbal information: 
1. Verbal + written 
2. Verbal only 
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3. Not this time [i.e. the information may have been given before, or was planned for a 
subsequent consultation] 
4. Not appropriate [e.g. the patient was unable to comprehend the information] 
All except ‘not this time’ were considered to demonstrate achievement of the quality indicator.  
v. Weight loss advice 
This was only relevant for people defined as overweight, i.e. with a BMI ≥25kgm-2 – and for such 
patients, it was considered that a similar approach, and responses, to the provision of OA 
information should be taken (see above).  
vi. Exercise advice 
This presumes that some assessment has been made of a patient’s prior exercise habits, although 
the template does not capture this. There was considerable similarity to the other advice domains: 
1. Verbal + written 
2. Verbal only 
3. Not necessary [i.e. the patient was already considered to be exercising adequately] 
4. Not this time [i.e. the information may have been given before, or was planned for a 
subsequent consultation] 
5. Not appropriate [e.g. the patient was unable to exercise] 
All except ‘not this time’ were considered to demonstrate achievement of the quality indicator. 
vii. Physiotherapy referral advised 
This domain captures discussion about physiotherapy referral, and overcomes the variation in 
physiotherapy access (such as use of physiotherapy triage telephone advice lines, private 
physiotherapy, etc.). The possible responses were: 
1. Offered referral 
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2. Not necessary [e.g. for patients already exercising adequately or using other sources of 
information such as the Arthritis Research UK information leaflets168 as a basis for 
structured exercise] 
3. Not this time [i.e. the referral may have been made before, or was planned for a 
subsequent consultation] 
4. Not appropriate [e.g. the patient was unable to exercise] 
All except ‘not this time’ were considered to demonstrate achievement of the quality indicator. 
The final agreed template (version 3) is shown with screen captures in Appendix E.3. 
Preliminary testing in the candidate’s practice 
The template was tested over 46 patients in four months. It was considered straightforward to 
complete, taking approximately an additional two minutes to populate all the domains. This caused 
difficulties if OA was not the primary reason for consultation and so the frequency of completion 
of the template was not as great as desired. No formal feedback was received from the other (EMIS) 
practice in which the template had been installed for preliminary testing purposes but ad hoc 
feedback suggested that the template was considered feasible. In light of the candidate’s 
experience of the template, in conjunction with ad hoc feedback from the other (EMIS) practice in 
which the draft template was tested, it was determined that no further changes to the template 
were required.  
 Discussion 
The evidence for template development applicable to primary care was not sufficiently strong to 
be able robustly to state clear principles by which a template should be developed and 
implemented, other than for the use of computer-generated reminders (computerisation being 
regarded as a ‘given’ in a paper-light NHS101) and for reminders to require an active response from 
the clinician. This left considerable scope for opinion-based development of the template, based 
upon the clinical experience of the GPs contributing to the template development and the 
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considerable experience the RIPCHS held collectively in developing templates for use in research 
studies. 
The main purpose of the template was to assist in the capture of information relevant to the core 
aspects of management identified in the 2008 NICE guidance: assessment, education, exercise, and 
weight loss advice where relevant. Inclusion of a template item to record consideration of 
physiotherapy referral was also identified as necessary to estimate use of ‘prescribed’ exercise. 
Recorded actual referral may not adequately capture clinical conversations about physiotherapy, 
and use of self-referral schemes such as Physio Direct169 potentially limited the completeness of the 
primary care record of use of physiotherapy services.  
There was inevitably some tension between the desire to include as much information as possible 
in the template and to maximise the possibility of clinicians completing it in consultations. The exact 
length of the template was the subject of much debate, and even once the one-screen size had 
been agreed, further discussion about the relative priority of different domains was required. A 
range of the aspects of holistic assessment referred to in the 2008 NICE OA guidelines5 were also 
excluded for the sake of brevity. Although the core management strategies were captured by the 
template or routine medical record, there are some of the wider aspects of management not 
captured, such as use of assistive devices, thermotherapy, shock-absorbing footwear, supports and 
braces and transcutaneous electrical nerve stimulation (TENS). Identification of onward referral 
(except for physiotherapy) was not included in the template and was therefore dependent upon 
the standard recording methodology in the primary care record. This may not identify all referrals 
made due to different referral methodologies including the use of electronic referral services such 
as ‘Choose and Book,’ as well as different recording strategies between practices, and was not able 
to capture discussion without actual referral.  
Assessment of pain and function was infrequently recorded in the routine records. The approach 
to assessment and recording adopted in the template was selected for ease and brevity, and due 
to the fact that it was the assessment of the pain and function itself which was required to pass the 
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quality indicator for each of these domains rather than valid and reliable longitudinal measures of 
pain and function. A feasible method of recording such an assessment of pain and function in 
musculoskeletal conditions would be a desirable change to introduce to primary care, though it was 
not considered to be within the scope of this project. The validity of some of the other template 
items could also be questioned, especially if clinicians completed the template at the end of a 
consultation rather than face-to-face with the patient during the consultation, as this approach 
risked information or recording bias. However, clinicians were not under any obligation to complete 
all domains of the template, and ‘Unknown’ was a possible response option (although it would not 
have achieved the quality indicator).  
It was not possible from the template data to identify the quality of verbal or written advice. There 
was a risk that response could be ticked without any meaningful engagement with patients. This 
problem was not unique to this template, as the same charge may be levelled at various information 
and advice or support indicators in the QOF.  
It was not planned that all of the template had to be completed at every relevant consultation and, 
just as with aspects of chronic disease reviews relevant to the QOF170 such as diabetes or asthma, 
elements could be completed at different consultation points within a period by any appropriate 
clinician (usually taken to be a GP or practice nurse).  
The template response options were constrained to give a pick list from which the pass and fail 
criteria for the quality indicators could straightforwardly be defined. Inevitably, some of the 
nuances from a well-completed full-text response will have been lost through this approach but it 
was considered that the benefits of easily-retrieved and standardised information outweighed this 
loss. Although some increased granularity of response options (as noted by Hersh et al.171) might 
be desirable, there was a risk that this would impact on template completion through increased 
complexity, though no empirical evidence was available to guide this. The choices made were 
considered to be pragmatic in light of previous RIPCHS experience of template use. 
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The criteria for passing or failing the indicator might also be considered debatable. The responses 
chosen were considered to reflect the most common clinical responses that might be given and so 
were all included as options rather than increase the risk of the template being left blank for some 
domains.  
Chapter Five examines the routinely-recorded care for OA in the MOSAICS practices, which did not 
have the formal training in recording provided to CiPCA practices, and so might be more 
representative of typical general practice. Chapter Six examines the use of the template in 
measuring quality of care in MOSAICS.  
 Implications 
Not all domains that would ideally have been captured by the template were included. However, it 
was not considered likely that the routine record would have differential recording patterns 
between intervention and control arms of the MOSAICS study, so resultant information bias was 
not considered likely.  
Quality indicator success was defined by predetermined response options, which may not always 
have suited a clinician’s consultation style – for example, a clinician might have felt that there 
should have been more flexibility in the responses and so not completed the template for some or 
all domains, or alternatively if the template were to be completed at the end of a consultation after 
a patient had left, some relevant information may not have been obtained. It seems likely that the 
template would generally act as a positive aid to recording, however, especially given the very low 
levels of coded information about many of the indicator domains identified in the routine record. 
3.5 Triggers for the template and a Read code definition of ‘clinical OA’ 
 Background 
Reminders that present themselves actively to clinicians appear to be more effective than those 
which are passive and have to be initiated by the clinician.162 Therefore, in order to maximise the 
possibility that a clinician would use the template to record a consultation with a patient regarding 
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OA, a list of candidate codes for OA was derived and subsequently used to trigger the template 
actively in a consultation. These codes were considered to be those a GP might use for OA, whether 
or not a formal diagnosis had been made. Symptom-based codes were included as candidates for 
OA, since it is known that OA is the most common cause of joint pain in the MOSAICS study target 
age group of 45 years and over.172,,173 
The Read code (version 2) system is a hierarchical list of 5-byte alphanumeric codes.146 Disease 
codes for OA are mainly listed under Chapter N.... Musculoskeletal and connective tissue diseases, 
though not exclusively under N05.. Osteoarthritis and allied disorders, with additional codes 
describing osteoarthritis symptoms being grouped in this musculoskeletal disease chapter. There 
were also symptom-based codes, which have potential relevance to OA, in Chapter 1.... History / 
symptoms and Chapter R.... [D] Symptoms, signs and ill-defined conditions. 
The aim of this developmental study was to identify a set of Read codes to define a working 
diagnosis for OA (hence “clinical OA”) to trigger the template in consultations, and to act as the 
MOSAICS study definition of clinical OA for the purposes of comparing intervention and control 
arms on recorded quality of care.  
 Methods 
A list of potential codes to trigger the template was created, drawn from the NHS Read code 
browser by the candidate.148 These codes were selected on the basis of relevance to the MOSAICS 
study (excluding codes relating to spinal OA and to shoulder and elbow joint pain). All codes 
specifically referring to non-spinal OA were included. Other symptom-based codes, whether or not 
they fall into a Read symptom or examination code (Read chapters 1 and 2) or disease classification 
(Read chapters A-Z) within the hierarchy, were included if they related to peripheral joint pain that 
might have implied clinical OA.  
Once a shortlist of codes had been created, a panel of six academic GPs in the RIPCHS (including 
the candidate), all with an interest in musculoskeletal research, were independently asked to 
decide whether or not the selected codes should be included in the list of candidate codes for OA. 
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This was done by sending a list of codes in a Microsoft® Excel® spreadsheet and asking the GPs to 
determine if the codes represented possible clinical OA (“The task: - to agree a list of Read 
codes/terms that will be used in the MOSAIC studies to define OA. All entrants will be aged 45 and 
over, so there is no need to be concerned about adolescent anterior knee pain, for example. Chapters 
1, 2, N and R contain codes of possible relevance. Not all child codes are listed (only where 
considered especially relevant) and some site specific codes will not be appropriate to the study. The 
full list of child codes can be seen via hyperlink from the child codes column if needed…”). Each 
respondent was blind to the others’ responses at the time of completion. Codes were to be included 
if there was a simple majority in favour. In case of a tie between recommendations to include and 
exclude, the code was retained. For consistency, some of the free text responses were adapted 
from the original (“Yes?” became ‘unsure’, “Why not…?” became ‘include’). 
Read coded consultation data were extracted from the CiPCA database22 for the year 2007 to 
determine whether or not the Read codes from the GP assessment had actually been used in clinical 
practice. Codes other than N05.. Osteoarthritis and allied disorders and its child codes were 
discarded from the trigger code list if they had not been recorded in CiPCA to simplify the technical 
aspects of template installation in the practices.  
In order to assess the specificity of the remaining non-N05.. codes to be potentially included in the 
definition of clinical OA, a random sample of 850 consultations (10% of the clinical OA 
consultations) held in the CiPCA database (in patients aged 45 years and over) was inspected to 
determine whether the consultation text provided any evidence that the clinical diagnosis was likely 
to be OA or not. This was necessarily rather subjective, as it depended on a post-hoc analysis of 
another clinician’s contemporaneous notes. Evidence that the consulting clinician considered the 
diagnosis to be OA (through use of terms like ‘OA’, ‘crepitus’, ‘degenerative’, ‘wear and tear’, or 
reference to X-ray evidence) or likely not to be OA (e.g. evidence of substantial early morning 
stiffness, other inflammatory symptoms or signs, neurological symptoms) was used to allocate the 
consultation to OA or not OA. The outcomes were discussed between the candidate, the MOSAICS 
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team, and the CRN health informatics team. Codes considered to have a low specificity for clinical 
OA were removed.  
Figure 3-2: Summary of template trigger code list determination  
 
 Results 
Trigger code list selection and GP panel assessment 
There were 348 Read codes in total that were assessed for inclusion, 23 higher-level codes and 325 
codes that were children of the other codes. These were screened initially by the candidate alone. 
Formal OA diagnoses (N05.. and child codes) represented 99 of these 348. Of the remainder, 41 
codes (the other 22 originally identified higher-level codes plus 19 of the most relevant child codes) 
were considered by the candidate sufficiently relevant for the other clinicians to consider 
individually; other child codes were considered in conjunction with their parent code. There were 
three identified ‘local codes’ created by practices within CiPCA 2007 that were also included in the 
template trigger code list. As these were determined by practices, their use is not generalisable, 
however.  
The list of candidate codes derived from the Read code browser is shown in Appendix E.4, page 
381. Also shown in the same appendix are the responses from the six RIPCHS GPs regarding 
proposed inclusion.  
Of the 42 codes or clusters of codes (i.e. a code with all child codes included) in the shortlist, the 
agreement about inclusion or exclusion is shown in Table 3-4 (any positive statement about 
inclusion as an acceptance of inclusion, and any other statement as a rejection of inclusion): 
Draft list of trigger codes derived by the candidate
Codes considered by a panel of 6 GPs
Code usage assessed in CiPCA 2007 database
Associated narrative assessed for codes remaining after the GP assesssment
Outcome discussed by MOSAICS team and final code list agreed
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Table 3-4: Inter-rater agreement on candidate code inclusion 
Inclusion Exclusion 
100% agreement to include 
3 codes/code 
clusters 
100% agreement to 
exclude 
5 codes/code 
clusters 
83% agreement to include  
(5 of 6 raters) 
3 codes/code 
clusters 
83% agreement to 
exclude 
(5 of 6 raters) 
9 codes/code 
clusters 
67% agreement to include 
(4 of 6 raters) 
5 codes/code 
clusters 
67% agreement to 
exclude 
(4 of 6 raters) 
11 codes/code 
clusters 
No overall agreement    
(3 raters for and 3 against) 
[codes retained] 
6 codes/code 
clusters 
  
Where there was no overall agreement, codes were retained, which was consistent with the 
recommendations of the two GPs most closely involved with the MOSAICS study 
Testing in CiPCA 2007 
The codes resulting from the GP assessment exercise were tested in CiPCA 2007. All N05.. codes 
were defined as required for inclusion but of the remaining codes, those not recorded in 2007 were 
removed from the list of trigger terms. Of the codes from the GP consensus (Appendix E.4), those 
removed at this stage were 1M12. Anterior knee pain and 2G26. O/E - hands - Heberden's nodes. 
The presence or absence of the codes in CiPCA is shown in Appendix E.5, page 383. 
Specificity assessment for non-N05.. draft clinical OA codes 
A random sample of 850 consultations in the CiPCA database drawn from 8445 (10%) Read-coded 
consultations using codes identified in Appendix E.5 were used to determine if the consultation was 
likely to reflect clinical OA or not. The process identified only a small proportion of consultations 
(104/850, 12.2%) were regarded as representing “true OA” by the candidate; 56/850 (6.6%) were 
considered not to be OA, and the great majority (81.2%) could not be allocated with any useful 
degree of certainty. This was found to be due to (i) constraints on the length of the consultation 
text extracted (EMIS LV allowed only limited narrative text associated with a problem title to be 
downloaded), (ii) the use in some cases of Read codes that were wholly unrelated to the free text, 
and (iii) the use of a Read code linked to prescription or administrative data with no additional 
clinical information. In some cases, it was unclear what the underlying working diagnosis was as the 
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narrative text appeared complete but was too vague to determine the diagnosis. A systematic 
assessment of diagnostic information in the MOSAICS practices, considered better to represent 
usual coding practice, is described in Chapter Four. 
The codes that had not been removed in the GP assessment or CiPCA 2007 inclusion assessment 
exercises were presented to the MOSAICS team by the candidate and a final determination was 
made on the basis of the study needs and feasibility for linkage of the template to the trigger codes. 
All N05.. Osteoarthritis and allied disorders codes were retained. The list of joint pain codes taken 
forward as template triggers is shown in Appendix E.6, page 386: those codes retained were 
considered to represent an acceptable balance of feasibility and inclusiveness and were recorded 
as having been used in the CiPCA database. 
 Discussion 
The risk of selection bias174 was reduced through the use of a reasonably wide definition of clinical 
OA. Clinicians had the option to avoid the template by simply pressing the ‘Escape’ key but it was 
harder to avoid the template triggering by avoiding coding OA or joint pain altogether. It was 
expected that this would reduce any potential for selective inclusion (bias) of OA patients in the 
population-level analysis, as might have happened if only N05.. codes were used to define OA. The 
internal validity of the trial was therefore considered to be strengthened by this approach.  
However, given the inclusion of terms not specific to OA, one would expect there to be some 
problems with misclassification, as patients with non-OA joint pain would under this approach be 
classed as having clinical OA. Depending on the extent of variation in nature of the coding of OA 
and joint pain within practices and between intervention and control arms, this could mean that 
the population with actual clinical OA may not be comparable between arms. One potential 
consequence would be that the proportion recorded as achieving the quality indicators may be 
different between arms due to the misclassified additional cases. Depending on the exact levels of 
baseline misclassification and any changes in coding behaviours throughout the trial, this could give 
rise to misclassification bias.174 Overall, however, since all patients with peripheral joint pain or OA 
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were designated as ‘clinical OA,’ misclassification was considered to be a bigger concern for external 
validity of the study rather than an issue of bias. As noted in 3.7 below, the feedback from the 
template implementation showed variable use of, and attitudes toward, the template and so the 
risk and possible effect of bias from misclassification was hard to assess. In terms of the external 
study validity (generalisability of the findings), some caution would have to be exercised in applying 
the findings to populations of people with disease thus defined, as it may not all be OA.  
Coding of OA and joint pain in the baseline phase of MOSAICS, before the template installation, is 
described in Chapter Four, with an assessment of the degree of diagnostic misclassification.  
3.6 Assessment of population OA disease burden 
 Background 
The aim of this developmental study was to identify the effect of inclusion of peripheral joint pain 
codes in people aged 45 years and over on the consultation prevalence of OA. This was also to be 
used as a guide for recruitment planning for the MOSAICS study. 
 Methods 
The codes identified in section 3.5.3 were used to define clinical OA. The data recorded in CiPCA 
were used to identify the proportion of the registered population consulting in a 12-month period 
(2007) with one of these codes recorded in their medical record. The registered population aged 
45 years and over was used as the denominator population, in line with the NICE definition of 
osteoarthritis.5 
Patients recorded as consulting in the whole of the CiPCA database (12 practices) in 2007 were 
stratified by age and sex. The results from CiPCA were used to create a “typical” representative 
practice of 10,000 patients. Also calculated was the expected annual consultation prevalence for 
OA in this representative practice, according to the wider definition (an N05.. OA diagnosis and the 
selected joint pain codes considered to represent clinical OA, from section 3.5.3) and the more 
narrow definition (Read code N05.. Osteoarthritis and allied disorders only).  
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 Results 
The total population of people aged 45 years and over in CiPCA 2007 was 46,927. The annual crude 
consultation prevalence rate, with clinical OA defined as either a formal OA diagnosis (N05..) or the 
selected joint pain codes as described, was estimated at 9.2% in patients aged 45 years and over 
(4.1% of the total all-age population). For a formal diagnosis of OA using N05.. Osteoarthritis and 
allied disorders Read codes only, the consultation prevalence was estimated at 4.1% in patients 
aged 45 years and over, and 1.8% in the population as a whole.  
Thus, in a representative practice of 10,000 patients typical of the population contributing to CiPCA, 
one might expect to see the number of cases displayed in Table 3-5. 
Table 3-5: Expected numbers of patients consulting annually with OA, per 10,000 population 
Registered population Males Females Total      
Age <45 years 2788 2713 5501    
Age ≥45 years 2116 2312 4499    
All ages 4905 5095 10000      
Consulters with OA Clinical OA Formally diagnosed OA 
 Males Females Total Males Females Total 
45-54 35 43 78 13 21 34 
55-64 47 66 113 18 32 50 
65-74 43 64 107 17 31 48 
75-84 27 56 82 10 27 37 
85+ 7 20 27 3 10 13 
Total 159 249 408 61 121 182 
% total population 3.2 4.9 4.1 1.2 2.4 1.8 
% population 45 years and over 7.5 10.8 9.2 2.9 5.2 4.1 
 Discussion 
These prevalence estimates were similar to other estimates from research studies. For example, 
Jordan et al.21 determined OA consultation prevalence rates in people 15 years and over for 2001, 
using the N05.. Osteoarthritis and allied disorders OA definition, of 164 to 276 per 10,000 (using 
data from the GPRD, the RCGP Weekly Returns Service (RCGP-WRS), and CiPCA).  
Subsequent to this analysis, another study has identified similar annual prevalence figures to those 
found here in both the CiPCA database for the year 2010 and in a similar consultation database in 
Lund, Sweden.23 This analysis used the both a narrow (N05.. and the International Classification of 
Disease v.10 [ICD-10] equivalent) and the clinical OA definition, in people aged 45 years and over. 
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Using data from primary care, and the using the clinical OA approach (diagnosed OA plus relevant 
symptom codes), consultation prevalence rates of 1074 per 10,000 in CiPCA and 967 per 10,000 in 
the Lund database were identified. These estimates were reasonably similar to the 9.2% 
consultation prevalence suggested from the CiPCA 2007 data.  
The extensive use of symptom-based codes, especially given the relatively low prevalence of 
osteoarthritis as a formal diagnosis (N05..) compared to the prevalence of OA using the clinical OA 
definition, might imply a lack of confidence or reluctance to diagnose osteoarthritis. This contrasts 
with GP behaviour in other clinical areas, such as asthma and hypertension, where there may have 
been some cases of over-diagnosis of these conditions (albeit with other cases remaining 
unidentified),175-177 tightened up by greater stringency in diagnostic requirements in the QOF (such 
as by a requirement to diagnose asthma with evidence of abnormal serial peak flow readings), or 
in national guidance on hypertension emphasising home-based or ambulatory blood pressure 
monitoring.178 Were a core set of codes introduced for OA into primary care (as a contractual 
requirement), one might expect to see a rise in the use of these core codes, given the incentives for 
higher prevalence in the QOF. This may be seen in the same light as other chronic disease registers 
where case finding and list-cleaning efforts have taken place. It should be noted, however, that not 
all conditions included in the QOF have seen an increase in prevalence as a consequence. One study 
of temporal trends in the prevalence of depression179 concluded that UK general practice had 
removed many patients with depression from the denominator for QOF and switched instead to 
the use of symptom codes, which could also happen with OA coding. 
 Implications 
A change in GP coding patterns to encourage the most specific diagnosis possible, such as required 
by the Morbidity Statistics in General Practice (in which GPs were asked to “[identify] the problem(s) 
or diagnosis(es) which in the opinion of the general practitioner most comprehensively describes the 
morbidity for which the patient consults” Fleming 1993 p.38180) would be of potentially substantial 
benefit in identifying a population of people who have clinical OA, and who may therefore be 
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candidates for structured disease management. At study inception, it appeared that there was too 
little specificity in some joint pain diagnoses to have complete confidence in the apparent 
population burden of OA as determined from general practice N05.. Osteoarthritis and allied 
disorders Read codes.  
3.7 Template implementation study 
 Background 
Although GPs and practice teams are well-used to templates as a routine part of their work, it was 
considered necessary to undertake some training in the use of the MOSAICS template to try to 
standardise the clinical use of the template for the purposes of the trial. The template was intended 
as a recording aid rather than a quality improvement intervention. The aim of the implementation 
strategies was to try to encourage its use as a recording tool for consultations considered possible 
to represent a diagnosis of clinical OA as noted above.  
 Method 
The training was deliberately low-key, and emphasised the role of the template as an aide to 
consultation recording rather than suggesting it as a care pathway to be followed. To that end, the 
type of extensive training seen with the implementation of reminder systems (as reported in studies 
included in the Cochrane review152) was not used in this study. Clinicians were encouraged to 
diagnose and treat OA as they normally would, but to use the template to help structure their 
medical record. No link was made during the training between the template and the quality 
indicators from which the domains had been derived.  
It was recognised that the use of the template added to practice’s usual work. In order that this did 
not result in financial loss (and thereby reduce the likelihood of practice participation in the study), 
the study contract entered into between the practice and the research network included a payment 
for use of the template. Practices subsequently randomly allocated to the intervention arm of the 
trial had additional payments for the further work this entailed. The details of the financial 
arrangements were not part of the candidate’s remit, but he advised that the payment be relatively 
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modest, and to be based on expected prevalence of OA and joint pain codes that would trigger the 
template rather than on the performance of the practice in using the template (to avoid as far as 
possible the risk of testing financial incentives alongside the template).  
The template was introduced to the eight study practices in meetings with GPs and practice nurses, 
undertaken by the candidate or his clinical academic or Primary Care Research Network (PCRN) GP 
Research Facilitators (GPRF) colleagues, depending upon availability. A formal appointment was 
scheduled for this training, weeks or months in advance, arranged by the Keele study coordinator. 
The template was demonstrated using the live EMIS system and a (so-called) “dummy” patient, 
where available, and using a mock-up template on a stand-alone laptop in other cases. The single, 
approximately one hour, introductory meeting provided opportunity for the practice staff to ask 
questions. The candidate and the GPRFs emphasised the consultation recording aspect of the 
template (to de-emphasise the use of the template as a quality of care prompt) (Appendix E.7, page 
390).  
As well as the face-to-face training, the practices received electronic versions of the presentation 
slides for reference and a training DVD, both created by the candidate. The intention was that 
practices could use the DVD if required, as a refresher or to train new starters or clinicians who had 
been absent from the meeting.  
The DVD was kept relatively brief and covered the mechanics of the triggering of the template, its 
completion, and the way in which the template and its data fitted into the medical record. Screen 
capture software was used to demonstrate the ways in which the template could be completed. 
No reference was made within the training materials to the quality indicators or the study more 
broadly. The script (which represents the notes made before the DVD creation rather than a 
verbatim transcript) upon which the DVD was based is reproduced in Appendix E.8. 
After practice training, the template was installed by the informatics staff in each practice. The six-
month pre-randomisation template phase of the MOSAICS study commenced at an agreed date 
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shortly after installation. The study commenced with the eight practices at two different time 
points, with four practices commencing at each point.  
Further practice visits were undertaken by the MOSAICS study team, (the study Chief Investigator, 
the academic GPs including the candidate, and the GPRFs), three to four months after the 
introduction of the template, to remind practices to use it and provide an opportunity for feedback. 
These review meetings were once again of up to an hour’s duration and there was an opportunity 
for the practice staff to ask questions. Comments from practices were captured on a brief data 
report form, with the following list of issues explored (data shared with a separate social science 
study181,182): 
a. Do all GPs use the template (or only a proportion)? 
b. For those GPs who use the template, how do they assess its usefulness with regard 
to diagnosing OA and treatment decisions? 
c. For those GPs who do not use the template, what reasons do they give for not 
doing so? 
d. Have the GPs talked to each other about the template? If so, do they have a shared 
perception [of the template feasibility and utility]?  
As an interim method of assessment of the template, data were collected from participating 
practices after three to four months’ template use. This assessment was originally referred to as an 
audit, though it does not have the qualities needed for such status, given the absence of established 
criteria and standards. The descriptive statistical analysis of these data was undertaken by the 
candidate’s principal supervisor due to the requirements of the main study for immediate 
information. These data were presented to practices, with anonymous peer-referencing of 
achievement, at the template review meetings, similar to a light educational outreach visit.183 
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 Results 
Of the initial eight practice template training visits, the candidate attended five. For the template 
review visits, the candidate participated in five of the eight, the remainder being conducted by 
other study staff.  
Template instruction meeting feedback 
At the template instruction meetings (often held in conjunction with meetings about other aspects 
of the MOSAICS study, and all before the commencement of template use), feedback was collected 
from practices as far as possible (though without going to the extent of this being an established 
qualitative study). 
Themes emerging from this feedback were: 
1. Some practices had insightful questions about the study methodology (mainly relating to 
the effect of the template itself on recorded  disease coding and care, and on the study 
analysis needed to identify this effect) 
2. One practice in particular was very enthusiastic about the study in general and thought that 
the template itself would add value to the clinical activity 
3. The organisation of the meetings was very variable. Some practices had a dedicated 
meeting for the purpose, in others it formed a component of a wider meeting. The facilities 
available were variable (internet access, clinical computer system access, projectors) and 
the proportion of staff attending was also very different between practices.  
4. There was a general sense that the template was less applicable to the practice nurses, 
since they do not traditionally do much musculoskeletal clinical practice 
5. It was not clear how the template training would be cascaded to other clinical staff in one 
practice 
6. Some practices questioned the pain scoring system, identifying that they would have been 
happier with a numerical rating scale. Another practice questioned the need to record pain 
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and function at all, since patient-level outcomes were not to be assessed through this 
means 
7. One practice had expected the template to be much more complex, such as to offer a direct 
(within-template) referral system to physiotherapy. Another practice had hoped to link the 
MOSAICS template directly with other service-driven templates (such as on falls and 
osteoporosis) 
The overall impression of the training events was that the practices were willing to use the template 
but regarded it as something to accept for the purposes of the research rather than as something 
with intrinsic value to clinical practice. Two of the practices seemed to be keen to use the study to 
access additional benefits for the practice, staff, and patients, in terms of additional resources 
(financial, professional input from additional nursing time) and training.  
Template review audit 
Based on the prevalence figures in CiPCA, above, it was expected that the template would be 
triggered in the eight study practices 1900 times in the first four months (three months for one 
practice). The actual figure was 1470 times. However, it was also projected that there would be 
1004 individual patients consulting with an OA trigger code recorded, whereas the actual figure was 
1093 (158/10,000 registered population). 
The template was used (i.e. had at least one entry made) on 828/1470 occasions (56%). The 
template was triggered but bypassed on the remaining 642/1470 (44%) of occasions. Information 
was entered on all eight indicators (excluding weight and BMI) on 378/1470 (26%) of occasions. 
There was variation in template use between practices, with a range of completion of at least one 
template item of 39%-79% of patients recorded as consulting with clinical OA; 9%-54% of patients 
consulting had all eight template items completed.  
Table 3-6 shows the aggregated frequency that entries were made when the template had at least 
one entry. Pain and function assessment were template domains the most frequently populated, 
with weight advice the least frequently. These were not rates of quality indicator achievement 
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(discussed in Chapter Six) but rather the frequencies with which any data was entered into each of 
the template fields. To some extent, this may be regarded as demonstrating an order effect, since 
pain assessment appears at the top of the template and physiotherapy referral at the bottom. 
Table 3-6: Frequency of template item completion where at least one entry made 
Domain Patients with data entry n (%) (n=828) 
Pain assessment 776 (94) 
Function assessment 746 (90) 
Record of paracetamol use/advice 715 (86) 
Record of topical NSAID use/advice 606 (73) 
Information provision 602 (73) 
Advice regarding weight 502 (61) 
Advice regarding exercise 615 (74) 
Advice regarding physiotherapy referral 575 (69) 
Template review meeting feedback 
Additional information collected from comments at the template review meetings was summarised 
as follows: 
1. The repeated triggering of the template in the same patient over time was raised as an 
issue, with clinicians preferring the idea that the template would have stayed silent once 
completed, at least for a defined time period. 
2. Self-reported estimates of ‘escape’ rates to avoid use of the template ranged up to from 
“not much” to 85% for one GP. The fact that the template triggered even when the clinician 
did not consider the diagnosis to be one of OA was brought up repeatedly. Another example 
was of a nurse practitioner using the template whenever it triggered whether or not the 
patient presentation was considered to be clinical OA. 
3. Some GPs felt the template was over-inclusive for clinical OA, with it being a particular issue 
in younger patients. One practice would have preferred no age restriction as the GPs felt 
that it would have also applied to some younger patients. 
4. Other staff felt the template was easy to use and had in fact become quite routine. 
5. One practice stated that the template had no utility as an aid to diagnosis; another felt 
there had been no change to diagnostic practices as a result of the template. 
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6. Lack of flexibility in the response options was mentioned in two practices. A longer list of 
options would have been preferred, to include for example the use of low dose analgesics 
(paracetamol and topical NSAIDs). 
7. Cascaded training for new staff was patchy, with some practices having only one member 
of staff present at the original training and no subsequent cascaded training despite the 
materials available. 
8. Some practice staff had a less than positive view of the template – “a list of instructions,” 
“generally a bit irritating,” though the views expressed were those of individuals, as no 
practices seemed to have an uniform practice view of the template. 
9. The implied recommendation for use of topical NSAIDs did not always mesh with clinicians’ 
therapeutic preferences, though they felt generally that if the prompt was there because 
NICE had endorsed their use, it must be “OK” and so could be recommended. 
10. There was a frustration in one practice that the template “doesn’t go anywhere”, “doesn’t 
do anything,” which, on further exploration, transpired to be a wish for it to actually 
constrain practice rather more than it did, and to generate referrals, such as to 
physiotherapy, automatically. 
 Discussion 
The data collection at the three to four month point suggested that the template was working 
reasonably well, in terms of the frequency with which data was entered, and broadly in line with 
internal study team expectations. Although the audit assessment identified variability in 
consultation and completion rates, and the narrative feedback also highlighted a range of beliefs 
about and attitudes towards the template, it was decided to make no subsequent adjustments to 
the template. This was in part due to study time constraints, the fact that the study practices had 
already been exposed to the template, and the requirement to use the template as an aid to 
recording relevant information rather than as a quality improvement tool in its own right. The 
individual practice achievement was provided in face-to-face review meetings between the 
practices and the study team including academic GPs, and compared to the aggregated 
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achievement. This strategy of peer-referencing achievement was a recognised method of improving 
outcomes (in this case, the intended outcome being the template completion rate), although audit 
and feedback does not generally lead to large improvements in professional practice.184 
Standardisation of the template response options was received with some criticism by the 
participating clinicians. It has previously been shown that alert systems open to customisation are 
associated with a better detection and resolution rate of prescribing problems154 than fixed alert 
systems. It was unclear whether allowing practices to customise the OA template would have 
changed the participation rate but in any event the resulting heterogeneity of responses through 
allowing customised responses would have reduced the data utility for the clinical trial.  
A method by which the training, as a study intervention, might be made more formal would have 
improved standardisation. This might take the form of a written prior agreement with practices to 
be available for standardised training to be used in conjunction with a detailed training schedule, 
including equipment lists, presentation outline, and expected attendance. It would have been 
helpful to have a third-party observer (a social scientist) present at all the meetings to identify the 
reactions of the recipients, and collate any themes arising in questioning across practices. 
In terms of testing the template, it would have been preferable to be able to undertake a formal 
preliminary study with wider testing and resultant data analysis and qualitative feedback in 
practice, comparing template use to a control group, with the same Read codes available for 
recording information in each (rather than bespoke codes in the template group). Once so tested, 
the template could then have been implemented in the MOSAICS study practices to test the main 
intervention. However, the constraints imposed by various factors including practice availability, 
funding, and time meant that this approach was not possible. 
 Implications 
The audited use of the template, although suboptimal, represented a big improvement on the 
routinely-recorded data for measuring quality achievement in OA care. There was considerable 
heterogeneity in the initial training and interim practice visit narrative feedback, also reflected in 
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variation in the use of the template as demonstrated by the audit assessment. Although it was not 
considered possible to adapt the template structure and trigger terms to address all of the feedback 
obtained, practitioners seemed to be content to maintain its use during the study period. Lack of 
adaptability for the template, due to the need for a constant approach across all practices, may 
have limited the degree of clinical engagement. Although this could not be overcome for a trial 
setting, such customisation could be delivered for implementation of the template in routine 
practice.  
3.8 Conclusion 
There is some evidence about the effects of reminder systems on recording and clinical practice but 
this effect seems small-to-moderate at most. This supports the view of the template predominantly 
as a consultation recording aid rather than as an intervention likely to cause a substantial change 
in clinical practice. There was little identified evidence to inform creation of the template. Although 
the quality indicators to be included were identified following a rigorous systematic review, it was 
not possible to define an optimum methodology for developing and testing a consultation recording 
template from previous literature. This left scope for the use of a pragmatic approach, in keeping 
with previous RIPCHS experience.  
In terms of the requirements of the MOSAICS study, the template development, training delivered 
and implementation operated broadly within the expected parameters. When the template was 
used (at least one item completed), it was generally well-completed. Although coded data recording 
through the template identified in the audit phase was much better than identified previously 
through the routine record, template use may have been limited by clinical practice in that it was 
dependent upon the clinician recording data obtained in a consultation. This required collection of 
the information by the clinician in the first place, and then sufficient time and motivation to record 
the data in the template. Two factors in particular raised the possibility that data capture through 
the template in the MOSAICS study might not be as complete as desired: (i) the additional time 
estimated to be required for coding clinical information in an EHR (30-40 seconds149) and (ii) the 
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fact that template audit data showed substantial variation in template completion between 
practices (in the context of previous studies suggesting that motivation was important for reminder 
adherence152). Another option might have been to use patient supplementation of the EHR with 
patient-reported achievement of quality indicators. EMIS already have a facility for patients with 
some smartphones or similar devices to transmit information to a healthcare provider.185 This does 
not yet facilitate writing of information directly to the EHR but rather to send messages to the 
healthcare provider or to create a personal health record. An extension of such technology to create 
a patient’s own space to record information within a unified EHR would be another potential route 
toward collecting the information needed to track quality of care over time, as well as facilitating 
potential cross-validation of quality as recorded through the medical record.  
Chapter Four will consider the baseline (pre-template) coding of OA and joint pain as a marker of 
existing quality of care, leading into the baseline recorded quality of care reported in Chapter Five 
and the quality of care captured through the template itself in Chapter Six. The effects of the 
template on recorded quality of care is examined in Chapter Seven.  
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Chapter Four: Patterns and associations with clinical OA coding in 
MOSAICS practices: a cross-sectional analysis 
4.1 Introduction 
Clinical coding of morbidity and processes of care in the UK is conducted primarily through the use 
of Read codes.146 In a consultation, a GP might typically enter one or more Read codes to reflect a 
diagnosis or clinical problem, with associated coded assessment items (for example, weight and 
BMI measurements), uncoded narrative text, and (coded) drug treatment. Clinicians in general 
practice do not always make a formal diagnosis, sometimes choosing to record a symptom code.  
The way in which UK primary care clinicians use Read codes has been found to be highly variable 
for conditions as diverse as osteoporosis,186 gastrointestinal infections,187, and diabetes.188 The 
general practice IM&T DES,189 from 2006/07, went some way to ensuring a more consistent general 
level of disease recording and improved information management in UK primary care though it did 
not include any assessment of joint pain or OA diagnostic rates. Although there have been 
incentives for some specific coding behaviours (most notably to do with diagnoses of certain 
conditions and processes of care relating to the QOF,102 and recently in dementia190), in general GPs 
are left to code clinical contacts in whatever way they prefer, and dependent upon their own beliefs 
and idiosyncrasies.191  
A 2004 systematic review192 of morbidity coding in general practice highlighted that, although it is 
possible to achieve high-quality coding, there are factors associated with the quality of morbidity 
coding in computerised general practice systems. These factors included  
- the nature of the morbidity (the presence of “clear diagnostic features,” such as numerical 
thresholds for diabetes, increased the likelihood of the diagnostic code appearing in the 
record). Although there is a definition of clinical osteoarthritis (Chapter One, section 1.2.2), 
this is vulnerable to clinical interpretation and diagnostic uncertainty 
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- the newness and perceived importance of the problem (with ongoing or potentially less 
important issues possibly being less well reported).193 Given the fact that patients may 
consult about joint pain before eventually receiving an OA diagnosis,194,195 and the reported 
negative attitudes (mainly by GPs) to OA in consultations,63 OA risks not being seen as 
having sufficient ‘newness’ or ‘importance’ to be coded 
- the “enthusiasm of practices and of individual GPs”196 
Influences on diagnostic coding may occur at the locality, practice, clinician, or patient level. 
Localities may influence recording depending upon the style and extent of support and monitoring 
(for example, Read code use training, data quality facilitation, QOF assessments). At the level of the 
practice, factors may include the cultural coding norms and external use of the recorded patient 
data such as contribution to research databases such as CPRD. No empirical evidence was identified 
in the literature that evaluated these influences for OA. No evidence regarding the influences on 
OA coding behaviour at a clinician level were identified, though Bertakis et al.197 reported various 
influences apparent on a primary care diagnosis of pain, including physician practice style. Other 
work in primary care has established an association between health status and physician practice 
style (better health being associated with a relatively low ratio of time spent history taking 
compared to examination).198 Other characteristics such as the individual health beliefs of the 
practitioner (e.g. perceptions of OA as a process of aging, or as an obesity-related condition) and 
communication style between practitioners and patients could be important factors and in principle 
may interact with patient-level characteristics.62,63,199 At a patient level, there are many potential 
factors that may influence coding behaviours, such as the presence of known risk factors for OA.17  
The capture of data for research purposes is not typically one of the primary aims of a clinician 
entering data and in consequence the data quality for research purposes may be further reduced. 
Hersh et al.171 identified potential limitations to high-quality coding, including inaccurate or 
incorrect data, the use of narrative data which cannot easily be used in research, and consultations 
about multiple problems that may appear under only one Read code with information about 
comorbidities in the narrative (or omitted altogether). These limitations risked some under-
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ascertainment of cases of clinical OA in the MOSAICS study, though the highly sensitive definition 
of clinical OA was expected largely to have ameliorated this.  
The use of a broad set of Read codes to define clinical OA was discussed in Chapter Three, section 
3.5. One benefit of such an approach was to reduce the risk of selection bias, as clinicians could not 
easily avoid a diagnostic term and remove the patient thereby from the denominator population 
needing care for OA. However, with the adoption of such an approach, there are risks to the 
generalisability of the MOSAICS study. The use of a wide definition of clinical OA brings a greater 
risk of misclassification of people who do not have OA into the population regarded as having 
clinical OA. This could affect the external validity of the study, as only a proportion of the total study 
population actually having OA would be eligible for processes of care and so the proportions of 
people identified as having received appropriate care may be erroneously low.  
Prior work to assess the utility of the medical record in determining the presence of OA in a patient 
(through a computerised algorithm200 compared to a gold standard manual medical record data 
abstraction) has demonstrated limited sensitivity: 45%201 to 78%202 of OA cases were identifiable 
through the algorithm, though with a positive predictive value of 63%.203 Harrold et al.204 sampled 
an administrative database for people with and without a recorded encounter with OA in 1994-
1996; of those with such an encounter, only 62% were rated as having definite OA from a medical 
record review with an additional 10% having possible OA, and of those without a recorded OA 
encounter, 18% were considered to have definite OA. In another sample of people with a recorded 
OA encounter from the same dataset, Harrold et al.205 found a validated OA diagnosis in 63%. A 
previous case-control study of the prevalence and history of knee OA in one North Staffordshire 
practice identified an estimated 12.5% prevalence of knee OA ever recorded in people aged 45 
years and over, but only 2.4% “currently recorded” (a recorded knee OA consultation within a 2-
year period) , and the median time of initial knee symptoms to a diagnosis of knee OA was 10 
years.194 This serves to illustrate the complexity of primary care coding for OA and joint pain, with 
apparently the same underlying condition being coded as OA or as a pain-based symptom code, 
and reinforces the need for a wide Read code definition of a working diagnosis of OA.  
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The overall aim of this chapter is to investigate potential determinants of a recorded formal OA 
diagnosis rather than joint pain record. First, the extent of variation in the prevalence of OA or joint 
pain was assessed with respect to clinicians and practices. Secondly, the strength of any possible 
association of (i) patient-level risk factors for OA (age,44 45 sex,206-209 BMI16,210-214, multimorbidity,215 
and X-ray information12) and (ii) potential clinician-level factors (volume of OA or joint pain 
consultations) with OA diagnosis rather than joint pain record was assessed. Finally, the extent of 
potential misclassification resulting from assuming that recorded joint pain in older adults is due to 
underlying OA was assessed through review of the narrative content of joint pain consultations and 
exploration of factors that may be used to discriminate between OA and ‘not OA’ will be 
investigated.  
4.2 Methods 
 Comparison of recorded formal OA diagnosis and joint pain symptom codes 
The reference period for usual coding practice in this analysis was taken to be the 12 months prior 
to template installation (baseline, phase one: see Figure 1-1, page 20). For practical purposes, the 
definition of the commencement of active involvement in the MOSAICS study was taken to be the 
installation and commencement of use of the template at the start of phase two. Although there 
were some prior meetings to describe the study (to gain participation) and set-up meetings, these 
were not considered to be sufficiently detailed to have caused a substantial change in practice 
within the phase one timeframe used for this analysis.   
The index clinician and index consultation 
Patients were allocated an index clinician. This was the first clinician to record a diagnosis of OA for 
that patient within the 12-month baseline period or, if no OA diagnosis was recorded, the first 
clinician to record a joint pain code in the period. The consultation with the first OA or joint pain 
record is the index consultation.  
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Case definition 
Cases were defined as patients aged 45 years and over with a Read code within phase one of the 
MOSAICS study (12 months prior to template installation) of clinical OA (as defined in Chapter 
Three, section 3.5) affecting only peripheral joints (hand, hip, knee or foot). Although shoulder and 
elbow OA codes triggered the recording template, there were no corresponding joint pain trigger 
codes for these sites and so people consulting with only a record of the N05.. codes for these sites 
were removed from the numerator population for the analysis reported in this chapter. All other 
patients were allocated to the formally-diagnosed OA group if there was any recorded N05.. code 
in phase one (regardless of whether there was also a joint pain code), and to the joint pain group if 
there was a record only of the specified joint pain codes in phase one. Together, the formally-
diagnosed OA and joint pain groups formed the overall clinical OA group.  
Population of interest 
The denominator population for the study was all patients aged 45 years or over registered at the 
point of the data collection (end of phase two, 2012). A static population for the MOSAICS practices 
was assumed.  
Assessed characteristics and hypotheses for associations with an OA diagnostic code 
The medical record data downloaded included all consultation records including reason for 
consultation, all prescriptions, and patient registration information. Also downloaded were 
relevant coded laboratory tests, radiology requests and results and referral data. 
Various factors might have an influence on a clinician’s tendency to use OA or joint pain codes. 
Based on the literature referred to in the introduction to this chapter, it was considered possible 
that the following recorded variables may have an effect: 
i. Practice 
ii. Clinician (hypothesis: that a large amount of residual variation in OA diagnostic coding 
would be at the level of the clinician) 
iii. Number of (index) consultations each clinician undertakes, dichotomised into clinicians 
undertaking greater or fewer than the median number of index consultations 
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iv. Patient sex 
v. Patient age (hypothesis: that older patients would be more likely to be given an OA 
diagnosis since age-specific rates for OA increase with age) 
vi. Patient BMI status (hypothesis: that people who are overweight or obese would be 
more likely to be given an OA diagnosis since weight is a recognised risk factor for OA) 
vii. Multiple patient consultations for OA/joint pain 
viii. Site(s) of symptoms or diagnosis 
ix. Patient morbidity burden 
x. Use of X-rays (of hand, hip, knee, or foot) within phase one (see Figure 1-1, page 20) 
but before the index consultation (hypothesis: that people with a recorded X-ray would 
be more likely to be given an OA diagnosis since a radiology report identifying OA may 
prompt recording of a formal diagnosis) 
Patients were allocated to one of four categories based on their most recent BMI prior to the index 
consultation in phase one as recorded in the dataset: BMI <25 (normal), 25-29.9 (overweight), ≥30 
(obese), or unknown. All recorded heights and weights for patients consulting in phase one were 
available back to three years before template installation. This method assumed a steady state for 
BMI in a population with clinical OA. No empirical evidence applicable to such a population was 
identified to support or refute this assumption, though for older adults BMI tends to decrease with 
time; substantial changes occur over relatively long periods compared to the three years considered 
here.216 Patients without a numeric BMI value but in whom a Read code of ‘overweight’ or ‘obese’ 
status had been recorded were allocated on the basis of the Read code type (e.g. C380. Obesity was 
allocated to the obese (BMI ≥30) category).  
Measurement of total morbidity burden 
The total burden of morbidity was determined through a count of drugs prescribed in the 12 
months prior to the index consultation (the first OA consultation in a period or, if none, the first 
joint pain consultation), based on individual BNF217 subchapters (the “BNF Chapter count”). This 
process has been found to be a simple proxy marker for prediction of future consultation and 
mortality218 (second to the Charlson Index score219). Polypharmacy has sometimes been defined as 
the use of five or more drugs,220,221 with more extreme polypharmacy defined as 10 or 
more.220,222,223 Based on this approach, the number of BNF subchapters prescribed in the 12 months 
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before the index consultation was collapsed into ordinal categories of 0-4 drugs, 5-9 drugs, and 10 
or more drugs. The use of subchapters reduces the risk of underestimating polypharmacy that may 
occur with higher-level aggregation of prescriptions as it would be unusual to take more than one 
drug from the most detailed subchapter classification (with the exception, for example, of 
emollients for eczema).  
The Read codes used in phase one were mapped to anatomical sites as shown in Appendix E.9. 
Patients with recorded joint pain at more than one site during phase one were designated as having 
multi-site joint pain, and patients with recorded OA at more than one site (including generalised 
OA) were designated as having multisite OA. 
Statistical analysis 
Period consultation prevalence of OA and joint pain 
Age-standardised rates (ASRs) allow the underlying rates of events in distinct populations with 
differing age structures to be compared without the potential masking effect of differences in age 
structure.224 Using the direct method, the ASR for a particular condition is that which would have 
occurred if the observed age-specific rates for the condition had applied in a given standard 
population. Directly ASRs have been calculated using the methodology outlined by the ONS.225 The 
European Standard Population (ESP) 2013 has been used.226 This does not differentiate in age 
structure between males and females, contrary to the observed female excess in older age groups 
in the UK.227 Age bands have been collapsed to 45-64, 65-74, 75-84 and 85+.  
Crude and adjusted rates for OA and joint pain by practice are shown, as well by sex, age, site, BMI 
status, morbidity load, multiple clinical OA consultation status, and prior X-ray use. Results are 
presented as rates per 10,000 population. 
OA diagnostic coding: associated factors 
The outcomes of interest (the presence of an OA or joint pain code in the medical record) occur at 
an individual patient level. From clinical experience, it is well-recognised that individual doctors 
tend to attract a certain type of patient (“Doctors get the patients they deserve”228) and clinicians 
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also will have their own beliefs about OA and its coding. It was also possible that practices may 
function within themselves more consistently than between practices, due to, for example, 
practice-level clinical protocols. This had a potential clustering effect on the observed outcomes, 
which would affect the statistical analysis if not corrected for, such as within a multilevel model. 
The analyses of factors associated with receipt of an OA rather than joint pain diagnosis were 
assessed using multilevel binary logistic regression models (patients within index clinicians) for 
unadjusted and adjusted effects. The multilevel model was estimated using iterative generalised 
least squares with second-order penalised quasi-likelihood approximation (PQL2). Interaction 
effects between sex and age in the odds of an OA diagnosis were assessed due to the observation 
of a potential interaction in the descriptive epidemiology, and random slope effects for sex, age, 
and BMI status across clinicians were also assessed to determine whether or not their associations 
with OA diagnosis varied across clinicians. The data were also re-structured as a three-level model 
(patients within clinicians within practices) and the model re-run to determine whether there was 
additional practice variation in OA diagnosis. Results are presented as odds ratios (OR) with 95% CI. 
 Identification of potential OA misclassification  
This aspect of the study was designed to identify which patients out of the population recorded as 
consulting with joint pain but not formally-diagnosed with OA (N05..) in phase one could be 
determined on the basis of narrative information from a joint pain consultation to have definite OA, 
‘not OA’, or joint pain that could not further be classified from the information available. Following 
this, combination of the reclassified joint pain-only consulters with those formally diagnosed with 
OA, facilitated an estimation of the true annual consultation prevalence of OA in the MOSAICS 
practices.  
For phase one, those patients identified as having consulted with joint pain and no recorded OA 
diagnosis in the same 12-month period were subject to a manual review of all joint pain 
consultations and their associated downloaded consultation narrative after export to a Microsoft® 
Access® 2013 database. Patients with joint pain but not an OA diagnosis who had been found to 
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have consulted with inflammatory joint disease prior to the index consultation (up to two years 
before the start of MOSAICS phase one) were removed from the dataset prior to the recoding 
exercise. 
The basis for the recoding decision was (perforce) clinical judgement, but informed by the EULAR 
criteria for diagnosis of knee OA and the NICE guidelines on management of OA in adults.5,11 The 
evidence relating to methods of diagnosis of OA is set out in Table 4-1.  
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Table 4-1: Guide for interpretation of narrative for reallocation of joint pain consultations 
 Evidence for probable OA Evidence for ‘not OA’ 
History “OA”, gonarthrosis, “? OA” or 
variants 
Red flags (rapidly progressive 
symptoms, weight loss, morning 
stiffness > 30 minutes, identified recent 
significant trauma) 
Other diagnosis substantially more likely 
(e.g. other apparent musculoskeletal 
diagnosis, neuropathy, arterial or 
venous disease, etc.) 
Can include people with symptoms e.g. 
of rapid or recent onset who do not 
meet other criteria for OA diagnosis.  
Degenerate, degenerative, wear and 
tear, wear and repair, worn 
Persistent (>6 weeks) pain and/or 
stiffness 
Joint pain worse at end of day or 
with use, eased by rest 
Examination OA, “?OA” Red flags (large effusion, redness or 
other signs of inflammation) Heberden’s/Bouchard’s nodes (H & 
B nodes), Other bony enlargement 
Painful, restricted movement at the 
hip, knee or foot 
Crepitus 
Changes in the joint suggestive of 
OA, including hallux valgus, other 
valgus or varus deformities 
Test results 
in text 
Osteoarthritis, OA 
Loss of joint space 
Osteophytes, sclerosis, or cysts on 
plain X-ray 
Red flags (e.g. any radiology comment 
advising other pathology to be 
considered or referral made) 
MRI report suggesting OA 
Degenerate, degenerative signs 
Other 
opinion 
Other clinical opinion cited (e.g. 
musculoskeletal or orthopædics) 
indicating OA 
 
Initially, two clinical investigators (including the candidate) independently (and blind to the other’s 
decision) examined the consultation narrative for evidence that the patient could actually be 
regarded as having OA. The consultations linked to a joint pain code were assessed and allocated 
on the balance of clinical probability to OA/not OA/not further classified, as in Box 4-1. 
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Box 4-1: Reclassification categories for joint pain consultations 
(i) Probable OA 
for example, in records where OA is explicitly mentioned as the cause for the coded joint pain, or 
in cases which seem to be in keeping with the diagnostic criteria listed in Table 4-1. 
(ii) Not OA 
for example, records which identify a non-OA cause for the coded joint pain or in which the 
information given is divergent from the diagnostic criteria for OA (perhaps including inflammatory 
symptoms or signs, recent significant trauma, red flag symptoms) as described in Table 4-1. 
(iii) Joint pain not further classified 
Insufficient information to permit classification: this category was used only for records which 
cannot sensibly be allocated to one of the other two. 
Where no agreement was achieved between the two reviewers, a third GP clinical reviewer was 
asked to assess the consultation and independently provide an opinion about its classification as 
above. A simple majority decision was taken as binding, except where all three reviewers disagreed 
(one reviewer allocating the consultation to each of the three categories), in which case the 
consultation was determined to belong to the joint pain not further classifiable group.  
Using all the consultations for clinical OA in phase one, patients with any joint pain consultation 
defined as probable OA were reclassified to the OA group; of the remainder, any ‘not OA’ 
consultation excluded the patient from the full clinical OA group. All remaining patients were left 
in a joint pain not further classified group, as shown in Figure 4-1). 
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Figure 4-1: Reclassification of patients with only joint pain codes 
 
Revised estimates of consultation prevalence for clinical OA 
After removal of all patients who had a recorded consultation for an inflammatory arthropathy in 
the two years prior to the start of phase one, three revised estimates of the consultation prevalence 
of clinical OA were derived: (i) patients with joint pain only who were reclassified as having OA were 
added to the formally-diagnosed (N05..) group and all other joint pain-only consulters were 
assumed not to have OA; (ii) those patients in the not further classified joint pain group were 
allocated to the clinical OA group on the basis that all were truly OA; (iii) those patients in the not 
further classified joint pain group were allocated to the OA and ‘not OA’ groups in the same age-
specific ratios as those patients previously re-allocated to OA or ‘not OA’. This final approach was 
considered to represent the best estimate of the valid consultation prevalence for OA in this 
population. 
 Data cleaning 
The data obtained were cleaned by the CRN informatics team and Professor Jordan.  
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 Statistical analysis 
Analysis of joint pain misclassification 
The numbers of consultations subjected to the reclassification exercise using the consultation 
narrative and the outcome (OA, joint pain not further classified, not OA) were identified and the 
agreement between raters measured by the (weighted) kappa statistic.  
Revised estimates of consultation prevalence for clinical OA  
Revised annual consultation prevalence estimates were produced using the methodology and three 
approaches described above. Results are presented as rates per 10,000 population. 
OA, ‘not OA’, and joint pain: associated factors 
For patients with only joint pain consultations in phase one, associations between the independent 
variables specified above and ‘not OA’ as an outcome of reclassification relative to reclassified OA 
or joint pain not further classified were estimated in a two level multinomial logistic regression 
model, to explore what variables were more or less strongly associated with the possibility of 
reclassification of joint pain to OA or ‘not OA’. Random slope effects were tested. Results are 
presented as relative risk ratios (RRR) with 95% CI.  
Variance partition coefficient 
The variance partition coefficient (VPC) was estimated thus: 
𝑉𝑃𝐶 =
𝜎𝑢
2
𝜎𝑢
2 + 𝜎𝑒
2 
where 𝜎𝑢
2 is the level two residual (unexplained) variance and 𝜎𝑒
2 is the level one residual variance, 
fixed at 3.29 in the logit model used. The resulting VPC, expressed as a decimal or percentage, 
estimates the amount of variance in the model accounted for by unobserved level two (clinician-
level) variables. In a multilevel logistic regression model, the VPC needs to be interpreted with some 
caution since the fixed value for the level one residual variance means that there would be a scaling 
effect on the VPC when explanatory variables were added to the model.229 
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All analyses were undertaken in IBM SPSS v.21,230 Microsoft® Excel® 2013,231 and CIA software.232 
Multilevel models were conducted in Stata v.13233 and MLwiN v.2.34234 via runmlwin,235 using PQL2, 
except where model convergence problems necessitate the use of other specified approximation 
methods.  
4.3 Results 
 Denominator population structure 
The denominator population totalled 33,726 (Table 4-2). One practice (ID number 1) was 
substantially larger than the other practices, accounting for more than one-third of the whole study 
population.  
 Morbidity coding of OA and joint pain 
Consultation prevalence rates by practice 
Annual consultation prevalence rates for OA and joint pain during phase one (crude and age 
standardised) by practice are shown in Table 4-3. Overall, the estimated consultation prevalence 
for combined clinical OA was 940 per 10,000. There was inter-practice variability with rates for joint 
pain varying between 404 and 839 per 10,000 and for OA varying between 83 and 495 per 10,000. 
Broadly, practices with higher rates of OA diagnoses had lower rates for recorded joint pain in 
people aged 45 years and over.  
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Table 4-2: Denominator population age and sex frequencies, by practice. 
 Practice ID 
 1 2 3 4* 5 6 7 8 Total 
Age band 
Fe
m
al
e
 (
%
) 
M
al
e
 (
%
) 
Fe
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al
e
 (
%
) 
M
al
e
 (
%
) 
Fe
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e
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%
) 
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e
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%
) 
Fe
m
al
e
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%
) 
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e
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%
) 
Fe
m
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e
 (
%
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e
 (
%
) 
Fe
m
al
e
 (
%
) 
M
al
e
 (
%
) 
Fe
m
al
e
 (
%
) 
M
al
e
 (
%
) 
<45 6222 
(51.4) 
6337 
(53.9) 
1740 
(62.8) 
1987 
(65.4) 
1869 
(44.8) 
1912 
(47.8) 
1778 
(40.9) 
1773 
(43.1) 
1935 
(52.2) 
1896 
(52.5) 
863 
(45.4) 
1016 
(48.9) 
1835 
(50.4) 
1895 
(53.1) 
1030 
(50.3) 
1080 
(53.3) 
17272 
(49.8) 
17896 
(52.3) 
45-64 3443 
(28.4) 
3423 
(29.1) 
632 
(22.8) 
680 
(22.4) 
1294 
(31.0) 
1223 
(30.6) 
1302 
(29.9) 
1260 
(30.6) 
1011 
(27.3) 
1021 
(28.3) 
544 
(28.6) 
650 
(31.3) 
1006 
(27.7) 
1011 
(28.3) 
586 
(28.6) 
581 
(28.6) 
9818 
(28.3) 
9849 
(28.8) 
65-74 1214 
(10.0) 
1142 
(9.7) 
214 
(7.7) 
215 
(7.1) 
514 
(12.3) 
520 
13.0) 
624 
(14.4) 
600 
(14.6) 
423 
(11.4) 
432 
(12.0) 
261 
(13.7) 
261 
(12..6) 
424 
(11.7) 
410 
(11.5) 
222 
(10.8) 
221 
(10.9) 
3896 
(11.2) 
3801 
(11.1) 
75-84 830 
(6.9) 
646 
(5.5) 
136 
(4.9) 
122 
(4.0) 
339 
(8.1) 
275 
(6.9) 
438 
(10.1) 
369 
(9.0) 
240 
(6.5) 
219 
(6.1) 
153 
(8.1) 
118 
(5.7) 
260 
(7.1) 
212 
(5.9) 
156 
(7.6) 
126 
(6.2) 
2552 
(7.4) 
2087 
(6.1) 
85+ 399 
(3.3) 
212 
(1.8) 
48 
(1.7) 
36 
(1.2) 
152 
(3.6) 
72 
(1.8) 
206 
(4.7) 
111 
(2.7) 
101 
(2.7) 
46 
(1.3) 
79 
(4.2) 
33 
(1.6) 
113 
(1.6) 
40 
(1.1) 
55 
(2.7) 
20 
(1.0) 
1153 
(3.3) 
570 
(1.7) 
Total all 
ages 
12108  11760 2770 3040 4168 4002 4348 4113 3710 3614 1900 2078 3638 3568 2049 2028 34691 34203 
Total aged 
≥45 years 
5886 
(48.6) 
5423 
(46.1) 
1030 
(37.2) 
1053 
(34.6) 
2299 
(55.2) 
2090 
(52.2) 
2570 
(59.1) 
2340 
(56.9) 
1775 
(47.8) 
1718 
(47.5) 
1037 
(54.6) 
1062 
(51.1) 
1803 
(49.6) 
1673 
(46.9) 
1019 
(49.7) 
948 
(46.7) 
17419 
(50.2) 
16307 
(47.7) 
*One female in practice 4 is missing due to a lack of birth date information in the dataset but is not included in the OA or joint pain consultation population and would form a 
part of the denominator only. 
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Table 4-3: Age-specific and directly age-standardised annual consultation prevalence rates by practice, peripheral joint pain or OA in phase one 
 Age-specific and standardised recorded disease prevalence rates per 10,000 (95% CI) by practice 
Age band 1 2 3 4 5 6 7 8 Combined 
Joint pain 
45-64 465 
(415,519) 
442 
(336,571) 
600 
(508,704) 
574 
(485,674) 
748 
(634,877) 
528 
(405,675) 
724 
(611,851) 
386 
(281,516) 
549 
(516,582) 
65-74 573 
(480,678) 
443 
(267,692) 
716 
(562,898) 
629 
(496,786) 
971 
(773,1203) 
728 
(515,999) 
839 
(654,1060) 
474 
(293,725) 
670 
(614,731) 
75-84 589 
(472,727) 
426 
(213,763) 
1010 
(774,1294) 
843 
(654,1068) 
1089 
(809,1436) 
701 
(422,1095) 
911 
(659,1227) 
355 
(170,652) 
754 
(677,838) 
85+ 589 
(413,816) 
476 
(130,1219) 
670 
(375,1104) 
915 
(613,1314) 
612 
(280, 1162) 
1250 
(683,2097) 
850 
(452,1453) 
400 
(82,1169) 
714 
(593,852) 
All aged 45+ 510 
(469,554) 
442 
(356,542) 
688 
(613,770) 
654 
(584,729) 
842 
(748,944) 
638 
(535,756) 
783 
(692,881) 
402 
(318,501) 
613 
(587,640) 
Age-standardised 
rate* per 10,000 
518 
(475,560) 
438 
(348,527) 
674 
(598,750) 
644 
(574,715) 
839 
(743,935) 
628 
(522,735) 
787 
(693,880) 
404 
(315,493) 
617 
(590,643) 
OA 
45-64 281 
(243,324) 
228 
(154,326) 
167 
(120,226) 
164 
(118,222) 
212 
(153,285) 
42 
(14,98) 
109 
(68,165) 
163 
(98,254) 
200 
(181,221) 
65-74 649 
(551,761) 
350 
(196,577) 
319 
(220,448) 
335 
(240,454) 
480 
(344,651) 
153 
(66,302) 
156 
(83,267) 
474 
(293,725) 
424 
(379,472) 
75-84 854 
(711,1017) 
426 
(213,763) 
277 
(161,443) 
335 
(220, 487) 
588 
(388,856) 
148 
(40,378) 
191 
(87,362) 
957 
(631,1393) 
530 
(466,601) 
85+ 1064 
(821,1356) 
357 
(74,1044) 
357 
(154,704) 
536 
(312,859) 
272 
(74,697) 
0 
(0,329) 
654 
(313,1202) 
267 
(32,963) 
612 
(509,751) 
All aged 45+ 475 
(436,517) 
283 
(216,365) 
228 
(185,277) 
259 
(216,308) 
329 
(272,395) 
81 
(47,130) 
144 
(107,190) 
351 
(273,444) 
318 
(299,338) 
Age-standardised 
rate* per 10,000 
495 
(453,537) 
303 
(226,380) 
220 
(177,263) 
247 
(204,290) 
330 
(270,390) 
83 
(43,122) 
148 
(107,189) 
354 
(270,437) 
323 
(304,342) 
* European Standard Population, age 45 years and over 
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Table 4-4: Consultation prevalence for peripheral joint pain or OA in phase one with aggregated crude and directly standardised period consultation rates 
Crude annual consultation 
prevalence rates  
Joint pain OA Clinical OA 
Female Male F:M ratio Female Male F:M ratio Female Male Both sexes 
45-64 
627 
(579,679) 
471 
(429,516) 
1.3 
260 
(229,294) 
142 
(120,168) 
1.8 
887 
(829,948) 
613 
(565,664) 
750 
(712,789) 
65-74 
757 
(673,849) 
587 
(512,669) 
1.3 
526 
(457,603) 
318 
(264,380) 
1.7 
1283 
(1173,1401) 
905 
(812,1006) 
1097 
(1024,1173) 
75-84 
886 
(774,1009) 
594 
(494,709) 
1.5 
615 
(523,719) 
426 
(342,525) 
1.4 
1501 
(1354,1659) 
1021 
(888,1167) 
1285 
(1184,1392) 
85+ 
703 
(558,873) 
737 
(531,996) 
1.0 
598 
(466,757) 
667 
(472,915) 
0.9 
1301 
(1101,1527) 
1404 
(1113,1747) 
1335 
(1168,1519) 
All aged ≥45 years, 
 per 10,000 (95% CI) 
699 
(661,740) 
523 
(489,559) 
1.3 
394 
(365,424) 
238 
(215,263) 
1.7 
1168 
(1116,1221) 
761 
(719,805) 
933 
(900,966) 
Age-standardised* annual 
consultation prevalence rate 
per 10,000 (95% CI) 
703 
(664,743) 
527 
(492,563) 
1.3 
391 
(361,420) 
252 
(227,278) 
1.6 
1094 
(1045,1143) 
780 
(737,823) 
940 
(907,973) 
* European Standard Population, age 45 years and over 
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Clinician effects 
There were 115 index clinicians identified, with a median of 10 patients (range 1-129, interquartile 
range (IQR) 2-51). Of 60 clinicians holding the median or fewer index consultations, 32 coded no 
consultations as OA and eight coded all as OA, whereas only one of the clinicians holding more than 
the median number of index consultations coded none as OA, though none coded all consultations 
as OA.  
Patient-level variable effects 
Age and sex effects: age-specific and standardised consultation prevalence rates 
The age-specific prevalence for both joint pain and OA was highest in women in the 75-84 years 
age band, and in men in the 85+ band (Table 4-4). The higher prevalence for females was less 
evident in the older age bands.  
Site of disease: consultation prevalence rates 
Table 4-5 gives the annual consultation prevalence rates by age and site. The site with the highest 
consultation prevalence was the knee for both joint pain (age standardised rate 317/10,000) and 
OA (age standardised rate 135/10,000). 
Body mass index 
As shown in Table 4-6, BMI status analysis shows that there was an increasing number of patients 
consulting in each of the diagnostic categories as the BMI increased, though the category with the 
most persons consulting was ‘BMI unknown,’ at around ⅓ of people consulting. An OA diagnosis 
relative to joint pain was most frequent (38.1%) in the obese (BMI ≥30kgm-2) category, consistent 
with known risk factors.  
Morbidity burden 
The ratio of OA to joint pain diagnoses increased with increasing morbidity, with approximately 
twice the ratio in the highest morbidity band compared to the lowest.  
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Prior X-ray use 
People with recorded use of an X-ray in phase one before the index consultation for OA or joint 
pain received a diagnosis of OA compared to joint pain more frequently than those in whom no X-
ray was recorded (ratio of 0.45 OA:joint pain in those with no X-ray increasing more than five-fold 
to 2.45 where a prior X-ray was recorded (Table 4-6).  
Multiple consultations 
Patients with more than one consultation for clinical OA recorded in phase one were recorded as 
having a diagnosis of OA rather than joint pain more frequently than those with only a single 
recorded consultation (Table 4-6).  
 
 120 
Table 4-5: Age-specific and directly age-standardised annual consultation prevalence rates in phase one by site, diagnosed peripheral joint pain or OA  
Age-specific 
rates per 
10,000 
Knee Hip Ankle/Foot Wrist/Hand Unspecified Multiple 
Joint 
pain OA 
Joint 
pain OA 
Joint 
pain OA 
Joint 
pain OA 
Joint 
pain OA 
Joint 
pain OA 
45-64 304 80 101 36 45 9 58 18 14 17 27 41 
65-74 344 169 165 88 60 8 66 23 18 45 19 90 
75-84 334 237 250 80 73 9 60 24 11 45 26 136 
85+ 302 290 279 70 41 6 70 17 6 70 17 168 
All aged 45 
years and 
over 
317 
(298,337) 
133 
(121,145) 
145 
(133,159) 
56 
(48,64) 
52 
(45,60) 
9 
(6,12) 
61 
(53,70) 
20 
(15,25) 
14 
(10,19) 
30 
(25,37) 
25 
(20,31) 
71 
(63,81) 
ASR per 
10,000* 
317 
(298,336) 
135 
(123,148) 
146 
(133,159) 
57 
(48,65) 
53 
(46,61) 
9 
(6,12) 
61 
(53,69) 
20 
(15,24) 
14 
(10,19) 
31 
(25,37) 
25 
(20,30) 
72 
(63,81) 
*Age-standardised consultation prevalence, European Standard Population, age 45 years and over 
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Table 4-6: Characteristics of patients consulting for peripheral joint pain or OA in phase one 
  
OA Joint pain OA:JP Total 
 
 
n (%) n (%) ratio n 
 Total 1074 (34.1%) 2071 (65.9%) 0.52 3145 
Site 
Knee 447 (29.5%) 1069 (70.5%) 0.42 1516 
Hip 188 (27.7%) 490 (72.3%) 0.38 678 
Ankle/foot 29 (14.2%) 175 (85.8%) 0.17 204 
Wrist/hand 67 (24.6%) 205 (75.4%) 0.33 272 
Unspecified 102 (68%) 48 (32%) 2.13 150 
Multiple 241 (74.2%) 84 (25.8%) 2.87 325 
BMI status 
BMI <25 141 (31.5%) 307 (68.5%) 0.46 448 
BMI 25 to <30 252 (33.8%) 493 (66.2%) 0.51 745 
BMI 30+ 346 (38.1%) 561 (61.9%) 0.62 907 
Unknown 335 (32.1%) 710 (67.9%) 0.47 1045 
BNF chapter count 
0-4 456 (29.0%) 1118 (71.0%) 0.41 1574 
5-9 331 (36.6%) 574 (63.4%) 0.58 905 
10+ 287 (43.1%) 379 (56.9%) 0.76 666 
Consultations in 
phase 1 
Single 536 (28.2%) 1368 (71.8%) 0.39 1904 
Multiple 538 (43.4%) 703 (56.6%) 0.77 1241 
Relevant XR recorded 
in phase 1, prior to 
index consultation 
No 910 (31.2%) 2004 (68.8%) 0.45 2914 
Yes 164 (71.0%) 67 (29.0%) 2.45 231 
Multilevel logistic regression analysis 
The associations with a diagnosis of OA compared to joint pain only, unadjusted and adjusted for 
each of the factors, are shown in Table 4-7.  
There was generally only a small difference between the results from unadjusted and adjusted 
models. Factors with a significant association with a recorded OA diagnosis were patients with older 
age: adjusted OR compared to age 45-64 of 1.83 (95% CI 1.47,2.27) for age 65-74 rising to 2.29 
(1.61,3.26) for age 85+; patents with unspecified (adjusted OR 7.32, 95% CI 4.62,11.0) or multisite 
disease (adjusted OR 6.07, 95% CI 4.44,8.30) compared to knee; patients with obesity compared to 
not overweight (adjusted OR 1.42, 95% CI 1.06,1.90); patients who had multiple consultations for 
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clinical OA compared to single (adjusted OR 1.43, 95% CI 1.19,1.73), and recorded prior use of X-
rays compared to not (adjusted OR 4.89, 95% CI 3.46,6.91). Those with ankle/foot disease were less 
likely to have an OA diagnosis compared to knee (adjusted OR 0.44, 95% CI 0.28,0.69). 
The VPC was estimated in the null (no independent variables) model at 0.19 (0.12, 0.25) and in the 
adjusted mode at 0.10 (0.05, 0.14) (that is, 10% of the residual variation in use of an OA code was 
due to unobserved clinician-level factors).  
Due to an observed potential interaction effect seen in the descriptive epidemiology, the multilevel 
model was repeated with the sex*age interaction effects specified in the independent variables and 
the resulting ORs are also shown in Table 4-7. The point estimate for the OR for each of the 
interaction terms suggested a positive interaction, though it was only statistically significant for the 
male*age band 75-84 age band (OR 1.67, 95% CI 1.02,2.72), indicating that older age had a greater 
impact on increased likelihood of OA diagnosis in males. 
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Table 4-7: Associations of independent variables with an OA diagnosis in phase one 
 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Interaction model 
adjusted OR 
(95% CI) 
Sex (reference: female)  0.80 (0.67,0.94) 0.87 (0.73,1.04)  0.74 (0.56,0.97) 
Age 65-74 (reference: 45-64)  1.81 (1.49,2.20)  1.83 (1.47,2.27)  1.76 (1.34,2.31) 
Age 75-84  1.98 (1.60,2.46)  1.93 (1.50,2.48)  1.60 (1.17,2.18) 
Age 85+  2.27 (1.66,3.09)  2.29 (1.61,3.26)  1.98 (1.28,3.05) 
Male*Age 65-74 interaction - - 1.12 (0.72,1.73) 
Male*Age75-84 interaction - -  1.67 (1.02,2.72) 
Male*Age 85+ interaction - - 1.50 (0.74,3.04) 
Hip (reference: knee) 0.98 (0.79,1.21) 0.85 (0.68,1.07) 0.85 (0.68,1.07) 
Ankle/foot  0.40 (0.26,0.62)  0.44 (0.28,0.69)  0.45 (0.29,0.70) 
Wrist/hand 0.80 (0.58,1.09) 0.97 (0.70,1.35) 0.97 (0.70,1.35) 
Unspecified  6.60 (4.43,9.83)  7.32 (4.86,11.0)  7.26 (4.82,10.9) 
Multisite  7.01 (5.21,9.43)  6.07 (4.44,8.30)  6.08 (4.45,8.32) 
BMI 25 to <30 (reference:  
BMI <25) 
1.09 (0.83,1.43) 1.12 (0.83,1.50) 1.12 (0.83,1.51) 
BMI 30+  1.42 (1.10,1.85)  1.42 (1.06,1.90)  1.44 (1.08,1.93) 
BMI unknown 1.03 (0.80,1.34) 1.14 (0.85,1.51) 1.16 (0.87,1.54) 
5-9 BNF chapters (reference: 0-4)  1.53 (1.26,1.84) 1.17 (0.95,1.46) 1.17 (0.94,1.45) 
10+ BNF chapters  1.93 (1.57,2.37) 1.23 (0.96,1.57) 1.23 (0.97,1.58) 
Multiple consultations in phase 1 
(vs. single) 
 2.08 (1.76,2.45)  1.43 (1.19,1.73)  1.44 (1.19,1.73) 
X-ray in phase 1 prior to index 
consultation (vs. none) 
 4.66 (3.37,6.43)  4.89 (3.46,6.91)  4.91 (3.48,6.93) 
Above the clinician median index 
consultation count (reference: at 
or below the median) 
 1.79 (1.08,2.98) 1.50 (0.91,2.47) 1.48 (0.90,2.45) 
Practice 2 (reference: Practice 1) 0.70 (0.28,1.79) 0.91 (0.37,2.22) 0.90 (0.37,2.21) 
Practice 3  0.29 (0.16,0.51)  0.34 (0.20,0.60)  0.34 (0.20,0.60) 
Practice 4  0.47 (0.26,0.86)  0.45 (0.25,0.80)  0.45 (0.25,0.80) 
Practice 5 0.56 (0.30,1.03) 0.66 (0.36,1.20) 0.66 (0.36,1.20) 
Practice 6  0.24 (0.09,0.61)  0.26 (0.10,0.67)  0.26 (0.10,0.68) 
Practice 7  0.28 (0.15,0.50)  0.27 (0.15,0.50)  0.27 (0.15,0.50) 
Practice 8 0.94 (0.46,1.92) 1.10 (0.53,2.32) 1.09 (0.52,2.30) 
Two-level multilevel logistic regression model, patients within clinicians 
No significant random slope effect was identified across clinicians for sex effects. There was a small 
degree of evidence that the association between the odds of an OA code and both age and BMI 
varied slightly across clinicians.  
A three-level model of patients within clinicians within practices showed no significant explanatory 
effect of the practice on the residual variance. 
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 OA misclassification and revised consultation prevalence for clinical OA 
There were 2058 patients coded with only joint pain in phase one, who had a total of 3209 
consultations with a range of 1 to 16 consultations per patient, median one consultation and IQR 
1-2 consultations.  
The recoding exercise using the consultation text with the first two GP raters resulted in agreement 
in 2196 (68.4%) of the 3209 recoded consultations and a Cohen’s kappa value for inter-rater 
agreement of 0.49, p<0.001, which indicated moderate agreement.236 Introduction of a third GP 
rater resulted in a kappa value for multiple raters of 0.46 (moderate agreement) from a majority 
decision in 895 (27.9%) additional consultations and complete disagreement in 118 (3.7%) 
consultations.  
Of the 2058 patients, 515 (25.0%) were recoded to ‘truly OA’, 718 (34.9%) to ‘not OA’, and 825 
(40.1%) were left in the joint pain (not further classifiable) group.  
The flow of patient numbers from the original clinical OA group to the three possible revised clinical 
OA groups is shown in Figure 4-2. If the 825 patients with unclassifiable joint pain consultations 
were assumed to belong to the OA or ‘not OA’ groups in the same ratio, stratified by age-group, as 
those which could be classified, this would add a further 483 people to the total misclassified (i.e. 
the ‘not OA’ group), to a total of 1201. Deduction of these from the 3126 people previously 
allocated to the clinical OA group (all OA plus defined peripheral joint pain), would equate to a 
crude annual consultation prevalence for ‘true’ clinical OA of 576 per 10,000 (95% CI 550,602). 
Allowing for the fact that it is uncertain what proportion of unclassifiable patients have OA, the 
potential range of crude consultation prevalence for true OA was 474 per 10,000 (where all 
unclassified joint pain patients were assumed not to have OA) to 720 per 10,000 (where all 
unclassified joint pain patients were assumed to have OA).  
The age and sex category-specific annual consultation prevalence sensitivity analysis estimates for 
the revised clinical OA and ‘not OA’ populations are given in Table 4-8.  
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Figure 4-2: Derivation of revised clinical OA group in phase one 
Original clinical OA group 
(n= 3145)
Consultation for diagnosed 
inflammatory disease in 
2 years before phase 1 
(n=19)
Remainder = 3126
Formally diagnosed OA 
consultation, phase 1
(n=1068)
Remainder = 2058
Joint pain consultation 
reclassified as OA
(at least one)
(n=515)
Remainder = 1543
Joint pain consultation 
reclassified as 'not OA' 
(at least one)
(n=718)
Remainder = 825
Joint pain not further 
classified group
(n=825)
515 reclassified OA patients 
added to revised OA group
1068 patients added to 
revised OA group
718 patients excluded from 
eligibility for revised OA 
group
3-way sensitivity analysis – 
added to revised OA group 
on the basis all eligible, none 
eligible, and pro-rata 515:718 
by age group to OA/‘not OA’
19 patients excluded from 
eligibility for revised OA 
group
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Table 4-8: Original and revised estimates of age-specific and directly age-standardised annual 
consultation prevalence rates per 10,000 for clinical OA  
Age category-specific 
rates per 10,000 
Original clinical 
OA group, 
phase 1 
Sensitivity analysis for final clinical OA group 
Point (best) 
estimate for all 
clinical OA 
Minimum 
possible 
clinical OA 
Maximum 
possible 
clinical OA 
45-64 750 416 327 327 
65-74 1097 712 599 854 
75-84 1285 880 742 1043 
85+ 1335 875 784 1021 
All aged 45 years 
and over 933 571 469 714 
Directly age-
standardised* rate per 
10,000 (95% CI) 
940 
(907,973) 
576 
(550,602) 
474 
(451,498) 
720 
(691,749) 
*European Standard Population, age 45 years and over 
Original and revised estimates including a sensitivity analysis comparing predicted OA consultation 
prevalence rates after reclassification of patients with only non OA (N05..) joint pain consultations 
 Factors associated with joint pain misclassification 
Only a small proportion (12.1%) of people with ankle/foot disease had definite OA in those recorded 
with joint pain and many (66.1%) had ‘not OA’ as shown in Table 4-9. 
Table 4-9: Final patient classification (OA, ‘not OA’, or joint pain unclassified), by disease site 
Site 
OA 
n (%) 
‘Not OA' 
n (%) 
Joint pain unclassified  
n (%) 
Knee 304 (28.5) 322 (30.2) 440 (41.3) 
Hip 113 (23.3) 141 (29.1) 231 (47.6) 
Ankle/foot 21 (12.1) 115 (66.1) 38 (21.8) 
Wrist/hand 39 (19.3) 88 (43.6) 75 (37.1) 
Unspecified 3 (6.4) 20 (42.6) 24 (51.1) 
Multiple 35 (41.7) 32 (38.1) 17 (20.2) 
Associations with reclassification as true OA, ‘not OA’ or joint pain unclassifiable) are shown in 
Table 4-10. 
Factors associated with reclassification of joint pain as true OA rather than ‘not OA’ were patients 
in age band 75-84 compared age 45-64 years (RRR 1.44, 95% CI 1.06,1.95), and patients with an 
overweight status (RRR 1.57, 95% CI 1.11,2.24) and obesity (RRR 1.45, 95% CI 1.03,2.05) compared 
to not overweight. Patients with knee disease had an increased risk of an OA diagnosis:  
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Table 4-10: RRRs for OA/not OA and joint pain/not OA, reclassified joint pain patients 
 
Clinical OA defined by joint pain codes only: 
comparison of reclassified groups 
 
OA vs. ‘not OA’ 
comparison 
RRRa (95% CI) 
Unclassifiable joint 
pain vs. ‘not OA’ 
comparison 
RRRa (95% CI) 
Sex (reference: female) 0.81 (0.66,1.01) 0.90 (0.74,1.08) 
Age 65-74 (reference: 45-64) 1.30 (1.00,1.68) 0.94 (0.75,1.18) 
Age 75-84  1.44 (1.06,1.95) 1.07 (0.81,1.41) 
Age 85+ 1.04 (0.65,1.67)  0.64 (0.41,0.97) 
Hip (reference: knee) 0.78 (0.60,1.02) 1.20 (0.95,1.50) 
Ankle/foot  0.18 (0.11,0.29)  0.22 (0.15,0.33) 
Wrist/hand  0.42 (0.28,0.62)  0.55 (0.40,0.76) 
Unspecified  0.20 (0.06,0.67) 1.12 (0.60,2.09) 
Multisite 0.99 (0.61,1.62) 0.61 (0.34,1.07) 
BMI 25 to <30 (reference: BMI <25)  1.57 (1.11,2.24)  1.42 (1.05,1.93) 
BMI 30+  1.45 (1.03,2.05) 1.34 (0.99,1.81) 
BMI unknown 1.21 (0.87,1.70) 1.21 (0.90,1.62) 
5-9 BNF chapters (reference: 0-4) 1.21 (0.94,1.57) 1.08 (0.85,1.35) 
10+ BNF chapters 1.05 (0.77,1.43) 1.18 (0.90,1.55) 
Multiple consultations in phase 1 
(vs. single) 
1.22 (0.98,1.52)  0.52 (0.42,0.64) 
X-ray in phase 1 prior to index consultation 
(vs. none) 
0.88 (0.49,1.60) 0.97 (0.57,1.64) 
Above the median for clinician index consultation 
count (reference: at or below the median) 
1.21 (0.80,1.85)  1.95 (1.32,2.88) 
Practice ID 2 (reference: Practice 1) 1.37 (0.67,2.79)  1.80 (1.03,3.14) 
Practice ID 3 0.76 (0.50,1.16)  0.67 (0.47,0.94) 
Practice ID 4  0.47 (0.29,0.75)  0.54 (0.38,0.77) 
Practice ID 5 0.86 (0.54,1.39) 0.74 (0.51,1.08) 
Practice ID 6 0.57 (0.29,1.12) 0.96 (0.58,1.59) 
Practice ID 7 0.93 (0.59,1.46)  0.62 (0.42,0.90) 
Practice ID 8 0.62 (0.30,1.28) 1.04 (0.59,1.83) 
aMultinomial two-level logistic regression (patients within clinicians) relative risk ratios, adjusted for all 
covariates. 
compared to distal limb or unspecified sites (with reference to the knee, risks of an OA  diagnostic 
outcome were: ankle/foot RRR 0.18, 95% CI 0.11,0.29; wrist/hand RRR 0.42, 95% CI 0.28,0.62; 
unspecified site RRR 0.20, 95% CI 0.06,0.67; hip and multisite disease were not statistically 
significantly different to the knee).  
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For joint pain unclassified compared to ‘not OA’, factors associated with an increased risk were 
patients with an overweight status compared to not overweight (RRR 1.42, 95% CI 1.05,1.93) and 
an index consultation with a clinician who had more than the median number of index consultations 
(RRR 1.95, 95% CI 1.32,2.88). Patients in age band 85+ had a lower risk of a joint pain compared to 
‘not OA’ compared to age 45-64 (RRR for joint pain compared to ‘not OA’ 0.64, 95% CI 0.41,0.97). 
Patients with a knee site of disease had an increased risk of a ‘not OA’ diagnosis than distal limb 
sites (compared to knee, risk of a joint pain outcome were: ankle/foot RRR 0.22, 95% CI 0.15,0.33; 
wrist/hand RRR 0.55, 95% CI 0.40,0.76; other sites were not statistically different to the knee). 
Multiple consultations were associated with reduced risk of a joint pain outcome (RRR for joint pain 
0.52, 95% CI 0.42,0.64). 
No random slope effects were identified for sex, age, or BMI status in the two-level models. Three-
level models of patients within clinicians within practices demonstrated no statistically significant 
explained variance at the practice level and only small differences in the RRR estimates compared 
to the two-level model.  
4.4 Discussion 
 Principal findings 
Clinical OA and the use of OA or joint pain diagnoses 
The age-standardised annual consultation prevalences for joint pain and OA were 617 and 323 per 
10,000 respectively, with a combined prevalence for the clinical OA category of 940 per 10,000. 
There was extensive variation by practice for both recorded joint pain and OA diagnoses. Once 
misclassification of patients with only joint pain codes had been corrected for, the possible range 
for true clinical OA lay between directly age-standardised rates of 474 (95% CI 451,498) and 720 
(691,749) per 10,000 per annum, with a best estimate of 576 (550,602) per 10,000.  
The patient-level factors independently associated with increased odds of an OA diagnosis were 
increasing age, site (unspecified or multisite disease), obesity, multiple consultations for clinical OA, 
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and recorded X-ray use prior to the index consultation. Ankle/foot site of disease was associated 
with reduced odds of an OA diagnosis.  
The association of prior X-ray use with an OA diagnosis suggested that clinicians may be using the 
results of X-rays to record a diagnosis of OA. This was not consistent with the NICE guidelines, which 
do not recommend routine use of radiological investigations to make a diagnosis of OA.5 
The association of multiple consultations for clinical OA with a formal (N05..) diagnosis of OA may 
reflect an increased severity of symptoms requiring more frequent consultation, or a clinical review 
of undifferentiated joint pain leading to a diagnosis of OA subsequently (akin to surveillance bias237). 
Although multiple consultation refers to only consultations for clinical OA, another explanation 
might be clinical comorbidity; given the known association of OA with obesity (and therefore by 
extension to other conditions also associated with obesity that may also require consultation) and 
with increased mortality,238-240 patients may potentially have primarily consulted about another 
matter and the clinical OA been recorded as a secondary issue. Clinical comorbidity with OA has 
previously been described as extensive, with propensity to consult as one identified possible 
explanation.241 This analysis did not identify any link between overall morbidity burden as measured 
by BNF chapter count and OA diagnostic code in an adjusted multilevel model, however, though 
any association may have been confounded by the effect of age as both prevalence of OA and 
polypharmacy increase with age.242  
There was no significant association between the numbers of index consultations (unique patients) 
undertaken by clinicians and an OA diagnosis, suggesting that musculoskeletal clinical workload did 
not affect coding behaviour.  
Joint pain misclassification 
The assessment of joint pain misclassification identified a substantial number (35% of those 
recorded as joint pain rather than diagnosed with OA) of patients who were included in the initial 
definition of ‘clinical OA’ who were determined at case note review to have consulted with joint 
pain that did not represent OA. This resulted in a lower point estimate of the annual consultation 
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prevalence for clinical OA in phase one (576 per 10,000 compared to the original estimate of 940 
per 10,000) though there was uncertainty about the correct classification of people whose joint 
pain consultations could not reliably be allocated to OA or ‘not OA’. The difference in the 
proportions of patients with joint pain reclassified to OA or ‘not OA’ (25% to 35%) suggests that 
there may be a difference in the type of narrative information recorded for people with joint pain 
according to the underlying working diagnosis. No other such exercise has been identified in the 
published literature and so this is a potentially important contribution to the understanding of the 
definition of clinical OA within health care databases.  
Nearly two-thirds of patients with an ankle/foot joint pain code were reclassified as ‘not OA’, and 
43.6% of those with wrist/hand disease. Taken with the association between ankle/foot and 
wrist/hand sites of disease and increased adjusted risk of a ‘not OA’ outcome after reclassification, 
this indicates a need for caution in attribution of patients with a joint pain coded consultation to a 
clinical OA group. Joint pain codes with an unspecified site of disease were infrequently reclassified 
as true OA and care regarding their inclusion in a clinical OA definition should be exercised.  
The associations between a diagnostic OA code and a joint pain symptom code showed some 
consistency with the associations in the reclassified joint pain OA compared to ‘not OA’. Age and 
overweight/obesity were common associations. Site effects showed some differences between the 
original and reclassified comparisons, though this may represent coding artefact due to the use of 
N05.. OA diagnostic codes that either do not specify a site (such as N05.. Osteoarthritis and allied 
disorders) or are known to be multisite (such as N050. Generalised osteoarthritis - OA). X-ray result 
information was not routinely available to the clinical reviewers of the joint pain consultations, 
unless referred to in the consultation narrative, which may explain the lack of association between 
prior X-ray use and a reclassified OA diagnosis in the assessment of misclassification. Multiple 
consultation was associated with an OA diagnosis compared to joint pain but in the reclassification 
assessment was associated only with increased risk of ‘not OA’ compared to joint pain not further 
classified. This may reflect a process of refinement of a diagnosis, either formally coded or reflected 
in the narrative, over more than one consultation.  
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Agreement between the first two clinicians, including the candidate, was moderate at best, but the 
solution of introducing a third clinical reviewer still left considerable difficulty in achieving 
agreement on the reclassification decisions. This suggests that the narrative information linked to 
the joint pain consultations was limited in its description of the working diagnosis.  
 Comparison with existing literature and implications 
This analysis has demonstrated that recording of an OA diagnosis was less common than a joint 
pain code and was associated with risk factors for development of OA such as age243-245 and 
obesity.246-249 The findings were not dissimilar to the analysis by Jordan et al. which linked (for those 
patients consenting) self-reported information to medical records in responders to a survey.17 That 
study was developed subsequently to complement and assess the generalisability of the analysis 
reported here and to allow inclusion of self-reported information, with the candidate inputting into 
the design and interpretation and a co-author on the publication. That study also found substantial 
variation between practices in coding an OA diagnosis or joint pain, and association of age and 
obesity with an OA diagnosis, as well as self-reported pain interference. The analysis reported here 
used the entire practice population consulting with clinical OA, rather than restricting analysis to 
patients who both responded to a survey and consented to medical record review. This analysis 
also included a measure of morbidity load (a count of prescription drug types) and use of X-rays, 
assessment of interactions between patient characteristics and between patient characteristics and 
clinicians in a multilevel model, and novel interrogation of narrative text.  
It has not hitherto been clear to what extent the proportion of people coded as having joint pain 
actually have OA. Interrogation of narrative text to establish likelihood of true OA in those recorded 
with joint pain leading to identification of an estimated rate of true clinical OA that is greater than 
that found by use of an OA diagnosis alone (but less than combined prevalence based on the highly-
sensitive set of joint pain or OA codes) is novel. Comparison of diagnosed OA consultation 
prevalence in different UK primary care datasets demonstrated a substantial spread in rates with 
3.6-19.2% of all musculoskeletal consultations recorded as OA, and absolute rates of 38 to 426 per 
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10,000 people aged 15 and over: considered to be most likely due to differences in recording 
practices.21 International comparisons of OA prevalence show only moderate differences between 
UK primary care consultation prevalence rates (aged 45 and over) and Swedish at 375 and 443 cases 
per 10,000 people respectively for OA and 1074 and 967 per 10,000 respectively for OA or joint 
pain.23 The rates obtained in this analysis were a little lower than generally reported at 284 per 
10,000 for OA, and a combined OA or joint pain annual consultation prevalence rate of 940 per 
10,000. This may in part reflect the use of the European Standard Population for age-
standardisation. However, unlike the CiPCA database22 used in the UK-Swedish comparison, the 
MOSAICS practices had not been through a prior regime of training and data quality assessment 
which may partly explain the difference.  
There remains a need to develop a standard definition of OA in administrative and primary care 
clinical datasets, as was highlighted by Harrold et al. for administrative data in 2000.204 This would 
not only assist the use of EHR databases for research purposes but would also facilitate a structured 
approach to care through use of recall systems and quality improvement tools such as audit.100 This 
has to some extent been tackled for come conditions through the QOF102 for conditions like COPD 
and asthma, which have to meet diagnostic criteria, and heart failure, which requires referral for 
echocardiography or a specialist opinion within a set period after diagnosis. This type of disease 
validation is harder to achieve for OA especially given the working diagnosis mandated by the 
National Collaborating Centre for Chronic Diseases4 as set out in Chapter One, section 1.2. That is 
to say, there is no external gold standard by which a diagnosis can be made.  
Delivery of enhanced diagnostic coding of OA in primary care would probably require a combination 
of strategies. A previous assessment of coding has concluded that current systems promote 
diversity rather than consistency in coding behaviours250 and this may reflect a need further to 
develop the use of diagnostic coding in practice. There is evidence that coding can be improved by 
a programme of training and feedback.22 Tai et al.250 critiqued existing methods of code selection 
in general practice and recommended a more limited set of diagnostic codes to limit unwarranted 
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variation in coding. Overall, enhanced morbidity recording seems to be feasible as demonstrated 
by the differences between databases noted above.21 Better morbidity coding might be regarded 
both as a marker of better quality of care in its own right and as a necessary prerequisite to delivery 
of better care for OA in general practice.  
 Strengths and limitations 
This analysis has a number of strengths. The use of an entire population of general practice 
population consulting with clinical OA has enabled an assessment that is free of the selection bias 
associated with some analyses, and should be more generalisable to general practice in the UK as 
a whole. The range of independent variables, which included known OA risk factors as well as 
adjustment for morbidity levels and a measure of a clinician’s OA workload (as the index 
consultation count), has reduced the risk of confounding of the associations.  
Practice 1 formed a large part of the total study population, which may have caused the results of 
the investigation to be unduly weighted by the behaviours of this practice and the characteristics 
of its practice population.  
Although the variables of interest were decided upon before the analytical work, there were 
multiple comparisons made within this analysis with no adjustment of the accepted level of 
statistical significance to reduce the probability of a type 1 error. However, Rothman argued that 
correction for multiple comparisons was not to be undertaken without a consideration of a 
corresponding rise in the risk of a type 2 error.251,252 Since interpretation has focussed more on 
consistent themes rather than on individual comparisons, an appropriate balance between these 
two types of error seems likely to have been struck.  
Many patients did not have a BMI record captured by the data download and some BMI records 
were not contemporaneous with the code used to allocate people to an OA group or joint pain. The 
apparent effect of BMI on coding behaviour may have been modified by the missing and non-
contemporaneous data. Documentation of weight status in the medical record may be more 
common with increasing BMI.253 To assess the effect of this potential bias, a sensitivity analysis was 
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conducted (not shown), reclassifying of all the BMI unknown patients to BMI <25 kgm-2, but this 
had very little effect on the adjusted ORs.  
The method of allocating patients to a morbidity load based on BNF chapter counts is a relatively 
new approach.218 The categories used of 0-4, 5-9 and 10+ drugs were based on prior work that used 
drug counts used in a 3-month period rather than the prior year.222 If an OA code represents one 
end of a severity spectrum (as inferred from the findings of Hensor et al.254 that knee OA is preceded 
by knee joint pain), one might expect that more drug groups (analgesics) be prescribed to people 
with an OA code. The use of a BNF chapter count as a measure of total morbidity may therefore 
cause the apparent morbidity level to be slightly inflated as the analgesics prescribed for OA add 
modestly to the apparent total burden. Classification of people to the morbidity groups of 0-4, 5-9 
and 10+ on the basis of 12 months’ prescriptions may not be generalisable to other definitions of 
polypharmacy that use only a week’s prescriptions in the assessment; it is however consistent with 
the work by Brilleman et al.218 Other morbidity measurements such as the Charlson Index as 
adapted for UK primary care codes255 would be an appropriate comparator methodology to validate 
the effect of morbidity itself.  
This analysis has examined associations with an OA diagnosis within a 12-month period, including 
an assessment of repeated consultation by way of a dichotomy between single and multiple clinical 
OA consultations. Ideally frequency of repeated consultations would be considered, though few 
patients in this study had more than two consultations for clinical OA. If clinicians ‘follow suit’ in 
coding behaviour, it is also possible that coding in subsequent consultations would have been 
influenced by the initial consultation (i.e. the codes used were not independent of each other at 
each time point). The potential for considerable complexity, especially where there is a crossover 
in coding between OA and joint pain within a period, made a repeated-measures approach 
unfeasible for this analysis. At the level of the patient, the effect of individual deprivation on coding 
behaviour would have been interesting to investigate: there is some evidence of an effect of social 
class, occupation, or deprivation on the incidence of musculoskeletal pain,256-260 though the effect 
on coding behaviour is unknown. A history of relevant joint trauma would also be relevant to 
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examine for effect on coding, given the evidence for trauma in the causation of some OA.212,249 
Although only 10% of the residual variance in coding OA and joint pain was estimated to be 
explained by unobserved clinician characteristics, factors that would have been desirable to analyse 
include those identified by Clarson et al. as significantly associated with agreement for an OA 
domain for the QOF or with monitoring OA (special interest in musculoskeletal disease, higher 
research or Master’s degree, familiarity with the NICE OA guidance, and working full-time). At the 
practice level, neighbourhood-level deprivation has not previously been identified to be 
significantly associated with OA incidence261 and so an effect on coding is less plausible. Practice 
size was not found by Broadbent et al.69 to be associated with quality achievement though it is 
possible that this or other practice-level variables, such as being active in education, research, or 
commissioning, may be associated with coding behaviour.  
Initially, a decision rule for the reclassification of joint pain to OA or ‘not OA’ was trialled but the 
information contained within the available consultation data was insufficient to apply a rule set. 
Despite several attempts to formalise the process, and to record the reasons behind the conclusion 
reached for each consultation, it remained a very subjective process (albeit one undertaken by 
three experienced clinicians). The process of agreeing on a reclassification outcome was limited as 
there was no measure of intra-rater reliability due to lack of availability of clinician time. 
 Conclusions 
Currently-used estimates of OA prevalence based on administrative datasets or primary care EHRs 
seem likely to be inaccurate as those that exclude all joint pain are insufficiently sensitive but those 
that accept joint pain as a synonym for OA are insufficiently specific. On the basis of the data 
presented in this analysis, a definition of clinical OA from the primary care EHR may be considered 
to be more specific and valid if it excluded joint pain codes for sites of ankle/foot and wrist/hand.  
Factors associated with increased odds of an OA diagnosis rather than joint pain code were mainly 
those known to be associated with increased risk of OA. It is not known to what extent the presence 
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of these risk factors was influencing a clinical decision to code a patient as OA rather than joint pain 
even where the underlying problem was similar. 
Development of improved coding techniques for OA and joint pain in primary care is needed better 
to define OA for ongoing clinical management and for OA studies in clinical databases. Analysis of 
joint pain coding to assess which codes were more likely to represent OA in the population as a 
whole or within subpopulations may help to make a definition of OA based on GP-recorded Read 
codes a viable prospect with the potential for better opportunity for structured disease 
management.  
Having considered here the clinical OA morbidity coding in phase one or MOSAICS, the next chapter 
will consider the quality of care for OA in general practice as measured from routinely-recorded 
data in the same phase.  
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Chapter Five: Baseline quality of care achievement for OA: a cross-
sectional analysis 
5.1 Introduction 
This chapter will provide an overview of the routinely recorded assessment and management of 
clinical OA in primary care. It is intended to show how the routinely coded electronic record can be 
used to assess some aspects of the recorded quality of care for OA and to highlight its limitations 
in measuring quality of care. It acts as a prelude to the quality assessment made through the 
template, which is discussed in the next chapter.  
Previous assessments of OA care have been described in Chapter One: success criteria used 
previously to determine the quality of care for OA have been variable. Although the OA quality 
indicators proposed in Chapter Two have an apparently clear numerator and denominator, the 
implementation of these or similar indicators in previous studies has tended to be dependent upon 
a somewhat broader interpretation of achievement of the quality criterion. Li et al.,80 in an 
assessment of the non-pharmacological care of OA through a survey self-report, used ‘severe’ or 
‘extreme’ pain on walking as the denominator and at least one visit to a physiotherapist or 
occupational therapist in the preceding year as the numerator (success criterion) for the quality 
indicator relating to assessment for ambulatory assistive devices for people with difficulty walking 
for at least three months. Similar interpretations were used for non-ambulatory assistive devices. 
Broadbent et al.69 used well-defined indicators but it was not apparent from the published article 
exactly how the numerator was arrived at – for example, clinical experience would suggest it 
unlikely that routine records would contain details that patients with OA had been offered 
information about its natural history, treatment, and self-management and yet there was a 30% 
pass rate identified for this indicator; a wider interpretation of the success criteria than that 
suggested by the indicator is therefore presumed. Influences relevant to UK general practice on 
recorded quality of care for OA have been suggested to include: patient age (different effects by 
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indicator), sex (female associated with higher achievement than male) and disease severity (severe 
OA associated with better achievement than less severe).69 
As noted in Chapter Three, there are many aspects of care for OA that are not the subject of routine 
coding, including the assessment of pain and function, information and education provision, and 
assessments of over-the-counter drug use. Zingmond et al.79 also found a lack of routine 
administrative data (similar to the electronic, coded information used in the MOSAICS medical 
record review study) hampered use of various indicators such as referral to an exercise programme, 
use of paracetamol, and oral NSAID risk communication. The assessment of quality of usual care 
described in this chapter is dependent upon those aspects of care that were routinely recorded and 
this required a similarly inclusive approach to the definition of success criteria as described above.  
The aims of this analysis were (i) to describe the baseline level of recommended and non-
recommended processes of care for OA in general practice identifiable from routinely recorded 
information (prior to the template installation), (ii) to validate which quality indicators for OA in 
general practice were usable without modification to recording practices, and (iii) to estimate 
associations between quality achievement and characteristics of patients and clinicians.  
5.2 Method 
 Denominator population 
This analysis was conducted on the same group of patients included in the analysis reported in 
Chapter Four, with the same use of an index consultation and index clinician as described in section 
4.2.  
 Assessed characteristics 
The independent variables assessed for their association with recorded achievement in this analysis 
were the same as those described in Chapter Four, section 4.2.  
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 Quality indicators and their success measures 
All of the processes analysed in this chapter are linked to quality of care as described by the NICE 
OA guidelines5 or the systematic review of primary care OA quality indicators described in Chapter 
Two.107 An additional indicator, relating to non-use of oral NSAIDs in the presence of relative 
contraindications, was derived by the candidate from advice in the British National Formulary 
(BNF).217 The indicators are listed in Table 5-1. 
Table 5-1: Quality assessment indicator domains for routinely recorded management of OA 
Indicator Source 
‘To do’ indicators  
Assessment of pain Systematic review 
Assessment of function Systematic review 
Evidence of education or advice for OA Systematic review 
Exercise or physiotherapy referral Systematic review 
Exercise assessment Systematic review 
Weight record 
[Prerequisite for weight 
loss advice indicator] 
Weight loss advice for people with a working diagnosis of OA and 
a BMI ≥25kgm-2  
Systematic review 
Assessment or referral for assistive devices (ambulatory or 
nonambulatory) – intended for people with functional impairment 
Systematic review 
Prescription for paracetamol  Systematic review 
Prescription for topical NSAIDs NICE guidelines5 
Prescription for standard oral NSAIDs  Systematic review 
Evidence of documentation of NSAID risk assessment (for people 
receiving a prescription for oral NSAIDs) 
Systematic review 
Co-prescription of gastroprotection (for people prescribed oral 
NSAIDs) 
Systematic review 
Prescription for capsaicin  NICE guidelines5 
Prescription for orlistat (weight loss agent) NICE guidelines5 
Completion of all the above before specialist referral.  Systematic review 
‘Do not do’ indicators  
Use of X-rays NICE guidelines5 
Prescription for oral NSAIDs in the context of relative 
contraindications 
British National 
Formulary217 
Prescription for etoricoxib 60mg (NSAID) NICE guidelines5 
Prescription for topical rubefacients NICE guidelines5 
Prescription for glucosamine NICE guidelines5 
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The indicators used were dependent upon coded data which could be analysed straightforwardly 
in standard statistical software programs rather than on the narrative contained within electronic 
or paper records. Some indicators from the systematic review were not relevant to this assessment 
of care – primary prevention of OA through weight loss for people who are overweight was 
excluded as the denominator population was people with established clinical OA, and first-use of 
paracetamol could not reliably be established due to the time-limited nature of the dataset. 
Individual and population-level indicators 
For most indicators, an assessment of the quality of care depends on aggregation of recorded 
outcomes to a population level. Some indicators were applicable to all patients – for example, pain 
and function assessment should be conducted annually at least (see the proposed indicators 
resulting from the systematic review, Chapter Two, section 2.3.2). Weight loss advice for people 
known to be overweight would also be applicable every year. Other indicators would not 
necessarily be recorded for all patients each year and so should be regarded as population-level 
measures. The relatively safe pharmacological management options may not be appropriate on an 
individual level but at a population level, better care would be likely to be associated with higher 
levels of recorded prescription. Some aspects of care were considered in the systematic review107 
to be necessary once after an OA diagnosis (education, exercise prescription), or annually (exercise 
review, weight loss advice for people who were considered overweight). Some outcomes were 
considered to be relatively undesirable at a population level on the basis of the 2008 NICE OA 
guidelines.5 In general, one might expect that the first-line agents (paracetamol and topical NSAIDs), 
along with gastroprotection for people prescribed oral NSAIDs, should be relatively commonly 
recorded compared to other agents. X-ray use should be relatively sparing given the NICE guidance 
on X-ray use.  
All patients consulting with clinical OA should ideally be recorded as having received an assessment 
of pain and function, an exercise review, and weight loss advice where the patient is known to be 
overweight. For other indicators, it was not possible to set target levels for the proportion of 
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patients expected to be recorded as ‘achieving’ them (prescriptions, X-rays, referrals) as 
requirements for treatment would vary with case mix.262 
Time period for quality indicator success 
The QOF102 uses a period of 12 months for achievement in many processes-of-care (such as asthma 
or diabetes reviews, and stroke risk assessment in atrial fibrillation) and six months for some 
prescribing processes (such as the definition of “currently treated” for some drugs after myocardial 
infarction or in heart failure).263 A single instance of the qualifying code is typically sufficient under 
the QOF processes for an indicator to have been achieved, except for value-based data (such as 
blood pressure measurement or laboratory results), which require the latest entry before QOF year-
end to be at or below a certain threshold. It was not possible to use the same approach for OA, as 
there were very few OA-specific process codes identified in the Read dictionary. Codes that could 
be used to define quality indicator achievement in OA were equally applicable to some other 
conditions. Although optimal temporal linkage would require the same date for processes of care 
and the clinical OA consultation code entry, a 14 days ‘grace period’ was added on the basis that at 
a consultation, the need for further assessment and treatment may be identified. Fourteen days 
was selected arbitrarily as the cut-off for such follow up, in line with previous practice at the RIPCHS 
for consideration of allocation of drug treatment to a consultation.264 The potential for mis-
attribution of care processes is acknowledged but it would be unusual for patients to consult 
general practice twice within a 14-day period as the median number of consultations per person 
per year was estimated at 5.4 (2008 figures).265 It was also possible that some care processes (such 
as for repeat prescriptions, for example) may be related to clinical OA but fall outside the 14 day 
period. As a compromise between over- and under-inclusiveness, it was determined that quality 
indicators could be achieved by a record of the success criteria within 14 days of any consultation 
for clinical OA in phase one. 
As a sensitivity analysis, the assessment codes, prescribing and referral data were also examined 
across the whole of phase one such that anyone consulting with clinical OA who had received the 
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process of care or prescription any time within phase one were included in the numerator for 
indicator achievement.  
Morbidity assessment and advice indicators 
The same Read codes were used as for the estimation of routinely-recorded care in CiPCA (Chapter 
Three, section 3.4). For each care process (assessment of pain and function, education, exercise 
assessment, exercise advice, weight loss advice, NSAID risk assessment), the indicator was regarded 
as achieved if there was a relevant Read code present in the electronic health record (EHR) within 
the time frame of interest. Records of relevant X-rays were treated in the same way. 
Prescription indicators 
The prescription of paracetamol, topical NSAIDS, opioids, oral NSAIDs, gastroprotection, capsaicin, 
and weight loss agents were assessed. It was not possible to identify from the records available 
what treatment, if any, had been trialled previously due to the time-limited nature of the data 
collection. Assumptions about quality of care were based on population levels of prescription, on 
the basis that relatively safe options (paracetamol, topical NSAIDs) should be prescribed more 
commonly than other analgesics within populations although at an individual level other 
treatments may be more clinically appropriate. Opioids in OA treatment have been identified in 
Cochrane reviews to have only small-to-moderate benefits and these were deemed to be 
outweighed by a substantial increase in risk of harm or withdrawal due to lack of tolerability.266,267 
A relatively low level of opioid prescribing would therefore be expected. Oral NSAID use could not 
be benchmarked against a gold standard target. NICE recommended that paracetamol and topical 
NSAIDs should be considered ahead of oral NSAIDs,5 so one might anticipate a lower level of oral 
NSAIDs compared to the two relatively safe analgesic options.267 
NICE mandate the use of PPIs for gastroprotection5 and so patients prescribed oral NSAIDs in the 
period of interest were assessed for PPI prescription in the same period. Since not all patients 
tolerate PPIs well, an additional descriptive analysis examined prescription of other 
gastroprotective agents in patients not prescribed a PPI. For the analysis of oral NSAID prescriptions 
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within 14-days of a clinical OA consultation, achievement was taken as a PPI prescription within the 
same time frame. The sensitivity analysis examined all gastroprotection prescriptions within phase 
one.  
The only licensed weight loss drug available for prescription during the study period was orlistat. 
This  has a stated indication for use in people with a body mass index (BMI) of 30 kgm-2 or more, 
and in individuals with a BMI of 28 kgm-2or more in the presence of other clinical risk factors.217 This 
analysis examined only people with the higher (obesity) BMI threshold as the presence of additional 
clinical risk factors had not been determined. It was not possible to set an expected level of orlistat 
prescribing given the known problems with tolerability and effectiveness.268 
Treatments recommended by NICE not to be given (etoricoxib 60mg, topical rubefacients, and 
glucosamine)5 were also assessed, with an expectation of non-use or only low level use of these 
drugs (low-level use might be expected due to difficulties in negotiating treatment cessation if 
patients have been taking these agents with a perception of benefit previously, and sometimes 
clinicians do not adhere to treatment guidelines for other potentially valid reasons).  
Relative contraindications to oral NSAID treatment 
There are many potential absolute and relative contraindications to treatment with oral NSAIDs set 
out in the BNF.217 Relevant comorbidities, identified on the basis of clinical experience augmented 
by the BNF217 and Read code browser,148 are shown in Box 5-1. This is not a comprehensive list of 
contraindications: others exist but were not selected due to limitations in retrieving some 
information from the electronically coded record (for example, NSAID-triggered asthma is not 
included). The use of a 24-month period was estimated (on the basis of an examination by the 
candidate of data from CiPCA21,22) to provide 90% sensitivity to the presence of a relevant co-morbid 
condition in the medical record compared to a 36-month period and so, for reasons of data 
download practicalities, a 24-month period prior to commencement of phase one was used to 
capture comorbidity. 
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It was not possible to set an expected level of oral NSAID prescription in the presence of recorded 
relative comorbid contraindications, as the clinical justification for such a prescription would vary 
depending upon OA severity, response to other treatments, comorbidity severity, and patient and 
clinician beliefs about balances of risks and benefits. The analysis was exploratory, with an 
expectation that levels of oral NSAID prescribing would be low where a relative comorbidity 
contraindication was present in the EHR within the two years prior.  
Box 5-1: Comorbidities as relative contraindications to oral NSAIDs 
Co-morbidity Read codes and terms 
- 195.. Indigestion symptoms (+ child codes) 
- 1Z1..  Chronic renal impairment (+ child codes) 
- G2… Hypertensive disease (+ child codes) 
- G3… Ischaemic heart disease (+ child codes) 
- G58.. Heart failure (+ child codes) 
- G6… Cerebrovascular disease (+ child codes) 
- G70.. Atherosclerosis (+ child codes) 
- G73.. Other peripheral vascular disease (+ child codes) 
- J1... Oesophageal, stomach and duodenal diseases (+ child codes) 
- J60.. Acute and subacute liver necrosis (+ child codes) 
- J61.. Cirrhosis and chronic liver disease (+ child codes) 
- J622. Hepatic coma 
- J623. Portal hypertension 
- J624. Hepatorenal syndrome 
- J625. [X] Hepatic failure 
- J62y. Other sequelae of chronic liver disease 
- J62z. Liver abscess and chronic liver disease causing sequelae NOS 
- J63.. Other liver disorders (+ child codes) 
- J68.. Gastrointestinal haemorrhage (+ child codes) 
- K0... Nephritis, nephrosis and nephrotic syndrome (+ child codes) 
- R071. [D]Heartburn. (+ child codes) 
Referral quality indicators 
Referral, within 14 days of a clinical OA consultation, to other services for exercise (physiotherapy 
or other specified exercise programmes), physiotherapy alone (as a proxy for ambulatory assistive 
devices), occupational therapy referral (as a proxy for non-ambulatory assistive devices), and 
specialist input was determined for all patients consulting in phase one. Referral at any point within 
phase one was also determined as a sensitivity analysis, though this was not used in the assessment 
of associations between referral outcome and the independent variables of interest.  
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 Data analysis 
Quality of care was described in terms of the percentage of patients achieving the indicators in 
phase one (baseline, 12 months prior to template installation), overall and stratified by the 
characteristics listed in Chapter Four (section 4.2), with the addition of diagnostic group (OA or joint 
pain at the index consultation) as an independent variable.  
Multilevel logistic regression analyses (patients within index clinician, adjusting for practice through 
the use of dummy variables) were used to estimate associations between the baseline patient 
characteristics and the clinician index consultation count, and quality indicator achievement. Except 
where stated, models were estimated using second-order penalised quasi-likelihood (PQL2) 
approximations. Results are presented as ORs with 95% CI. The random slope effects of age, sex, 
and BMI by clinician were assessed, on the basis that studies have previously identified age and sex 
discrimination,269-271 and clinicians have previously been found to be prone to negative stereotypes 
about obesity.272 Adjusted three-level models, of patients within index clinician within practice, 
were tested as sensitivity analyses and are reported in Appendix F (the findings were similar to the 
adjusted two-level models). Some processes of care were too infrequently provided for any logistic 
regression model to be used successfully; these are identified and descriptive epidemiology used 
to assess patterns of provision.  
The data were analysed in SPSS v21,230 Stata 13.1233 and MLwiN273 using the runMLwiN235 command. 
Results are presented as counts with percentages for the descriptive epidemiology, and OR with 
95% CI for the multilevel models. Statistically significant associations in the adjusted two-level 
logistic regression models are shown in the results with positive associations in blue bold text and 
negative in red bold. 
5.3 Results 
Except where specified, in the multilevel model analyses no statistically significant sex*age 
interaction, or random slope effects across clinicians for sex, age, or BMI status was identified. In 
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the three-level models of patients within clinicians within practices no statistically significant 
explanation of variance at the practice level was identified.  
 Baseline characteristics 
The baseline characteristics for the population of clinical OA consulters in phase one are shown in 
Table 5-2 (these were shown for OA and joint pain consulters in Chapter Four, Table 4-6). As shown 
in Chapter Four, the ratio of people recorded only with joint pain to those diagnosed with OA 
formally was approximately 2:1 (65.9% joint pain only). A majority were female (60.5%). Knee was 
the site of disease most frequently recorded (48.2%) followed by hip (21.6%) with ankle/foot (6.5%) 
and unspecified sites (4.8%) the least frequently recorded. Only 14.2% were known not to be 
overweight, 28.8% were known to be obese, and one-third had no recorded BMI status. Half of 
consulters were in the lowest morbidity band of 0-4 BNF chapters and 21.2% in the greatest. Few 
patients had an X-ray recorded within phase one before the index consultation (7.3%). Single 
consultations were recorded in 60.5% and multiple in 39.5% of consulters. 
The denominator population for the majority of assessments was the population consulting with 
clinical OA in phase one (n=3145). For measurements of gastroprotection and etoricoxib 60mg, the 
denominator was the proportion of patients prescribed an oral NSAID (n=565). For the oral NSAIDs 
in the presence of a relative comorbidity contraindication, the denominator was the number of 
clinical OA consulters with a recorded comorbidity in the period of up to two years before the start 
of phase one (n=1599). Assessment of prescribing of orlistat (for weight loss) had a denominator 
population of 907 people (all those known to have a BMI≥30kgm-2). 
 Quality indicator assessment 
Patient assessment and advice indicators: Read-coded elements of consultations 
No patients were recorded as receiving education or an oral NSAID risk assessment within 14 days 
of a clinical OA consultation or within phase one overall; these processes of care are not shown in 
Table 5-3. 
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Pain assessment was not recorded within 14 days of a clinical OA consultation in phase one at all 
(Table 5-3), and only six OA-consulters (0.2%) had a recorded pain assessment at any time within 
phase one overall. Function assessment likewise was not recorded within 14 days of a clinical OA 
consultation and only 11 patients (0.3%) had such an assessment recorded at any time in phase 
one. Exercise assessment was not recorded within 14 days of a clinical OA consultation but was 
recorded in nine (0.3%) clinical OA consulters within phase one overall. Exercise advice (three 
patients, 0.1%) and weight advice (one patient, 0.1%) were infrequently recorded, always within 14 
days of a clinical OA consultation.  
Table 5-2: Baseline characteristics of MOSAICS clinical OA consulters, 
phase one 
  n (%) 
Total 
 
3145 
Diagnostic group 
Joint pain 2071 (65.9) 
OA 1074 (34.1) 
Sex Female 1904 (60.5) 
Age band 
45-64 1477 (47.0) 
65-74 842 (26.8) 
75-84 598 (19.0) 
85+ 228 (7.2) 
Site of disease 
Knee 1516 (48.2) 
Hip 678 (21.6) 
Ankle/foot 204 (6.5) 
Wrist/hand 272 (8.6) 
Unspecified 150 (4.8) 
Multiple 325 (10.3) 
BMI status 
Not overweight 448 (14.2) 
25<=BMI<30 745 (23.7) 
BMI>=30 907 (28.8) 
Unknown 1045 (33.2) 
Morbidity load (BNF chapter count) 
0-4 1574 (50.0) 
5-9 905 (28.8) 
10+ 666 (21.2) 
X-ray, phase 1a 231 (7.3) 
Multiple consultations 1241 (39.5) 
arelevant recorded X-ray in phase one prior to index consultation  
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Table 5-3: Frequency of recording of holistic assessment and core management processes in phase one. 
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Overall  0 (0) 6 (0.2) 0 (0) 11 (0.3) 0 (0) 9 (0.3) 3 (0.1) 3 (0.1) 1 (0.1) 1 (0.1) 
Diagnostic group 
Joint pain - 4 (0.2) - 4 (0.2) - 6 (0.3) 2 (0.1) 2 (0.1) 0 (0.0) 0 (0.0) 
OA - 2 (0.2) - 7 (0.7) - 3 (0.3) 1 (0.1) 1 (0.1) 1 (0.2) 1 (0.2) 
Sex 
Female - 4 (0.2) - 6 (0.3) - 3 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Male - 2 (0.2) - 5 (0.4) - 6 (0.5) 3 (0.2) 3 (0.2) 1 (0.1) 1 (0.1) 
Age 
45-64 - 4 (0.3) - 0 (0.0) - 2 (0.1) 1 (0.1) 1 (0.1) 1 (0.1) 1 (0.1) 
65-74 - 1 (0.1) - 1 (0.1) - 3 (0.4) 1 (0.1) 1 (0.1) 0 (0.0) 0 (0.0) 
75-84 - 1 (0.2) - 6 (1.0) - 2 (0.3) 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 
85+ - 0 (0.0) - 4 (1.8) - 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Site 
Knee - 1 (0.1) - 6 (0.4) - 3 (0.2) 3 (0.2) 3 (0.2) 1 (0.1) 1 (0.1) 
Hip - 1 (0.1) - 2 (0.3) - 2 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Ankle/Foot - 1 (0.5) - 0 (0.0) - 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Wrist/Hand - 1 (0.4) - 0 (0.0) - 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Unspecified - 0 (0.0) - 1 (0.7) - 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Multiple - 2 (0.6) - 2 (0.6) - 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
BMI Category 
BMI <25 - 4 (0.9) - 1 (0.2) - 3 (0.7) 0 (0.0) 0 (0.0) - - 
BMI 25 to <30 - 0 (0.0) - 3 (0.4) - 1 (0.1) 1 (0.1) 1 (0.1) - - 
BMI 30+ - 2 (0.2) - 3 (0.3) - 3 (0.3) 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.1) 
Unknown - 0 (0.0) - 4 (0.4) - 2 (0.2) 2 (0.2) 2 (0.2) - - 
           (con’t) 
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BNF chapter count 
0-4 - 2 (0.1) - 1 (0.1) - 4 (0.3) 1 (0.1) 1 (0.1) 0 (0.0) 0 (0.0) 
5-9 - 3 (0.3) - 3 (0.3) - 2 (0.2) 2 (0.2) 2 (0.2) 1 (0.2) 1 (0.2) 
10+ - 1 (0.2) - 7 (1.1) - 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
X-ray, phase 1a  
No  4 (0.1)  11 (0.4)  7 (0.2) 3 (0.1) 3 (0.1) 1 (0.1) 1 (0.1) 
Yes - 2 (0.9) - 0 (0.0) - 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Multiple consultations 
Single - 4 (0.2) - 2 (0.1) - 4 (0.2) 3 (0.2) 3 (0.2) 0 (0.0) 0 (0.0) 
Multiple - 2 (0.2) - 9 (0.7) - 5 (0.4) 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.1) 
Staff index consultation count 
At or below the median - 0 (0.0) - 0 (0.0) - 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Above the median - 6 (0.2) - 11 (0.4) - 8 (0.3) 3 (0.1) 3 (0.1) 1 (0.1) 1 (0.1) 
arelevant recorded X-ray in phase one prior to index consultation  
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity analysis considered processes at any point within phase one. 
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Due to low levels of recording of these processes within 14 days of a consultation for clinical OA, 
no logistic regression analysis to assess associations with baseline characteristics was possible for 
any of these outcomes. 
Patient assessment indicators: weight records and X-ray use 
10% of patients consulting for clinical OA in phase one had a recorded weight within 14 days of such 
a consultation (Table 5-4). Achievement of weight recording considered across the whole of phase 
one of a clinical OA consultation was substantially better at 49.9%. Compared to age band 45-64, 
patients in age bands 75-84 (adjusted OR 0.64, 95% CI 0.44,0.93) and 85+ (adjusted OR 0.31, 95% 
CI 0.15,0.63) had significantly lower odds of weight recording and those with an unknown BMI 
status before the index consultation also had lower adjusted odds at 0.41 (95% CI 0.26,0.64) 
compared to BMI known not to be overweight. Those with multiple OA or joint pain consultations 
had greater odds of a weight measurement within 14 days (adjusted OR 2.38, 95% CI 1.83,3.10), 
compared to single consulters. Estimates of the VPC suggested that 7% of variation was explained 
by unobserved clinician-level factors in the null model, reducing to 3% in the adjusted model.  
18.5% of clinical OA consulters had an X-ray within 14 days of their index consultation. X-ray use 
across the whole of phase one was slightly greater at 25.8% overall. People with an OA diagnosis 
had reduced odds of an X-ray within 14 days of a clinical OA consultation compared to joint pain 
(adjusted OR 0.54, 95% CI 0.41,0.71), although the unadjusted proportion of people with a recorded 
X-ray was greater in the OA group. Patients in the oldest age band (85+) had reduced odds of a 
recorded X-ray compared to the youngest (45-64) (adjusted OR 0.48, 95% CI 0.28,0.82). Compared 
to the knee, people with hip disease had greater odds of a recorded X-ray (adjusted OR 1.92, 95% 
CI 1.46,2.51) but those with ankle/foot, hand/wrist disease or unspecified site were less likely to be 
X-rayed. Other associations with recorded X-ray use were BMI status overweight compared to not 
overweight (adjusted OR 1.61, 95% CI 1.10,2.34), multiple clinical OA consultation compared to 
single (adjusted OR 4.99, 95% CI 3.95,6.31), and X-ray use before the index consultation (adjusted 
OR 1.82, 95% CI 1.30, 2.55). Those with higher levels of morbidity had reduced odds of X-ray use 
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compared to the lowest (adjusted OR 0.63, 95% CI 0.46, 0.87). Estimates of the VPC suggested that 
44% of variation was explained by unobserved clinician-level factors in the null model, reducing to 
4% in the adjusted model. 
Table 5-4: Weight and X-ray records in phase one. 
 
 Weight 
record  
within 14 
days 
n (%) 
Weight 
record  
at any point 
in phase 1 n 
(%) 
X-ray record 
within 14 
days n (%) 
X-ray record 
at any point 
in phase 1 n 
(%) 
Overall  314 (10.0) 1569 (49.9) 583 (18.5) 811 (25.8) 
Diagnostic group 
Joint pain 191 (9.2) 1024 (49.4) 375 (18.1) 505 (24.4) 
OA 123 (11.5) 545 (50.7) 208 (19.4) 306 (28.5) 
Sex 
Female 175 (9.2) 934 (49.1) 361 (19.0) 504 (26.5) 
Male 139 (11.2) 635 (51.2) 222 (17.9) 307 (24.7) 
Age 
45-64 162 (11.0) 679 (46.0) 288 (19.5) 399 (27.0) 
65-74 92 (10.9) 461 (54.8) 161 (19.1) 216 (25.7) 
75-84 51 (8.5) 331 (55.4) 110 (18.4) 155 (25.9) 
85+ 9 (3.9) 98 (43.0) 24 (10.5) 41 (18.0) 
Site 
Knee 155 (10.2) 744 (49.1) 276 (18.2) 367 (24.2) 
Hip 56 (8.3) 335 (49.4) 174 (25.7) 255 (37.6) 
Ankle/Foot 16 (7.8) 108 (52.9) 18 (8.8) 30 (14.7) 
Wrist/Hand 24 (8.8) 143 (52.6) 30 (11.0) 44 (16.2) 
Unspecified 13 (8.7) 75 (50.0) 9 (6.0) 14 (9.3) 
Multiple 50 (15.4) 164 (50.5) 76 (23.4) 101 (31.1) 
BMI Category 
BMI <25 45 (10.0) 255 (56.9) 70 (15.6) 102 (22.8) 
BMI 25 to <30 76 (10.2) 455 (61.1) 157 (21.1) 209 (28.1) 
BMI 30+ 145 (16.0) 635 (70.0) 186 (20.5) 264 (29.1) 
Unknown 48 (4.6) 224 (21.4) 170 (16.3) 236 (22.6) 
BNF chapter count 
0-4 136 (8.6) 648 (41.2) 297 (18.9) 403 (25.6) 
5-9 95 (10.5) 503 (55.6) 176 (19.4) 248 (27.4) 
10+ 83 (12.5) 418 (62.8) 110 (16.5) 160 (24.0) 
X-ray, phase 1a 
No 280 (9.6) 1452 (49.8) 479 (16.4) 580 (19.9) 
Yes 34 (14.7) 117 (50.6) 104 (45.0) 231 (100.0) 
Multiple 
consultations 
Single 126 (6.6) 934 (49.1) 200 (10.5) 331 (17.4) 
Multiple 188 (15.1) 635 (51.2) 383 (30.9) 480 (38.7) 
Staff index 
consultation count 
At or below the 
median 
17 (8.0) 120 (56.3) 55 (25.8) 75 (35.2) 
Above the 
median 
297 (10.1) 1449 (49.4) 528 (18.0) 736 (25.1) 
arelevant recorded X-ray in phase one prior to index consultation  
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity 
analysis considered processes at any point within phase one. 
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Table 5-5: Estimates of associations between weight record and relevant X-ray 
within 14 days of a clinical OA consultation and the independent variables 
 
Weight record 
adjusted OR 
(95% CI) 
Relevant X-ray 
adjusted OR 
(95% CI) 
Diagnosis OA (reference: joint 
pain) 1.00 (0.75,1.34)  0.54 (0.41,0.71) 
Sex (reference: female) 1.26 (0.98,1.62) 0.88 (0.70,1.10) 
Age 65-74 (reference: 45-64) 0.89 (0.66,1.19) 1.15 (0.88,1.51) 
Age 75-84  0.64 (0.44,0.93) 1.07 (0.78,1.47) 
Age 85+  0.31 (0.15,0.63)  0.48 (0.28,0.82) 
Hip (reference: knee) 0.88 (0.63,1.23)  1.92 (1.46,2.51) 
Ankle/foot 0.85 (0.48,1.49)  0.54 (0.31,0.95) 
Wrist/hand 1.05 (0.65,1.69)  0.55 (0.35,0.88) 
Unspecified 0.91 (0.48,1.71)  0.39 (0.18,0.86) 
Multisite 1.22 (0.83,1.79) 1.01 (0.70,1.45) 
BMI 25 to <30  
(reference: BMI <25) 0.93 (0.62,1.39)  1.61 (1.10,2.34) 
BMI 30+ 1.40 (0.96,2.05) 1.26 (0.87,1.81) 
BMI unknown  0.41 (0.26,0.64) 1.09 (0.76,1.57) 
5-9 BNF chapters (reference: 0-4) 1.05 (0.77,1.42) 0.90 (0.69,1.18) 
10+ BNF chapters 1.35 (0.96,1.89)  0.63 (0.46,0.87) 
Multiple consultations in phase 1 
(vs. single)  2.38 (1.83,3.10)  4.99 (3.95,6.31) 
X-ray, phase 1a 1.39 (0.89,2.16)  1.82 (1.30,2.55) 
Above the clinician median index 
consultation count (reference: at 
or below the median) 1.34 (0.74,2.40) 1.06 (0.69,1.65) 
Practice 2 (reference: Practice 1) 1.52 (0.73,3.16) 0.90 (0.46,1.78) 
Practice 3  0.53 (0.29,0.97)  0.12 (0.07,0.21) 
Practice 4 1.59 (0.98,2.60)  0.01 (0.00,0.05) 
Practice 5 1.29 (0.77,2.17)  0.01 (0.00,0.05) 
Practice 6 1.88 (0.96,3.67)  0.01 (0.00,0.08) 
Practice 7 0.93 (0.53,1.64) 1.42 (0.92,2.19) 
Practice 8 1.04 (0.51,2.14) 0.83 (0.46,1.50) 
VPCb (null model) 0.07 (0.02,0.11) 0.44 (0.33,0.52) 
VPCb (adj. model) 0.03 (0.00,0.07) 0.04 (0.00,0.07) 
arelevant recorded X-ray in phase one prior to index consultation; bvariance 
partition coefficient. Adjusted for all covariates. 
Prescribing assessment using routine prescription data 
The prescribing processes are shown grouped into those recommended by NICE as first-line 
relatively safe options, the second-tier options, and those recommended not to be used.  
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Recommended relatively-safe pharmacological options 
Paracetamol prescription within 14 days of a clinical OA consultation was recorded at 13.8% overall 
(Table 5-6). Analysis of paracetamol prescription across the whole of phase one showed that there 
was a much greater proportion of people prescribed paracetamol once the restriction to 14 days of 
a clinical OA consultation was removed (29.1% overall). A significant association for paracetamol 
prescription within 14 days of a clinical OA consultation was found for a formal OA diagnosis 
compared to joint pain code (adjusted OR 1.58, 95% CI 1.23,2.03). Males had lower odds of a 
paracetamol prescription (adjusted OR 0.76, 95% CI 0.60,0.95) compared to females. Increasing age 
had a gradient of increasing odds up to OR 3.75 (95% CI 2.53,5.55) for people in age band 85+, 
compared to 45-64 years. Site effects varied: people with hip disease had slightly increased odds of 
prescription compared to knee disease (adjusted OR 1.47, 95% CI 1.04,1.79) whilst those with 
ankle/foot disease had reduced odds (adjusted OR 0.51, 95% CI 0.27,0.96). Increasing morbidity 
showed a gradient of increasing odds up to adjusted OR 2.04 (95% CI1.53,2.74) for people 
prescribed from 10+ BNF chapters compared to 0-4. People with multiple clinical OA consultations 
in phase one also had increased odds of prescription (adjusted OR 1.83 [95% CI 1.46,2.30] compared 
to single consultation). Estimates of the VPC suggested that 3% of variation was explained by 
unobserved clinician-level factors in the null model, reducing to 1% in the adjusted model. 
Topical NSAID use within 14 days of a clinical OA consultation was recorded in 16.5% of patients 
with clinical OA. There was no association between odds of a topical NSAID prescription and receipt 
of an OA diagnosis compared to joint pain (adjusted OR 0.97, 95% CI 0.75,1.24). Similar to 
paracetamol, there was an apparent gradient of increasing odds of prescription of a topical NSAID 
with increasing age (adjusted OR 2.71 [95% CI 1.80,4.07] for people in age band 85+ compared to 
45-64 years). Males again had reduced odds of prescription compared to females (adjusted OR 0.67, 
95% CI 0.53,0.83). Patients with disease at the hip (adjusted OR 0.34, 95% CI 0.25,0.47) and 
ankle/foot (adjusted OR 0.53, 95% CI 0.32,0.88) had reduced odds of prescription compared to 
those with knee disease. Increasing morbidity was associated with increased odds of prescription 
(adjusted OR 1.82 [95% CI 1.37,2.41] for people prescribed from 10+ BNF chapters compared to 0-
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4). Multiple clinical OA consultation was associated with increased odds of topical NSAID 
prescription (adjusted OR 1.59, 95% CI 1.27,1.98). Estimates of the VPC suggested that 11% of 
variation was explained by unobserved clinician-level factors in the null model, reducing to 10% in 
the adjusted model. 
The proportions of people receiving either paracetamol or topical NSAIDs within 14 days of a clinical 
OA consultation was 27.1%), and within phase one overall 48.0%. Findings from the multilevel 
modelling were very similar to those for topical NSAIDs alone although (similar to paracetamol 
prescription alone) having a OA diagnosis compared to joint pain was associated with increased 
odds of prescription of either topical NSAID or paracetamol (adjusted OR 1.27, 95% CI 1.03,1.55). 
Estimates of the VPC suggested that 5% of variation was explained by unobserved clinician-level 
factors in both the null and adjusted models. 
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Table 5-6: Frequency of recommended relatively safe pharmacological options in phase one 
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Overall  435 (13.8) 916 (29.1) 520 (16.5) 1038 (33.0) 853 (27.1) 1511 (48.0) 
Diagnostic  
group 
Joint pain 216 (10.4) 507 (24.5) 317 (15.3) 629 (30.4) 479 (23.1) 889 (42.9) 
OA 219 (20.4) 409 (38.1) 203 (18.9) 409 (38.1) 374 (34.8) 622 (57.9) 
Sex 
Female 294 (15.4) 618 (32.5) 357 (18.8) 707 (37.1) 583 (30.6) 1007 (52.9) 
Male 141 (11.4) 298 (24.0) 163 (13.1) 331 (26.7) 270 (21.8) 504 (40.6) 
Age 
45-64 100 (6.8) 223 (15.1) 159 (10.8) 326 (22.1) 240 (16.2) 456 (30.9) 
65-74 124 (14.7) 264 (31.4) 177 (21.0) 321 (38.1) 267 (31.7) 465 (55.2) 
75-84 147 (24.6) 292 (48.8) 131 (21.9) 280 (46.8) 243 (40.6) 412 (68.9) 
85+ 64 (28.1) 137 (60.1) 53 (23.2) 111 (48.7) 103 (45.2) 178 (78.1) 
Site 
Knee 189 (12.5) 403 (26.6) 282 (18.6) 520 (34.3) 417 (27.5) 707 (46.6) 
Hip 116 (17.1) 231 (34.1) 60 (8.8) 181 (26.7) 159 (23.5) 323 (47.6) 
Ankle/Foot 12 (5.9) 38 (18.6) 23 (11.3) 57 (27.9) 33 (16.2) 79 (38.7) 
Wrist/Hand 18 (6.6) 50 (18.4) 54 (19.9) 91 (33.5) 67 (24.6) 114 (41.9) 
Unspecified 24 (16.0) 51 (34.0) 29 (19.3) 49 (32.7) 50 (33.3) 80 (53.3) 
Multiple 76 (23.4) 143 (44.0) 72 (22.2) 140 (43.1) 127 (39.1) 208 (64.0) 
       (con’t) 
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BMI Category 
BMI <25 65 (14.5) 135 (30.1) 68 (15.2) 138 (30.8) 121 (27.0) 209 (46.7) 
BMI 25 to <30 110 (14.8) 226 (30.3) 128 (17.2) 249 (33.4) 212 (28.5) 367 (49.3) 
BMI 30+ 138 (15.2) 297 (32.7) 154 (17.0) 336 (37.0) 265 (29.2) 498 (54.9) 
Unknown 122 (11.7) 258 (24.7) 170 (16.3) 315 (30.1) 255 (24.4) 437 (41.8) 
BNF chapter  
count 
0-4 122 (7.8) 257 (16.3) 190 (12.1) 339 (21.5) 285 (18.1) 499 (31.7) 
5-9 154 (17.0) 334 (36.9) 169 (18.7) 354 (39.1) 287 (31.7) 520 (57.5) 
10+ 159 (23.9) 325 (48.8) 161 (24.2) 345 (51.8) 281 (42.2) 492 (73.9) 
X-ray, phase 1a 
No 393 (13.5) 836 (28.7) 483 (16.6) 960 (32.9) 783 (26.9) 1390 (47.7) 
Yes 42 (18.2) 80 (34.6) 37 (16.0) 78 (33.8) 70 (30.3) 121 (52.4) 
Multiple  
consultations 
Single 193 (10.1) 487 (25.6) 265 (13.9) 584 (30.7) 425 (22.3) 832 (43.7) 
Multiple 242 (19.5) 429 (34.6) 255 (20.5) 454 (36.6) 428 (34.5) 679 (54.7) 
Staff index  
consultation count 
At or below  
the median 
25 (11.7) 54 (25.4) 37 (17.4) 63 (29.6) 56 (26.3) 92 (43.2) 
Above  
the median 
410 (14.0) 862 (29.4) 483 (16.5) 975 (33.3) 797 (27.2) 1419 (48.4) 
a relevant recorded X-ray in phase one prior to index consultation  
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity analysis considered processes at any point within phase one. 
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Table 5-7: Estimates of associations between recommended relatively safe pharmacological 
options within 14 days of a clinical OA consultation and the independent variables 
 
Paracetamol 
adjusted OR 
(95% CI) 
Topical NSAID 
adjusted OR 
(95% CI) 
Paracetamol or 
topical NSAID 
adjusted OR 
(95% CI) 
Diagnosis OA (reference: joint 
pain)  1.58 (1.23,2.03) 0.97 (0.75,1.24)  1.27 (1.03,1.55) 
Sex (reference: female)  0.76 (0.60,0.95)  0.67 (0.53,0.83)  0.65 (0.54,0.78) 
Age 65-74 (reference: 45-64)  1.93 (1.44,2.60)  2.45 (1.88,3.19)  2.29 (1.84,2.85) 
Age 75-84  3.29 (2.43,4.45)  2.32 (1.72,3.13)  3.04 (2.39,3.88) 
Age 85+  3.75 (2.53,5.55)  2.71 (1.80,4.07)  3.75 (2.69,5.23) 
Hip (reference: knee)  1.37 (1.04,1.79)  0.34 (0.25,0.47)  0.69 (0.55,0.87) 
Ankle/foot  0.51 (0.27,0.96)  0.53 (0.32,0.88)  0.51 (0.34,0.79) 
Wrist/hand 0.59 (0.35,1.00) 1.27 (0.89,1.82) 0.99 (0.71,1.37) 
Unspecified 1.22 (0.74,2.03) 0.92 (0.56,1.50) 1.22 (0.81,1.83) 
Multisite 1.19 (0.84,1.66) 1.03 (0.73,1.46) 1.14 (0.85,1.52) 
BMI 25 to <30 (reference: BMI 
<25) 1.07 (0.75,1.52) 1.16 (0.82,1.65) 1.10 (0.83,1.47) 
BMI 30+ 1.08 (0.76,1.53) 1.04 (0.73,1.47) 1.09 (0.82,1.44) 
BMI unknown 0.93 (0.66,1.32) 1.23 (0.87,1.72) 1.04 (0.79,1.38) 
5-9 BNF chapters (reference: 0-4)  1.62 (1.23,2.13)  1.40 (1.08,1.82)  1.53 (1.24,1.89) 
10+ BNF chapters  2.04 (1.53,2.74)  1.82 (1.37,2.41)  2.11 (1.67,2.67) 
Multiple consultations in phase 1 
(vs. single)  1.83 (1.46,2.30)  1.59 (1.27,1.98)  1.69 (1.41,2.03) 
X-ray, phase 1a (vs. none) 0.95 (0.64,1.41) 1.00 (0.66,1.53) 1.00 (0.71,1.40) 
Above the clinician median index 
consultation count (reference: at 
or below the median) 1.01 (0.62,1.65) 0.75 (0.44,1.25) 0.85 (0.56,1.28) 
Practice 2 (reference: Practice 1) 0.76 (0.41,1.43)  4.61 (1.87,11.4)  2.27 (1.15,4.51) 
Practice 3 1.20 (0.82,1.75) 1.20 (0.67,2.14) 1.10 (0.72,1.70) 
Practice 4  0.53 (0.35,0.81) 1.21 (0.66,2.24) 0.78 (0.49,1.23) 
Practice 5 0.90 (0.59,1.37)  2.59 (1.39,4.83)  1.76 (1.09,2.82) 
Practice 6 1.10 (0.62,1.97) 0.74 (0.28,1.99) 0.98 (0.49,1.94) 
Practice 7 0.80 (0.51,1.26) 0.68 (0.35,1.32) 0.71 (0.44,1.15) 
Practice 8 0.55 (0.29,1.04)  2.56 (1.19,5.51) 1.48 (0.81,2.72) 
VPCb (null model) 0.03 (0.00,0.06) 0.11 (0.06,0.16) 0.05 (0.02,0.08) 
VPCb (adj. model) 0.01 (0.00,0.03) 0.10 (0.04,0.15) 0.05 (0.02,0.08) 
arelevant recorded X-ray in phase one prior to index consultation; bvariance partition coefficient. 
Adjusted for all covariates. 
Adjunct pharmacological management options 
Opioids were relatively frequently prescribed at 33.9% of patients (within 14 days of a clinical OA 
consultation), compared to 13.8% of patients prescribed paracetamol and 16.5% a topical NSAID 
(Table 5-8). Across phase one as a whole, the proportion of patients prescribed an opioid increased 
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to 56.0%. An OA diagnosis compared to joint pain was associated with increased odds of opioid 
prescription (adjusted OR 1.44, 95% CI 1.19,1.75), as was increased age (adjusted OR 1.72 [95% CI 
1.24,2.39] for age 85+ compared to age 45-64 years). People with hip disease were more likely to 
have an opioid prescription (adjusted OR 1.36 [95% CI 1.11,1.68] compared to knee), whereas 
ankle/foot (adjusted OR 0.43, 95% CI 0.28,0.65) and wrist/hand (adjusted OR 0.56, 95% CI 
0.39,0.79) disease had lower odds of prescription. Patients with obesity had increased odds of an 
opioid prescription (adjusted OR 1.44 [95% CI 1.10,1.89] compared to not overweight), as did those 
with an increased morbidity burden (adjusted OR 2.66 [95% CI 2.13,3.34] for those prescribed from 
10+ BNF chapters compared to 0-4), and those with multiple clinical OA consultations in phase one 
compared to single (adjusted OR 3.05, 95% CI 2.57,3.63). Estimates of the VPC suggested that 5% 
of variation was explained by unobserved clinician-level factors in the null model, reducing to 2% 
(not statistically significantly different to no effect) in the adjusted model. 
Oral NSAID prescription was recorded in 18.0% of people within 14 days of a clinical OA consultation 
and 54.1% across phase one as a whole. Diagnosis was not significantly associated with odds of 
prescription. Older age was associated with lower odds of an oral NSAID prescription (adjusted OR 
0.22 [95% CI 0.12,0.39] for age 85+ c.f. 45-64 years). The highest total morbidity burden was 
negatively associated with oral NSAID prescription (adjusted OR 0.73, 95% CI 0.54,0.98) compared 
to the lowest. Having multiple clinical OA consultations compared to a single consultation was 
associated with such a prescription (adjusted OR 2.61, 95% CI 2.12,3.22). Estimates of the VPC 
suggested that 11% of variation was explained by unobserved clinician-level factors in the null 
model, reducing to 6% in the adjusted model. 
The NICE-mandated target of co-prescription of a PPI for all patients with OA who are prescribed 
an oral NSAID was not achieved. Overall 35.6% of patients prescribed an NSAID within 14 days of a 
clinical OA consultation were also prescribed a PPI. Addition of other forms of gastroprotection 
(non-PPI) added only modestly (2%) to the proportions of people prescribed an oral NSAID also 
prescribed gastroprotection. Across phase one overall, 54% of patients prescribed oral NSAIDs also 
received a PPI prescription. OA was not associated with odds of a PPI prescription. Increasing age 
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was positively associated with odds of such a prescription (adjusted OR 2.11 [95% CI 1.33,3.35], 
2.16 [95% CI 1.19,3.90], 9.66 [95% CI 2.35,39.6] for age bands 65-74, 75-84, 85+ compared to age 
45-64). Being in the highest morbidity band (10+ chapters) was also associated with increased odds 
(adjusted OR 3.11, 95% CI 1.75,5.55, compared to the lowest total morbidity band), as was having 
multiple clinical OA consultations (adjusted OR 1.73, 95% CI 1.14,2.63). The analysis including 
sex*age interaction effects was statistically significant for male*age band 75-84 (adjusted OR 5.84 
[95% CI 1.77,19.3]) but not for the other interaction terms (which also had point estimates of OR 
closer to no effect at 1.32 (for male*age band 65-74) and 1.53 (male*age band 85+). Estimates of 
the VPC suggested that 6% of variation was explained by unobserved clinician-level factors in the 
null model, reducing to 4% in the adjusted model. 
There was a low level of capsaicin prescription at 1.3% overall within 14 days and only 2.3% across 
all of phase one. Capsaicin prescription was not confined to its licenced indications for hand and 
knee OA, with recorded prescription in hip, ankle/foot, unspecified and multisite disease. The low 
level of prescribing of capsaicin made use of a logistic regression analysis unfeasible.  
Low levels of orlistat use were shown in this patient group during this period at 1.5% within 14 days 
of a clinical OA consultation and 3.9% over phase one as a whole. Again, the low frequency of use 
of orlistat made use of a logistic regression analysis unfeasible.  
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Table 5-8: Frequency of adjunct recommended prescribing processes in phase one 
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Overall  1065 (33.9) 1760 (56.0) 565 (18.0) 1703 (54.1) 201 (35.6) 920 (54.0) 12 (2.1) 30 (1.8) 42 (1.3) 72 (2.3) 14 (1.5) 35 (3.9) 
Diagnostic 
group 
Joint pain 601 (29.0) 1053 (50.8) 346 (16.7) 1075 (51.9) 115 (33.2) 568 (52.8) 5 (1.4) 17 (1.6) 28 (1.4) 44 (2.1) 8 (1.4) 21 (3.7) 
OA 464 (43.2) 707 (65.8) 219 (20.4) 628 (58.5) 86 (39.3) 352 (56.1) 7 (3.2) 13 (2.1) 14 (1.3) 28 (2.6) 6 (1.7) 14 (4.0) 
Sex 
Female 678 (35.6) 1112 (58.4) 332 (17.4) 1009 (53.0) 128 (38.6) 572 (56.7) 7 (2.1) 15 (1.5) 25 (1.3) 43 (2.3) 11 (2.0) 28 (5.1) 
Male 387 (31.2) 648 (52.2) 233 (18.8) 694 (55.9) 73 (31.3) 348 (50.1) 5 (2.1) 15 (2.2) 17 (1.4) 29 (2.3) 3 (0.8) 7 (2.0) 
Age 
45-64 405 (27.4) 720 (48.7) 344 (23.3) 734 (49.7) 95 (27.6) 353 (48.1) 5 (1.5) 6 (0.8) 17 (1.2) 30 (2.0) 12 (2.7) 27 (6.2) 
65-74 314 (37.3) 510 (60.6) 134 (15.9) 510 (60.6) 58 (43.3) 286 (56.1) 3 (2.2) 9 (1.8) 7 (0.8) 16 (1.9) 2 (0.8) 7 (2.6) 
75-84 241 (40.3) 368 (61.5) 72 (12.0) 336 (56.2) 36 (50.0) 207 (61.6) 4 (5.6) 10 (3.0) 12 (2.0) 17 (2.8) 0 (0.0) 1 (0.6) 
85+ 105 (46.1) 162 (71.1) 15 (6.6) 123 (53.9) 12 (80.0) 74 (60.2) 0 (0.0) 5 (4.1) 6 (2.6) 9 (3.9) 0 (0.0) 0 (0.0) 
Site 
Knee 497 (32.8) 802 (52.9) 267 (17.6) 783 (51.6) 92 (34.5) 396 (50.6) 5 (1.9) 11 (1.4) 27 (1.8) 41 (2.7) 8 (1.7) 23 (5.0) 
Hip 267 (39.4) 436 (64.3) 116 (17.1) 370 (54.6) 46 (39.7) 200 (54.1) 1 (0.9) 4 (1.1) 2 (0.3) 4 (0.6) 4 (2.2) 7 (3.9) 
Ankle/Foot 31 (15.2) 86 (42.2) 29 (14.2) 120 (58.8) 11 (37.9) 63 (52.5) 0 (0.0) 3 (2.5) 4 (2.0) 5 (2.5) 1 (1.7) 2 (3.4) 
Wrist/Hand 51 (18.8) 117 (43.0) 43 (15.8) 134 (49.3) 12 (27.9) 70 (52.2) 0 (0.0) 2 (1.5) 2 (0.7) 6 (2.2) 1 (1.7) 2 (3.4) 
Unspecified 55 (36.7) 92 (61.3) 28 (18.7) 89 (59.3) 11 (39.3) 51 (57.3) 0 (0.0) 3 (3.4) 1 (0.7) 4 (2.7) 0 (0.0) 0 (0.0) 
Multiple 164 (50.5) 227 (69.8) 82 (25.2) 207 (63.7) 29 (35.4) 140 (67.6) 6 (7.3) 7 (3.4) 6 (1.8) 12 (3.7) 0 (0.0) 1 (0.9) 
             (con’t) 
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BMI 
Category 
BMI <25 137 (30.6) 215 (48.0) 64 (14.3) 209 (46.7) 21 (32.8) 99 (47.4) 1 (1.6) 2 (1.0) 10 (2.2) 13 (2.9) - - 
BMI 25 to <30 236 (31.7) 419 (56.2) 133 (17.9) 422 (56.6) 51 (38.3) 241 (57.1) 3 (2.3) 10 (2.4) 7 (0.9) 18 (2.4) - - 
BMI 30+ 387 (42.7) 610 (67.3) 162 (17.9) 544 (60.0) 60 (37.0) 307 (56.4) 2 (1.2) 7 (1.3) 13 (1.4) 23 (2.5) 14 (1.5) 35 (3.9) 
Unknown 305 (29.2) 516 (49.4) 206 (19.7) 528 (50.5) 69 (33.5) 273 (51.7) 6 (2.9) 11 (2.1) 12 (1.1) 18 (1.7) - - 
BNF 
chapter 
count 
0-4 370 (23.5) 639 (40.6) 318 (20.2) 737 (46.8) 88 (27.7) 306 (41.5) 1 (0.3) 7 (0.9) 7 (0.4) 14 (0.9) 1 (0.3) 5 (1.5) 
5-9 350 (38.7) 583 (64.4) 160 (17.7) 541 (59.8) 64 (40.0) 317 (58.6) 4 (2.5) 11 (2.0) 15 (1.7) 21 (2.3) 7 (2.3) 12 (3.9) 
10+ 345 (51.8) 538 (80.8) 87 (13.1) 425 (63.8) 49 (56.3) 297 (69.9) 7 (8.0) 12 (2.8) 20 (3.0) 37 (5.6) 6 (2.3) 18 (6.8) 
X-ray, 
phase 1a 
No 959 (32.9) 1607 (55.1) 496 (17.0) 1565 (53.7) 171 (34.5) 834 (53.3) 12 (2.4) 30 (1.9) 40 (1.4) 70 (2.4) 13 (1.6) 34 (4.1) 
Yes 106 (45.9) 153 (66.2) 69 (29.9) 138 (59.7) 30 (43.5) 86 (62.3) 0 (0.0) 0 (0.0) 2 (0.9) 2 (0.9) 1 (1.3) 1 (1.3) 
Multiple 
consultations 
Single 443 (23.3) 939 (49.3) 241 (12.7) 979 (51.4) 69 (28.6) 505 (51.6) 6 (2.5) 19 (1.9) 22 (1.2) 38 (2.0) 5 (1.0) 20 (3.9) 
Multiple 622 (50.1) 821 (66.2) 324 (26.1) 724 (58.3) 132 (40.7) 415 (57.3) 6 (1.9) 11 (1.5) 20 (1.6) 34 (2.7) 9 (2.3) 15 (3.8) 
Staff  
index 
consultation 
count 
At or below  
the median 
91 (42.7) 126 (59.2) 41 (19.2) 106 (49.8) 15 (36.6) 60 (56.6) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5) 1 (1.3) 3 (3.8) 
Above  
the median 
974 (33.2) 1634 (55.7) 524 (17.9) 1597 (54.5) 186 (35.5) 860 (53.9) 12 (2.3) 30 (1.9) 41 (1.4) 71 (2.4) 13 (1.6) 32 (3.9) 
a relevant recorded X-ray in phase one prior to index consultation  
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity analysis considered processes at any point within phase one. 
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Table 5-9: Estimates of associations between adjunct recommended pharmacological options within 14 days of a 
clinical OA consultation and the independent variables 
 
Opioid adjusted OR 
(95% CI) 
Oral NSAID adjusted OR 
(95% CI) 
PPI adjusted OR 
(95% CI) 
Diagnosis OA (reference: joint pain)  1.44 (1.19,1.75) 1.03 (0.81,1.31) 1.06 (0.67,1.68) 
Sex (reference: female) 0.88 (0.74,1.04) 1.10 (0.90,1.35) 0.71 (0.48,1.05) 
Age 65-74 (reference: 45-64)  1.38 (1.13,1.70)  0.62 (0.49,0.79)  2.11 (1.33,3.35) 
Age 75-84  1.33 (1.05,1.69)  0.46 (0.34,0.62)  2.16 (1.19,3.90) 
Age 85+  1.72 (1.24,2.39)  0.22 (0.12,0.39)  9.66 (2.35,39.6) 
Hip (reference: knee)  1.36 (1.11,1.68) 1.06 (0.82,1.38) 1.10 (0.66,1.86) 
Ankle/foot  0.43 (0.28,0.65) 1.01 (0.65,1.58) 1.23 (0.51,2.97) 
Wrist/hand  0.56 (0.39,0.79) 1.10 (0.75,1.60) 0.87 (0.40,1.92) 
Unspecified 1.20 (0.81,1.80) 1.36 (0.85,2.19) 0.97 (0.39,2.41) 
Multisite 1.13 (0.86,1.49) 1.24 (0.89,1.72) 0.65 (0.35,1.21) 
BMI 25 to <30 (reference: BMI <25) 1.00 (0.76,1.33) 1.26 (0.89,1.79) 1.35 (0.67,2.70) 
BMI 30+  1.44 (1.10,1.89) 1.14 (0.81,1.61) 1.43 (0.71,2.86) 
BMI unknown 1.02 (0.78,1.34) 1.33 (0.96,1.85) 1.41 (0.72,2.75) 
5-9 BNF chapters (reference: 0-4)  1.62 (1.32,1.98) 0.99 (0.78,1.26) 1.33 (0.84,2.11) 
10+ BNF chapters  2.66 (2.13,3.34)  0.73 (0.54,0.98)  3.11 (1.75,5.55) 
Multiple consultations in phase 1  
(vs. single) 
 3.05 (2.57,3.63)  2.61 (2.12,3.22)  1.73 (1.14,2.63) 
X-ray, phase 1a (vs. none) 1.04 (0.76,1.42) 1.38 (0.97,1.96) 1.28 (0.68,2.42) 
Above the clinician median index 
consultation count (reference: at or 
below the median) 
0.71 (0.50,1.01) 0.90 (0.58,1.41) 1.03 (0.47,2.29) 
   (con’t) 
    
 163 
 
Opioid adjusted OR 
(95% CI) 
Oral NSAID adjusted OR 
(95% CI) 
PPI adjusted OR 
(95% CI) 
Practice 2 (reference: Practice 1)  2.42 (1.45,4.06) 0.90 (0.42,1.92) 0.56 (0.18,1.77) 
Practice 3 0.97 (0.69,1.37) 1.19 (0.76,1.85) 0.88 (0.47,1.65) 
Practice 4  0.66 (0.46,0.94) 0.87 (0.54,1.42) 0.77 (0.38,1.58) 
Practice 5 0.95 (0.65,1.38)  0.35 (0.20,0.63) 2.19 (0.91,5.28) 
Practice 6 1.45 (0.87,2.44) 0.91 (0.44,1.89) 0.86 (0.30,2.46) 
Practice 7  1.81 (1.26,2.60)  0.29 (0.16,0.52)  2.90 (1.11,7.55) 
Practice 8 1.13 (0.69,1.85) 0.59 (0.29,1.17) 0.92 (0.34,2.54) 
VPCb (null model) 0.05 (0.02,0.07) 0.11 (0.06,0.16) 0.06 (0.01,0.12) 
VPCb (adj. model) 0.02 (0.00,0.04) 0.06 (0.02,0.09) 0.04 (0.00,0.10) 
arelevant recorded X-ray in phase one prior to index consultation; bvariance partition coefficient. 
Adjusted for all covariates. 
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Non-recommended pharmacological management options 
Overall, 14.1% of patients with a recorded relative comorbidity contraindication to oral NSAIDs 
received a prescription for an oral NSAID within 14 days of a clinical OA consultation in phase one 
(Table 5-10). In the analysis of prescribing across the whole of phase one, there was a large increase 
in the proportion of people with a recorded relative contraindication receiving an oral NSAID 
prescription, at 56.0%. The associations for a prescription for oral NSAIDs in the presence of a 
recorded relative contraindication were similar as for oral NSAIDs as a whole. Patients with older 
age had reduced odds of an oral NSAID prescription (diminishing adjusted OR of 0.53 [95% CI 
0.37,0.76], 0.37 [0.24,0.56], 0.29 [95% CI 0.15,0.58] for age bands 65-74, 75-84, 85+ compared to 
age 45-64). Patients with multiple consultations had increased odds of prescription (adjusted OR 
2.00, 95% CI 1.44,2.76). Estimates of the VPC suggested that 9% of variation was explained by 
unobserved clinician-level factors in the null model, reducing to 2% in the adjusted model. 
There was a low level of etoricoxib 60mg prescription (0.9% of patients receiving an oral NSAID 
prescription within 14 days were prescribed etoricoxib 60mg), in line with the NICE 
recommendation that it not be used as a first-line oral NSAID choice. This proportion is similar 
across the phase one aggregated prescriptions at 0.8%. It was not feasible with such low 
frequencies to undertake a logistic regression model.  
Only a low level of prescribing of rubefacients within 14 days of a clinical OA consultation was 
identified (in seven people, or 0.2% of patients). Across phase one as a whole, this increased to 
0.7%. Again, it was not feasible with such small frequencies to undertake a logistic regression 
model. 
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Table 5-10: Frequency of non-recommended prescribing processes in phase one. 
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Overall  226 (14.1) 895 (56.0) 5 (0.9) 13 (0.8) 7 (0.2) 21 (0.7) 18 (0.6) 63 (2.0) 
Diagnostic 
group 
Joint pain 124 (12.6) 534 (54.2) 4 (1.2) 11 (1.0) 3 (0.1) 10 (0.5) 14 (0.7) 38 (1.8) 
OA 102 (16.6) 361 (58.9) 1 (0.5) 2 (0.3) 4 (0.4) 11 (1.0) 4 (0.4) 25 (2.3) 
Sex 
Female 133 (13.8) 521 (54.2) 5 (1.5) 9 (0.9) 6 (0.3) 16 (0.8) 10 (0.5) 39 (2.0) 
Male 93 (14.6) 374 (58.7) 0 (0.0) 4 (0.6) 1 (0.1) 5 (0.4) 8 (0.6) 24 (1.9) 
Age 
45-64 112 (20.6) 282 (51.9) 1 (0.3) 6 (0.8) 3 (0.2) 9 (0.6) 6 (0.4) 20 (1.4) 
65-74 61 (12.6) 280 (57.6) 3 (2.2) 6 (1.2) 1 (0.1) 5 (0.6) 4 (0.5) 17 (2.0) 
75-84 41 (9.7) 245 (57.9) 1 (1.4) 1 (0.3) 2 (0.3) 5 (0.8) 5 (0.8) 23 (3.8) 
85+ 12 (8.2) 88 (59.9) 0 (0.0) 0 (0.0) 1 (0.4) 2 (0.9) 3 (1.3) 3 (1.3) 
Site 
Knee 99 (13.2) 396 (52.9) 2 (0.7) 5 (0.6) 3 (0.2) 13 (0.9) 9 (0.6) 29 (1.9) 
Hip 46 (13.1) 189 (53.7) 2 (1.7) 3 (0.8) 3 (0.4) 5 (0.7) 3 (0.4) 10 (1.5) 
Ankle/Foot 15 (14.0) 66 (61.7) 0 (0.0) 2 (1.7) 0 (0.0) 0 (0.0) 2 (1.0) 2 (1.0) 
Wrist/Hand 17 (12.5) 73 (53.7) 0 (0.0) 1 (0.7) 0 (0.0) 1 (0.4) 2 (0.7) 10 (3.7) 
Unspecified 8 (13.3) 39 (65.0) 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7) 1 (0.7) 5 (3.3) 
Multiple 41 (20.9) 132 (67.3) 1 (1.2) 2 (1.0) 0 (0.0) 1 (0.3) 1 (0.3) 7 (2.2) 
BMI Category 
BMI <25 23 (9.9) 111 (47.8) 0 (0.0) 0 (0.0) 1 (0.2) 3 (0.7) 0 (0.0) 8 (1.8) 
BMI 25 to <30 67 (15.3) 259 (59.0) 2 (1.5) 4 (0.9) 2 (0.3) 5 (0.7) 7 (0.9) 21 (2.8) 
BMI 30+ 90 (15.4) 346 (59.1) 2 (1.2) 8 (1.5) 4 (0.4) 9 (1.0) 4 (0.4) 19 (2.1) 
Unknown 46 (13.4) 179 (52.2) 1 (0.5) 1 (0.2) 0 (0.0) 4 (0.4) 7 (0.7) 15 (1.4) 
         (con’t) 
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BNF chapter  
count 
0-4 75 (14.7) 228 (44.8) 0 (0.0) 0 (0.0) 1 (0.1) 3 (0.2) 0 (0.0) 16 (1.0) 
5-9 82 (14.1) 333 (57.2) 4 (2.5) 9 (1.7) 1 (0.1) 5 (0.6) 9 (1.0) 24 (2.7) 
10+ 69 (13.6) 334 (65.7) 1 (1.1) 4 (0.9) 5 (0.8) 13 (2.0) 9 (1.4) 23 (3.5) 
X-ray, phase 1a 
No 192 (13.1) 816 (55.8) 4 (0.8) 12 (0.8) 7 (0.2) 19 (0.7) 18 (0.6) 61 (2.1) 
Yes 34 (25.0) 79 (58.1) 1 (1.4) 1 (0.7) 0 (0.0) 2 (0.9) 0 (0.0) 2 (0.9) 
Multiple  
consultations 
Single 94 (10.1) 505 (54.4) 2 (0.8) 8 (0.8) 3 (0.2) 13 (0.7) 11 (0.6) 39 (2.0) 
Multiple 132 (19.7) 390 (58.1) 3 (0.9) 5 (0.7) 4 (0.3) 8 (0.6) 7 (0.6) 24 (1.9) 
Staff index  
consultation count 
At or below  
the median 14 (13.1) 58 (54.2) 0 (0.0) 2 (1.9) 1 (0.5) 2 (0.9) 0 (0.0) 2 (0.9) 
Above  
the median 212 (14.2) 837 (56.1) 5 (1.0) 11 (0.7) 6 (0.2) 19 (0.6) 18 (0.6) 61 (2.1) 
arelevant recorded X-ray in phase one prior to index consultation  
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity analysis considered processes at any point within phase one. 
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Table 5-11: Estimates of associations between non-recommended pharmacological options within 
14 days of a clinical OA consultation and the independent variables 
 
Oral NSAID where 
relative contra-
indication present  
adjusted OR (95% CI) 
Diagnosis OA (reference: joint pain) 1.18 (0.82,1.69) 
Sex (reference: female) 1.14 (0.83,1.55) 
Age 65-74 (reference: 45-64)  0.53 (0.37,0.76) 
Age 75-84  0.37 (0.24,0.56) 
Age 85+  0.29 (0.15,0.58) 
Hip (reference: knee) 1.03 (0.69,1.53) 
Ankle/foot 1.29 (0.69,2.41) 
Wrist/hand 1.23 (0.68,2.21) 
Unspecified 1.24 (0.54,2.86) 
Multisite 1.37 (0.86,2.17) 
BMI 25 to <30 (reference: BMI <25) 1.49 (0.88,2.55) 
BMI 30+ 1.28 (0.76,2.16) 
BMI unknown 1.18 (0.67,2.08) 
5-9 BNF chapters (reference: 0-4) 1.09 (0.75,1.59) 
10+ BNF chapters 1.10 (0.73,1.64) 
Multiple consultations in phase 1 (vs. single)  2.00 (1.44,2.76) 
X-ray, phase 1a (vs. none) 1.60 (0.99,2.60) 
Above the clinician median index consultation count (reference: at or 
below the median) 
1.06 (0.55,2.05) 
Practice 2 (reference: Practice 1) 0.67 (0.26,1.71) 
Practice 3  1.78 (1.09,2.89) 
Practice 4 0.83 (0.43,1.58) 
Practice 5  0.44 (0.23,0.87) 
Practice 6 1.27 (0.63,2.55) 
Practice 7  0.24 (0.10,0.55) 
Practice 8 0.74 (0.34,1.61) 
VPCb (null model) 0.09 (0.02,0.15) 
VPCb (adj. model) 0.02 (0.00,0.06) 
arelevant recorded X-ray in phase one prior to index consultation; bvariance partition coefficient. 
Adjusted for all covariates. 
There was a low level of prescription recorded (18 patients, or 0.6%). Across phase one as a whole, 
this increased modestly to 2.0%. Due to small numbers of patients recorded as receiving a 
glucosamine prescription, logistic regression models were not feasible to undertake. 
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Referral patterns assessment using routine data 
The exercise referral domain was dominated by physiotherapy referrals which accounted for all of 
the 6.7% of patients (n=212) identified as being referred for exercise or physiotherapy within 14 
days of a consultation for clinical OA. When all such referrals within phase one or within 14 days of 
a clinical OA consultation were considered, 13.2% of patients were identified as referred. As no 
additional referrals other than to physiotherapy were identified for exercise within 14 days of a 
clinical OA consultation, the associations in the adjusted multilevel logistic regression model are 
shown under physiotherapy, below.  
Assessment of indicators for assistive devices, in Table 5-12, has been derived from the codes 
shown in Appendix E.1. Overall 6.7% were recorded with a physiotherapy referral within 14 days of 
a clinical OA consultation (no additional patients with other assistive device referrals within 14 
days), and 13.2% within phase one overall, of which 12.3% was physiotherapy referral. A PQL1 
estimation approach to the multilevel logistic regression analysis of recorded physiotherapy referral 
was used. Patients with a formal OA diagnosis (N05.. Read code) were less likely to be referred to 
physiotherapy than people with joint pain diagnosis only (adjusted OR 0.51, 95% CI 0.35,0.75). 
Ankle/foot (adjusted OR 0.24, 95% CI 0.07,0.79) and wrist/hand disease (adjusted OR 0.48, 95% CI 
0.24,0.97) were also associated with reduced odds of referral. Multiple consultation was associated 
with increased odds of physiotherapy referral (adjusted OR 2.75, 95% CI 2.00,3.79) as was a 
recorded relevant X-ray before the index consultation (adjusted OR 1.78, 95% CI1.14,2.79). 
Estimates of the VPC suggested that 21% of variation was explained by unobserved clinician-level 
factors in the null model, reducing to 3% in the adjusted model. 
Table 5-12 shows the OT referrals as a proxy for non-ambulatory assistive devices; very low levels 
of referral (1.1% within 14 days of a clinical OA consultation and 2.4% across phase one as a whole) 
were found, with no evidence of a substantial variation in frequency by age or disease type. In an 
adjusted single-level model, patients with a formal OA diagnosis compared to joint pain had 
reduced odds of referral (adjusted OR 0.24, 95% CI 0.08,0.66), as did those with unknown BMI 
status compared to not overweight (adjusted OR 0.18, 95% CI 0.04,0.75). Patients with wrist/hand 
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disease (adjusted OR 12.9, 95% CI 4.01,41.6), unspecified (adjusted OR 31.3, 95% CI 6.02,163) or 
multisite disease (adjusted OR 4.83, 95% CI 1.41,16.6) compared to knee had increased odds of OT 
referral, as did those with multiple clinical OA consultations in phase one compared to single 
(adjusted OR 5.08, 95% CI1.29,19.9) and those with a recorded X-ray prior to the index consultation 
compared to none (adjusted OR 5.73, 95% CI 2.22,14.8). 
Only one (<0.1%) patient was identified as having a referral for weight management support within 
14 days of a clinical OA consultation. Across phase one as a whole, this extended to 18 people 
(0.6%). No logistic regression analysis was feasible.  
If all the primary care referrals (to physiotherapy as the main referral destination, supervised 
exercise programmes, OT, podiatry, or weight management) were considered jointly, 7.8% of 
people were referred within 14 days of a clinical OA consultation and 14.3% across phase one as a 
whole. Diagnosis was not significantly associated with primary are referral but patients were more 
likely to be referred if there was recorded multisite disease compared to knee (adjusted OR 1.62, 
95% CI 1.05,2.51), but those with ankle/foot disease compared to the knee had lower odds of 
referral (adjusted OR 0.29, 95% CI 0.10,0.84). Patients with unknown BMI status compared to not 
overweight (adjusted OR 0.64, 95% CI 0.41,0.99) had lower odds of referral; those with multiple 
consultation for clinical OA in phase one compared to single had increased odds of referral 
(adjusted OR 3.07, 95% CI 2.26,4.15) as did those with a prior X-ray compared to none (adjusted OR 
1.95,1.27,3.01). Estimates of the VPC suggested that 28% of variation was explained by unobserved 
clinician-level factors in the null model, reducing to 4% in the adjusted model. 
Table 5-13 shows the percentage of patients referred to orthopædics (18%), rheumatology (0.2%) 
and the pain clinic (0.1%) within 14 days of a clinical OA consultation. People with OA were more 
likely to be referred to secondary care (a composite of rheumatology, orthopædics, and pain clinic 
referrals) than those with joint pain (adjusted OR 1.31, 95% CI 1.04,1.64, Table 5-14).Patients in the 
oldest age band were less likely to be referred (adjusted OR 0.34 [95% CI 0.20,0.55] for age 85+ 
compared to 45-64). Patients with ankle/foot problems (adjusted OR 0.36, 95% CI 0.20,0.64) were 
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less likely to be referred as were those with wrist/hand (adjusted OR 0.48, 95% CI 0.31,0.76) and 
unspecified site of disease (adjusted OR 0.23, 95% CI 0.11,0.47). Patients with multiple clinical OA 
consultation in phase one had increased odds of referral (adjusted OR 3.24, 95% CI 2.64,3.98), as 
did those with prior X-ray use (adjusted OR 1.67, 95% CI 1.19,2.33). Estimates of the VPC suggested 
that 3% of variation was explained by unobserved clinician-level factors in the null model, reducing 
to 1% in the adjusted model. 
24.5% of clinical OA consulters were recorded as receiving any relevant referral within 14 days of a 
clinical OA consultation in phase one, increasing to 35.2% for relevant referrals across phase one.  
In the adjusted multilevel model, odds of referral diminished for patients with increasing age, 
judging by the point estimate of effect, but the relationship was only significant for age 85+ 
compared to 45-64 (adjusted OR 0.37, 95% CI 0.25,0.57). Patients with disease at one of three sites 
had reduced odds of referral– compared to the knee, ankle/foot (adjusted OR 0.33, 95% CI 
0.20,0.56), wrist/hand (adjusted OR 0.64, 95% CI 0.44,0.91), and unspecified (adjusted OR 0.36, 
95% CI 0.20,0.62). Patients with multiple consultations for clinical OA in phase one had increased 
odds of referral (adjusted OR 3.48, 95% CI 2.89,4.19), as did those with recorded X-ray use before 
the index consultation (adjusted OR 1.88, 95% CI 1.37,2.58). 
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Table 5-12: Frequencies of primary care referrals in phase one. 
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Overall  212 (6.7) 416 (13.2) 212 (6.7) 387 (12.3) 34 (1.1) 77 (2.4) 1 (0.0) 18 (0.6) 245 (7.8) 451 (14.3) 
Diagnostic 
 group 
Joint pain 139 (6.7) 277 (13.4) 139 (6.7) 255 (12.3) 24 (1.2) 47 (2.3) 1 (0.0) 12 (0.6) 163 (7.9) 294 (14.2) 
OA 73 (6.8) 139 (12.9) 73 (6.8) 132 (12.3) 10 (0.9) 30 (2.8) 0 (0.0) 6 (0.6) 82 (7.6) 157 (14.6) 
Sex 
Female 134 (7.0) 262 (13.8) 134 (7.0) 249 (13.1) 23 (1.2) 54 (2.8) 1 (0.1) 10 (0.5) 157 (8.2) 295 (15.5) 
Male 78 (6.3) 154 (12.4) 78 (6.3) 138 (11.1) 11 (0.9) 23 (1.9) 0 (0.0) 8 (0.6) 88 (7.1) 156 (12.6) 
Age 
45-64 118 (8.0) 219 (14.8) 118 (8.0) 209 (14.2) 16 (1.1) 38 (2.6) 1 (0.1) 7 (0.5) 134 (9.1) 243 (16.5) 
65-74 50 (5.9) 101 (12.0) 50 (5.9) 90 (10.7) 7 (0.8) 13 (1.5) 0 (0.0) 7 (0.8) 56 (6.7) 102 (12.1) 
75-84 34 (5.7) 74 (12.4) 34 (5.7) 68 (11.4) 6 (1.0) 18 (3.0) 0 (0.0) 4 (0.7) 40 (6.7) 80 (13.4) 
85+ 10 (4.4) 22 (9.6) 10 (4.4) 20 (8.8) 5 (2.2) 8 (3.5) 0 (0.0) 0 (0.0) 15 (6.6) 26 (11.4) 
Site 
Knee 112 (7.4) 202 (13.3) 112 (7.4) 191 (12.6) 9 (0.6) 18 (1.2) 1 (0.1) 10 (0.7) 120 (7.9) 209 (13.8) 
Hip 48 (7.1) 104 (15.3) 48 (7.1) 95 (14.0) 3 (0.4) 11 (1.6) 0 (0.0) 5 (0.7) 51 (7.5) 102 (15.0) 
Ankle/Foot 3 (1.5) 14 (6.9) 3 (1.5) 12 (5.9) 1 (0.5) 2 (1.0) 0 (0.0) 3 (1.5) 4 (2.0) 14 (6.9) 
Wrist/Hand 10 (3.7) 25 (9.2) 10 (3.7) 23 (8.5) 9 (3.3) 12 (4.4) 0 (0.0) 0 (0.0) 19 (7.0) 33 (12.1) 
Unspecified 2 (1.3) 13 (8.7) 2 (1.3) 9 (6.0) 5 (3.3) 12 (8.0) 0 (0.0) 0 (0.0) 7 (4.7) 18 (12.0) 
Multiple 37 (11.4) 58 (17.8) 37 (11.4) 57 (17.5) 7 (2.2) 22 (6.8) 0 (0.0) 0 (0.0) 44 (13.5) 75 (23.1) 
           (con’t) 
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BMI Category 
BMI <25 36 (8.0) 62 (13.8) 36 (8.0) 58 (12.9) 7 (1.6) 13 (2.9) 0 (0.0) 1 (0.2) 43 (9.6) 68 (15.2) 
BMI 25 to <30 45 (6.0) 98 (13.2) 45 (6.0) 90 (12.1) 10 (1.3) 20 (2.7) 0 (0.0) 2 (0.3) 54 (7.2) 102 (13.7) 
BMI 30+ 66 (7.3) 143 (15.8) 66 (7.3) 131 (14.4) 13 (1.4) 24 (2.6) 1 (0.1) 13 (1.4) 79 (8.7) 154 (17.0) 
Unknown 65 (6.2) 113 (10.8) 65 (6.2) 108 (10.3) 4 (0.4) 20 (1.9) 0 (0.0) 2 (0.2) 69 (6.6) 127 (12.2) 
BNF chapter 
count 
0-4 114 (7.2) 202 (12.8) 114 (7.2) 192 (12.2) 12 (0.8) 32 (2.0) 0 (0.0) 4 (0.3) 126 (8.0) 222 (14.1) 
5-9 57 (6.3) 111 (12.3) 57 (6.3) 103 (11.4) 9 (1.0) 21 (2.3) 1 (0.1) 7 (0.8) 65 (7.2) 122 (13.5) 
10+ 41 (6.2) 103 (15.5) 41 (6.2) 92 (13.8) 13 (2.0) 24 (3.6) 0 (0.0) 7 (1.1) 54 (8.1) 107 (16.1) 
X-ray, phase 1a 
No 176 (6.0) 350 (12.0) 176 (6.0) 324 (11.1) 30 (1.0) 69 (2.4) 1 (0.0) 16 (0.5) 205 (7.0) 382 (13.1) 
Yes 36 (15.6) 66 (28.6) 36 (15.6) 63 (27.3) 4 (1.7) 8 (3.5) 0 (0.0) 2 (0.9) 40 (17.3) 69 (29.9) 
Multiple 
 consultations 
Single 79 (4.1) 181 (9.5) 79 (4.1) 163 (8.6) 9 (0.5) 27 (1.4) 0 (0.0) 8 (0.4) 88 (4.6) 187 (9.8) 
Multiple 133 (10.7) 235 (18.9) 133 (10.7) 224 (18.0) 25 (2.0) 50 (4.0) 1 (0.1) 10 (0.8) 157 (12.7) 264 (21.3) 
Staff index 
 consultation count 
At or below the median 13 (6.1) 33 (15.5) 13 (6.1) 30 (14.1) 5 (2.3) 9 (4.2) 0 (0.0) 2 (0.9) 18 (8.5) 35 (16.4) 
Above the median 199 (6.8) 383 (13.1) 199 (6.8) 357 (12.2) 29 (1.0) 68 (2.3) 1 (0.0) 16 (0.5) 227 (7.7) 416 (14.2) 
arelevant recorded X-ray in phase one prior to index consultation 
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity analysis considered processes at any point within phase one.  
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Table 5-13: Frequencies of secondary care referrals in phase one 
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Overall  7 (0.2) 57 (1.8) 565 (18.0) 759 (24.1) 4 (0.1) 22 (0.7) 574 (18.3) 804 (25.6) 772 (24.5) 1107 (35.2) 
Diagnostic 
 group 
Joint pain 5 (0.2) 38 (1.8) 332 (16.0) 470 (22.7) 1 (0.0) 9 (0.4) 336 (16.2) 497 (24.0) 473 (22.8) 696 (33.6) 
OA 2 (0.2) 19 (1.8) 233 (21.7) 289 (26.9) 3 (0.3) 13 (1.2) 238 (22.2) 307 (28.6) 299 (27.8) 411 (38.3) 
Sex 
Female 3 (0.2) 36 (1.9) 324 (17.0) 457 (24.0) 2 (0.1) 16 (0.8) 328 (17.2) 489 (25.7) 459 (24.1) 689 (36.2) 
Male 4 (0.3) 21 (1.7) 241 (19.4) 302 (24.3) 2 (0.2) 6 (0.5) 246 (19.8) 315 (25.4) 313 (25.2) 418 (33.7) 
Age 
45-64 4 (0.3) 33 (2.2) 292 (19.8) 388 (26.3) 1 (0.1) 11 (0.7) 295 (20.0) 414 (28.0) 399 (27.0) 563 (38.1) 
65-74 1 (0.1) 16 (1.9) 166 (19.7) 226 (26.8) 2 (0.2) 4 (0.5) 169 (20.1) 236 (28.0) 214 (25.4) 305 (36.2) 
75-84 2 (0.3) 7 (1.2) 85 (14.2) 113 (18.9) 1 (0.2) 4 (0.7) 88 (14.7) 121 (20.2) 125 (20.9) 187 (31.3) 
85+ 0 (0.0) 1 (0.4) 22 (9.6) 32 (14.0) 0 (0.0) 3 (1.3) 22 (9.6) 33 (14.5) 34 (14.9) 52 (22.8) 
Site 
Knee 2 (0.1) 18 (1.2) 310 (20.4) 398 (26.3) 1 (0.1) 8 (0.5) 312 (20.6) 408 (26.9) 405 (26.7) 546 (36.0) 
Hip 4 (0.6) 17 (2.5) 129 (19.0) 176 (26.0) 2 (0.3) 5 (0.7) 135 (19.9) 190 (28.0) 180 (26.5) 263 (38.8) 
Ankle/Foot 0 (0.0) 2 (1.0) 14 (6.9) 25 (12.3) 0 (0.0) 2 (1.0) 14 (6.9) 29 (14.2) 18 (8.8) 38 (18.6) 
Wrist/Hand 0 (0.0) 5 (1.8) 25 (9.2) 45 (16.5) 0 (0.0) 1 (0.4) 25 (9.2) 50 (18.4) 44 (16.2) 72 (26.5) 
Unspecified 0 (0.0) 7 (4.7) 8 (5.3) 20 (13.3) 1 (0.7) 1 (0.7) 9 (6.0) 28 (18.7) 16 (10.7) 40 (26.7) 
Multiple 1 (0.3) 8 (2.5) 79 (24.3) 95 (29.2) 0 (0.0) 5 (1.5) 79 (24.3) 99 (30.5) 109 (33.5) 148 (45.5) 
           (con’t) 
            
            
            
 174 
 
 
R
h
e
u
m
at
o
lo
gy
  
≤1
4
 d
ay
s 
n
 (
%
) 
R
h
e
u
m
at
o
lo
gy
  
in
 p
h
as
e
 1
 n
 (
%
) 
O
rt
h
o
p
æ
d
ic
s 
 
≤1
4
 d
ay
s 
n
 (
%
) 
O
rt
h
o
p
æ
d
ic
s 
 in
 p
h
as
e
 1
 n
 (
%
) 
P
ai
n
 c
lin
ic
  
≤1
4
 d
ay
s 
n
 (
%
) 
P
ai
n
 c
lin
ic
  
in
 p
h
as
e
 1
 n
 (
%
) 
A
n
y 
se
co
n
d
ar
y 
 
ca
re
 r
e
fe
rr
al
 n
 (
%
) 
A
n
y 
se
co
n
d
ar
y 
 
ca
re
 r
e
fe
rr
al
  
p
h
as
e
 1
 n
 (
%
) 
A
n
y 
re
fe
rr
al
 ≤
1
4
 
d
ay
s 
n
 (
%
) 
A
n
y 
re
fe
rr
al
  
p
h
as
e
 1
 n
 (
%
) 
BMI Category 
BMI <25 3 (0.7) 8 (1.8) 58 (12.9) 77 (17.2) 1 (0.2) 4 (0.9) 62 (13.8) 85 (19.0) 95 (21.2) 133 (29.7) 
BMI 25 to <30 2 (0.3) 20 (2.7) 143 (19.2) 186 (25.0) 1 (0.1) 4 (0.5) 146 (19.6) 198 (26.6) 190 (25.5) 272 (36.5) 
BMI 30+ 1 (0.1) 17 (1.9) 183 (20.2) 252 (27.8) 1 (0.1) 11 (1.2) 184 (20.3) 266 (29.3) 250 (27.6) 358 (39.5) 
Unknown 1 (0.1) 12 (1.1) 181 (17.3) 244 (23.3) 1 (0.1) 3 (0.3) 182 (17.4) 255 (24.4) 237 (22.7) 344 (32.9) 
BNF chapter 
count 
0-4 2 (0.1) 27 (1.7) 279 (17.7) 361 (22.9) 1 (0.1) 3 (0.2) 282 (17.9) 377 (24.0) 379 (24.1) 529 (33.6) 
5-9 4 (0.4) 17 (1.9) 174 (19.2) 231 (25.5) 2 (0.2) 6 (0.7) 178 (19.7) 244 (27.0) 229 (25.3) 322 (35.6) 
10+ 1 (0.2) 13 (2.0) 112 (16.8) 167 (25.1) 1 (0.2) 13 (2.0) 114 (17.1) 183 (27.5) 164 (24.6) 256 (38.4) 
X-ray, phase 1a 
No 6 (0.2) 53 (1.8) 487 (16.7) 665 (22.8) 4 (0.1) 21 (0.7) 496 (17.0) 710 (24.4) 666 (22.9) 976 (33.5) 
Yes 1 (0.4) 4 (1.7) 78 (33.8) 94 (40.7) 0 (0.0) 1 (0.4) 78 (33.8) 94 (40.7) 106 (45.9) 131 (56.7) 
Multiple 
consultations 
Single 0 (0.0) 21 (1.1) 205 (10.8) 340 (17.9) 3 (0.2) 12 (0.6) 208 (10.9) 361 (19.0) 290 (15.2) 504 (26.5) 
Multiple 7 (0.6) 36 (2.9) 360 (29.0) 419 (33.8) 1 (0.1) 10 (0.8) 366 (29.5) 443 (35.7) 482 (38.8) 603 (48.6) 
Staff index 
consultation count 
At or below the median 1 (0.5) 5 (2.3) 32 (15.0) 43 (20.2) 1 (0.5) 1 (0.5) 34 (16.0) 47 (22.1) 48 (22.5) 72 (33.8) 
Above the median 6 (0.2) 52 (1.8) 533 (18.2) 716 (24.4) 3 (0.1) 21 (0.7) 540 (18.4) 757 (25.8) 724 (24.7) 1035 (35.3) 
arelevant recorded X-ray in phase one prior to index consultation  
The main analysis examined processes of care within 14 days of a clinical OA consultation; a sensitivity analysis considered processes at any point within phase one. 
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Table 5-14: Estimates of associations (OR, 95%CI) between referrals within 14 days of a clinical OA consultation and the independent variables.  
 
Physiotherapy 
referral  
adjusted ORa (95% CI) 
OT referral  
adjusted ORb (95% CI) 
Any primary 
healthcare team 
referral  
adjusted  
OR (95% CI) 
Any secondary care 
referral  
adjusted  
OR (95% CI) 
Any referral  
adjusted  
OR (95% CI) 
Diagnosis OA (reference: joint pain)  0.51 (0.35,0.75)  0.24 (0.08,0.66) 0.44 (0.31,0.64)  1.31 (1.04,1.64) 0.97 (0.79,1.20) 
Sex (reference: female) 0.87 (0.64,1.18) 1.12 (0.46,2.71) 0.85 (0.63,1.14) 1.18 (0.97,1.44) 1.07 (0.89,1.28) 
Age 65-74 (reference: 45-64) 0.85 (0.58,1.23) 0.72 (0.26,2.01) 0.81 (0.56,1.16) 0.92 (0.72,1.16) 0.88 (0.71,1.10) 
Age 75-84 0.81 (0.52,1.28) 0.65 (0.20,2.05) 0.81 (0.53,1.24) 0.59 (0.44,0.79) 0.64 (0.49,0.83) 
Age 85+ 0.52 (0.25,1.07) 1.53 (0.41,5.76) 0.67 (0.36,1.26)  0.34 (0.20,0.55)  0.37 (0.25,0.57) 
Hip (reference: knee) 0.99 (0.68,1.44) 0.91 (0.21,3.89) 0.96 (0.67,1.40) 1.01 (0.80,1.29) 1.05 (0.84,1.31) 
Ankle/foot  0.24 (0.07,0.79) 1.35 (0.15,12.45)  0.29 (0.10,0.84)  0.36 (0.20,0.64)  0.33 (0.20,0.56) 
Wrist/hand  0.48 (0.24,0.97)  12.9 (4.01,41.6) 0.94 (0.55,1.63)  0.48 (0.31,0.76)  0.64 (0.44,0.91) 
Unspecified 0.30 (0.07,1.28)  31.3 (6.02,163). 1.12 (0.48,2.62)  0.23 (0.11,0.47)  0.36 (0.20,0.62) 
Multisite 1.40 (0.88,2.21)  4.83 (1.41,16.6)  1.62 (1.05,2.51) 0.78 (0.57,1.07) 0.87 (0.65,1.17) 
BMI 25 to <30 (reference: BMI <25) 0.68 (0.42,1.11) 0.67 (0.20,2.18) 0.70 (0.45,1.11) 1.35 (0.95,1.90) 1.16 (0.86,1.57) 
BMI 30+ 0.75 (0.47,1.20) 0.66 (0.21,2.11) 0.77 (0.50,1.19) 1.23 (0.88,1.73) 1.14 (0.85,1.54) 
BMI unknown 0.70 (0.44,1.11)  0.18 (0.04,0.75)  0.64 (0.41,0.99) 1.15 (0.83,1.61) 1.00 (0.75,1.34) 
5-9 BNF chapters (reference: 0-4) 0.82 (0.56,1.19) 1.53 (0.54,4.32) 0.85 (0.59,1.22) 1.04 (0.82,1.32) 0.99 (0.80,1.23) 
10+ BNF chapters 0.79 (0.51,1.22) 2.32 (0.79,6.81) 0.94 (0.62,1.41) 0.98 (0.74,1.30) 1.04 (0.81,1.33) 
Multiple consultations in phase 1 (vs. single)  2.75 (2.00,3.79)  5.08 (1.29,19.9)  3.07 (2.26,4.15)  3.24 (2.64,3.98)  3.48 (2.89,4.19) 
X-ray, phase 1c (vs. none)  1.78 (1.14,2.79)  5.73 (2.22,14.8)  1.95 (1.27,3.01)  1.67 (1.19,2.33)  1.88 (1.37,2.58) 
Above the clinician median index consultation 
count (reference: at or below the median) 1.23 (0.64,2.34) 0.80 (0.02,35.52) 1.03 (0.57,1.86) 1.25 (0.82,1.92) 1.24 (0.85,1.81) 
     (con’t) 
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Physiotherapy 
referral  
adjusted ORa (95% CI) 
OT referral  
adjusted ORb (95% CI) 
Any primary 
healthcare team 
referral  
adjusted  
OR (95% CI) 
Any secondary care 
referral  
adjusted  
OR (95% CI) 
Any referral  
adjusted  
OR (95% CI) 
Practice 2 (reference: Practice 1) 0.75 (0.35,1.61) Omitted (collinearity) 0.65 (0.30,1.44) 0.93 (0.52,1.65) 0.83 (0.52,1.34) 
Practice 3  0.16 (0.08,0.32) Omitted (collinearity)  0.14 (0.07,0.28) 0.71 (0.48,1.04)  0.39 (0.28,0.55) 
Practice 4  0.02 (0.00,0.11) Omitted (collinearity)  0.05 (0.02,0.15)  1.67 (1.18,2.36) 0.80 (0.59,1.10) 
Practice 5  0.00 (0.00,0.00) Omitted (collinearity)  0.04 (0.01,0.14) 0.71 (0.47,1.07)  0.36 (0.25,0.52) 
Practice 6 0.48 (0.21,1.06) Omitted (collinearity) 0.48 (0.22,1.06) 1.33 (0.78,2.27) 0.91 (0.57,1.45) 
Practice 7  0.40 (0.22,0.71) Omitted (collinearity)  0.41 (0.23,0.72) 1.11 (0.75,1.65) 0.76 (0.54,1.07) 
Practice 8  0.07 (0.02,0.32) Omitted (collinearity)  0.12 (0.04,0.38) 0.90 (0.53,1.53)  0.51 (0.32,0.83) 
VPCd (null model) 0.21 (0.12,0.29) - 0.28 (0.16,0.37) 0.03 (0.00,0.05) 0.05 (0.02,0.07) 
VPCd (adj. model) 0.03 (0.00,0.07) - 0.04 (0.00,0.08) 0.01 (0.00,0.03) 0.01 (0.00,0.02) 
Adjusted two-level (patients within clinicians) logistic regression model, PQL2 approximation (patients within index clinician) except for aadjusted two-level model with PQL1 
approximation and badjusted single-level model (practice and clinician accounted for through dummy variables); crelevant recorded X-ray in phase one prior to index consultation; 
dvariance partition coefficient  
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5.4 Discussion 
  Main findings and comparison with previous literature 
Of the processes of care for OA in general practice, prescription and referral data seemed to be 
well-recorded. Conversely, and consistent with the CiPCA analysis described in Chapter Three, 
section 3.4, coded information about assessment (pain, function) and advice (education, exercise, 
weight loss) appeared very infrequently in the general practice routinely-recorded EHR. Of the 
fifteen quality indicators set out in the systematic review in Chapter Two, it is concluded that six 
indicators at a population-level may be wholly or partially measurable from the routine record, 
consistent with the findings from the CiPCA analysis in Chapter Three: (i) referral for physiotherapy 
(though the exercise advice component of this domain seems less measurable from the routine 
record); (ii) referral for ambulatory assistive devices (if physiotherapy referral is taken as a proxy); 
(iii) referral for (non-ambulatory) assistive devices (if OT referral is taken as a proxy); 
(iv) paracetamol prescription; (v) oral NSAID prescription; and (vi) PPI prescription. The 
supplementary topical NSAID prescription indicator proposed in the review also seems measurable. 
Other processes of care recommended or referred to in the NICE guidance that could be measured 
at a population level include capsaicin prescription and orlistat prescription, though these are 
recorded at such low levels that drawing conclusions about factors associated with their use is not 
feasible. Those processes recommended not to be undertaken (rubefacient, glucosamine, or 
etoricoxib prescription) could also be assessed descriptively. X-ray use could also be assessed at a 
population level though the appropriateness or otherwise of individual investigations could not be 
determined.  
Associations across all measures 
The main feature generally associated with increased odds of an indicator being met (in both a 
desirable sense, such as for the assessment or recommended management indicators, and 
undesirable, such as for use of oral NSAIDs in the context of a relative contraindication or use of X-
rays) is multiple clinical OA consultation in phase one compared to single. The effect of multiple 
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consultation was discussed in Chapter Four, section 4.4.1and the issue of surveillance bias may also 
apply to quality achievement, as may clinical severity being linked to both frequency of consultation 
and more assiduous treatment.274 It may also reflect a different attitude to medical care in patients 
consulting more frequently (potentially more ‘consumerist’275).  
For the prescribing measures, an OA diagnosis compared to joint pain was associated with 
paracetamol prescription and for opioids but not topical or oral NSAIDs, nor PPIs. This contrasted 
with the lack of any significant association between analgesic type and diagnostic code in the 
analysis of influences on diagnostic code by Jordan et al. (for which the candidate was a co-
author).17 Male sex was associated with lower odds of prescription of paracetamol and topical 
NSAIDs. Increasing age was associated with all prescriptions except oral NSAIDs (which showed 
reducing odds with increasing age). Increasing levels of morbidity measured by the BNF chapter 
count were associated with increased odds of recorded prescription for all agents except oral 
NSAIDs, which showed reduced odds in the highest morbidity band. Some of the association 
between morbidity and pharmacological processes of care may be explained by the fact that a 
prescription of a drug from the groups defined would increase the number of identified BNF 
chapters used. Another explanation may be the improvement in quality of care for people with 
higher levels of multimorbidity as has previously been shown in vulnerable elders by Min et al.276 
For referral measures, an OA diagnosis compared to joint pain was associated with reduced odds 
of a primary care referral but increased odds of a secondary care referral. Site effects were mixed, 
though ankle/foot and wrist/hand disease compared to the knee was associated with reduced odds 
of physiotherapy or secondary care referral, whilst wrist/hand, unspecified and multisite disease 
compared to the knee was associated with increased odds of OT referral. A recorded X-ray before 
the index consultation in phase one compared to none was associated with increased odds of all 
referrals.  
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Measure-specific associations 
For the recording of weight within 14 days of a clinical OA consultation, the rate of achievement at 
10% overall in people known to be overweight was lower than expected given advice about weight 
reduction as a core component of the NICE OA management guidance.5 The reduced odds of a 
weight record with increased age may have been due to the requirement to tackle other issues in 
a consultation or to greater frailty in the very old making a weight measurement less physically 
practicable. The reduced odds associated with unknown prior BMI status suggests that some people 
are less likely to be weighed at any point, possibly as their appearance indicates that they are not 
overweight, or due to patient preference. It has previously been identified that people are more 
likely to have a BMI recorded if they are overweight.253  
The National Collaborating Centre for Chronic Conditions argue for a diagnosis of OA made on 
clinical grounds without recourse to use of imaging techniques and highlight the “unreliable” nature 
of radiographic reports as a basis for referral.4 In this context, the frequency of recorded X-rays 
within 14 days of a clinical OA consultation (18.5%,) was unexpected. Various studies have 
highlighted that the grade of OA affects both patient and clinician willingness to consider surgical 
intervention.4 The outcome of recorded X-ray use within 14 days of a clinical OA consultation was 
associated with reduced odds of a recorded OA diagnostic code. This may be due to clinicians using 
X-rays diagnostically, converse to the NICE guidance, especially given the association between prior 
X-ray use and an OA diagnostic code as discussed in Chapter Four. The hip was associated with 
greater odds of X-ray use compared to the knee, whilst the ankle/foot, wrist/hand and unspecified 
sites were associated with reduced odds. Although no prior analysis of the use of X-rays in 
diagnosing hip OA was identified in the literature, this may have reflected a perception of hip OA 
as more difficult to diagnose since the joint cannot so easily be inspected or palpated, or due to 
difficulty in separating hip and back symptoms. Included in the model was X-ray use recorded 
before the index consultation. This showed a positive association, which may suggest that some 
patients receive X-rays relatively frequently. However, due to the assignation of X-rays relative to 
the index consultation, there was a risk for people consulting multiple times in phase one (those 
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with a joint pain consultation resulting in an X-ray followed later in phase one by an OA 
consultation) that some X-rays would have been counted in both the predictor and outcome 
variables.  
Comparison with achievement rates from other studies 
Rates of adherence to the assessment (pain, function) and non-pharmacological management 
indicators (assessment, education and advice) as derived from routinely recorded Read codes was 
very poor at zero to 0.3%, depending upon the eligibility period used. Compared to rates identified 
from other studies as shown in Table 5-15 (some of which used self-report or analysis of narrative 
information within medical records), the conclusion is that recording practice for these indicators 
could be much improved.  
Recorded prescription of paracetamol within 14 days of a clinical OA consultation is lower than 
other estimates of use (Table 5-15). This may be due to the restriction to 14 days for eligibility in 
this study. All prevalent cases of clinical OA were included (nearly 40% of phase one consulters had 
consulted about OA or joint pain in the two years before phase one) and not only incident cases, 
for whom the analgesic options of paracetamol and topical NSAIDs could most strongly be argued. 
Another explanation may be over-the-counter analgesic use not captured by the prescribing data 
download. 
Topical NSAIDs prescriptions were also lower than other studies’ estimates (Table 5-15). Due to 
their recommended indication being OA of the hand or knee (as well as for the relief of general 
musculoskeletal pains),217 it is unsurprising that hip and ankle/foot were associated with reduced 
odds of prescription.  
Relatively high levels of oral NSAID use (33.9% of patients) were identified, with only approximately 
one third of people prescribed oral NSAIDs also prescribed gastroprotection (35.6%). This level of 
oral NSAID prescription is a little lower than previous studies. High levels of NSAID use are not 
necessarily inappropriate, especially given that the analysis does not discriminate between a one-
off prescription and continuous use. Lack of routine prescription of gastroprotection given the NICE  
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Table 5-15: Comparison of measures from MOSAICS phase one with previous literature 
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Assessment  
Pain - 57.3a 40 80 - - - - 60.6  
23 - 
30 
27 - - - 36 64 0.0 
Function - - - - 41 - - - -  
42 - 
44 
43 - - 
6.9b - 
29.2c  
24 40 0.0 
Weight recording - - - - - - - - -  - - - - - -  10.0 
X-ray use - - - - - - - - -  - - - - - -  18.5 
Advice  
Education - - 
33 - 
36 
- - - - - 68.7 16.4d 
29 - 
31 
30 17.7 - - -  0.0 
Education (patient self-
report) 
- - - - - - - - -  - - 77.8 - - 
19 – 
24e 
36-
55e 
- 
Exercise - 57.3a - 27 - - - - - 46.3 - - - - 25.2 49 84 0.1 
Weight loss - - - - - - - - - 38.8 - - - - 25 34 40 0.1 
NSAID risk advice - - 4 - - - - 4 
38.6 - 
50.0 
 
14 - 
20 
17 - - - -  0.0 
Non-pharmacological management   
Physio referral/exercise 
‘prescription’ 
- - 0 - 16 - - - 46 16 44 40.3 - - 24.8 - - 43 76 6.7f 
Walking aids          54.2       27 - 
OT referral - - - - - - - - - 4.5 - - - - - -  1.1f 
Appliances          5.0       18 - 
Weight loss programme - - - - - - - - -  - - - - - 5 8 <0.1f 
(con’t) 
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Pharmacological management   
Paracetamol first 
analgesic 
45g 57.3a 43 73 - 79 26 43 58.7 70.6 
45 - 
51 
48 41.1 - - 46 72 13.8h 
Paracetamol maximum 
dose before alternative 
- - 33 - - - 37 33 -  3 - 6 5 - - - -  - 
Topical NSAID - - - - - - - - - 41.8 - - - - - -  16.5h 
Oral NSAID 45g - - - - - -  - 59.2i 
58 – 
60e 
59j - - - 46 56 18.0h 
PPI used with oral 
NSAIDs 
45g - 11 - - - - 11 27.4  - - - 26.6 - -  35.6h 
Opioid/stronger 
analgesic 
- - - - - - - - - 59.2 - - - - - 37 43 33.9h 
Capsaicin - - - - - - - - - 3.0 - - - - - -  1.3h 
Glucosamine - - - - - - - - - 40.3 - - - - - -  0.6h 
Rubefacient - - - - - - - - -  - - - - - -  0.2h 
Referral once 
nonsurgical treatment 
failed 
45g - 90 - - - - 90 72.7 24.9k 
90 - 
95 
90 35.8 - - 47 41 18.3k 
acomposite of 3 indicators; bnonambulatory; cambulatory; dwritten information; edepending on component of education; frecorded referral; gcomposite of 4 indicators - 
individual indicator pass rates 27 – 100; gwritten information; hrecorded prescription; inon-selective NSAIDs;  jfor ibuprofen or COX2 as first used oral NSAID; ktotal proportion 
advised referral, not confined to treatment failure 
 183 
guidance to co-prescribe a PPI with oral NSAIDs is a greater concern. Likewise, the use of oral 
NSAIDs in the presence of a possible relative contraindication (14.1% of those with a potential 
contraindication had an oral NSAID prescribed within 14 days) is not necessarily inappropriate, 
given that the identification of the contraindications in this analysis depends upon relative and not 
absolute contraindications. This marker is of potentially greater use in comparisons between 
clinicians and practices rather than as a definitive view of the quality of care in a cross-sectional 
survey.  
Few patients in this phase were recorded as receiving weight management advice compared to 
other estimates (Table 5-15). Low levels of prescription for orlistat in the management of obesity 
may reflect a wider belief about obesity as a self-inflicted condition, or one that does not respond 
well to medical intervention.272 
The low levels of prescription for capsaicin (1.3%) were not in keeping with the patient preferences 
identified by Fraenkel et al. in 2004,278 who reported that 40% of patients with knee OA preferred 
capsaicin to the alternatives of oral NSAIDs, glucosamine, or opioids. The rate of use in this analysis 
was comparable with the 3% found by Porcheret.66  
Low levels of prescription for rubefacients and glucosamine were consistent with NICE guidance, 
and for the latter were substantially lower than the 40.3% identified by Porcheret,66 suggesting that 
either there has been a change in prescribing behaviour since that 2007 survey, during which 
interval the NICE guidance on OA has been produced and updated, or that patients obtain it without 
prescription.  
The apparent rate of referral for physiotherapy or exercise programmes, at 6.7%, was much lower 
than the comparator rates shown in Table 5-15. The association between reduced odds of 
physiotherapy referral and a diagnosis of OA compared to joint pain was notable and may suggest 
that primary care teams, or patients themselves, do not share the confidence in physiotherapy as 
an effective intervention expressed in the NICE guidelines or relevant systematic reviews.5,279,280  
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Referrals for assistive device assessment or provision was hard to determine and relies on 
identification of physiotherapy or OT referral as a proxy, suggesting only a low level of assessment 
in this analysis. Memel et al. have previously suggested that GPs miss functional limitation in 
patients with OA, with only 31% of moderate to severely disabled patients with OA of the hip or 
knee correctly identified as such.281 Overall, recorded referral to OT seems very much lower than 
would have been suggested by the other studies. Greater information about functional limitation 
within the routine EHR would have been required to establish the degree of need that was 
appropriately identified.  
The orthopædics referral rate within 14 days of a clinical OA consultation of 18.0% seen here was 
rather low compared to other estimates but it is not possible to determine from this dataset which 
patients would be regarded as needing an onward referral. The optimum level for referral has not 
been determined. Dawson et al. argued that the incidence rate for OA of the hip and knee requiring 
surgery could not reliably be calculated.282 Frankel et al. estimated prevalence of health care need 
for hip replacement at 107 per 1000 for men and 173 per 1000 for women (both ages 35 years and 
over); incidence was estimated at 2.23 per 1000.283 These figures would suggest that the referral 
frequency identified in this study is substantially more than the proportion of the population with 
a health care need for hip replacement. Even if a generous allowance for knee replacement referral 
is made, and further allowance for a less than perfectly efficient identification of those with a need 
for joint arthroplasty in primary care, there still appears to be scope for improved primary care 
based OA management without referral. The reduced odds in the adjusted model for specialist 
assessment seen for the oldest age group (85+) is of potential concern, raising the possibility of age-
related discrimination in access to services, though the method of adjustment for morbidity may 
be insufficient and have resulted in residual confounding. A previous assessment of provision of 
joint arthroplasty compared to need284 identified an ‘n’ shaped curve of the provision:need ratio 
plotted against age, with the youngest and oldest not having access to arthroplasty at the same 
rate as the middle age groups. Referral clearly does not equal access to arthroplasty but is a 
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necessary prerequisite in the UK, where general practice acts as a gatekeeper to secondary care 
referral.  
In general, no evidence to support any hypothesis of a variable effect of age, sex and BMI on 
prescribing behaviours across clinicians was found.  
The amount of variation in process measures explained at the level of the clinician in the null models 
was between 3% (paracetamol, secondary care referral) and 44% (X-ray use within 14 days of a 
clinical OA consultation). After the addition of explanatory variables (in the fully adjusted model), 
the VPC reduced to between 1% (paracetamol, secondary care referral) and 10% (topical NSAIDs), 
though again not all were statistically significant.  
Practice effects are harder to interpret. There may well be an element of practice culture affecting 
clinical behaviour, such as with some of the prescribing and referral behaviours found to have a 
significant effect in the two-level multilevel model. A three-level multilevel model might have 
identified any practice-level effect, though eight clusters is a small number for such an analysis, and 
no statistically significant degree of variance at the practice level was explained by such a model in 
an exploratory analysis. There was no apparent consistency between indicators about which 
practices were outliers.  
 Strengths and limitations 
The use of the entire population of clinical OA consulters in eight practices with data gathered 
before exposure to any of the MOSAICS study interventions, or to CiPCA-like coding training, has 
enabled conclusions to be drawn about recorded care in a natural setting.  
There were some limitations to this analysis. There was a risk of minor adjustments to routine 
practice during phase one in the study practices, due to their recruitment to the MOSAICS study 
during this time, though it remained essentially usual care for UK general practice.  
There were many comparisons made within this analysis and one would expect that some of those 
identified as statistically significant will have occurred by chance, with the acceptable probability of 
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a type 1 error kept at 5%, as discussed in Chapter Four, section 4.4.3. Some of the effects were 
reasonably consistent, such as age, gender, morbidity, and multiple clinical OA consultation, though 
others were harder to explain, such as the effect of disease site on co-prescription of a PPI with 
NSAIDs, or practice effects.  
It is acknowledged that some evidence of achievement may be present in the free text. This has a 
lower utility for audit and other quality improvement activity (the need for information accessibility 
as outlined by Baker100).  
The use of a 14-day period following a consultation for clinical OA to attribute assessment or clinical 
management actions to the care of OA was arbitrary but in keeping with previous practice at the 
RIPCHS.264 It has the advantage of increasing the sensitivity of the analysis to relevant care but at 
the expense of reducing its specificity. For example, a patient may consult regarding another matter 
within that timeframe (though with the median number of consultations per patient in a year of 
5.4 (2008 figures265), two unrelated consultations within 14 days would seem very unlikely to be a 
frequent occurrence). Drugs that were available on repeat prescription may have been out of 
synchronisation with consultations, so a patient taking a drug on a longer term basis may not 
receive the prescription within a 14 day period after a relevant consultation.  
The increase in proportions of patients with recorded processes of care across the whole of phase 
one, when the 14-day restriction to a clinical OA consultation was removed, suggests that the main 
analysis may have under-estimated actual levels of achievement, though for many indicators 
achievement rates remained very suboptimal even with the broader time period analysis.  
No analysis of defined daily doses (DDD)285 of the pharmacological processes of care has been 
undertaken, and so it is possible that there was a discrepancy between quantities of oral NSAIDS 
prescribed and the gastroprotection prescribed for some patients taking NSAIDs. An analysis that 
included an assessment of DDD would provide a better insight into the quality of the 
gastroprotection provided. Ideally, the primary care record would explicitly link processes of care 
and prescriptions to the relevant morbidities they treated, which would overcome problems of 
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repeat prescriptions for conditions not appearing on the same day in the record as a morbidity 
code. Although this facility exists within some clinical systems, such linkage was not available within 
the dataset obtained.  
Co-therapy and co-status as relative contraindications, through assessment of interacting drugs and 
cardiac, renal and hepatic function test results, would have potentially widened the group of 
patients considered to have a relative contraindication to oral NSAID use, but it was considered too 
complex and insufficiently reliable for this purpose.  
The use of recorded X-ray within phase one prior to the index consultation meant that there was a 
variable time at-risk for patients to have such a recorded X-ray. No prior evidence to suggest an 
appropriate period for X-ray use to be considered was identified in the literature.  
Referrals cannot be directly linked to the consultation with OA or joint pain as the referral reason, 
if Read coded, is not identifiably present in the extracted data. As referrals may be processed 
outside of the clinical system (such as via the secure web-based Choose and Book286 electronic 
referral system), or at a different time point to the consultation (such as by administrative staff), 
referrals cannot clearly be linked by date to a consultation either. Therefore, this analysis provides 
a broad overview of referrals to relevant services and specialities rather than being a definitive 
assessment of referrals for OA and joint pain.  
 Conclusion 
Overall, this chapter has served to demonstrate that certain elements of quality of care for OA can 
be derived from the routine record, with prescribing and referral measures showing promise for 
measurement at a population level. Assessment and advice indicators are less feasible to measure 
from the routine record. In general, the indicators used are more likely to be relevant for 
longitudinal monitoring of care at a population level rather than as a device to definitively state the 
current level of quality achieved in the primary care of OA. The next chapter will examine how the 
level of quality achieved might be derived from the information coded in the electronic recording 
template discussed in Chapter Three.  
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Chapter Six: Quality of care for osteoarthritis measured through the 
template: a cross-sectional study 
6.1 Introduction 
This chapter introduces the quality assessment derived from the electronic consultation recording 
template described in Chapter Three. It will report on the recorded assessment and management 
of OA in primary care during phase two of the MOSAICS trial (the first six months of consultation 
template use) in the eight MOSAICS practices, i.e. prior to randomisation. 
As shown in Chapter Five, the level of routine recording of some important aspects of quality of 
care (predominantly patient assessment [pain, function] and provision of education and advice) 
was very low. The template was introduced to improve identification in patient records of elements 
of care for OA. The aim of the analysis presented in this chapter is to describe the level of recorded 
quality of care for OA in general practice following the introduction of the consultation recording 
template. Chapter Seven will explore whether the template was associated with improvements in 
routinely recorded quality of care. The work reported in these two chapters comprises part of the 
study reported in a peer-reviewed publication regarding the template and its effect on recorded 
quality of care, reproduced in Appendix B.99 
6.2 Aim 
The aims of this analysis were to describe the level of recorded quality of care for OA in general 
practice using quality indicator data captured through a consultation recording template and to 
compare this to information about similar aspects of care recorded routinely (outside the 
template). Variation in recorded quality of care associated with patient characteristics, clinician and 
clinical OA workload, and practice will also be explored.  
6.3 Method 
For reference, the timeline of the MOSAICS study can be seen in Figure 1-1, page 20. The analysis 
reported in this chapter examines recorded quality of care in phase two, 0-6 months after template 
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installation and before randomisation of practices to the model OA consultation intervention or 
control arms. Data were collected from the eight MOSAICS practices by the informatics team of the 
comprehensive research network (CRN),287 from a specification determined by the candidate, just 
as for the data used in Chapter Five. The data obtained were cleaned by the informatics team and 
Professor Jordan. 
 Denominator population 
This analysis was conducted on patients consulting at least once for peripheral joint clinical OA 
during phase two. All patients with the selected Read codes as described in Chapter Three, section 
3.5 were eligible except for those consulting about shoulder or elbow OA as previously discussed in 
Chapter Five.  
It should be noted that all patients consulting and recorded with a relevant OA or joint pain code 
within phase two should have automatically caused the recording template to trigger upon entry 
of the Read code to the medical record causing a bespoke trigger marker to be written to the record. 
However as the results show, this did not always happen and there was a small group of patients 
with a relevant Read code but no record of a template marker. This affected 6.5% of patients 
overall. Three practices contributed 72% of the episodes in which the template did not trigger but 
only 39% of the affected patients (see Appendix G.1). The template non-triggering was presumed 
to result from a software anomaly. The analysis of quality achieved applied only to those patients 
identified as having triggered the template.  
As in Chapter Four (section 4.2, page 104), patients were allocated to an index consultation and 
index clinician in phase two. Similarly, BMI status was determined as for Chapter Four but the 
information used was extended to that prior to the index consultation in phase two rather than 
phase one. 
 Quality indicators 
The recorded measures to be investigated were taken predominantly from the systematic review 
in Chapter Two.107 An additional quality measure was derived from the NICE guidelines on OA5 
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(topical NSAID use). Achievement of the indicators was determined as described in Chapter Three, 
section 3.4.3.  
Table 6-1: Quality indicator domains for template-derived recorded management of OA 
Quality indicator Indicator origin  
Assessment data 
source(s) 
Patient assessment   
Assessment of pain Systematic review Template 
Assessment of function Systematic review Template 
Weight/BMI record 
[Prerequisite for 
advice indicator] 
Routinely recorded 
or template 
Prescribing   
Assessment or advice about paracetamol 
use 
Systematic review Template 
Assessment or advice about topical NSAID 
use 
NICE guidance Template 
Education & advice   
Evidence of education or advice for OA Systematic review Template 
Evidence of exercise advice Systematic review Template 
Weight loss advice for people with 
peripheral joint clinical OA and a BMI 
≥25kgm-2 
Systematic review Template 
Physiotherapy   
Consideration of physiotherapy referral Systematic review Template 
All template indicators in people referred   
Completion of all 8 template indicators 
above for people receiving specialist referral 
Systematic review Template 
The template indicators were used to describe the quality of care and were compared with their 
corresponding routinely-recorded indicators (if any) (Table 3-3). The bespoke Read codes used in 
the template described in Chapter Three, section 3.4.3, were used to determine the level of 
recorded quality of care achieved through the template system. The template could be completed 
at any clinical OA consultation during phase two. The routinely-recorded measures were considered 
to be applicable to a clinical OA consultation if they were recorded within 14 days of any such 
consultation in phase two, as used in Chapter Five. 
 Data analysis 
The frequency of triggering of the template was determined for all clinical OA consulters in phase 
two.  
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Associations were estimated for each of the independent variables used in Chapter Five. Results 
are presented within the assessment and management themes of assessment, prescribing, 
education and advice, and physiotherapy, with an assessment of completion of all 8 template 
indicators in all clinical OA consulters and in people receiving an onward referral.  
Descriptive epidemiology 
Baseline characteristics of the population of clinical OA consulters were identified and described in 
relation to the independent variables.  
Quality of care was described initially in terms of the percentage of eligible patients achieving the 
indicators in phase two (six months after template installation). This was repeated for patients in 
whom at least one template entry had been made, as a sensitivity analysis, on the basis that 
clinicians may be more likely to make a template entry in those regarded as having significant 
clinical OA. 
Association between quality achievement and independent variables of interest: multilevel logistic 
regression 
The same independent variables as assessed in Chapter Four and Chapter Five were used to identify 
associations with recorded quality of care. The main analysis was repeated, restricted to patients 
with at least one completed template entry (other than weight or BMI) in phase two, to assess the 
associations in the subpopulation in whom clinicians were most engaged with template use. A 
further exploratory analysis also included recorded X-ray within 14 days after any clinical OA 
consultation in phase two as an independent variable given that the decision to refer people for an 
X-ray is known to be associated with management decisions in knee pain even before the X-ray 
result is known.12 
Using achievement criteria for the quality indicators as the outcomes, the independent variables of 
interest were assessed in a two-level binary logistic regression multilevel model of patients nested 
within the index clinician, using a second order penalised quasi-likelihood (PQL2) approximation, 
unless otherwise specified. Although tested (and found not to indicate a large or statistically 
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significant amount of variation in achievement of the quality indicators at the topmost (practice) 
level), a three-level model was not considered to be feasible to undertake with only 8 practices and 
so the practice level was adjusted for by use of dummy variables in the model. As assessed in the 
associations for coding behaviours (Chapter Four), age-sex interaction was investigated for 
recorded quality of care. The VPC was estimated as described in Chapter Four, section 4.2.4. 
Estimates of associations between the independent variables and routinely-recorded information 
linked to the same domains as assessed via the template (weight recording, paracetamol and 
topical NSAID prescription, and physiotherapy referral) are shown in Appendix G.2. Except where 
specified, the estimates were similar to those in phase one.  
The data were analysed in SPSS v21230 for the descriptive epidemiology and, for the multilevel 
modelling, in Stata 13.1233 and MLwiN273 v 2.34 using the runMLwiN235 command. Adjusted models 
account for all covariates. Results are presented as ORs and 95% CI, with estimates of the clinician-
level variance partition coefficients for the null and fully adjusted models.  
6.4 Results 
 Eligible population 
During the six months of phase two, there were 1851 patients identified as consulting with OA or 
joint pain. Of these, 1730 (93.5%) triggered the recording template, and six further patients were 
then excluded from the analysis due to records indicating only shoulder or elbow sites of disease. 
This left 1724 patients, which is the figure taken as the denominator for quality indicator 
achievement measurement.  
Two-thirds of patients triggered the template on only one day, with a median one template trigger, 
IQR 1-2 trigger days. For patients in whom the template triggered, there were index consultations 
with 86 clinicians who had a median number of 14 index consultations (unique patients) each (range 
1-82). 
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The characteristics of patients consulting for defined clinical OA in phase two are shown in 
Table 6-2; they were very similar to the characteristics of consulters in phase one (Chapter Five, 
Table 5-2, page 147).  
Table 6-2: Characteristics of clinical OA consulters, phase two 
  n (%) 
Total 1724 
Diagnostic group, n (%) OA 582 (33.8) 
Sex, n (%) Female 1014 (58.8) 
Age band, n (%) 45-64 817 (47.4) 
65-74 442 (25.6) 
75-84 349 (20.2) 
85+ 116 (6.7) 
Site, n (%) Knee 855 (49.6) 
Hip 363 (21.1) 
Ankle/foot 125 (7.3) 
Wrist/hand 152 (8.8) 
Unspecified 99 (5.7) 
Multiple 130 (7.5) 
BMI status, n (%) Not overweight 312 (18.1) 
Overweight 525 (30.5) 
Obese 540 (31.3) 
Unknown 347 (20.1) 
BNF chapter count group, n (%)  0-4 485 (28.1) 
5-9 578 (33.5) 
10+ 661 (38.3) 
Multiple clinical OA consultations, phase 2, n (%) 532 (30.9) 
Recorded X-ray in phase 2 prior to the index consultation, n (%) 86 (5.0) 
Patients with a comorbidity as a relative contraindication  
to oral NSAIDs in 2 years prior to index consultation, phase 2 
799 (46.3) 
Weight measurement (denominator for weight-related interventions) 
The proportions of males and females with a weight record were similar; males were more 
frequently recorded as being overweight but not obese. Older people were more frequently 
recorded as being not overweight and substantially less frequently as obese.  
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Table 6-3: BMI status prior to the phase two index consultation, stratified by sex and age 
 
BMI <25 
n (%) 
BMI 25-29.9 
n (%) 
BMI 30+ 
n (%) 
BMI status not 
recorded n (%) Total n 
Total 312 (18.1) 525 (30.5) 540 (31.3) 347 (20.1) 1724 
Sex  
Male 102 (14.2) 242 (34.1) 221 (31.1) 146 (20.6) 710 
Female 211 (20.8) 283 (27.9) 319 (31.5) 201 (19.8) 1014 
Age   
45-64 136 (16.6) 207 (25.3) 277 (33.9) 197 (24.1) 817 
65-74 67 (15.2) 153 (34.6) 164 (37.1) 58 (13.1) 442 
75-84 71 (20.3) 125 (35.8) 88 (25.2) 65 (18.6) 349 
85+ 38 (32.8) 40 (34.5) 11 (9.5) 27 (23.3) 116 
 Overall template use in phase two 
The levels of recorded template use in patients with clinical OA in phase two are shown in Table 6-4, 
stratified (for the purposes of comparison) by trial arm as used in the cluster trial described in 
Chapter Eight. Overall recorded use was 61.9% of patients with at least one template entry, and 
19.0% in whom all template indicators were achieved. When restricted to only those patients in 
whom the template successfully triggered, usage was a little better with two-thirds of patients with 
at least one entry and 20.4% in whom all template indicators were achieved.  
 Quality assessment: general observations 
As shown in Table 6-5, pain (63.3% of patients) and function (62.1%) assessments had relatively 
good levels of achievement compared to the other recorded measures. There then appeared to be 
an ordering effect within the template with diminishing frequency of indicator achievement down 
to 45.3% for weight loss advice and 35.8% for consideration of physiotherapy referral. Provision of 
written, as opposed to verbal, information, exercise advice and weight loss advice were 
substantially lower at 0.8 to 2.7%. There appeared to be differences between practices in 
achievement for all indicators. 
None of the template-derived indicators was found to have a significant age-sex interaction except 
for exercise advice, described below.  
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Table 6-4: Template use in phase two, patients with clinical OA 
 Practice ID  
Intervention arm Control arm Overall 
1 2 7 8 Total 3 4 5 6 Total Total 
All patients 
% patients for whom template fired 97.9 98.9 90.6 97.4 96.6 89.8 81.8 93.5 99.0 89.6 93.4 
% patients with at least 1 template entry 70.6 78.7 60.6 89.6 71.7 56.7 40.1 38.8 86.6 50.0 61.9 
% patients with at least 1 template indicator achieved 70.6 78.7 60.0 89.6 71.6 56.7 40.1 38.8 86.6 50.0 61.8 
% patients with all eligible template indicators achieved 30.7 12.8 7.8 24.3 24.2 7.8 9.7 6.1 49.5 12.7 19.0 
Restricted to patients in whom the 
template fired 
% patients with at least 1 template entry 72.1 79.6 66.9 92.0 74.2 63.2 49.0 41.5 87.5 55.8 66.2 
% patients with at least 1 template indicator achieved 72.1 79.6 66.3 92.0 74.1 63.2 49.0 41.5 87.5 55.8 66.2 
% patients with all eligible template indicators achieved 31.4 12.9 8.6 25.0 25.1 8.6 11.9 6.6 50.0 14.2 20.4 
 196 
 Quality assessment: patient assessment indicators 
Pain assessment 
A record of pain assessment was the most frequently achieved template indicator (63.3%, 95% CI 
61.0,65.6). The adjusted multilevel model (Table 6-5) showed significantly increased likelihood of 
pain assessment indicator achievement for older ages (75-84 years compared to age 45-64: 
adjusted OR 1.46 (95% CI 1.02,2.10). Reduced odds of pain assessment were identified for patients 
with ankle/foot site of disease (compared to knee): adjusted OR 0.40, 95% CI 0.24,0.66), and for 
increased morbidity load (BNF chapter count of 10 or more compared to 0-4) (adjusted OR 0.58. 
95% CI 0.41,0.84). Patients with multiple clinical OA consultations compared to single (adjusted OR 
3.03, 95% CI 2.24,4.11), and those with an index consultation with a clinician who had more than 
the median number of index consultations (adjusted OR 2.42, 95% CI 1.11,5.27) both had increased 
odds of pain assessment.  
The VPC was estimated at 43% in a constant-only two-level model. This reduced in the fully-
adjusted model to an estimated 36% of the residual variation in the model of recording of pain 
assessments explained by unobserved clinician-level characteristics.  
Function assessment 
Function assessment was the second most frequently achieved indicator (62.1%, 95% CI 59.8,64.3). 
The adjusted multilevel model (Table 6-5) showed similar significant associations for achievement 
of the function assessment indicator as the pain assessment achievement, though the age 
association for function was not statistically significant. Ankle/foot site of disease compared to knee 
(adjusted OR 0.35, 95% CI 0.21,0.57), unknown BMI status compared to not overweight (adjusted 
OR 0.59, 95% CI 0.40,0.88), and increased morbidity load compared to lowest 0-4 chapters (10 or 
more drugs adjusted OR 0.58, 95% CI 0.41,0.83 were associated with less likelihood of achievement. 
Multiple consultations compared to single (adjusted OR 3.11, 95% CI 2.31,4.19), and index 
consultation with a clinician who had more than the median number of index consultations  
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Table 6-5: Frequency of assessment achievement, phase two, and estimates of association with the independent variables 
 Pain assessment Function assessment Weight record within 14 days 
 n (%) 
OR (95% CI) adjusted 
2-level model n (%) 
OR (95% CI) adjusted 
2-level model n (%) 
OR (95% CI) adjusted 
2-level model 
Overall 1092 (63.3)  1070 (62.1)  424 (24.6)  
Diagnosis       
Joint pain 694 (60.8) 1.00 683 (59.8) 1.00 255 (22.3) 1.00 
OA 398 (68.4) 1.26 (0.93,1.72) 387 (66.5) 1.15 (0.85,1.56) 169 (29.0) 0.95 (0.70,1.30) 
Sex       
Female 456 (64.2) 1.00 445 (62.7) 1.00 188 (26.5) 1.00 
Male 636 (62.7) 1.09 (0.84,1.41) 625 (61.6) 1.01 (0.78,1.30) 236 (23.3) 1.27 (0.98,1.65) 
Age       
45-64 506 (61.9) 1.00 497 (60.8) 1.00 201 (24.6) 1.00 
65-74 288 (65.2) 1.21 (0.87,1.67) 286 (64.7) 1.32 (0.96,1.82) 121 (27.4) 1.12 (0.82,1.55) 
75-84 226 (64.8)  1.46 (1.02,2.10) 219 (62.8) 1.40 (0.98,1.99) 83 (23.8) 0.90 (0.62,1.30) 
85+ 72 (62.1) 1.35 (0.78,2.35) 68 (58.6) 1.16 (0.67,1.98) 19 (16.4) 0.58 (0.31,1.09) 
Site       
Knee 564 (66.0) 1.00 554 (64.8) 1.00 216 (25.3) 1.00 
Hip 238 (65.6) 0.92 (0.66,1.27) 228 (62.8) 0.84 (0.61,1.16) 82 (22.6) 1.06 (0.75,1.48) 
Ankle/Foot 55 (44.0)  0.40 (0.24,0.66) 53 (42.4)  0.35 (0.21,0.57) 27 (21.6) 0.97 (0.57,1.65) 
Wrist/Hand 85 (55.9) 0.83 (0.53,1.29) 87 (57.2) 0.90 (0.58,1.41) 28 (18.4) 0.69 (0.41,1.14) 
Unspecified 54 (54.5) 0.67 (0.39,1.15) 49 (49.5) 0.56 (0.33,0.95) 27 (27.3) 1.19 (0.68,2.08) 
Multiple 96 (73.8) 0.66 (0.39,1.12) 99 (76.2) 0.91 (0.53,1.55) 44 (33.8) 1.34 (0.82,2.20) 
BMI Category (prior to index consultation, phase 2) 
BMI <25 203 (65.1) 1.00 201 (64.4) 1.00 89 (28.5) 1.00 
BMI 25 to <30 352 (67.3) 1.31 (0.90,1.91) 348 (66.5) 1.31 (0.91,1.90) 140 (26.7) 0.78 (0.54,1.11) 
BMI 30+ 351 (65.2) 1.35 (0.93,1.98) 348 (64.7) 1.29 (0.89,1.88) 163 (30.2) 1.09 (0.76,1.56) 
Not recorded 186 (53.0) 0.67 (0.45,1.00) 173 (49.3)  0.59 (0.40,0.88) 32 (9.2)  0.26 (0.16,0.42) 
BNF subchapter count    
0-4 302 (62.3) 1.00 300 (61.9) 1.00 106 (21.9) 1.00 
5-9 385 (66.6) 0.90 (0.64,1.26) 368 (63.7) 0.72 (0.52,1.01) 168 (29.1) 1.28 (0.90,1.80) 
10+ 405 (61.3)  0.58 (0.41,0.84) 402 (60.8)  0.58 (0.41,0.83) 150 (22.7) 0.77 (0.53,1.12) 
      (con’t) 
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 Pain assessment Function assessment Weight record within 14 days 
 n (%) 
OR (95% CI) adjusted 
2-level model n (%) 
OR (95% CI) adjusted 
2-level model n (%) 
OR (95% CI) adjusted 
2-level model 
Single/multiple consultations for clinical OA in phase 2 
Single 696 (58.4) 1.00 677 (56.8) 1.00 260 (21.8) 1.00 
Multiple 396 (74.4)  3.03 (2.24,4.11) 393 (73.9)  3.11 (2.31,4.19) 164 (30.8)  2.13 (1.61,2.82) 
X-ray use prior to index consultationa 
No 918 (63.0) 1.00 897 (61.5) 1.00 351 (24.1) 1.00 
Yes 174 (65.4) 1.04 (0.57,1.91) 173 (65.0) 1.37 (0.75,2.49) 73 (27.4) 0.88 (0.49,1.56) 
Staff member index consultation count dichotomy 
At or below the 
median 96 (48.7) 1.00 84 (42.6) 1.00 75 (38.1) 1.00 
Above the median 996 (65.2)  2.42 (1.11,5.27) 986 (64.6)  3.28 (1.58,6.82) 749 (49.1) 1.31 (0.69,2.46) 
Practice       
Practice 1 428 (70.3) 1.00 418 (68.6) 1.00 189 (31.0) 1.00 
Practice 2 70 (75.3) 1.49 (0.16,13.4) 69 (74.2) 1.94 (0.24,15.5) 37 (39.8) 1.94 (0.50,7.53) 
Practice 3 127 (57.7) 0.48 (0.17,1.33) 118 (53.6) 0.48 (0.18,1.24) 31 (14.1)  0.35 (0.15,0.79) 
Practice 4 87 (43.1)  0.22 (0.06,0.78) 86 (42.6)  0.29 (0.09,0.93) 61 (30.2) 0.95 (0.39,2.33) 
Practice 5 90 (39.3)  0.08 (0.02,0.30) 94 (41.0)  0.11 (0.03,0.38) 28 (12.2)  0.30 (0.12,0.77) 
Practice 6 84 (87.5) 1.20 (0.20,7.29) 84 (87.5) 1.66 (0.30,9.22) 29 (30.2) 0.93 (0.27,3.22) 
Practice 7 104 (63.8) 0.70 (0.21,2.29) 104 (63.8) 0.86 (0.28,2.60) 12 (7.4)  0.22 (0.08,0.60) 
Practice 8 102 (91.1) 2.31 (0.34,15.6) 97 (86.6) 2.40 (0.41,14.0) 37 (33.0) 1.52 (0.45,5.14) 
VPCb estimates      
Null model - 0.43 (0.32,0.52) - 0.41 (0.29,0.49) - 0.25 (0.15,0.33) 
Adjusted model - 0.36 (0.25,0.45) - 0.33 (0.22,0.41) - 0.18 (0.09,0.26) 
arelevant recorded X-ray in phase two prior to index consultation; bvariance partition coefficient. Adjusted ORs for achievement include all covariates. 
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compared to those with the median number or below (adjusted OR 3.28, 95% CI 1.58,6.82) were 
associated with achievement.  
The level-2 VPC was estimated 41% in a constant-only two-level model. This reduced in the fully-
adjusted model to 33%, approximately in keeping with the 37% estimate for pain assessment.  
A cross-tabulation of the achievement of the pain and function indicators (Table 6-6) shows 
considerable, but not complete, overlap (94.3% agreement) in achievement, indicating that not all 
patients with function assessment indicator achievement also achieved the pain indicator. 
Table 6-6: Pain and function assessment indicator achievement cross-tabulation 
 
Function assessment 
No Yes Total 
Pain assessment 
No 594 38 632 
Yes 60 1032 1092 
Total 654 1070 1724 
Weight recording 
The levels of recording of a weight measurement through the template or within 14 days of a 
consultation for clinical OA in the routine records in this period were rather modest at 24.6% 
overall. The point estimates for adjusted odds of weight recording in age bands 75-84 and 85+ 
compared to 45-64 were a little greater than in phase one at 0.90 and 0.58 compared to 0.64 and 
0.31 respectively, though the statistical significance was lost in the phase two analysis (with smaller 
patient numbers). There was increased odds of a weight recording if a patient had multiple clinical 
OA consultations compared to single (adjusted OR 2.13, 95% CI 1.61,2.82) and reduced odds if BMI 
status was unknown prior to the index consultation compared to known not-overweight (adjusted 
OR 0.26, 95% CI 0.26,0.42). These were similar to the findings for phase one reported in Chapter 
Five, though in phase two the statistical significance of increased age and reduced odds of a weight 
record was lost (with a modest shift in the point estimate of odds toward no effect of age: for age 
78-84 compared to 45-64, OR in phase two was 0.90 (95% CI 0.62,1.30) and for age 85+ the OR was 
0.58 (95% CI 0.31,1.09)).  
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The VPC was estimated at 25%. This reduced in the fully-adjusted model to an estimated 18% of 
residual variation explained by unobserved clinician-level factors.  
 Quality assessment: core management indicators 
Education and information provision 
Overall, 49.2% were recorded as receiving verbal or written information about OA. The adjusted 
model showed a significant association between achievement and an OA diagnosis compared to 
joint pain (OR 1.60, 95% CI 1.19,2.14), age 65-74 (compared to 45-64: OR 1.47, 95% CI 1.08,2.01 – 
and similar but nonsignificant estimates for ages 75-84 and 85+). Compared to the knee, the 
ankle/foot site (OR 0.47, 95% CI 0.29,0.78) and unspecified site of disease (OR 0.43, 95% CI 
0.25,0.74) had reduced odds of achievement, as did having the highest morbidity burden (BNF 
chapter count 10+ compared to 0-4 chapters, OR 0.64, 95% CI 0.45,0.90). Multiple consultation 
compared to single (OR 2.87, 95% CI 2.18,3.77), and consultation with a clinician who undertook 
more than the median number of index consultations compared to below or at the median (OR 
3.16, 95% CI 1.54,6.48) showed increased odds of success.  
The VPC in the constant-only model was estimated at 40%. This reduced in the fully-adjusted model 
to an estimated 29% of residual variation explained by unobserved clinician-level factors.  
Exercise advice 
50.1% of patients were recorded as having achieved the exercise indicator via the recording 
template. The adjusted model showed a significant association between indicator achievement and 
a diagnosis of OA compared to joint pain (OR 1.56, 95% CI 1.18,2.08), age band (compared to 45-
64 years) 65-74 (OR 1.36, 95% CI 1.01,1.83). Disease sites (compared to the knee) of the ankle/foot 
(OR 0.46, 95% CI 0.28,0.74), wrist/hand (OR 0.45, 95% CI 0.29,0.69), or unspecified (OR 0.53, 95% 
CI 0.32,0.89) were associated with reduced odds of success, as was unknown BMI compared to not 
overweight (OR 0.67, 95% CI 0.46,0.98), and the highest total morbidity category of BNF chapters 
10+ compared to 0-4 (OR 0.65, 95% CI 0.47,0.91). Multiple consultation compared to single (OR 
2.20, 95% CI 1.69,2.86), and consultation with a clinician who undertook more than the median 
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number of index consultations compared to below or at the median (OR 2.43, 95% CI 1.28,4.59) 
both showed increased odds of success.  
Analysis of the random slope models showed some evidence that the association of age with 
exercise advice varied between clinicians. In particular, clinicians with a greater propensity to offer 
exercise advice had a still greater tendency to offer it in age band 75-84 than clinicians with a lower 
propensity to offer such advice. There was no evidence that the association of gender and BMI with 
exercise advice varied between clinicians. 
 The VPC in the constant-only model was 35%. This reduced in the fully-adjusted model to an 
estimated 24% of remaining variation caused by unobserved clinician-level factors.  
Weight loss advice in people with BMI ≥25kgm-2 
This indicator was deemed applicable only to patients known to be overweight. Even correcting for 
this, only modest levels of advice were recorded, at 45.2%. The adjusted model showed significantly 
reduced likelihood of achievement with disease at the wrist/hand compared to knee (lower odds -
adjusted OR 0.52, 95% CI 0.29,0.94). Multiple consultation compared to single (adjusted OR 2.00, 
95% CI 1.42,2.80) was associated with increased odds of success. Other trends, which did not 
achieve statistical significance in this sample, were for diminishing odds of advice in the older age 
bands, in all disease sites compared to the knee, and with increased morbidity load.  
The constant-only model VPC for weight loss advice was estimated at 34%. This reduced in the fully-
adjusted model to an estimated 21% of residual variation in provision of weight advice to those 
known to be overweight explained by unobserved clinician-level factors.  
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Table 6-7: Frequency of core management achievement, phase two, and estimates of association with the independent variables 
 
Education provision  
n (%) 
Education provision  
OR (95% CI) 
Exercise advice  
n (%) 
Exercise advice  
OR (95% CI) 
Weight advicea 
n (%) 
Weight advicea 
OR (95% CI) 
Overall 849 (49.2) - 864 (50.1) - 482 (44.6) - 
Diagnosis       
Joint pain 513 (44.9) 1.00 522 (45.7) 1.00 284 (40.6) 1.00 
OA 336 (57.7)  1.60 (1.19,2.14) 342 (58.8)  1.56 (1.18,2.08) 198 (52.0) 1.29 (0.91,1.85) 
Sex       
Female 357 (50.3) 1.00 361 (50.8) 1.00 273 (44.5) 1.00 
Male 492 (48.5) 1.01 (0.79,1.29) 503 (49.6) 1.04 (0.82,1.32) 209 (44.8) 0.96 (0.70,1.30) 
Age       
45-64 382 (46.8) 1.00 396 (48.5) 1.00 218 (44.5) 1.00 
65-74 240 (54.3)  1.47 (1.08,2.01) 246 (55.7)  1.36 (1.01,1.83) 149 (46.4) 1.21 (0.83,1.76) 
75-84 171 (49.0) 1.30 (0.92,1.83) 173 (49.6) 1.06 (0.76,1.48) 94 (42.7) 0.99 (0.63,1.53) 
85+ 56 (48.3) 1.36 (0.81,2.31) 49 (42.2) 0.74 (0.44,1.24) 21 (42.9) 0.77 (0.36,1.68) 
Site       
Knee 450 (52.6) 1.00 462 (54.0) 1.00 274 (48.2) 1.00 
Hip 171 (47.1) 0.81 (0.59,1.10) 178 (49.0) 0.79 (0.58,1.06) 87 (43.1) 0.78 (0.52,1.18) 
Ankle/Foot 44 (35.2)  0.47 (0.29,0.78) 45 (36.0)  0.46 (0.28,0.74) 26 (31.3) 0.54 (0.29,1.01) 
Wrist/Hand 63 (41.4) 0.79 (0.51,1.22) 51 (33.6)  0.45 (0.29,0.69) 30 (33.0)  0.52 (0.29,0.94) 
Unspecified 36 (36.4)  0.43 (0.25,0.74) 41 (41.4)  0.53 (0.32,0.89) 21 (36.2) 0.60 (0.31,1.19) 
Multiple 85 (65.4) 0.74 (0.46,1.21) 87 (66.9) 0.90 (0.55,1.46) 44 (57.1) 0.82 (0.44,1.51) 
BMI Category (prior to index consultation, phase 2)    
BMI <25 152 (48.7) 1.00 159 (51.0) 1.00 - - 
BMI 25 to <30 284 (54.3) 1.34 (0.94,1.90) 288 (55.1) 1.31 (0.93,1.85) 225 (44.0) 1.00 
BMI 30+ 281 (52.2) 1.39 (0.97,1.97) 284 (52.8) 1.29 (0.91,1.82) 245 (46.1) 1.29 (0.94,1.76) 
Not recorded 132 (37.6) 0.82 (0.56,1.21) 133 (37.9)  0.67 (0.46,0.98) 12 (33.3) - 
BNF subchapter count       
0-4 224 (46.2) 1.00 234 (48.2) 1.00 106 (45.5) 1.00 
5-9 302 (52.2) 0.88 (0.64,1.20) 307 (53.1) 0.88 (0.64,1.20) 172 (44.6) 0.79 (0.52,1.22) 
10+ 323 (48.9)  0.64 (0.45,0.90) 323 (48.9)  0.65 (0.47,0.91) 204 (44.3) 0.71 (0.45,1.11) 
      (con’t) 
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Education provision  
n (%) 
Education provision  
OR (95% CI) 
Exercise advice  
n (%) 
Exercise advice  
OR (95% CI) 
Weight advicea 
n (%) 
Weight advicea 
OR (95% CI) 
Single/multiple consultations for clinical OA in phase 2    
Single 530 (44.5) 1.00 551 (46.2) 1.00 306 (41.2) 1.00 
Multiple 319 (60.0)  2.87 (2.18,3.77) 313 (58.8)  2.20 (1.69,2.86) 176 (52.1)  2.00 (1.42,2.80) 
X-ray use prior to index consultationb     
No 706 (48.4) 1.00 719 (49.3) 1.00 447 (43.9) 1.00 
Yes 143 (53.8) 1.06 (0.61,1.85) 145 (54.5) 1.15 (0.66,2.00) 35 (57.4) 1.32 (0.66,2.66) 
Staff member index consultation count dichotomy    
At or below the 
median 55 (27.9) 1.00 59 (29.9) 1.00 33 (27.0) 1.00 
Above the median 794 (52.0)  2.87 (1.28,6.45) 805 (52.7)  3.16 (1.54,6.48) 449 (46.9)  2.43 (1.28,4.59) 
Practice ID       
Practice 1 366 (60.1) 1.00 359 (58.9) 1.00 104 (54.7) 1.00 
Practice 2 58 (62.4) 1.40 (0.22,8.75) 57 (61.3) 1.40 (0.28,7.05) 15 (62.5) 2.55 (0.53,12.4) 
Practice 3 55 (25.0)  0.14 (0.05,0.37) 63 (28.6)  0.22 (0.09,0.50) 13 (22.0)  0.24 (0.10,0.60) 
Practice 4 74 (36.6) 0.36 (0.12,1.09) 75 (37.1) 0.40 (0.15,1.07) 21 (32.3) 0.45 (0.17,1.19) 
Practice 5 65 (28.4)  0.10 (0.03,0.33) 68 (29.7)  0.14 (0.05,0.40) 8 (12.9)  0.10 (0.03,0.30) 
Practice 6 80 (83.3) 2.14 (0.45,10.2) 79 (82.3) 2.17 (0.53,8.87) 36 (78.3) 3.02 (0.76,12.0) 
Practice 7 66 (40.5) 0.39 (0.14,1.08) 70 (42.9) 0.49 (0.20,1.23) 7 (18.4)  0.28 (0.11,0.75) 
Practice 8 85 (75.9) 2.07 (0.42,10.2) 93 (83.0) 2.61 (0.62,10.9) 21 (77.8) 2.95 (0.73,11.9) 
VPCc estimates      
Null model - 0.40 (0.29,0.49) - 0.35 (0.24,0.43) - 0.34 (0.22,0.43) 
Adjusted model - 0.29 (0.18,0.37) - 0.24 (0.15,0.31) - 0.21 (0.11,0.30) 
adenominator 1065 patients known to have BMI ≥25; brelevant recorded X-ray in phase two prior to index consultation; cvariance partition coefficient. Adjusted ORs for 
achievement include all covariates. 
 
 204 
 Quality assessment: pharmacological management indicators 
Assessment or consideration of paracetamol use 
Analysis of responses to the paracetamol assessment indicator demonstrated an overall 
achievement rate of 56.3%. The adjusted model showed increased odds of achievement of 
assessment or consideration of paracetamol use (compared to 45-64) in patients in age groups 65-
74 (adjusted OR 1.63, 95% CI 1.20,2.22), 75-84 (adjusted OR 1.64, 95% CI 1.15,2.27), and age 85+ 
(adjusted OR 1.70, 95% CI 1.02,2.83). Patients with ankle/foot disease compared to the knee 
(adjusted OR 0.44, 95% CI 0.27,0.71), and unknown BMI status compared to not overweight 
(adjusted OR 0.61, 95% CI 0.42,0.89) had lower odds of achievement. Patients with multiple 
consultations compared to single (adjusted OR 2.98, 95% CI 2.26,3.94) and consultation with 
clinicians conducting more than the median number of index consultations compared to at or below 
the median (adjusted OR 3.18, 95% CI 1.66,6.08) had increased odds of achievement.  
As a comparison, paracetamol prescription was recorded in 17.3% of patients within 14 days of a 
clinical OA consultation during phase two (identified from the routine record).  
The VPC was estimated at 35% in the constant-only model. This reduced in the fully-adjusted model 
to 26% of residual variation estimated to be due to clinician-level factors.  
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Table 6-8: Frequency of pharmacological management, phase two, and estimates of association 
with the independent variables 
 Paracetamol considered Topical NSAID considered, 
 n (%) OR (95% CI) n (%) OR (95% CI) 
Overall 970 (56.3) - 832 (48.3) - 
Diagnosis     
Joint pain 606 (53.1) 1.00 522 (45.7) 1.00 
OA 364 (62.5) 1.32 (0.99,1.76) 310 (53.3)  1.36 (1.01,1.83) 
Sex     
Female 394 (55.5) 1.00 345 (48.6) 1.00 
Male 576 (56.8) 0.90 (0.71,1.14) 487 (48.0) 0.87 (0.68,1.12) 
Age     
45-64 425 (52.0) 1.00 380 (46.5) 1.00 
65-74 271 (61.3)  1.63 (1.20,2.22) 230 (52.0)  1.38 (1.01,1.88) 
75-84 208 (59.6)  1.62 (1.15,2.27) 172 (49.3)  1.50 (1.06,2.13) 
85+ 66 (56.9)  1.70 (1.02,2.83) 50 (43.1) 1.22 (0.71,2.10) 
Site     
Knee 495 (57.9) 1.00 438 (51.2) 1.00 
Hip 218 (60.1) 1.03 (0.76,1.39) 156 (43.0)  0.68 (0.50,0.93) 
Ankle/Foot 50 (40.0)  0.44 (0.27,0.71) 47 (37.6)  0.56 (0.34,0.93) 
Wrist/Hand 70 (46.1) 0.72 (0.47,1.10) 68 (44.7) 0.86 (0.55,1.34) 
Unspecified 47 (47.5) 0.61 (0.37,1.03) 36 (36.4)  0.43 (0.25,0.75) 
Multiple 90 (69.2) 0.73 (0.44,1.19) 87 (66.9) 0.93 (0.56,1.54) 
BNF subchapter count     
BMI <25 187 (59.9) 1.00 139 (44.6) 1.00 
BMI 25 to <30 315 (60.2) 1.09 (0.77,1.54) 279 (53.3)  1.48 (1.04,2.12) 
BMI 30+ 314 (58.4) 1.08 (0.76,1.54) 286 (53.2)  1.71 (1.19,2.45) 
Not recorded 154 (43.9)  0.61 (0.42,0.89) 128 (36.5) 0.83 (0.56,1.23) 
BMI Category (prior to index consultation, phase 2) 
0-4 248 (51.1) 1.00 216 (44.5) 1.00 
5-9 352 (60.9) 1.08 (0.79,1.48) 306 (52.9) 1.01 (0.73,1.39) 
10+ 370 (56.0) 0.72 (0.51,1.01) 310 (46.9)  0.69 (0.48,0.97) 
Single/multiple consultations for clinical OA in phase 2   
Single 602 (50.5) 1.00 521 (43.7) 1.00 
Multiple 368 (69.2)  2.98 (2.26,3.94) 311 (58.5)  2.75 (2.08,3.65) 
X-ray use prior to index consultationa    
No 809 (55.5) 1.00 704 (48.3) 1.00 
Yes 161 (60.5) 1.33 (0.76,2.35) 128 (48.1) 1.03 (0.58,1.82) 
Staff member index consultation count dichotomy   
At or below the median 70 (35.5) 1.00 58 (29.4) 1.00 
Above the median 900 (58.9)  3.18 (1.66,6.08) 774 (50.7)  2.87 (1.28,6.45) 
Practice ID     
Practice 1 387 (63.5) 1.00 352 (57.8) 1.00 
Practice 2 51 (54.8) 0.60 (0.12,3.02) 50 (53.8) 0.68 (0.08,5.54) 
Practice 3 101 (45.9) 0.48 (0.21,1.13) 61 (27.7)  0.22 (0.07,0.65) 
Practice 4 83 (41.1) 0.36 (0.13,0.99) 79 (39.1) 0.41 (0.11,1.47) 
Practice 5 80 (34.9)  0.16 (0.06,0.46) 78 (34.1)  0.15 (0.04,0.57) 
Practice 6 84 (87.5) 2.87 (0.63,13.1) 77 (80.2) 1.53 (0.25,9.27) 
Practice 7 86 (52.8) 0.69 (0.27,1.79) 78 (47.9) 0.48 (0.14,1.60) 
Practice 8 98 (87.5) 3.40 (0.72,16.0) 57 (50.9) 0.81 (0.12,5.45) 
VPCb estimates   
Null model - 0.35 (0.24,0.43) - 0.41 (0.30,0.49) 
Adjusted model  0.26 (0.16,0.33)  0.37 (0.26,0.46) 
arelevant recorded X-ray in phase two prior to index consultation; bvariance partition coefficient. 
Adjusted ORs for achievement include all covariates. 
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Assessment or consideration of topical NSAID use 
Achievement of the topical NSAID indicator was a little lower than for paracetamol at 48.3% overall. 
There was considerable overlap (87% agreement) between the assessment and consideration of 
paracetamol indicator with the topical NSAID indicator as shown in Table 6-9. 
Table 6-9: Paracetamol and topical NSAID consideration cross-tabulation 
 
Achievement of topical NSAID 
consideration indicator 
Not achieved Achieved Total 
Achievement of paracetamol 
consideration indicator 
Not achieved 712 42 754 
Achieved 180 790 970 
Total 892 832 1724 
The adjusted model shows increased odds of topical NSAID indicator achievement and OA diagnosis 
compared to joint pain (OR 1.36, 95% CI 1.01,2.14). Age (compared to 45-64 years) showed 
increased achievement for patients in age bands 65-74 years (OR 1.38, 95% CI 1.01,1.88) and 75-84 
years (OR 1.50, 95% CI 1.06,2.13). Patients with BMI status, compared to not overweight, of 
overweight (OR 1.48, 95% CI 1.04,2.12) or obese (OR 1.71, 95% CI 1.19,2.45) also had increased 
odds of achievement, as did those with multiple clinical OA consultations compared to single (OR 
2.75, 95% CI 2.08,3.65), and those who had an index consultation with a clinician who undertook 
more than the median number of index consultations compared to below or at the median (OR 
2.87, 95% CI 1.28,6.45). Patients with recorded disease sites, compared to the knee, of the hip (OR 
0.68, 95% CI 0.50,0.93), ankle/foot (OR 0.56, 95% CI 0.34,0.93) and unspecified (OR 0.43, 95% CI 
0.25,0.75) had reduced odds of achievement, as did those with high levels of total morbidity (BNF 
chapter count 10+ compared to 0-4 OR 0.69, 95% CI 0.48,0.97).  
Topical NSAID prescription was identified from the routine record in 24.9% of people within 14 days 
of a clinical OA consultation in phase two, compared to 48.3% of patients in whom the topical NSAID 
indicator was achieved (i.e. topical NSAID use was assessed or considered) through the template.  
In the constant-only model, VPC was estimated at 41%. This reduced in the fully-adjusted model to 
an estimated 37% of residual variance explained by unobserved clinician-level factors.  
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 Quality assessment: physiotherapy consideration and recorded referral 
Consideration of physiotherapy 
The rate of achievement for the physiotherapy referral indicator was the lowest of the eight 
indicators at 35.8%. The adjusted model showed significantly lower odds of achievement in patients 
with unspecified site of disease compared to the knee (OR 0.50, 95% CI 0.28,0.88). Patients with 
multiple clinical OA consultations compared to single (OR 2.20, 95% CI 1.71,2.84), and consultation 
with a clinician who undertook more than the median number of index consultations compared to 
below or at the median (OR 2.49, 95% CI 1.32,4.73) had increased odds of achievement.  
For comparison, physiotherapy referral within 14 days of a clinical OA consultation in phase two 
was recorded within the routine records in 7.2% (95% CI 6.0,8.6) of patients. Estimates of the OR 
indicated no statistically significant association between receipt of an OA diagnosis and odds of 
physiotherapy referral in phase two, unlike in phase one. 
The constant-only model VPC estimate was 27%. This reduced in the fully-adjusted model to an 
estimated 20% of residual variation in consideration of physiotherapy referral explained by 
unobserved clinician-level factors.  
 Achievement of all template indicators 
Achievement of all 8 template-derived indicators 
To assess complete achievement of all indicators, patients known not to be overweight or with 
unknown weight status were measured out of seven indicators, and those known to be overweight 
or obese out of eight – including weight loss advice. Weight recording within 14 days of a clinical 
OA consultation was not included. Overall, the achievement rate for all applicable indicators was 
20.4% (95% CI 18.5,22.3). The adjusted model (Table 6-11) showed a positive association between 
achievement of all indicators and an OA diagnosis compared to joint pain (OR 1.84, 95% CI 
1.30,2.60), having multiple clinical OA consultation compared to single (OR 2.14, 95% CI 1.56,2.92), 
and consultation with a clinician who undertook more than the median number of index 
consultations compared to below or at the median (OR 2.37, 95% CI 1.04,5.42).  
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Table 6-10: Frequency of physiotherapy indicator achievement, phase two, and estimates of 
association with the independent variables 
 Physiotherapy referral considered 
 n (%) OR (95% CI) 
Overall 617 (35.8) - 
Diagnosis   
Joint pain 374 (32.7) 1.00 
OA 243 (41.8)  1.34 (1.01,1.78) 
Sex   
Female 263 (37.0) 1.00 
Male 354 (34.9) 1.12 (0.89,1.42) 
Age   
45-64 296 (36.2) 1.00 
65-74 148 (33.5) 0.80 (0.59,1.07) 
75-84 129 (37.0) 1.06 (0.76,1.48) 
85+ 44 (37.9) 1.02 (0.62,1.69) 
Site   
Knee 317 (37.1) 1.00 
Hip 126 (34.7) 0.97 (0.72,1.30) 
Ankle/Foot 33 (26.4) 0.79 (0.48,1.31) 
Wrist/Hand 50 (32.9) 1.10 (0.71,1.69) 
Unspecified 23 (23.2)  0.50 (0.28,0.88) 
Multiple 68 (52.3) 1.05 (0.67,1.65) 
BMI Category (prior to index consultation, phase 2) 
BMI <25 118 (37.8) 1.00 
BMI 25 to <30 200 (38.2) 0.93 (0.66,1.31) 
BMI 30+ 194 (36.1) 1.03 (0.73,1.46) 
Not recorded 105 (29.9) 0.76 (0.52,1.12) 
BNF subchapter count 
0-4 167 (34.4) 1.00 
5-9 211 (36.5) 0.96 (0.70,1.31) 
10+ 239 (36.2) 0.86 (0.62,1.21) 
Single/multiple consultations for clinical OA in phase 2 
Single 387 (32.5) 1.00 
Multiple 230 (43.2)  2.20 (1.71,2.84) 
X-ray use prior to index consultationa  
No 500 (34.3) 1.00 
Yes 117 (44.0) 1.26 (0.76,2.12) 
Staff member index consultation count dichotomy 
At or below the median 39 (19.8) 1.00 
Above the median 578 (37.9)  2.49 (1.32,4.73) 
Practice ID    
Practice 1 287 (47.1) 1.00 
Practice 2 43 (46.2) 1.20 (0.27,5.32) 
Practice 3 50 (22.7)  0.35 (0.16,0.76) 
Practice 4 55 (27.2) 0.42 (0.17,1.06) 
Practice 5 33 (14.4)  0.10 (0.03,0.29) 
Practice 6 54 (56.3) 0.88 (0.24,3.28) 
Practice 7 53 (32.5) 0.56 (0.23,1.34) 
Practice 8 42 (37.5) 0.53 (0.14,2.02) 
VPCb estimate  
Null model - 0.27 (0.17,0.34) 
Adjusted model - 0.20 (0.12,0.28) 
arelevant recorded X-ray in phase two prior to index consultation; bvariance partition coefficient. 
Adjusted ORs for achievement include all covariates. 
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For the 8 indicators combined, in a null (constant-only) two-level model, VPC was estimated at 33%. 
This reduced in the fully-adjusted model to an estimated 23% of the residual variation in 
achievement of all 8 indicators explained by unobserved clinician-level factors.  
Achievement of all template-derived indicators prior to referral 
There were 358 (20.8%) patients who were referred on for further care within 14 days of a 
qualifying consultation. Overall, only a modest proportion (26.0%, 95% CI 21.7,30.8) were recorded 
as having achieved all of the applicable indicators within phase two prior to referral. Although there 
were small numbers of patients involved, the adjusted model shows a significant association 
between achievement of all indicators in people who were referred on for further care and multiple 
clinical OA consultation compared to single (adjusted OR 4.45, 95% CI 2.04,9.70 (Table 6-11).  
VPC in a constant-only two-level model of achievement of all 8 template indicators in people 
referred was estimated at 48%. This reduced in the fully-adjusted model to 36%, somewhat larger 
than for achievement of the 8 indicators in the whole study population. 
 Restriction of template derived indicators to people with at least one template entry: 
a sensitivity analysis 
When the number of people with recorded achievement of the template quality indicators was 
assessed as a proportion of those with at least one template entry recorded in phase two (n=1142), 
rates of pain and function assessment achievement increased to 95.6% and 93.7% respectively 
compared to 63.3% and 62.1% respectively for all consulters (Table 6-12). The indicator 
achievement rate was 54.0% for consideration of physiotherapy referral and 30.7% for completion 
of all applicable template indicators.  
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Table 6-11: Frequency of all indicator achievement, phase two, and estimates of association with 
the independent variables 
 All template indicatorsa 
Achievement of all template indicatorsa 
before referral 
 n (%) OR (95% CI) n (%) OR (95% CI) 
Overall 351 (20.4)  93 (26.0)  
Diagnosis     
Joint pain 189 (16.5) 1.00 57 (25.1) 1.00 
OA 162 (27.8)  1.84 (1.30,2.60) 36 (27.5) 1.47 (0.63,3.43) 
Sex     
Female 155 (21.8) 1.00 49 (28.7) 1.00 
Male 196 (19.3) 1.13 (0.84,1.51) 44 (23.5) 0.77 (0.37,1.59) 
Age     
45-64 157 (19.2) 1.00 52 (26.7) 1.00 
65-74 93 (21.0) 0.94 (0.65,1.35) 23 (25.8) 0.81 (0.32,2.05) 
75-84 78 (22.3) 1.15 (0.76,1.74) 14 (23.0) 0.80 (0.26,2.47) 
85+ 23 (19.8) 0.78 (0.41,1.47) 4 (30.8) 1.16 (0.14,9.71) 
Site     
Knee 177 (20.7) 1.00 59 (28.2) 1.00 
Hip 65 (17.9) 0.94 (0.65,1.38) 17 (23.0) 0.94 (0.37,2.40) 
Ankle/Foot 21 (16.8) 0.96 (0.51,1.79) 2 (20.0) 1.15 (0.13,10.1) 
Wrist/Hand 24 (15.8) 0.92 (0.52,1.61) 2 (9.1) 0.39 (0.05,2.88) 
Unspecified 16 (16.2) 0.69 (0.35,1.37) 1 (9.1) 1.13 (0.07,17.2) 
Multiple 48 (36.9) 1.11 (0.67,1.83) 12 (37.5) 1.53 (0.46,5.10) 
BMI Category (prior to index consultation, phase 2) 
BMI <25 69 (22.1) 1.00 11 (20.0) 1.00 
BMI 25 to <30 120 (22.9) 0.81 (0.53,1.22) 38 (32.8) 1.09 (0.35,3.39) 
BMI 30+ 107 (19.9) 0.83 (0.54,1.27) 30 (26.8) 0.87 (0.27,2.77) 
Not recorded 55 (15.7) 0.80 (0.50,1.29) 14 (18.7) 0.70 (0.21,2.40) 
BNF subchapter count    
0-4 88 (18.1) 1.00 26 (22.4) 1.00 
5-9 119 (20.6) 0.95 (0.64,1.40) 33 (27.7) 0.88 (0.35,2.20) 
10+ 144 (21.8) 0.95 (0.62,1.44) 34 (27.6) 1.19 (0.39,3.68) 
Single/multiple consultations for clinical OA in phase 2 
Single 215 (18.0) 1.00 31 (17.4) 1.00 
Multiple 136 (25.6)  2.14 (1.56,2.92) 62 (34.4)  4.45 (2.04,9.70) 
X-ray use prior to index consultationa    
No 286 (19.6) 1.00 72 (25.5) 1.00 
Yes 65 (24.4) 1.28 (0.72,2.29) 21 (27.6) 2.49 (0.77,8.05) 
Staff member index consultation count dichotomy   
At or below the 
median 18 (9.1) 1.00 4 (9.5) 1.00 
Above the median 333 (21.8)  2.37 (1.04,5.42) 89 (28.2) 5.02 (0.88,28.5) 
Practice ID     
Practice 1 191 (31.4) 1.00 48 (32.9) 1.00 
Practice 2 12 (12.9) 0.32 (0.06,1.71) 1 (8.3) 0.07 (0.00,4.33) 
Practice 3 19 (8.6)  0.20 (0.07,0.56) 6 (14.0) 0.30 (0.05,1.85) 
Practice 4 24 (11.9) 0.34 (0.12,1.01) 1 (2.9) 0.04 (0.00,1.09) 
Practice 5 15 (6.6)  0.11 (0.03,0.39) 2 (10.0) 0.08 (0.00,1.49) 
Practice 6 48 (50.0) 1.87 (0.45,7.77) 24 (77.4) 7.77 (0.85,71.1) 
Practice 7 14 (8.6)  0.25 (0.08,0.79) 5 (8.9) 0.18 (0.03,1.34) 
Practice 8 28 (25.0) 0.65 (0.15,2.93) 6 (40.0) 1.51 (0.13,17.0) 
VPCb estimates    
Null model - 0.33 (0.20,0.42) - 0.48 (0.24,0.61) 
Adjusted model - 0.23 (0.12,0.32) - 0.36 (0.10,0.50) 
arelevant recorded X-ray in phase two prior to index consultation; bvariance partition coefficient. 
Adjusted ORs for achievement include all covariates. 
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Table 6-12: Quality indicator summary of template-derived achievement, all patients triggering the template and those with at least one entry recorded 
 
All patients in whom template triggered, 
phase 2 
Patients with at least one template entry, 
phase 2 
Indicator Numerator 
Denominator 
(patients eligible 
for the indicator) 
% achieving 
the indicator  
(95% CI) Numerator 
Denominator 
(patients eligible 
for the indicator) 
% achieving 
the indicator  
(95% CI) 
Pain assessment 1092 1724 
63.3 
(61.0,65.6) 1092 1142 
95.6 
(94.3,96.7) 
Function assessment 1070 1724 
62.1 
(59.8,64.3) 1070 1142 
93.7 
(92.1,95.0) 
Education or information provision 849 1724 
49.2 
(46.9,51.6) 849 1142 
74.3 
(71.7,76.8) 
Exercise advice or provision 864 1724 
50.1 
(47.8,52.5) 864 1142 
75.7 
(73.1,78.1) 
Weight loss advice for people with BMI ≥25kgm-2 477 1065 
44.8 
(41.8,47.8) 477 741 
65.0 
(61.5,68.4) 
Assessment of/recommendation for  
paracetamol therapy 970 1724 
56.3 
(53.9,58.6) 970 1142 
84.9 
(82.7,86.9) 
Assessment of/recommendation for  
topical NSAID therapy 832 1724 
48.3 
(45.9,50.6) 832 1142 
72.9 
(70.2,75.4) 
Consideration of physiotherapy referral 617 1724 
35.8 
(33.6,38.1) 617 1142 
54.0 
(51.1,56.9) 
Achievement of all applicable indicatorsa 351 1724 
20.4 
(18.5,22.3) 351 1142 
30.7 
(28.1,33.5) 
Achievement of all applicable indicators in patients 
recorded as referred within 14 days of a clinical OA 
consultation, phase 2a 93 358 
26.0 
(21.7,30.8) 93 261 
35.6 
(30.1,41.6) 
aAchievement of all applicable indicators refers to all 7 excluding weight in those not known to be overweight or obese, and all 8 indicators in those known to be overweight or 
obese.  
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 Effects of a decision to request an X-ray following a clinical OA consultation 
When an X-ray recorded within 14 days after a clinical OA consultation in phase two was also 
included as an independent variable in the multilevel models, there was a significant association 
between such a recorded X-ray and achievement of pain, function, consideration of paracetamol 
or topical NSAIDs, information provision and exercise advice, with estimated adjusted ORs between 
1.75 (95% CI 1.22,2.51) for exercise advice and 2.38 95% CI 1.53,3.68) for pain assessment for a 
recorded X-ray compared to none).  
Table 6-13: Template-derived quality indicator measures, phase two: association of 
achievement with recorded X-ray within 14 days of a clinical OA consultation 
Indicator 
X-ray recorded within 14 days of a clinical OA 
consultation vs. none OR (95% CI)a 
Pain  2.38 (1.53,3.68) 
Function  2.19 (1.44,3.32) 
Weight record 0.86 (0.58,1.27) 
Paracetamol considered  2.35 (1.60,3.45) 
Top. NSAID considered  2.06 (1.41,3.02) 
Information provision  1.98 (1.36,2.86) 
Exercise advice  1.75 (1.22,2.51) 
Weight loss advice 1.34 (0.66,2.68) 
Physio considered 1.26 (0.75,2.12) 
All eight QI 1.18 (0.65,2.12) 
All eight QI in patients with a 
recorded  referral 
2.59 (0.80,8.35) 
aFully adjusted two-level logistic regression model including recorded X-ray within 14 days after 
a clinical OA consultation in phase two as well as the other independent variables (not shown) 
6.5 Discussion 
 Main findings and comparison with previous literature 
The levels of quality achieved were best for the first two items on the template: pain and function 
assessment recording, at 63% and 62% achievement respectively. Most of the remaining template-
derived indicators were achieved in the 45% to 56% range, with the exception of consideration of 
physiotherapy referral at 36%. The rates of achievement for the assessment and advice indicators 
were substantially better than the rates identified in Chapter Five, section 5.3.2 for the baseline 
recording through the routine EHR (0% to 0.3%) and compare much more favourably with recorded 
achievement in other studies as shown in Table 5-15, page 181. 
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The fact that the first two items on the template were the most frequently-completed may have 
been due to an ordering effect. The relatively low frequency of achievement for the physiotherapy 
consideration indicator compared to the other template indicators may have been due to its 
position at the end of the template, but may also have reflected clinician beliefs about the utility of 
physiotherapy for OA such as those underlying the variation and under-use of exercise in knee pain 
and OA as described by Cottrell et al.288 It may also have reflected the availability of physiotherapy 
services in primary care, as clinicians may not have wished to raise the issue of physiotherapy 
referral with patients if there was not adequate service provision to meet demand.289  
Common associations with indicator achievement 
For the template-derived quality measures, the most frequent associations with indicator 
achievement were a diagnosis of OA rather than joint pain, older age rather than age 45-64, the 
patient making multiple rather than single consultations for clinical OA within phase two, and an 
index consultation with a clinician who held more than the median number of index consultations, 
compared to the median or fewer. The most consistent associations with reduced odds of indicator 
achievement were a disease site of the ankle/foot (and, with less consistency, unspecified site) 
compared to the knee, unknown BMI status compared to not overweight, a higher total morbidity 
measure based on a BNF subchapter count of 10 or more compared to 0-4 chapters, and lower 
achievement by two practices (3 and 5) compared to practice 1.  
Comparison of template-derived and routinely-recorded achievements 
When comparing recorded achievement of consideration and use of paracetamol or topical NSAID 
prescription between the template-derived assessment and recorded prescription, it was apparent 
that the quality achievement data for assessment from the template show substantially higher 
achievement than that the recorded actual prescription in the routine record. Paracetamol 
consideration was achieved in 56.3% of clinical OA consulters in phase two, whereas 17.3% were 
recorded as receiving a prescription within 14 days of a clinical OA consultation. Similarly, for topical 
NSAIDs, 48.3% of patients were recorded as having been assessed for these, whilst 24.9% were 
recorded as receiving a prescription within 14 days of a clinical OA consultation in phase two. It may 
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be that the relatively safe options had previously been tried in some patients and found to be 
ineffective. Estimation of ORs for the effects of the independent variables for the prescribing 
indicators measured in the template and routine record showed similar trends for age, though the 
effect of increasing age on actual prescription was substantially greater than on the consideration 
indicator. Odds of recorded prescription were increased by the morbidity burden as measured by 
BNF chapter count.  
Physiotherapy consideration via the template was substantially more frequent at 35.8% compared 
to the recorded actual referral within 14 days of a clinical OA consultation at 7.2%. The independent 
variables showed a positive association for patients with an OA diagnosis compared to joint pain in 
the template physiotherapy consideration, unlike for the recorded referral (which showed lower 
odds of referral for people with OA in phase one and no difference in phase two), and likewise for 
the staff index consultation count above the median compared to at or below the median. The 
wrist/hand site compared to the knee was associated with reduced odds of actual referral, whereas 
unspecified site was associated with reduced odds of recorded consideration in the template. 
Actual referral to physiotherapy, rather than recorded consideration, may depend on factors such 
as health beliefs and access, as noted above. Further work to understand the origin (patient or 
clinician) and cause of the discrepancy would be required. It was notable that there was no 
association between consideration of physiotherapy use or referral and BNF chapter count, unlike 
for many pharmacological options, suggesting that clinicians or patients tend to increase 
pharmacological options rather than make use of other strategies.  
An assessment of random effects of age, sex, and BMI across clinicians was made, on the basis that 
studies have previously identified age and sex discrimination,269-271 and as previously noted, some 
clinicians are prone to negative stereotypes about obesity.272 However, no strong or consistent 
evidence was found to support any hypothesis of a variable effect across clinicians of age, sex or 
BMI on recorded quality of care behaviours.  
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Increased odds of template indicator achievement or of a record of recommended management 
options for people with an OA diagnosis may to some extent reflect the misclassification effects 
identified in Chapter Four, section 4.3.3 (partial over-inclusion of clinical OA through use of joint 
pain codes that in fact do not always represent OA). The possibility that patients with joint pain and 
OA are a homogenous population was discussed by Jordan et al.,17 concluding that the populations 
of older adults (50 years and over) with joint pain and OA are not in fact homogenous. An OA 
diagnosis may represent a group more akin to a stereotypical OA patient (older, more likely to be 
overweight, more symptomatic) than people with joint pain.17 
The highest level of morbidity (BNF chapter count 10+) was associated with reduced odds of several 
template-derived quality measures including pain and function assessment, topical NSAID 
assessment of treatment, education/information provision, and exercise advice. The association 
between recorded paracetamol prescription and level of total morbidity as measured by a count of 
BNF chapters could have been to a small extent self-fulfilling – the prescribed drugs for OA (if 
prescribed in the 12 months before the index consultation) adding to the apparent level of 
morbidity as measured. However, reduced odds of topical NSAID prescription was seen in the 
highest morbidity band. The highest morbidity burden being negatively associated with several 
assessment and advice indicators suggests that in patients with higher apparent morbidity loads, 
either clinicians or patients have a preference for further pharmacological rather than non-
pharmacological management.  
It has previously been shown that a decision to use X-ray investigation at a consultation is 
associated with other aspects of care for knee pain, including increased odds of referral to 
physiotherapy, rheumatology or orthopædics and reduced odds of advice regarding exercise, even 
before a result is available.12 In the adjusted multilevel analyses, recorded X-ray use before the 
index consultation in phase two was not significantly associated with any of the template-derived 
indicators or routinely-recorded prescribing or referral patterns. There was a significant association 
between a recorded X-ray within 14 days after a clinical OA consultation and achievement of many 
of the template-derived indicators (pain, function, consideration of paracetamol or topical NSAIDs, 
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information provision and exercise advice) but not the routinely-recorded prescribing or referral 
indicators. Given that associations with a recorded X-ray after a clinical OA consultation had been 
adjusted for all other covariates (including recorded X-ray prior to the index consultation, total 
morbidity load, and multiple clinical OA consultations) one possible explanation for the association 
between X-ray use after a clinical OA consultation and achievement of the associated indicators is 
that some clinicians requested X-rays as a component of what might be termed a ‘thorough OA 
consultation.’ The reason for this disparity is unclear but may reflect unmeasured characteristics 
such as social class or disease severity. 
Outcomes for surgical procedures have been found to be related to the volumes of the procedures 
undertaken at a provider and surgeon level.290-292 It is conceivable that the increased achievement 
of quality indicators by clinicians who undertake more than the median number of index 
consultations was a similar phenomenon, that their greater clinical OA workload was associated 
with higher recorded quality. On the other hand, it is possible that this represents information bias, 
in that clinicians who achieved lower levels of recorded quality of care may have seen as many 
patients with clinical OA as their higher-achieving counterparts but not recorded diagnostic 
information about them in a coded way (and so for the purposes of an EHR review based on Read 
codes, those patients would not form a part of the numerator or denominator). However, it seems 
unlikely that there was a major problem with ascertainment bias as odds of OA diagnosis rather 
than joint pain coding (Chapter Four) were unrelated to the staff index consultation count, 
suggesting that musculoskeletal clinical workload did not affect coding behaviour, and the recorded 
prevalence of total clinical OA was broadly stable between periods, as described fully in Chapter 
Seven, section 7.3.1, and in keeping with national and international comparisons of OA consultation 
prevalence.  
There were significant differences between practices overall in the quality of care for OA as 
measured through the template-derived, pharmacological management and referral processes. 
This type of variation would be consistent with the variability in QOF scores between practices such 
as reported by Ashworth.293  
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Comparison with previous literature 
Broadbent et al.69 found that female sex and older age were negatively associated with provision 
of information, and older age was positively associated with an initial trial of paracetamol, and with 
ibuprofen or a COX-2 selective NSAID where an oral NSAID was used. In Broadbent’s study, more 
severe OA (defined as failure to respond to therapy) was positively associated with assessment for 
function and pain within the prior 12 months. Severity was not measured in the MOSAICS medical 
record review study, but neither age nor sex showed consistent effects across quality achievement 
or recorded clinical management in this study. Li et al.80 found that women were more likely to 
receive a record of weight loss advice than men (OR 2.64), as were people aged 55-64 compared to 
those aged 75 or over (OR 1.96). Li et al. also identified that neither a record of exercise advice nor 
assessment for assistive devices had a significant association with age or sex.  
 Limitations 
Many of the limitations applicable elsewhere were also relevant to this chapter, including the issues 
of multiple comparison, dataset limitations (Chapter Four, section 4.4.3 and Chapter Five, section 
5.4.2), and interpretation of the VPC (Chapter Four, section 4.4.3). 
The template did not always trigger as designed, and a small group of patients who should have 
formed part of the denominator for this study were excluded. There was no reason to believe that 
this forms a deliberate selection bias as there was no facility for clinicians to prevent the template 
triggering, and any ‘escape’ from the template should still have flagged the record as the template 
having triggered. The age/sex distribution for people in the template triggering and non-triggering 
categories were broadly similar, and all practices were affected by the template not triggering as 
anticipated with a range of 1-18% of patients consulting with clinical OA. The differences in 
successful triggering between practices were unexplained. The only reason that a bias would have 
had an effect on the results is if there was a difference in characteristics between patients for whom 
the template was or was not triggered. Before implementation of the template in routine care, the 
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reasons behind the failure to trigger consistently for all specified Read codes should be identified 
and resolved.  
 Conclusion 
Overall, the template-derived data was found to have added substantially to the information 
available to assess the quality of care for OA. The next Chapter will assess whether the introduction 
of the template was associated with improvements in routinely-recorded indicators of care. 
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Chapter Seven: Effects of the template on disease coding and 
management of osteoarthritis: a before-and-after study 
7.1 Introduction 
As noted in Chapter Three, the consultation recording template was intended to be an aid to 
recording of consultations for clinical OA in the MOSAICS study rather than an intervention to 
promote adherence to the NICE guidance in its own right. Nevertheless, given the evidence base 
for templates in changing clinical behaviour, 152,162 it was necessary to determine the extent to 
which the template was associated with a change in clinical behaviour in the study.  
The baseline assessment of recorded quality of care for OA (Chapter Five) has shown that various 
quality indicators were not routinely captured by the medical record, including pain and functional 
assessment, provision of education or information regarding OA, weight loss, and exercise advice. 
Chapter Six reported the quality of care as recorded through the template, with a comparison 
between the template-derived measures and their routinely-recorded counterparts where 
possible. However, it is not possible to use the indicators recorded through the template to assess 
any effect of the template itself on delivery of quality care. Rather, such an assessment must 
depend on indicators that were routinely captured such as those relating to prescriptions, referrals, 
and weight recording (though the latter could be captured both through the routine record and the 
template).  
The objective of this chapter was to estimate the effects of the template intervention on those 
aspects of care for OA captured routinely by the medical record. 
7.2 Method 
The analysis used in this chapter was based upon that determined and undertaken by Professor 
Jordan for the associated publication Quality of care for OA: the effect of a point-of-care 
consultation recording template99 (Appendix B), for which the candidate was lead author and led 
the design and interpretation. This chapter used an extended set of covariates (as used in Chapter 
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Four to Chapter Six) compared to the analysis for the publication, and is based on a slightly smaller 
denominator population of people consulting with clinical OA as defined in Chapter Four (diagnosed 
OA or peripheral joint pain, excluding shoulder or elbow disease). This analysis was devised and 
performed by the candidate.  
As noted in previous chapters, the MOSAICS study was divided into periods of six months each. The 
first two 6-month periods represented the 12 months immediately before template installation and 
the third period covered the six months immediately after template installation in all eight practices 
(see Figure 1-1, page 20). Although there is no evidence of a seasonal variation in the processes of 
care in general practice,294 a seasonal fluctuation in practice nurse workload has previously been 
identified295 which could have an impact on the delivery of some chronic disease management. 
Therefore, period one was used as the calendar control to which recording of management in 
period three was compared. Management in period two was also compared to that in period one 
to assess whether there was evidence of any natural change in management over time. As in 
previous analyses, patients were allocated to an index clinician (the first clinician to make a 
diagnosis of OA in a period, or, if no OA diagnosis was made in a period, the first clinician to record 
a relevant joint pain code). To link each aspect of care in time to a consultation for clinical OA, a 
period of 14 days from each such consultation was permitted for the care to be recorded, as 
previously used by the RIPCHS and consistent with analyses in previous chapters.99,264 
It was considered possible that the introduction of the template could have caused clinicians to 
either avoid recording a clinical OA diagnosis (to avoid the template triggering during a 
consultation) or, potentially, to have caused clinicians to become habituated to recording and 
managing clinical OA (and thereby record more cases). Therefore, the analysis first considered the 
diagnostic coding behaviours of clinicians (recording of OA or joint pain in patients within periods), 
to determine whether or not rates of clinical OA morbidity recording were stable across periods.  
To determine the effect of the template on recorded management of clinical OA, indicators of 
clinical assessment and management (from the systematic review,107 NICE guidance,5 or British 
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National Formulary217) described in the baseline quality assessment (Chapter Five) were used to 
assess the change in quality of care received by populations of patients consulting in each period. 
However, as the data used had to rely on the routinely recorded (non-template data), certain data 
were less feasible to use (such as a record of pain and function assessment, provision of education 
or information, exercise or weight loss advice, risk assessment for oral NSAIDs, and referral for non-
ambulatory aids and devices assessment) due to very low levels of routinely recorded indicator 
achievement in the first two six-month periods and so were excluded from this analysis. Some 
pharmacological interventions were also not suitable for comparison of care between periods 
(capsaicin, glucosamine, etoricoxib 60mg, weight loss agents, and rubefacients) as the numerators 
for these interventions were too small to make meaningful comparisons. Comparisons of OA 
management between periods were therefore based on data representing weight recording, 
pharmacological management (paracetamol, topical NSAIDs, opioids, oral NSAIDs, gastroprotection 
with PPIs), recorded X-ray usage, and referrals (physiotherapy, or all onward referral), using the 
previously described definitions. Of the feasible routinely recorded management options, those 
considered most likely to be influenced by the template (as included as template domains) were 
weight recording, paracetamol and topical NSAID prescribing, and physiotherapy referral. The 
remaining indicators examined were expected to remain relatively stable as they did not form part 
of the template recording prompt.  
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Table 7-1: Routinely recorded measures used to estimate the effect of the template on recorded quality of care for OA 
Indicator domain Indicator origin  
Assessment data 
source(s) 
Associated 
template 
domain 
Anticipated change if template 
functioned as an intervention 
Weight/BMI record 
[Prerequisite for advice 
indicator] 
Routinely recorded 
or template 
Yes Increase 
Prescription for paracetamol Systematic review 
Routinely recorded 
prescriptions 
Yes Increase 
Prescription for topical NSAIDs NICE guidance 
Routinely recorded 
prescriptions 
Yes Increase 
Exercise or physiotherapy referral Systematic review 
Routinely recorded 
codes 
Yes Increase 
Prescription for opioid analgesics NICE guidance 
Routinely recorded 
prescriptions 
No 
No effect or possible reduction as 
paracetamol/topical NSAID increases 
Prescription for oral NSAIDs NICE guidance 
Routinely recorded 
prescriptions 
No 
No effect or possible reduction as 
paracetamol/topical NSAID increases 
Prescription for oral NSAIDs in people with 
recorded comorbidity as a relative 
contraindication 
NICE guidance 
Routinely recorded 
prescriptions 
No 
No effect or possible reduction as 
paracetamol/topical NSAID increases 
Co-prescription of gastroprotection (for 
people prescribed oral NSAIDs) 
Systematic review 
Routinely recorded 
codes 
No No effect 
Recorded use of X-rays within 14 days of a 
consultation for peripheral joint clinical OA 
NICE guidance 
Routinely recorded 
codes 
No No effect 
Any onward referral 
[Aggregation of NICE 
possible referral 
interventions]  
Routinely recorded 
codes 
No No effect 
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7.2.1 Statistical analysis 
The denominator population was assumed to be static, as discussed in Chapter Four, and the 
practice population used was the same as that used for the baseline periods one and two.  
Age-standardised period consultation prevalence rates per 100,000 population were calculated for 
each practice and overall as described in Chapter Four (section 4.2.4), using the European Standard 
Population.226 The differences in rates between periods were calculated via the standardised rate 
ratio and its 95% CI.296  
The routinely recorded care for clinical OA in the populations consulting in the three six-month 
periods of interest were described initially. The frequency of achievement by month was also 
plotted across periods one to three as used in the associated publication99 and are reproduced here.  
Recorded management in periods two and three (the six month periods immediately before and 
after template installation) were then compared to that in period one using two-level binary logistic 
multilevel models (patients within index clinicians). The model was adjusted for the same variables 
used in previous chapters: sex, age, site of disease, BMI status, morbidity burden as assessed by a 
count of drug types, single or multiple clinical OA consultations within periods, recorded X-ray use 
prior to the index consultation, the number of index consultations undertaken by the staff member 
consulted (dichotomised into above or at-or-below the median number), and the practice.  
Patients’ consultations within periods were aggregated to a single summary of the diagnosis and 
management within that period. Consultations by the same patient in different time periods were 
treated independently, as attempts to use a three-level model to account for repeated 
consultations within patients across periods were unsuccessful.  
As well as the primary analysis, which included all clinical OA consulters in each of the three periods, 
sensitivity analyses were undertaken. The effect of the template was estimated using the same 
methodology as noted above in patients for whom the template was recorded as having triggered 
in period three (n=1724) (but with no change to the eligible population in periods one and two), 
and in those with a recorded template entry other than weight or BMI (n=1142). Whereas the main 
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analysis estimates the effect of the template implementation strategy (akin to an intention-to-treat 
analysis), the first of the two sensitivity analyses is regarded as a truer estimate of the effect of the 
template itself whilst the second sensitivity analysis estimates the effect in people in whom 
clinicians have engaged with the template use.  
The data were analysed for the descriptive epidemiology in Microsoft® Excel®,231 CIA,232 
StatsDirect,297 and SPSS v21230 and, for the multilevel modelling, in Stata 14.1298 and MLwiN234 using 
the runMLwiN235 command. 
7.3 Results 
7.3.1 Consultations by period 
Over the three periods, 4393 unique patients consulted for clinical OA: 3496 in just one period 
(79.6%), 771 in two periods (17.6%), and 126 (2.9%) in all three periods. There was a slight trend to 
increasing frequency of consultation with 1750 patients consulting in period one, 1821 in period 
two, and 1845 (of whom 1724 triggered the template) in period three (approximately a 5% overall 
increase). The practice-specific age-standardised rates are shown in Table 7-3, with the SRRs and 
their 95% CI. 
Table 7-2: Patients consulting by time period with OA or joint pain classification 
 Patients consulting within each time period 
1: 6-12 months before 
template fire n (%) 
2: 0-6 months before 
template fire n (%) 
3: 0-6 months after 
template fire n (%) 
Joint pain 1174 (67) 1184 (65) 1237 (67) 
OA 576 (33) 637 (35) 608 (33) 
Total 1750 1821 1845 
There was substantial variation within practices between periods in the age-standardised rates of 
joint pain and OA between periods. There was evidence only of a statistically significant increase in 
recorded non-OA joint pain and combined clinical OA between periods two and three in practice 
six and an increase in combined clinical OA in practice eight between periods one and three, and 
two and three.  
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Table 7-3: Age-standardised disease rates (ASR) per 10,000 adults aged ≥45 years with 95% CI, and standardised rate ratios (SRR) with 95% CI, total and by practice 
   Practice 1 Practice 2 Practice 3 Practice 4 Practice 5 Practice 6 Practice 7 Practice 8 Total 
Jo
in
t 
p
ai
n
 
A
SR
 Period 1  287 (256,319) 229 (164,294) 382 (325,440) 340 (288,391) 528 (451,604) 390 (305,474) 438 (368,509) 229 (163,295) 230 (217,243) 
Period 2  309 (276,342) 253 (183,322) 366 (309,422) 383 (328,437) 486 (413,560) 300 (227,374) 440 (370,511) 219 (153,284) 232 (219,246) 
Period 3 291 (260,323) 217 (153,282) 419 (358,480) 348 (296,400) 542 (465,620) 429 (339,518) 467 (394,539) 320 (241,399) 242 (228,255) 
SR
R
 
Period 2:1 
1.07 
(0.92,1.25) 
1.10 
(0.74,1.64) 
0.96 
(0.77,1.19) 
1.13 
(0.91,1.39) 
0.92 
(0.75,1.14) 
0.77 
(0.56,1.07) 
1.01 
(0.80,1.26) 
0.95 
(0.63,1.44) 
1.01 
(0.93,1.10) 
Period 3:1 
1.01 
(0.87,1.18) 
0.95 
(0.63,1.43) 
1.10 
(0.89,1.35) 
1.03 
(0.83,1.27) 
1.03 
(0.84,1.26) 
1.10 
(0.81,1.49) 
1.06 
(0.85,1.33) 
1.40 
(0.96,2.04) 
1.05 
(0.97,1.14) 
Period 3:2 
0.94 
(0.81,1.10) 
0.86 
(0.57,1.29) 
1.15 
(0.93,1.42) 
0.91 
(0.74,1.12) 
1.12 
(0.91,1.37) 
1.42 
(1.03,1.97) 
1.06 
(0.85,1.32) 
1.46 
(1.00,2.15) 
1.04 
(0.96,1.13) 
Fo
rm
al
ly
 d
ia
gn
o
se
d
 O
A
 
A
SR
 Period 1  273 (242,305) 162 (104,219) 114 (82,145) 111 (82,140) 171 (127,215) 64 (29,97) 77 (47,107) 202 (140,263) 113 (104,122) 
Period 2  292 (260,325) 178 (119,238) 137 (103,171) 150 (116,183) 197 (150,243) 34 (9,59) 87 (55,119) 216 (152,280) 125 (115,135) 
Period 3 267 (237,298) 251 (180,322) 134 (99,168) 139 (106,171) 156 (115,215) 32 (8,56) 53 (28,78) 274 (201,347) 118 (109,128) 
SR
R
 
Period 2:1 
1.07 
(0.91,1.25) 
1.10 
(0.68,1.79) 
1.21 
(0.83,1.75) 
1.35 
(0.95,1.90) 
1.15 
(0.81,1.63) 
0.54 
(0.22,1.34) 
1.13 
(0.66,1.92) 
1.07 
(0.70,1.64) 
1.11 
(0.99,1.24) 
Period 3:1 
0.98 
(0.83,1.15) 
1.55 
(0.99,2.44) 
1.18 
(0.80,1.72) 
1.25 
(0.88,1.77) 
0.91 
(0.63,1.32) 
0.51 
(0.20,1.27) 
0.69 
(0.38,1.26) 
1.36 
(0.90,2.04) 
1.05 
(0.93,1.17) 
Period 3:2 
0.92 
(0.78,1.07) 
1.41 
(0.91,2.18) 
1.10 
(0.92,1.32) 
0.93 
(0.68,1.28) 
0.80 
(0.56,1.14) 
0.94 
(0.33,2.69) 
0.61 
(0.34,1.10) 
1.27 
(0.85,1.89) 
0.94 
(0.85,1.06) 
C
o
m
b
in
e
d
 c
lin
ic
al
 O
A
 
A
SR
 Period 1  561 (516,605) 391 (304,478) 496 (430,562) 451 (392,510) 699 (610,787) 452 (361,544) 515 (438,592) 431 (339,523) 343 (327,359) 
Period 2  601 (555,647) 431 (340,523) 503 (437,569) 532 (468,597) 683 (596,770) 334 (256,412) 527 (450,604) 435 (341,528) 357 (341,374) 
Period 3 559 (515,605) 468 (373,564) 553 (483,623) 487 (426,548) 699 (610,787) 461 (368,553) 520 (443,596) 593 (484,703) 360 (343,377) 
SR
R
 
Period 2:1 
1.07 
(0.96,1.20) 
1.10 
(0.81,1.50) 
1.01 
(0.84,1.22) 
1.18 
(0.99,1.41) 
0.98 
(0.82,1.17) 
0.74 
(0.54,1.01) 
1.02 
(0.83,1.26) 
1.01 
(0.74,1.37) 
1.04 
(0.98,1.11) 
Period 3:1 
1.00 
(0.89,1.11) 
1.20 
(0.89,1.62) 
1.12 
(0.92,1.34) 
1.08 
(0.90,1.29) 
1.00 
(0.84,1.20) 
1.02 
(0.77,1.35) 
1.01 
(0.82,1.24) 
1.38 
(1.04,1.83) 
1.05 
(0.98,1.12) 
Period 3:2 
0.93 
(0.83,1.04) 
1.09 
(0.81,1.46) 
1.10 
(0.92,1.32) 
0.91 
(0.77,1.09) 
1.02 
(0.86,1.22) 
1.38 
(1.01,1.87) 
0.99 
(0.80,2.21) 
1.37 
(1.03,1.81) 
1.01 
(0.94,1.08) 
Statistically significant standardised rate ratios are shown in bold  
 226 
7.3.2 Descriptive epidemiology 
Characteristics of patients consulting within each time period are shown in Table 7-4. Most of the 
characteristics remain fairly stable in prevalence, although there was evidence of better BMI status 
recording (21.3% patients in the ‘unknown’ category in period three compared to 35.7% in period 
one). 
The levels of recording of the outcome measures from the routinely-collected data sources are 
shown in Table 7-5. These measures were relatively stable across periods for most measures, 
though there was an apparent increase in weight recording (8.9% in period one to 23.4% in period 
three) and prescription of paracetamol or topical NSAIDs (25.5% in period one to 35.2% in period 
three), within 14 days of a consultation for clinical OA.  
The change in weight recording and prescription of relatively safe pharmaceutical options can be 
seen as shown through the charted monthly data in Figure 7-1.99 The timeline commenced 12 
months before template introduction (i.e. at the start of period one). By inspection, an increase in 
weight recording, and paracetamol and topical NSAID prescribing can be seen at the start of period 
three (template introduction), though weight recording does appear to fall back somewhat though 
remaining above baseline levels as seen in periods one and two.  
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Table 7-4: Patient characteristics within each time period 
 
Period 1  
n (%) 
Period 2  
n (%) 
Period 3  
n (%) 
  Total 1750  1821 1845 
Sex 
Male 718 (41.0) 693 (38.1) 760 (41.2) 
Female 1032 (59.0) 1128 (61.9) 1085 (58.8) 
Age-band 
45-64 812 (47.4) 850 (47.4) 880 (48.5) 
65-74 475 (27.7) 482 (26.9) 469 (25.8) 
75-84 336 (19.6) 354 (19.8) 370 (20.4) 
85+ 91 (5.3) 106 (5.9) 97 (5.3) 
Site affected 
Knee 904 (51.7) 881 (48.4) 928 (50.3) 
Hip 376 (21.5) 414 (22.7) 378 (20.5) 
Ankle/foot 116 (6.6) 113 (6.2) 130 (7.0) 
Hand/wrist 148 (8.5) 172 (9.4) 168 (9.1) 
Unspecified 91 (5.2) 118 (6.5) 122 (6.6) 
Multiple 115 (6.6) 123 (6.8) 119 (6.4) 
BMI status 
BMI <25 235 (13.4) 276 (15.2) 327 (17.7) 
BMI 25 to <30 418 (23.9) 421 (23.1) 548 (29.7) 
BMI 30+ 473 (27.0) 586 (32.2) 577 (31.3) 
BMI unknown 624 (35.7) 538 (29.5) 393 (21.3) 
Count of BNF chapters in 12m prior 
0-4 572 (32.7) 547 (30.0) 560 (30.4) 
5-9 536 (30.6) 623 (34.2) 614 (33.3) 
10+ 642 (36.7) 651 (35.7) 671 (36.4) 
Multiple consultations in period 
Single 1171 (66.9) 1228 (67.4) 1294 (70.1) 
Multiple 579 (33.1) 593 (32.6) 551 (29.9) 
XR recorded within 21 months prior 
to index consultation 
No 1652 (94.4) 1714 (94.1) 1758 (95.3) 
Yes 98 (5.6) 107 (5.9) 87 (4.7) 
Consultation with staff member 
holding greater or fewer than the 
median number of index 
consultations 
Below the 
median 
208 (11.9) 137 (7.5) 197 (10.7) 
Above the 
median 
1542 (88.1) 1684 (92.5) 1648 (89.3) 
Practice 
1 619 (35.4) 660 (36.2) 622 (33.7) 
2 80 (4.6) 87 (4.8) 94 (5.1) 
3 223 (12.7) 227 (12.5) 245 (13.3) 
4 228 (13.0) 268 (14.7) 247 (13.4) 
5 244 (13.9) 239 (13.1) 245 (13.3) 
6 95 (5.4) 72 (4.0) 97 (5.3) 
7 176 (10.1) 183 (10.0) 180 (9.8) 
8 85 (4.9) 85 (4.7) 115 (6.2) 
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Table 7-5: Clinical process measures for the care of OA derived from routinely-recorded data, by 
time period 
 Period 1  
n (%) 
Period 2  
n (%) 
Period 3  
n (%) 
  Total 1750 1821 1845 
R
e
le
va
n
t 
te
m
p
la
te
 d
o
m
ai
n
 
Any OA or only joint pain (JP) within period 
JP 1174 (67.1) 1184 (65.0) 1237 (67.0) 
OA 576 (32.9) 637 (35.0) 608 (33.0) 
Weight record within 14 days of a consultation 
for clinical OA 
No 1595 (91.1) 1654 (90.8) 1413 (76.6) 
Yes 155 (8.9) 167 (9.2) 432 (23.4) 
Paracetamol prescription within 14 days of a 
consultation for clinical OA 
No 1517 (86.7) 1591 (87.4) 1529 (82.9) 
Yes 233 (13.3) 230 (12.6) 316 (17.1) 
Topical NSAID prescription within 14 days of a 
consultation for clinical OA 
No 1482 (84.7) 1547 (85.0) 1387 (75.2) 
Yes 268 (15.3) 274 (15.0) 458 (24.8) 
Paracetamol or a topical NSAID within 14 days of 
a consultation for clinical OA 
No 1303 (74.5) 1362 (74.8) 1196 (64.8) 
Yes 447 (25.5) 459 (25.2) 649 (35.2) 
Physio referral within 14 days of a consultation 
for clinical OA 
No 1641 (93.8) 1717 (94.3) 1720 (93.2) 
Yes 109 (6.2) 104 (5.7) 125 (6.8) 
N
o
 r
e
le
va
n
t 
te
m
p
la
te
 d
o
m
ai
n
 
Opioid prescription within 14 days of a 
consultation for clinical OA 
No 1179 (67.4) 1222 (67.1) 1259 (68.2) 
Yes 571 (32.6) 599 (32.9) 586 (31.8) 
Oral NSAID prescription within 14 days of a 
consultation for clinical OA 
No 1443 (82.5) 1525 (83.7) 1547 (83.8) 
Yes 307 (17.5) 296 (16.3) 298 (16.2) 
Oral NSAID prescribed where comorbidities as a 
relative contraindication are recorded (n=2639) 
No 730 (86.1) 787 (88.3) 781 (86.8) 
Yes 118 (13.9) 104 (11.7) 119 (13.2) 
PPI prescription within 14 days of a consultation 
for clinical OA 
No 1425 (81.4) 1430 (78.5) 1488 (80.7) 
Yes 325 (18.6) 391 (21.5) 357 (19.3) 
X-ray investigation within 14 days of a 
consultation for clinical OA 
No 1468 (83.9) 1511 (83.0) 1573 (85.3) 
Yes 282 (16.1) 310 (17.0) 272 (14.7) 
Referral within 14 days of a consultation for 
clinical OA 
No 1352 (77.3) 1408 (77.3) 1474 (79.9) 
Yes 398 (22.7) 413 (22.7) 371 (20.1) 
7.3.3 The effect of time period on outcomes: multilevel model  
There was no evidence of a substantial change in any of the management options between periods 
one and two (no naturally-occurring temporal change in OA quality of care), and none of the ORs 
were found to be statistically significant. Of the management aspects with a relevant template 
domain, the OR of a weight record in period three compared to period one was 3.06 (95% CI 
2.46,3.82), with prescriptions of paracetamol (adjusted OR 1.46, 95% CI 1.19,1.79) and topical 
NSAIDs (adjusted OR 2.00, 95% CI 1.64,2.44) also increasing. When the paracetamol and topical 
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NSAID options were combined, there was a significant increased odds of prescription of either 
option (adjusted OR 1.79 in period three, 95% CI 1.52,2.12). There was no significant change 
physiotherapy referral (adjusted OR 1.10, 95% CI 0.82,1.48). Other aspects of care showed no 
significant change (Table 7-6). 
Figure 7-1: Recorded assessment, prescriptions and referral within 14 days of a consultation for 
clinical OA, by month, in phases one and two 
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Table 7-6: Associations between routinely recorded care for OA and time period  
  Time period (vs. Period 1) 
  Period 2 Period 3 
  Unadjusted 
OR (95% CI) 
Adjusteda 
OR (95% CI) 
Unadjusted 
OR (95% CI) 
Adjusteda 
OR (95% CI) 
 
Diagnosed OA vs. joint pain 1.04 (0.89,1.21) 1.04 (0.88,1.23) 1.01 (0.87,1.19) 1.01 (0.85,1.21) 
R
e
le
va
n
t 
te
m
p
la
te
 
d
o
m
ai
n
 
Weight record 1.02 (0.80,1.30) 0.95 (0.74,1.22) 3.22 (2.60,3.98) 3.06 (2.46,3.82) 
Paracetamol prescription 0.94 (0.77,1.15) 0.92 (0.74,1.14) 1.39 (1.15,1.69) 1.46 (1.19,1.79) 
Topical NSAID prescription 0.97 (0.80,1.17) 1.00 (0.81,1.23) 1.81 (1.51,2.17) 2.00 (1.64,2.44) 
Paracetamol or topical NSAID 
prescription combined 
0.98 (0.84,1.15) 0.99 (0.83,1.17) 1.61 (1.38,1.88) 1.79 (1.52,2.12) 
Physiotherapy referral 0.90 (0.66,1.22) 0.87 (0.64,1.17) 1.13 (0.83,1.52) 1.10 (0.82,1.48) 
N
o
 r
e
le
va
n
t 
te
m
p
la
te
  
d
o
m
ai
n
 
Opioid prescription 1.03 (0.89,1.19) 1.01 (0.86,1.18) 0.97 (0.84,1.12) 0.98 (0.84,1.15) 
Oral NSAID prescription 0.91 (0.76,1.10) 0.93 (0.61,1.12) 0.89 (0.73,1.07) 0.94 (0.78,1.15) 
Oral NSAIDs in the presence of 
contraindicating comorbidity 
0.79 (0.59,1.06) 0.83 (0.61,1.12) 0.92 (0.69,1.24) 0.99 (0.74,1.34) 
PPI with oral NSAIDs 1.11 (0.78,1.57) 1.27 (0.86,1.87) 0.98 (0.69,1.40) 1.07 (0.72,1.58) 
Recorded X-ray use 1.07 (0.87,1.31) 1.11 (0.90,1.38) 0.92 (0.74,1.14) 0.96 (0.77,1.20) 
Any referral 0.99 (0.84,1.17) 0.98 (0.82,1.16) 0.88 (0.74,1.04) 0.87 (0.73,1.04) 
aadjusted for all covariates 
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Table 7-7: Associations between routinely recorded care for OA and time period with restriction to patients in period three for whom the template triggered and those 
for whom at least one template entry was made 
  Time period (vs. Period 1) Time period (vs. Period 1) 
  
Period 2 
Patients triggering 
template only in  
Period 3 Period 2 
Patients with at least 
one template entry in  
Period 3 
  
 
 
Adjusteda 
OR (95% CI) 
Adjusteda 
OR (95% CI) 
Adjusteda 
OR (95% CI) 
Adjusteda 
OR (95% CI) 
 
Diagnosed OA vs. joint pain 1.04 (0.88,1.23) 1.03 (0.86,1.23) 1.04 (0.88,1.23) 1.04 (0.85,1.27) 
R
e
le
va
n
t 
te
m
p
la
te
 
d
o
m
ai
n
 
Weight record 0.95 (0.74,1.22) 3.20 (2.56,3.99) 0.92 (0.72,1.18) 4.60 (3.64,5.82)
Paracetamol prescription 0.93 (0.75,1.15) 1.46 (1.18,1.79) 0.93 (0.75,1.15) 1.53 (1.22,1.92)
Topical NSAID prescription 1.00 (0.82,1.23) 2.06 (1.68,2.51) 1.01 (0.82,1.24) 2.96 (2.38,3.68)
Paracetamol or topical NSAID 
prescription combined 
0.99 (0.83,1.17) 1.81 (1.53,2.15) 1.00 (0.84,1.18) 2.38 (1.97,2.87)
Physiotherapy referral 0.86 (0.64,1.17) 1.13 (0.84,1.53) b0.87 (0.64,1.17) b1.27 (0.94,1.73) 
N
o
 r
el
ev
an
t 
te
m
p
la
te
  
d
o
m
ai
n
 
Opioid prescription 1.01 (0.87,1.19) 0.99 (0.84,1.16) 1.01 (0.86,1.19) 0.95 (0.79,1.14) 
Oral NSAID prescription 0.93 (0.77,1.13) 0.95 (0.78,1.16) 0.93 (0.77,1.13) 0.98 (0.79,1.22) 
Oral NSAIDs in the presence of 
contraindicating comorbidity 
0.83 (0.61,1.12) 0.99 (0.74,1.34) 0.82 (0.60,1.11) 1.06 (0.76,1.48) 
PPI with oral NSAIDs 1.27 (0.86,1.87) 1.07 (0.72,1.58) 1.27 (0.85,1.87) 1.12 (0.72,1.75) 
Recorded X-ray use 1.11 (0.90,1.37) 0.97 (0.78,1.21) 1.11 (0.90,1.38) 1.13 (0.89,1.43) 
Any referral 0.98 (0.83,1.16) 0.89 (0.75,1.07) 0.98 (0.83,1.16) 0.89 (0.73,1.08) 
aadjusted for all covariates; bPQL1 estimation, patients within clinicians 
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A repeat analysis of the same outcomes, but restricting the eligible population in period three to 
only those in whom the template triggered, showed very little change to the OR estimates, as 
shown in Table 7-7. A further restriction to patients in period three who had at least one template 
entry recorded suggested a stronger association between the template with weight recording and 
relatively safe pharmacological management options. 
7.4 Discussion 
7.4.1 Main findings and comparison with previous literature 
Consultation rates for clinical OA were fairly stable across the three periods, though there was some 
variation between practices and overall there was a slight increase in recorded consultation 
prevalence which did not reach statistical significance. There was no evidence of any significant 
change in the routinely recorded management of OA between periods one and two (i.e. the periods 
prior to template introduction), suggesting that over this period there was no ‘naturally-occurring’ 
quality improvement in OA care. The template installation was associated with improvements in 
weight recording and use of relatively safe pharmacological management options (paracetamol and 
topical NSAIDs) between periods one and three (the calendar control period and the first six 
months’ template use). There was no statistically significant change in any of the other 
management options. Sensitivity analyses to distinguish effects in sub-populations of consulters in 
period three (those in whom the template actually triggered and those in whom at least one entry 
was made) showed some indication of a greater effect in patients with at least one entry. 
Rose et al. reported that recording templates in a USA study were associated with improvements 
in documentation (of the clinical, family, and social history, and of clinical examination findings) but 
they found no effect on coding.299 
Evidence from the Cochrane review of the effects of computer reminders,152 described in Chapter 
Three, section 3.3, identified a median 4.2% (interquartile range [IQR] 0.8-18.8%) improvement in 
process measures overall, with recommended medication ordering improving by a median 6.2% 
(IQR 3.0-28.0%). In this study, the weight recording process improved from around 9% in periods 
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one and two to 23.4% in period three. The improvement in weight recording was rather more than 
would have been expected by the Cochrane review evidence. It was uncertain to what extent the 
increased recording of weight reflected an increase in the number of patients actually weighed 
rather than just an increase in the proportion of the measurements made being recorded.  
Paracetamol and topical NSAIDs prescribing processes increased from around 13-15% in periods 
one and two to 17.1-24.8% in period three, in line with what would be expected from the Cochrane 
review. The increase in prescribing was most likely to reflect an actual change in clinical behaviour, 
since prescriptions, with few exceptions, are electronically generated and thereby recorded in a 
standard manner in the clinical computer systems. 
Although there was a trend toward increased physiotherapy referral, this was small and did not 
achieve statistical significance. The absence of any significant change in physiotherapy referral 
suggested that the template was not effective at changing clinical behaviour in this respect. This 
may have been due to other influences such as beliefs about the benefits of physiotherapy for OA288 
(at either the patient or clinician level), or access to physiotherapy services (either due to lack of 
sufficient service provision,289 thereby discouraging referral for conditions considered to be either 
less important or suitable for self-management, or due to open access without referral such as 
through Physio Direct169). Also, the physiotherapy prompt was the final item on the template, and 
it is possible that there was an order effect such that the earlier items received preferential 
attention, though no evidence regarding the order of items in reminder systems has been identified 
in the literature.  
The lack of any statistically significant changes in the other routinely recorded clinical management, 
excluded from and therefore not directly influenced by the template, was notable.  
Although some improvements in recorded quality of care were identified in this analysis, it was not 
clear from the available information how durable the changes would be in routine clinical practice. 
It was unclear from the prior literature how long the effect of the template may be expected to 
last.162 This warrants further investigation.  
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7.4.2 Limitations 
There were some limitations to this study. Limitations relating to the interpretation of multiple 
comparisons, as described in Chapter Five, were applicable to this chapter. The linkage of processes 
of care to clinical OA consultations through a 14-day timeframe should not have caused bias in the 
assessment of the template effect. 
All observational studies suffer from limitations in attribution of causality to an intervention.300 
However, this study was based upon all consulters for clinical OA in period three and so risks of 
selection and information biases had been ameliorated. There remained a risk that the association 
between improvements in recorded quality of care and the template introduction was not due to 
the template but rather to another cause, such as study inception overall. That is, the association 
between the template as an exposure and the apparent quality improvement may be the result of 
confounding, such as by clinician self-directed learning resulting from inclusion into an academic 
study, independently related to both the exposure and the outcome. It is possible that the 
commencement of the study in the eight practices prompted greater awareness of OA 
management in general.  
Given the temporal sequence and strength of association between several of the domains included 
in the template and improvement in quality measures, not seen in any of the non-template 
domains, it is considered likely that it was the template itself that prompted the quality 
improvement.  
The fact that this analysis does not account for repeated consultations by patients across periods 
was an analytical limitation. This may have caused some underestimation of standard errors of the 
coefficients in the multilevel models as the clustering of clinical management within patients was 
not accounted for by this analysis.229 Ideally, an analysis of consultations within patients within 
clinicians within practices as a four-level model would have been undertaken but this would have 
dramatically increased the complexity of the model (as patients were able to consult with more 
than one clinician within practices, a cross-classified model would have been required) and a larger 
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dataset would have been needed for this degree of complexity to be analysed. The small number 
of practices (clusters) also limited the potential for the use of a more complex model that would 
have incorporated practice as the topmost level.  
7.4.3 Conclusion 
In conclusion, the template seems not to have been a neutral intervention but rather was 
associated with some important changes in clinical behaviour. Although a causal effect has not been 
conclusively demonstrated, either in terms of promoting better recording (such as with weight 
records) or in terms of promoting increased use of relatively safe pharmaceutical options, it seems 
reasonable to conclude that the template does have a small to moderate effect. It is not clear from 
the available data why no significant change was seen to the low levels of physiotherapy referral 
but it is possible that this related to factors not addressed by the template, including practitioner 
beliefs about exercise in OA management, or service availability.  
In Chapter Eight, the use of the quality indicators in a trial of the MOSAICS intervention will be 
described. 
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Chapter Eight: Implementation of quality indicators in a cluster-
randomised trial of a model OA consultation  
8.1 Introduction 
It has previously been shown (in Chapter Two) how quality of care for OA can be assessed through 
evidence-based quality indicators,107 and that primary care for OA has been found to be suboptimal 
when compared to quality indicators and guideline adherence. The limited utility of the routinely-
recorded medical record data for assessment of quality of care through the quality indicators was 
described in Chapter Five, and Chapter Six & Chapter Seven described the quality assessments that 
could be made through medical records enhanced by the template recording system and the effect 
of the template on recorded care.99  
There are a few examples of clinical trials that use indicators of care as outcome measures, such as 
the use of prescribing process indicators in a trial of hospital feedback on care of people with 
myocardial infarction,301 a cluster trial of payment for performance incentives on prescribing 
processes and surrogate patient outcomes,302 and a trial of the introduction of a system to improve 
prevention of maternal HIV transmission through HIV testing and prescription of antiretroviral 
drugs.303 However, the use of indicators as outcome measures is not a highly-developed trial 
methodology.  
The MOSAICS study,1 outlined in Chapter One, section 1.7, was conceived as a trial of a complex 
intervention with the intention of increasing uptake of the NICE-recommended interventions for 
OA in primary care.5 The final step in the synthesis and testing of the quality indicators for OA was 
to implement them in the MOSAICS study, as trial outcome measures. This analysis complements 
other MOSAICS trial analyses that were not part of this thesis, relating to the individual patient-
level clinical effectiveness of the intervention (Dziedzic KS, et al., in submission) and to the survey 
of the practice populations (Healey E, et al., in submission). This analysis is based on the same data 
and a similar analysis reported in Jordan KP, et al., in submission, for which the candidate was a co-
author and co-designed the analysis, but due to the objectives of this chapter which focus on 
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exploration of the use and feasibility of quality indicators as outcomes in trials rather than to assess 
effectiveness of the intervention, used a different approach to adjustment for covariates and 
undertakes additional analysis relevant to the clustered nature of the trial.  
The objective of this chapter is to describe how the effects of a complex intervention to improve 
uptake of NICE-recommended management strategies for OA in general practice registered 
populations could be assessed through quality indicators including those recorded via a template 
integrated in the clinical information system.  
8.2 Methods 
8.2.1 The MOSAICS trial  
This analysis used data taken from the MOSAICS study, the protocol for which has been published 
previously.1 Although the objective of this chapter is to describe the use of quality indicators in a 
trial setting rather than to report the MOSAICS trial in full, the description given here is based upon 
the CONSORT statement for reporting of cluster trials.92 The cluster trial took place between May 
2012 and February 2014. It was approved by the North West 1 Research Ethics Committee, Cheshire 
(REC reference: 10/H1017/76, Appendix C) and monitored by an independent Trial Steering 
Committee and Data Monitoring Committee (trial registration number ISRCTN06984617).  
Trial design 
MOSAICS was a parallel cluster-randomised controlled clinical trial. A cluster design was considered 
to be necessary due to a substantial risk of contamination of the control element were clinicians 
expected to offer either usual care or enhanced care to patients who had been randomised at an 
individual level. Practices were randomly assigned in a 1:1 ratio to intervention or control arms, 
stratified by practice size to maintain, as far as possible, a population size balance between arms.  
Setting and Population 
The trial was undertaken in eight clusters, each a general practice in the North-West Midlands and 
Cheshire, UK. Practices were resourced for participation in the trial as set out in the trial protocol.1 
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All patients aged 45 years and over, consulting at least once with recorded clinical OA (defined as 
formally diagnosed OA (excluding shoulder or elbow) or selected hand, hip, knee, or foot joint pain 
Read codes as described in Chapter Three, section 3.4.3) in the six month period after 
randomisation and training (trial period four) were eligible for inclusion in this aspect of the trial 
analysis unless dissent to secondary use of their primary care clinical data had previously been 
recorded in the medical record, such as has been used by some patients due to privacy concerns. 
During the trial baseline period, six months prior to randomisation (see the MOSAICS timeline in 
Figure 1-1, page 20), practices were encouraged to use the template described earlier in 
consultations for clinical OA,99 to capture relevant aspects of OA care not routinely coded in the 
EHR. The template was automatically triggered by entry of a Read code for clinical OA as defined in 
the template development (Chapter Three, section 3.4.3). Within the EMIS clinical computer 
system, it was also possible to manually invoke the template if required (such as if the template 
had been bypassed in error, or failed to trigger as expected).  
Intervention 
The development of the trial intervention was not part of this thesis and is described fully 
elsewhere.1,304-306 An overview of the intervention is set out below.  
The Model OA Consultation 
Based on theories of support for behaviour change307-309 and self-management,310 and the 
outcome of Delphi consensus exercises for GPs305 and nurses,306 a model OA consultation 
(MOAC) was developed. This consisted of an initial GP consultation (for all patients 
consulting with clinical OA, not only people with a new diagnosis) to make and 
communicate the OA diagnosis, provide a self-management guidebook, and address 
analgesia requirements, and was followed by a series of up to four consultations with a 
practice nurse to support self-management of OA.  
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Training  
Practices in the intervention arm received a package of training for the GPs and practice 
nurses, and trial orientation training for other relevant clinical primary care team members. 
The GPs received model consultation training, including use of simulated patients, in four 
sessions totalling seven hours. Practice nurses received training on aspects of self-
management including the core NICE interventions (education, physical activity, and 
maintenance of a healthy weight), goal setting, and pain management (through exercise 
and analgesia); their training lasted four days and again included simulated patients.  
Guidebook 
Both GP and practice nurse consultations were designed to be supported by the use of an 
OA self-management guidebook.304 This patient-focussed guide is available at 
http://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA_Guidebook.pdf 
[accessed 03.09.2016]. This was designed to be issued at the initial GP consultation and to 
be used in the interlude between GP and nurse consultations for patients to develop their 
understanding of OA in advance of the nurse consultation at which any follow up questions 
could be answered. 
Control 
Practices in the control arm continued with usual care as in the baseline period (defined as 
standard GP care supplemented with the template for recording consultations), and with 
access to written materials except the OA guidebook. No training or resource for additional 
nurse consultations was provided to the control practices.  
Outcomes 
The trial outcomes were analysed and reported at two levels: (i) the patient-reported outcomes, in 
a subgroup of patients consenting to take part in the survey aspect of the trial (Dziedzic KS, et al., 
in submission), and (ii) the population-level quality of care, reported in Jordan KP, et al. (in 
submission) and in this analysis. The primary outcomes used here were the rates of achievement 
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of quality indicators in each study arm, recorded either through the routine record or the template, 
during the six-month period after randomisation and MOAC training (period four, Figure 1-1). These 
indicators were those used in the previous chapters, with extension of the analysis to examine in 
particular rates of recorded provision of written information and written advice regarding exercise 
and weight loss, as provision of written, as opposed to purely verbal, information and advice was a 
core component of NICE-recommended OA management.5 The four outcome domains of quality of 
care were (i) assessment (pain, function, weight or BMI record, X-ray use), NICE-recommended 
(ii) core management (information provision, exercise advice, weight loss advice where relevant), 
(iii) non-pharmacological management (referrals to a physiotherapist), and (iv) pharmacological 
management (paracetamol, topical NSAIDs, oral NSAIDs, gastroprotection with proton pump 
inhibitors (PPIs), opioids) (Table 8-1).  
Outcomes were measured through codes recorded in the EHR. Just as in earlier chapters, these 
comprised the indicators identified via routinely recorded management (Chapter Five) and those 
from the template (Chapter Six and Chapter Seven).  
All outcomes were considered to have occurred if they were recorded within 120 days of an index 
consultation occurring in the trial period (which provided enough time for patients in the 
intervention arm to have completed nurse clinic follow-up). Measures derived from the routine 
record also had to be recorded within 14 days of a consultation for clinical OA. For PPIs, the 
prescription additionally had to have occurred on the same day as a prescription for an oral NSAID.  
Table 8-1 gives the direction of change that would be expected at a population level if the primary 
care for OA was improving. For example, although X-rays are not considered necessary to make a 
diagnosis of OA nor to determine the need for onward referral,4 their use may still be appropriate 
on an individual level; but at a population level, one would expect that better care would be 
associated with lower aggregated use. One might expect use of relatively safe pharmacological 
options to increase but for X-rays, oral NSAIDs, and opioids and to decrease if care was consistent 
with NICE guidance. 
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Table 8-1: Indicators of quality of care for OA used in the MOSAICS trial 
Domain Quality indicator 
Indicator 
sourcea Data source Evidence of achievement (dichotomous outcome) 
Change indicative of 
improved careb 
Assessment 
Pain assessed Review Template Recorded level of painc Increase 
Function assessed Review Template Recorded level of functionc Increase 
BMI measurement/weight record Review Template or routine EMR Recorded BMI or weight Increase 
X-ray requested Guideline Routine EMR Recorded X-ray of knee, hip, hand, or foot Decrease 
Core 
interventions 
OA information  Review Template Recorded as verbal or written; or not appropriated Increase 
 Written OA information Guideline Template Recorded as written Increase 
Exercise advice Review Template 
Recorded as verbal or written; or not necessary or 
not appropriated 
Increase 
 Written exercise advice Guideline Template Recorded as written Increase 
Weight loss advicee  Review Template Recorded as verbal or written; or not appropriated Increase 
 Written weight loss advice Guideline Template Recorded as written Increase 
Non-
pharmacological 
interventions 
Consideration of physiotherapy 
referral 
Guideline Template 
Recorded as offered; or not necessary or not 
appropriated 
Increase 
Physiotherapy referral made Guideline Routine EMR Recorded referral to physiotherapy Increase 
Pharmacological 
interventions 
Consideration of paracetamol use Review Template 
Recorded as tried, offered, or declined full dose; or 
not appropriatef 
Increase 
Paracetamol prescribed Review Routine EMR Recorded prescription Increase 
Consideration of topical NSAID use Guideline Template 
Recorded as tried, offered or declined full dose; or 
not appropriatef 
Increase 
Topical NSAID prescribed Guideline Routine EMR Recorded prescription Increase 
Oral NSAID prescribed Guideline Routine EMR Recorded prescription Decrease 
Oral NSAID prescribed in the presence 
of a relative comorbid contraindication 
BNF Routine EMR Recorded prescription Decrease 
Gastroprotection (PPI use with oral 
NSAIDs) 
Review Routine EMR Recorded prescription (if oral NSAID prescribed) Increase 
Opioid prescribed Guideline Routine EMR Recorded prescription Decrease 
aSystematic review,107 NICE guideline5, or British National Formulary (BNF);217 indicators taken from routine record had to be within 14 days of a clinical OA consultation; bcompared to 
control group; cnone, mild, moderate, severe; dnot this time or no entry indicates non-achievement; ein those with last recorded BMI ≥ 25kgm-2 in up to previous three years; funknown or 
no entry indicates non-achievement. 
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Due to a lack of established longitudinal monitoring of routinely-recorded care for OA, population 
benchmarks for the quality indicators cannot be set.  
As previously stated, people with no record of a quality indicator outcome were assumed not to 
have that outcome, both for the template and routinely recorded management. The weight advice 
outcome assessment was restricted to patients known to be overweight at the index consultation. 
Oral NSAID use in the presence of relative contraindications was restricted to patients with a 
relevant recorded comorbidity in the previous two years. Gastroprotection was restricted to those 
patients with a record of a relevant oral NSAID prescription.  
Sample size 
The sample size required for the trial was based upon the requirements of the clinical effectiveness 
analysis, determined by the trial statisticians and reported elsewhere (Dziedzic et al., in 
submission). On the basis of a projected 10% annual consultation rate for clinical OA in patients 
aged 45 years and over,21,311 the anticipated total population for this age group in eight practices 
(30,000 people) was expected to yield 3,000 OA consultations per annum. Accounting for repeat 
consultations, 2,000 unique patients were expected to consult in a six-month period, equating to 
approximately 1,000 patients per study arm. Allowing for an expected 50 clinicians consulted per 
arm, and an intraclass correlation coefficient (ICC) of 0.1, it was estimated that an OR of 1.6 in the 
dichotomous outcomes could be identified with 80% power and significance level (α)=0.05. The 
projected ICC used was similar to that reported for recorded items of advice as identified by Russell 
et al.312 but rather larger than the majority of those reported by Adams et al.313 for diverse variables 
in 31 primary care studies. 
Blinding 
The candidate and the trial statisticians were kept blind to the intervention or control group 
allocation until after the analysis was complete. 
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The index consultation 
As in previous analyses, patients were allocated to an index consultation, namely the first 
consultation for any clinical OA in the trial period (codes starting N05.. formal OA diagnosis, or 
selected joint pain codes as in Chapter Three, section 3.4.3). The clinician consulted at this 
consultation was the index clinician. The index consultation was used to determine the start point 
for outcome success (120 days). In addition to the index clinician, BMI status and total morbidity 
were determined as the closest prior record and number of BNF subchapters prescribed in the 12 
months prior,218 respectively.  
8.2.2 Statistical analysis 
Baseline characteristics of each trial arm are first described in terms of demographics and the 
patient-level characteristics used as independent variables in previous chapters.  
Baseline template use by practice within each trial arm was determined. This was used to facilitate 
a comparison between intervention and control arms, given the known variation in use of the 
template described in Chapter Six.  
Bias is a recognised hazard in cluster trials.314 The interpretation of cluster trials can be affected by 
an inability to include non-recruited participants in the analysis.163 This analysis, however, was 
analogous to an intention to treat analysis by including all patients aged 45 years and over who 
consulted for clinical OA during the trial period, thereby substantially reducing the risk of selection 
bias. Intention-to-treat analysis in this context meant that patients were analysed as part of their 
practice randomised arm regardless of whether the individual patient received that arm’s allocated 
care and regardless of whether template successfully fired. This approach was chosen as the aim of 
the study was to assess how quality indicators could be used (in a cluster trial) to assess the effect 
of an intervention. Just as with an intention to treat analysis in an individual patient-level 
randomised controlled trial, it was important to assess the outcomes on the basis of the way in 
which intervention and control arms had been assigned, not correcting post hoc for any problems 
in the way in which the indicators and recording template had been implemented.  
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Just as the in baseline period, the template did not trigger for every eligible person (see Chapter 
Six, section 6.4.1); non-triggering would have made it unlikely that the codes contained within the 
template would have been recorded as the codes were non-standard and only easily recorded via 
the template itself. 
A main analysis of the trial period outcomes and several sensitivity analyses were undertaken, as 
shown in Figure 8-1. The first part of the main analysis examined overall template use. Associations 
of the intervention with recording at least one entry, achievement of at least one template 
indicator, and achievement of all template indicators were determined. The analysis used a two-
level (patients within clinicians) multilevel logistic regression model. Adjustments were made for 
diagnostic category (OA or joint pain), sex, age band, and variables found to be significantly 
associated with quality achievement in Chapter Six (site of disease, BMI status, morbidity as 
measured by the BNF chapter count, multiple clinical OA consultations, and staff index consultation 
count) and baseline achievement of outcomes at a practice level. As baseline practice achievement 
was included in the model, practice was not separately included as an independent variable 
(although inclusion of practice as an additional independent variable was tested, it gave rise to 
model convergence problems and so was excluded from the final model). The second part of the 
main analysis explored associations of the intervention with the individual quality indicators. 
Multilevel logistic regression analysis was again used to compare the intervention and control arms 
on the quality indicators described, as dichotomous outcomes, adjusting for the same covariates as 
the first analysis.  
As well as the intention-to-treat analysis, sensitivity analyses were undertaken in (i) those patients 
in whom the template was triggered in at least one consultation for clinical OA in the trial period, 
(ii) new consulters (defined as first clinical OA consultation since the introduction of the template 
and with at least 365 days since any previous OA or joint pain consultation) with at least one 
template entry, and (iii) those in whom at least one entry was made in the template in the trial 
period.  
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Figure 8-1: Main analysis and subpopulation analyses outline 
 
The main analyses reported were two-level multilevel logistic regression models (patients within 
clinicians, though three-level models (patients within clinicians within practices) were also 
undertaken as sensitivity analyses. Analyses were undertaken through MLwiN 2.34234 via the 
runmlwin235 command in Stata 14.1.298 Where possible, second-order penalised quasi-likelihood 
(PQL2) approximations were used; in some models, this was not possible due to model convergence 
problems, and other specified approximations were used instead. Results are presented as ORs 
with 95% CI. Results are reported to three significant figures. 
8.3 Results 
8.3.1 Trial population characteristics 
The characteristics of the intervention and control arm aggregated practice populations consulting 
for clinical OA in the trial period are shown in Table 8-2. As expected (due to differences in practice 
population sizes) there were more clinical OA consulters in the intervention compared to the 
control arm (1110 to 836). There was substantial variation in the proportions of people with an OA 
Analysis of whole 
population consulting with 
clinical OA (‘intention to 
treat’) - MAIN ANALYSIS
Analysis of whole 
population restricted to 
new consulters
Analysis restricted to 
people in whom the 
template triggered
Analysis of template 
triggered population 
restricted to new 
consulters
Analysis of template 
triggered population 
restricted to those with at 
least one template entry
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diagnostic code between arms (44.4% to 28.2%). There was some, but less pronounced, variation 
between arms in other characteristics including BMI status, and morbidity burden.  
Table 8-2: Characteristics of clinical OA consulters aged 45 years and over, trial period 
  Intervention Control 
Total 1110 836 
Diagnostic group, n (%) OA 493 (44.4) 236 (28.2) 
Sex, n (%) Female 652 (58.7) 511 (61.1) 
Age band, n (%) 45-64 531 (47.8) 370 (44.3) 
65-74 268 (24.1) 232 (27.8) 
75-84 220 (19.8) 180 (21.5) 
85+ 91 (8.2) 54 (6.5) 
Site, n (%) Knee 548 (49.4) 393 (47.0) 
Hip 219 (19.7) 184 (22.0) 
Ankle/foot 62 (5.6) 73 (8.7) 
Wrist/hand 104 (9.4) 103 (12.3) 
Unspecified 66 (5.9) 45 (5.4) 
Multiple 111 (10.0) 38 (4.5) 
BMI status, n (%) Not overweight 221 (19.9) 146 (17.5) 
Overweight 340 (30.6) 256 (30.6) 
Obese 383 (34.5) 246 (29.4) 
Unknown 166 (15.0) 188 (22.5) 
BNF chapter count group, n (%)  0-4 462 (41.6) 425 (50.8) 
5-9 353 (31.8) 236 (28.2) 
10+ 295 (26.6) 175 (20.9) 
Number of clinical OA consultations, mean (SD) 1.53 (0.94) 1.79 (1.24) 
New consulters, n (%) 574 (68.7) 741 (66.8) 
Multiple consulter with clinical OA, period 4, n (%) 295 (35.3) 465 (41.9) 
Recorded X-ray in period 4a, n (%) 10 (7.0) 48 (12.4) 
Number of index consultations undertaken by the 
consulted clinician, n (%) 
Above the 
median 
988 (89.0) 763 (91.3) 
Patients with a comorbidity as a relative contraindication  
to oral NSAIDs in previous 2 years 
431 (38.8) 278 (33.3) 
aRelevant recorded X-ray within trial period 4, before the index consultation 
8.3.2 Recorded achievement by trial arm, baseline period 
As shown in Table 8-3, there was substantial variability between trial arms in the levels of outcome 
achieved in the six-month baseline period with generally higher levels in the intervention arm. 
There were uniformly low levels of written information and advice recorded. Recorded prescription 
outcomes were more similar between arms, except for recorded PPI use in people prescribed an 
oral NSAID (13.0% to 1.7%).  
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Table 8-3: Outcome achievement by trial arm in trial baseline period 
Outcome measure 
Number of patients with outcome in period 3, 
pre-randomisation n (%) 
 Intervention arm Control arm 
Total 977 747 
Assessment   
Pain assessment 704 (72.1) 388 (51.9) 
Function assessment 688 (70.4) 382 (51.1) 
Weight record 275 (28.1) 149 (19.9) 
X-ray recorded 242 (24.8) 21 (2.8) 
Core interventions   
OA information provision 575 (58.9) 274 (36.7) 
 Written OA information 36 (3.7) 6 (0.8) 
Exercise advice provision 579 (59.3) 285 (38.2) 
 Written exercise advice 38 (3.9) 8 (1.1) 
Weight loss advice provisiona 311 (52.9) 158 (35.1) 
 Written weight loss advicea 7 (1.2) 1 (0.2) 
Non-pharmacological management   
Consideration of physiotherapy referral 425 (43.5) 192 (25.7) 
Physiotherapy referral made 90 (9.2) 34 (4.6) 
Pharmacological management   
Consideration of paracetamol use 622 (63.7) 348 (46.6) 
Paracetamol prescribed 154 (15.8) 145 (19.4) 
Consideration of topical NSAID use 537 (55.0) 295 (39.5) 
Topical NSAID prescribed 255 (26.1) 174 (23.3) 
Oral NSAID prescribed 176 (18.0) 108 (14.5) 
Oral NSAID prescribed in the presence of a 
relative comorbid contraindication 
39 (11.8) 73 (15.6) 
Gastroprotection  
(PPI use with oral NSAIDs) 
3 (1.7) 14 (13.0) 
Opioid prescribed 331 (33.9) 226 (30.3) 
ain those known to be overweight at the index consultation 
8.3.3 General patterns of template use, trial period 
As shown in Table 8-4, there was wide variation between practices and between arms in the 
frequency of template use and achievement of quality indicators derived from the template during 
the trial period. Between 38% and 80% of patients had at least one template indicator achieved 
across the eight practices, and this was reflected in a substantial difference between control 
(39.2%) and intervention (56.8%) arms. There was also a wide variation in the proportions of 
patients with all eligible template indicators achieved (<5% to >40% between practices).  
Although there was a greater level of template use in the intervention arm during the trial period, 
the adjusted ORs (which adjusted for baseline achievement) for patients having at least one entry  
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Table 8-4: Recorded template use and proportions of template-derived quality indicators achieved in intervention and control practices, trial period 
 Practice ID  
Intervention Control  
1 2 7 8 Total 3 4 5 6 Total 
Adjusted ORa 
(95% CI) 
All patients 
% patients for whom template fired 95.1 99.2 89.3 98.5 94.9 82.8 90.4 93.5 97.8 89.9 - 
% patients with at least 1 template entry 50.1 79.5 48.5 81.5 56.8 26.9 37.9 38.4 77.2 39.2 1.47 (0.61,3.54) 
% patients with at least 1 template indicator achieved 50.1 79.5 48.5 81.5 56.8 26.9 37.9 38.4 77.2 39.2 1.47 (0.61,3.55) 
% patients with all eligible template indicators achieved 23.1 12.6 10.2 40.0 21.5 4.6 19.3 7.3 37.0 13.8 1.58 (0.65,3.85) 
Restricted to 
patients in 
whom the 
template fired 
% patients with at least 1 template entry 52.6 80.2 54.3 82.8 59.8 32.5 41.9 41.0 78.9 43.6 1.48 (0.68,3.65) 
% patients with at least 1 template indicator achieved 52.6 80.2 54.3 82.8 59.8 32.5 41.9 41.0 78.9 43.6 1.49 (0.61,3.66) 
% patients with all eligible template indicators achieved 24.2 12.7 11.4 40.6 22.6 5.6 21.3 7.8 37.8 15.3 1.59 (0.65,3.90) 
aReference category is the control arm; adjusted for all covariates.            
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and recorded as having all template indicators achieved showed a trend of a positive effect of the 
intervention on quality of care but the results were not statistically significant. This remained true 
when the analysis was restricted to patients for whom the template fired. 
23.8% of clinicians in the intervention arm made no entry in the template for any of their patients; 
15.9% made at least one entry (and achieved at least one template-derived quality indicator) on 
every patient. For the control arm, the corresponding figures were 34% and 4%. In the intervention 
arm, 49.2% of clinicians did not achieve all template indicators in any patient, and 1.6% achieved 
all in every patient. For the control arm, 58% of clinicians did not achieve all template indicators in 
every patient and 2% did in all patients. 
8.3.4 Intention-to-treat analysis of individual quality indicators 
The outcome percentages for the individual indicators in each arm, with OR unadjusted and 
adjusted for all covariates can be seen in Table 8-5. Although the unadjusted odds for many 
outcomes were statistically significant, once adjustment for the relevant covariates was made, 
many of these became non-significant. 
Compared to the levels of outcome achieved in the baseline period three (Table 8-3), population 
levels of recorded quality achievement generally fell in the trial period. There was generally a higher 
level of baseline achievement in the intervention practices and this persisted into the trial period. 
The recorded levels of the core interventions of information provision, exercise advice, and weight 
loss advice for those known to be overweight were similar in both arms with a non-significant trend 
toward greater use in the intervention arm. However, when restricted to written provision, written 
information (adjusted OR 23.2, 95% CI 7.10,75.8) exercise advice (adjusted OR 21.4, 95% CI 
6.69,68.8) and weight loss advice in people known to be overweight (adjusted OR 23.5, 9% CI 
4.61,120, PQL1 model) all strongly favoured the intervention arm. 
Use of written information and advice was relatively stable in the control arm at 0.2% to 1.1% at 
baseline and 0.4% to 1.4% in the trial period; however recorded use of the various written materials 
increased substantially in the intervention arm (from 1.2%-3.9% to 13.7%-26.3%). Use of gastro- 
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Table 8-5: Adjusted odds of specified outcomes in intervention practices compared to control, trial period (95% CI). Intention-to-treat analysis. 
Outcome measure Number of patients with outcome n (%) OR (intervention vs. control arm) (95% CI) 
 
Intervention arm Control arm 
Unadjusted two-
level modeld 
Adjusted two-level 
modeld 
Adjusted two-level 
modeld in new 
consulterse only 
(n=1323) 
Total 1110 836    
Assessment      
Pain assessment 612 (55.1) 317 (37.9) 2.69 (1.39,5.20) 1.34 (0.54,3.32) 1.60 (0.54,4.68) 
Function assessment 606 (54.6) 307 (36.7) 2.71 (1.41,5.22) 1.14 (0.46,2.82) 0.69 (0.27,1.79) 
Weight record 305 (27.5) 143 (17.1) 1.78 (1.07,2.97) 1.15 (0.66,2.03) 0.93 (0.53,1.64) 
X-ray recorded 163 (14.7) 47 (5.6) 3.43 (1.68,7.00) 0.43 (0.09,1.99) 0.34 (0.08,1.52) 
Core interventions      
OA information provision 549 (49.5) 267 (31.9) 2.97 (1.52,5.80) 1.31 (0.56,3.03) 0.78 (0.33,1.85) 
 Written OA information 292 (26.3) 12 (1.4) 25.7 (8.89,74.4)  23.2 (7.10,75.8)  24.6 (6.80,89.4) 
Exercise advice provision 522 (47.0) 245 (29.3) 2.63 (1.45,4.77) 1.50 (0.68,3.29) 0.90 (0.42,1.92) 
 Written exercise advice 230 (20.7) 7 (0.8) 27.6 (8.57,89.1)  21.4 (6.69,68.8)  11.7 (4.14,32.8) 
Weight loss advice provisiona 327 (45.2) 130 (25.9) 3.08 (1.52,6.24) 1.39 (0.66,2.96) 0.98 (0.46,2.09) 
 Written weight loss adviceab 99 (13.7) 2 (0.4) 24.8 (5.47,113)  23.5 (4.61,120).  12.9 (2.32,71.8) 
Non-pharmacological management 
Consideration of physiotherapy 
referralb 
94 (8.5) 65 (7.8) 2.17 (1.18,3.97) 1.41 (0.56,3.57) 0.99 (0.39,2.48) 
Physiotherapy referral made 109 (9.8) 19 (2.3) 7.66 (3.07,19.1)  5.50 (2.13,14.2)  5.73 (1.74,18.9) 
     (con’t) 
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Outcome measure Number of patients with outcome n (%) OR (intervention vs. control arm) (95% CI) 
 
Intervention arm Control arm 
Unadjusted two-
level modeld 
Adjusted two-level 
modeld 
Adjusted two-level 
modeld in new 
consulterse only 
(n=1323) 
Pharmacological management      
Consideration of paracetamol use 549 (49.5) 282 (33.7) 2.69 (1.49,4.86) 1.42 (0.67,3.04) 0.97 (0.44,2.14) 
Paracetamol prescribed 241 (21.7) 117 (14.0) 1.77 (1.32,2.39)  1.58 (1.14,2.20)  1.70 (1.10,2.62) 
Consideration of topical NSAID use 496 (44.7) 274 (32.8) 2.00 (1.14,3.53) 0.91 (0.43,1.92) 0.56 (0.26,1.23) 
Topical NSAID prescribed 326 (29.4) 184 (22.0) 1.46 (1.01,2.10) 1.13 (0.75,1.70) 1.03 (0.63,1.67) 
Oral NSAID prescribed 176 (15.9) 136 (16.3) 1.26 (0.99,1.60) 0.79 (0.53,1.16) 1.05 (0.66,1.67) 
Oral NSAID prescribed in the 
presence of a relative comorbid 
contraindication 
52 (12.1) 43 (15.5) 0.74 (0.41,1.33) 0.74 (0.42,1.32) 0.88 (0.43,1.82) 
Gastroprotection prescribed (PPI)c 69 (39.2) 49 (36.0) 0.90 (0.60,1.35) 0.96 (0.50,1.82) 1.33 (0.43,4.16) 
Opioid prescribed 364 (32.8) 228 (27.3) 1.05 (0.62,1.78) 0.85 (0.66,1.09) 0.87 (0.64,1.17) 
Adjusted for OA or joint pain code, sex, age band, site of disease, BMI status, morbidity load (BNF chapter count), multiple clinical OA consultation, staff 
member index consultation count dichotomy, and practice pre-trial achievement; ain those known to be overweight at time of index consultation; bPQL1 
model; cdenominator: those prescribed an oral NSAID; dpatients within clinicians; enew consulters defined as first clinical OA consultation since the 
introduction of the template and with at least 365 days since any previous OA or joint pain consultation 
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protection increased in the control arm (1.7% up to 5.9%) but diminished in the intervention arm 
(dropping from 13.0% to 6.2%).  
Achievement of assessment measures were more similar between intervention and control arms 
for pain and function, and weight recording (all of which were recorded in the e-template). X-ray 
use fell in the intervention arm (24.8% to 14.7%) and increased from 2.8% to 5.6% in the control 
arm with adjusted OR 0.43 (95% CI 0.09,1.99). However, statistical significance was not achieved.  
Physiotherapy referral was recorded as considered (captured by the template) at a similar level in 
each arm, though there was a non-significant trend toward increased consideration in the 
intervention arm (adjusted OR 1.41, 95% CI 0.56,3.57). Recorded use of actual referral to 
physiotherapy was significantly greater in the intervention arm (adjusted OR 5.50, 95% CI 
2.13,14.2). 
There were greater odds of consideration of paracetamol via the template in the intervention arm 
compared to control, though this did not achieve statistical significance (adjusted OR 1.42, 95% CI 
0.67,3.04), and greater odds of a recorded actual prescription (adjusted OR 1.58, 95% CI 1.14,2.20). 
There were reduced odds of prescription of oral NSAIDs in the intervention arm (adjusted OR 0.79. 
95% CI 0.53,1.16) and for reduced prescription of oral NSAIDs amongst people with a recorded 
comorbidity that was considered to be a relative contraindication to their use (adjusted OR 0.74, 
95% CI 0.42,1.32) but neither achieved statistical significance.  
The analysis was repeated as a three-level model of patients within clinicians within practices. This 
did not demonstrate any statistically significant explanation of residual variance at the practice level 
in the adjusted model. The effects on the OR estimates showed a moderate increase for the written 
information (adjusted OR up to 29.5 from 23.2) and advice outcomes (for exercise, increasing from 
21.4 to 25.5 and for weight loss in people known to be overweight from 23.5 to 28.8) but no change 
for physiotherapy referral or paracetamol prescription.  
Restriction of the eligible population to new consulters only did not substantially change the results, 
with all significant associations remaining so. 
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8.3.5 Patients in whom the template triggered 
Restriction of the analysis to those patients in whom the template was triggered (n=1804, 92.7%) 
did not change the findings. A further restriction to new episode consulters only was undertaken. 
This showed a tendency for the control arm to have generally slightly higher frequencies of the 
specified outcomes and for the intervention arm to have slightly lower frequencies. The 
achievement of statistical significance of the ORs was unchanged, though there was slight 
fluctuation in the estimates except for written weight loss advice, which sustained a big drop in the 
estimated adjusted OR.  
8.3.6 Patients in whom at least one template entry was made 
As shown in section 8.3.3 above, there was a marked discrepancy between intervention and control 
arms in the frequency with which at least one template entry was made, with the control arm 
achieving at least one entry in 39.2% of patients whilst the intervention arm achieved this in 56.8% 
of patients.  
Pain and function assessments were the most frequently-completed items on the template, with 
completion rates (when at least one entry was made) of over 90% in both trial arms. This led to 
problems with the covariates chosen in the models with pain and function as the outcomes. The 
intended model had to be discarded in favour of a restricted model which included only diagnostic 
category, sex, age at index consultation (continuous variable), and practice baseline achievement. 
Other outcomes were assessed using the standard model.  
Findings were similar to previous analyses except for written weight loss advice in people known to 
be overweight, which dropped to 17.6 from 34.3 in the analysis of template-triggering patients 
(Appendix H.2). 
When restricted to those patients with at least one template entry (Appendix H.3) there was no 
statistically significant explained variance at the practice level. For written information, the 
adjusted OR estimate increased to 29.5 from 24.5 and for written exercise advice from 21.8 to 23.5.  
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8.4 Discussion 
8.4.1 Main findings 
The objective of this chapter was to describe how the effects of a complex intervention to improve 
uptake of NICE-recommended management strategies for OA in general practice registered 
populations could be assessed through quality indicators including those recorded via a template 
integrated to the clinical information system. 
This analysis of the MOSAICS trial period data has shown that the model OA consultation 
intervention was associated with substantial improvements in some important components of the 
primary care of OA as recorded within the template: written information and written advice about 
exercise and weight loss, recorded physiotherapy referral, and paracetamol prescription.  
However, the intervention arm had higher levels of template use (as measured both by template 
triggering and by recording of at least one item in the template) at baseline and during the trial 
period, though there was a fall in template use between the baseline and trial periods in both arms. 
Wide variation during the baseline period between clinicians, practices, and trial arms caused 
difficulty in estimation of the effects in the trial period. The effect of item order seen in the 
assessment of the template (in which the final template items were less frequently completed than 
the initial items) remained a problem with the biggest falls in recording in the domains listed later 
in the template. Given this, it is unclear to what extent the greater use of the template in the 
intervention arm in the trial period was due to the greater level of use in the baseline period or 
whether the MOAC intervention helped sustain template usage. The signal from the findings 
relating to the template use measures might be taken to imply some sustaining effect on template 
usage from the intervention, though statistical significance was not achieved and caution is needed 
in drawing conclusions.  
Stratified block-randomisation was used to allocate practices to intervention or control arms. The 
randomisation process was conducted by computerised random number generation in accordance 
with good research practice by the Keele CTU, independently of the trial investigators. In common 
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with the trial statisticians, the candidate was kept blind to the allocations until after the outcomes 
analyses.  
With any randomisation process, an imbalance of baseline characteristics can occur purely by 
chance and this is presumed to be the cause of the differences in baseline characteristics between 
the trial arms, with the small numbers of practices in each arm (four clusters per arm has been 
suggested to be the minimum number required315,316).  
The sample size for the MOSAICS trial was calculated to meet the requirements of the main 
outcome (patient-level clinical effectiveness measures). On the basis of a projected 10% annual 
consultation rate for clinical OA in patients aged 45 years and over,21,311 the anticipated total 
population for this age group in 8 practices (30,000 people) was expected to yield 3,000 OA 
consulters per annum. Accounting for repeat consultations, 2,000 unique patients were expected 
to consult in a six-month period, equating to approximately 1,000 patients per study arm. Allowing 
for an expected 50 clinicians consulted per arm, and an intraclass correlation coefficient (ICC) of 
0.1, it was estimated that an odds ratio of 1.6 in the dichotomous outcomes between trial arms 
could be identified with 80% power at a significance level (α)=0.05. The projected ICC used was 
similar to that reported for recorded items of advice as identified by Russell et al.312 but rather 
larger than the majority of those reported by Adams et al.313 for diverse variables in 31 primary care 
studies.  
Actual variability between clinicians was greater than expected for some indicators. For example, 
the odds ratio for recorded pain assessment in the trial period (in new consulters only) between 
intervention and control arms was estimated to be 1.6 but this did not achieve statistical 
significance (95% CI 0.54,4.68), suggesting that the study may have been under-powered for some 
indicators. However, this analysis was intended to test the feasibility of quality indicators as trial 
outcomes and in this context, the ability of the indicators to discriminate between trial arms on 
several aspects of care (significant differences in written information/advice, paracetamol 
prescription, and physiotherapy referral) suggests potential for indicators to be used in this way.  
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One conclusion from this analysis is that researchers should use conservative estimates of the ICC 
when undertaking sample size calculations for clustered designs which examine process measures, 
such as in this study.  
The increased use of written information seen in the intervention arm was likely to represent the 
use of the OA guidebook provided to the intervention arm only (though other printed materials 
were available by request to the control arm for use had the practices so chosen).  
There was a trend toward reduced use of X-ray investigations and, although this did not achieve 
statistical significance, the apparent direction of change was in accordance with the NICE guidance.5 
There was a small reduction in odds of an oral NSAID prescription in the intervention arm, which 
again would be consistent at a population level with the NICE guidelines to use other analgesics in 
preference to oral NSAIDs. There was also a trend toward lower oral NSAID prescription amongst 
people with a recorded comorbidity that presented a relative contraindication to such prescription. 
Again, this did not achieve statistical significance and it is not clear whether this was a chance 
finding, or whether the study lacked power to detect a real difference.  
8.4.2 Comparison with previous literature 
Despite a fall in the recorded levels of achievement, levels remained higher in the intervention arm 
than those reported in prior literature. For assessment of pain and function, as the most frequently-
completed items on the template, rates of recorded quality indicator achievement of 55% in the 
intervention arm (37%-38% in the control arm) were lower than achieved in the baseline period99 
but still exceeded those reported by Broadbent et al.69 (27% for pain and 43% for function). Rates 
of information provision at 50% (26% for written) in the intervention arm also exceeded the 30% 
reported by Broadbent et al.,69 and was similar to the 55% (patient self-reported) found by Østerås 
et al.317 though rates in the control arm at 32% (1.4% written) were more in line with Broadbent’s 
assessment. Provision of exercise information at 47% (intervention) and 29% (control) compared 
well to the 25% reported by Li et al.,80 and for the intervention arm at least were comparable to the 
49% reported by Østerås et al.82 Advice about weight loss was similar at 45% compared to 46% 
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(patient self-reported) in Østerås et al.317 but lower than a prior estimate by the same author 
(68%82). Recorded physiotherapy referral at 31% compared favourably to the estimate of 25% of 
people advised to exercise (which included physiotherapy referral) by Li et al.80  
In Chapter Seven, it was shown that the template was associated with an increased recorded 
prescription frequency for paracetamol and topical NSAIDs.99 This prior association meant that it 
was additionally difficult for the MOSAICS intervention to demonstrate an effect in these domains. 
The recorded frequency of patients receiving a prescription for paracetamol within 14 days of a 
clinical OA consultation that occurred within 120 days of the index consultation (22% in the 
intervention arm and 14% in control) has no direct comparator in the prior literature: Broadbent et 
al.69 examined recorded first use of paracetamol, identifying a rate of 48%, and Steel et al. 41%.70 
However, there was not the same time period restriction to those analyses.  
8.4.3 Use of quality indicators as outcomes in clinical trials 
Quality indicators have an established role in service evaluation and audit. However, unlike many 
established outcome measures, quality indicators do not have a well-established use in clinical trials 
for assessment of outcomes. Eyssen et al.318 used indicators as secondary outcome measures in an 
assessment of occupational therapy in multiple sclerosis care. The CARAT trial for diabetes care 
used several diabetes quality of care indicators as outcome measures (nephropathy screening, 
retinopathy screening, foot examination, and peripheral neurological testing).319 Again in the field 
of diabetes, Shah et al.320 used diabetes quality indicators as outcomes in a cluster trial of an 
educational toolkit. Performance indicators have also been compared to outcome indicators in a 
study of major trauma incident exercises.321 The protocol for a randomised controlled trial of a 
quality initiative in chronic obstructive pulmonary disease also states that quality indicators will be 
used as outcome measures.322 The use of quality indicators as outcomes in this trial of a complex 
intervention to increase adherence to the NICE OA guidelines extends the knowledge base for use 
of indicators as trial outcomes. Quality indicators often refer to processes of care.44,124 Where such 
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processes are considered intrinsically desirable, it should generally be feasible to use indicators as 
outcome measures in implementation trials.  
However, there are issues which need to be overcome. In trials that seek to improve clinical 
outcomes in osteoarthritis, further work to understand how well recorded process measures are 
linked to clinically-meaningful outcomes would be required before indicators could be used in place 
of more traditional outcome measures.46,107 This might be particularly true for core interventions 
such as education/information and lifestyle advice (exercise, weight loss) where the content of 
advice would be expected to vary across clinicians and potentially by patient characteristics. 
Due to the e-template not firing in all patients (5% missing in the intervention arm and 10% in the 
control arm), some information is likely to have been lost since it seems probable that clinicians 
would have recorded at least some information on some of those patients in whom the e-template 
did not trigger. This loss of information may cause a bias in treatment effect if there is a differential 
rate of non-triggering between intervention and control arms as happened here. The consistent 
satisfactory functioning of the e-template is an important consideration for any future trials using 
indicators as their primary outcome measures.  
The high baseline achievement, and baseline variability between trial arms and between clinicians 
may have reduced the power to detect a difference in some of the outcome measures. The use of 
the e-template was lower in this trial period compared to the baseline period. It is possible that this 
was the result of so-called ‘initiative fatigue’, such as has been reported for the QOF.323-325  
Multiple comparisons were unavoidable when assessing multiple indicators of quality of care. In 
the MOSAICS study, given the consistency of the findings across the written information and advice 
indicators, and the strength of the physiotherapy referral association with the intervention, a 
genuine trial effect seems likely. The effect on paracetamol prescription was less dramatic but given 
the routinely-recorded nature of this outcome, its promotion by the NICE 2008 guidelines, and a 
prior increase associated with the template introduction, a genuine increase is again plausible.  
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8.4.4 Conclusion 
In principle, quality indicators for OA management identified from a systematic review and 
supported by an enhanced recording method in general practice should be implementable as 
outcome measures in an intervention trial for OA management. However, the introduction of an 
indicator recording method itself (the template) was found to have some effects on recorded 
quality of care, and this, coupled with high levels of achievement at baseline in both trial arms for 
some processes of care (such as pain and function assessment), and baseline variation in indicator 
achievement limited the scope of the study to detect a difference between arms.  
Quality indicators may function better as trial outcome measures in trials that have a greater 
number of randomly allocated clusters, such that the differences in baseline achievement between 
intervention and control arms may be less pronounced. Whilst indicators could in principle be used 
in trials that use individual-level randomisation, it is likely that relatively few interventions that are 
likely to have an effect on recorded processes of care would be suitable for individual patient-level 
randomisation. 
Chapter Nine will summarise the findings across the thesis as a whole, and link these to the original 
aims and objectives. The overall conclusions arising from the work are set out, with proposals for 
implementation of the findings and implications for future research.  
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Chapter Nine: Discussion and conclusions 
The overall aim of the work described in this thesis was to identify indicators of quality of care for 
OA in general practice, to assess how they night be implemented in a general practice EHR, and to 
test their feasibility as outcome measures in a clinical trial. This chapter will summarise the main 
findings from the research and link these to the initial aims and objectives. The strengths and 
limitations of the work overall will be discussed, and future implications and conclusions 
considered.  
9.1 Summary of findings 
 Identification and synthesis of indicators 
Objective (i) to review the existing evidence for quality indicators for OA, applicable to general 
practice 
Quality indicators for the primary care of OA were identified from a systematic review, grouped 
into assessment and treatment themes derived from the NICE OA management guidelines, and 
synthesised into indicators considered suitable for implementation in UK general practice. Overall, 
fifteen OA indicators were considered suitable for implementation. A need for additional indicators 
relating to treatment (topical NSAIDs) and to certain ‘do not do’ indicators (such as referral for 
arthroscopic lavage) was identified.  
 Development of a template for OA consultations 
Objective (ii) to identify how the quality indicators may be assessed through general practice 
medical records and develop a mechanism for enhanced recording where necessary 
The need for additional data capture in general practice to enable routine measurement of the 
quality indicators was identified, concluding that only measures of prescribing and referral could 
be used without improved data recording.  
An enhanced recording tool, the OA template, was developed and implemented. This single-screen 
(10-item) template was produced to facilitate recording of the main items of care for OA that were 
 261 
not well-covered by the routine record: assessment of pain and function, a record of or advice about 
relatively safe pharmacological options (paracetamol, topical NSAIDs), information provision and 
advice about exercise and weight loss (where relevant) and consideration of physiotherapy referral.  
A variable response rate to the template questions was identified in the initial six-month use of the 
template (Chapter Six), possibly related to the question order in the template may have affected 
response rates. There was considerable variation between clinicians in whether or not the template 
was used, and if it was used, how fully-completed it was. The high levels of completion achieved by 
some clinicians suggests that the template was feasible in principle but that additional work to 
understand how the variation could be minimised is needed.   
 The denominator population for quality indicators: a Read-code definition of clinical 
OA 
The interpretation of quality of care depends upon the patient group to whom quality of care 
indicators are applied. A definition of clinical OA for the MOSAICS study was developed through a 
robust process involving an initial draft list of codes selected by the candidate which was then 
revised through a process of consensus, assessment in the locally-derived CiPCA database, and then 
finally a review by the MOSAICS research team. The process sought to strike a balance between 
practicality for clinicians and the informatics team (avoiding making the definition too sensitive) 
and on the other hand reducing the risk of selection bias in the MOSAICS study (through an overly 
specific set of codes that could have been avoided in clinical use). Residual concern about a lack of 
specificity in the clinical definition of OA used to trigger the template and assess study outcomes 
was considered further in the assessment of coding in the baseline phase one. 
 Naturally-occurring coding patterns for clinical OA 
Objective (iii) to describe the naturally-occurring patterns of OA and peripheral joint pain morbidity 
coding in general practice 
In the eight MOSAICS study practices, before inception of the study (phase one), the age-
standardised diagnosed OA consultation prevalence over the 12-month period was 3.2%. 
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Factors associated with a diagnosis of OA rather than joint pain were found to be older age, 
unspecified or multisite disease, obesity, multiple clinical OA consultation, and X-ray use prior to 
the index consultation. Ankle/foot site of disease was associated with reduced odds of an OA 
diagnosis compared to joint pain compared to the knee. A hypothesis that patients with a higher 
total level of morbidity as assessed by BNF chapter count (as a measure of biological rather than 
chronological age) would be more likely to receive a diagnosis of OA was not found to be supported. 
Investigation of diagnostic misclassification (attribution of a clinical OA label to people with joint 
pain who actually have non-OA joint pain), suggested that the true annual consultation prevalence  
rate for clinical OA lay between 4.7% and 7.2%, with a point estimate of 5.7%. Compared to the 
knee, ankle/foot and wrist/hand pain codes were least likely to represent clinical OA.  
The restriction of the definition of clinical OA in this thesis to peripheral joints, excluding the axial 
skeleton, shoulder, and elbow, is considered likely to have increased the specificity of the definition 
of true OA. As noted in Chapter Four, additional improvement in diagnostic specificity may have 
been achieved by exclusion of the ankle/foot joints. It is unknown to what extent the recorded 
quality of care, and the effects of the template and model OA consultation, would have been altered 
by a change in the definition of OA. Given the identified link between an OA diagnosis and some 
aspects of recorded quality of care, it seems plausible that a clinical OA definition that included the 
axial skeleton, shoulder and elbow (with use of pain as well as formal OA Read codes) may have 
reduced the apparent effects of the template and trial intervention in the combined clinical OA 
population due to lower specificity for joint pain as a marker of OA at these sites.  
 Naturally-occurring coded quality of care for OA 
Objective (iv) to describe the routinely-recorded and coded quality of care for clinical OA in general 
practice 
Assessment of routinely recorded quality of care for OA in the eight MOSAICS practices during 
phase one (Chapter Five), before study commencement, identified very low levels of coded 
information relating to pain and function assessment and the core interventions of education and 
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advice regarding exercise and weight loss (where relevant). It was possible to measure quality 
indicators related to prescribing and referral activity.  
Factors associated with better routinely-recorded quality of care were, for prescribing measures, 
those associated with increased risk of OA (female sex, older age), higher total morbidity, and 
multiple clinical OA consultation. Primary care referral was more likely for people with joint pain, 
whereas secondary care was more likely for people with diagnosed OA. The oldest patients had 
reduced odds of secondary care referral. Site had differing associations but generally patients with 
the ankle/foot, wrist/hand and unspecified sites had lower odds of referral. Patients with a 
recorded X-ray and multiple clinical OA consultations had greater odds of referral.  
Increased age was associated with reduced odds of some assessment measures but increased 
prescribing processes and reduces referral processes, raising a question about equitable access to 
appropriate treatments for the very elderly. 
 OA quality of care measured through the template 
Objective (v) to describe the coded quality of care for OA as captured by the enhanced recording 
mechanism 
Pain and function assessments were relatively well-recorded in the initial six months after 
introduction of the template, at 63% and 62% of patients respectively. The rest of the indicators 
were achieved in the range of 45 – 56% with the exception of physiotherapy referral and recording 
of weight measurements. Achievement of the template-derived indicators was more common than 
the complementary routinely-recorded indicators (i.e. consideration of processes was more 
common than actual prescription or referral).  
An OA diagnosis rather than joint pain was associated with achievement of all template indicators. 
Older age, multiple clinical OA consultation, and consultation with a clinician with a higher clinical 
OA workload (as measured by the index consultation count) were also associated with greater odds 
of achievement. Ankle/foot disease was associated with reduced odds of indicator achievement as 
were, though with less consistency, an unknown BMI status and higher total morbidity burden.  
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Prior recorded X-ray use was not associated with template-derived quality of care measures but a 
record of X-ray within 14 days was associated with various template measures.  
 Effects of the template on recorded quality of care 
Objective (vi) to estimate the effect of the enhanced recording mechanism on quality of care 
determined by routinely-recorded and coded means 
Amongst measures recorded through routine mechanisms in the EHR, the template was found to 
be associated with a rise in weight recording and a rise in use of the relatively safe pharmacological 
options (paracetamol, topical NSAIDs).  
 The implementation of quality indicators as outcomes in a clinical trial 
Objective (vii) to investigate the feasibility of use of quality indicators in assessment of a cluster-
randomised controlled clinical trial of a complex intervention to improve care for OA 
The use of quality indicators as, and templates as a source of, outcomes in a cluster-randomised 
controlled trial of a model OA consultation intervention were investigated. Due to variation in 
baseline performance between the control and intervention arms in aspects of care measured by 
the e-template, assessment of change relating to the intervention itself was difficult. However, 
there was clear evidence of improved recording of written information and written advice to 
exercise and lose weight (where relevant), and evidence of increased physiotherapy referral.  
9.2 Strengths and limitations 
There were a number of important strengths to this work. It was founded on a rigorous systematic 
review and narrative synthesis which has since been cited by the NICE 2014 OA guidelines. The 
introduction of the indicators into the enhanced recording template was considered in the light of 
the best available evidence. 
This was a large study, with 1946 patients included in the trial analysis stage, compared to 525 in 
the clinical effectiveness assessment (not reported here). Estimates of the effects of the template 
and the model consultation have been adjusted for a wide range of potential confounding factors, 
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especially through the use of a simple measure of total morbidity load (the BNF chapter count) and 
a measure of clinical OA workload for clinicians.  
The data collection from the MOSAICS practices was designed to have a high sensitivity to clinical 
OA and thus avoid recording bias (by shifting diagnostic recording patterns) once the template had 
been introduced as well as during the cluster trial. A novel aspect of this work was the additional 
estimation of diagnostic misclassification through the extensive analysis of joint pain consultation 
narrative, giving rise to new estimates of the consultation prevalence of clinical OA, at 
approximately 53% to 80% of the consultation prevalence before misclassification assessment 
(point estimate of 64% of the original estimate).  
In datasets that are time-limited (i.e. do not include the whole primary care record since first 
presentation of clinical OA), caution should be exercised about inference of individual-level quality 
of care. Routine determination of care processes such as exercise advice or referral at least once 
since diagnosis, or first-use of relatively safe analgesics options, cannot be made without 
consideration of the full record. The timeframe used for linking clinical activity to quality indicators 
was arbitrary, though in keeping with previous research practice.264 There was a risk of 
misclassification in attribution of patients to prescribing and referral outcomes, as some patient not 
identified as having received such a process may actually have received one but outside of the 14 
days after a consultation for clinical OA, for example, those on repeat prescriptions. Some patients 
receiving such processes within 14 days may in fact have received it for an unrelated condition. The 
direction and effect of such misclassification is not possible to determine with any certainty. There 
is no reason to suppose that it would have resulted in a bias in assessment of the trial outcomes, 
though the absolute levels of achievement of the prescribing indicators should be interpreted with 
caution. Referrals were more likely to be recorded within a relatively short space of time after a 
consultation as no similar repeat facility exists for referrals, and so it is considered that less 
misclassification results from the use of a 14-day period for referrals.  
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It would have been desirable to include additional variables in the models. For example, an OA 
severity measure would be relevant to adjust for the case-mix issue described in Chapter One. A 
health literacy measure would have been desirable to include to identify to what extent patients’ 
health literacy influenced provision of care for OA as it has previously been found that there is an 
inverse relationship.326 The risk of lack of health literacy increases with worse deprivation327 but 
Broadbent69 did not demonstrate a link between individual or practice-level deprivation and 
achievement of quality indicators for OA. Clinician factors such as those determined by Clarson et 
al.328,329 to predict agreement about a QOF domain for OA (special interest in musculoskeletal 
disease, a higher research degree, familiarity with the NICE guidance) and OA monitoring (belief in 
the importance of monitoring, special interest in musculoskeletal disease, a Master’s degree, 
familiarity with the NICE guidance, and working full-time) would also have been of potential 
importance in this study. 
The MOSAICS study practices, drawn from a mix of urban, suburban, and rural areas of the North-
West Midlands and Cheshire, were considered to form a representative sample of general practice. 
The generalisability of the findings may be affected by various factors, however. There was a 
substantial difference in the way in which practices coded clinical OA (as formally-diagnosed OA, or 
as peripheral joint pain), as described in Chapter Four. Practice 1, as the largest contributor practice, 
recorded more OA as a proportion of all clinical OA than the other practices. The study practices 
were all willing to participate in the research and received additional resources to participate in the 
study. It is uncertain to what extent the findings might be replicated in other general practices. An 
evaluation of a similar approach in routine practice forms part of the JIGSAW implementation, 
discussed in 9.4, Proposals for implementation.  
The apparent selection bias potentially arising due to the differences in baseline characteristics 
(generally higher levels of achievement of core OA management processes in the intervention arm 
but a greater proportion of people with an OA rather than joint pain diagnosis in the control arm) 
should have been largely adjusted for through inclusion of baseline levels of achievement in the 
multilevel logistic regression models, as well as the inclusion of a diagnostic group (OA or joint pain) 
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variable. There remained a risk of unbalanced and unmeasured confounding factors between trial 
arms which may have affected the trial outcomes. The magnitude and direction of these effects are 
uncertain but are considered likely to have favoured the recorded quality of care in the intervention 
arm. Even within arms, there was substantial variation in the recorded proportions of people with 
OA or joint pain diagnoses by practice. Variation between practices is likely to be a typical finding. 
The variation seen between practices in this relatively small number of clusters does limit the 
generalisability of the findings. 
The estimates of effects described were shown to be greater in patients for whom at least one 
template entry was recorded. This may reflect greater use of the template by clinicians for patients 
they considered to have clinically significant OA and as such, the analyses that restricted the eligible 
population to those with at least one entry may be a truer marker of the efficacy of the template 
and the model consultation.  
As noted in Chapter Three, the use of a medical record review for assessment of quality of care has 
limitations predominantly relating to completeness of information and retrievability through use of 
codes.171 It is uncertain to what extent recording reflects actual delivery of quality of care, as the 
analysis was dependent upon the coding of information from consultations and it is known that 
such information capture is not entirely reliable.330 It has been identified that the content of the 
medical record may be at variance with the findings from standardised or observed 
consultations.331-333 However patient-reported quality indicator achievement in MOSAICS317 
showed broadly comparable achievement rates for those indicators measured through both patient 
self-report and medical records.  
9.3 Discussion 
 Quality indicators for the primary care of OA 
A set of quality robust indicators for primary care were identified but implementation of these in 
routine practice without a change to recording practice does not seem to be possible. Through use 
of an enhanced recording template, there was substantially better coverage of the indicator set, 
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though recorded performance in the MOSAICS practices in the first six months of template use was 
variable between clinicians and practices. There was evidence of a reduction in template use in 
both arms during the trial period (second six-month period of use).  
A lack of comprehensiveness of indicators (omissions related to the absence of indicators on topical 
NSAIDs and other NICE-recommended OA treatments, as well as to the absence of ‘do not do’ 
indicators), was perhaps in part related to a lack of continuous refinement of indicator sets in light 
of emerging evidence. The NICE quality standards334 have partly addressed this but there remains 
a gap in coverage between the indicators (or standards) and recommended practice. Routinely 
collected information that could be used to assess indicators of OA care in Maxwell’s domains of 
effectiveness, efficiency, equity, acceptability, access, and relevance56 would be useful 
development for primary care. The indicators identified herein go some way toward measuring 
efficiency (as one indicator would measure how often all of the other indicators have been met 
prior to specialist referral). New indicators, including patient-reported process (and possibly 
outcome) measures would be needed to address the remaining domains for OA in primary care. 
Limitations in the understanding of quality indicators themselves were identified, notably a lack of 
information about quality improvement resulting from implementation of such indicators (external 
validity). Some evidence suggests that in fact simple monitoring of quality indicators implemented 
in laboratory medicine did not consistently result in quality improvement.335  
It is known that the medical record provides at best a partial picture of the consultation with 
inherent, systematic bias in coded information.330 332 Marshall et al.144 argued that some aspects of 
care were sufficiently important that a failure to capture them in the medical record would in itself 
be a marker of poor quality of care. However, the threshold for a minimally acceptable record is 
hard to define. Certainly, the evidence-based management of OA in general practice would add 
more time to a consultation compared to treating it as a low clinical priority. Levene et al. have 
proposed four principles for general practice data collection: to understand population health 
needs better, collection of only necessary data, rational use of data to help improve outcomes and 
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policies, and maximisation of practice engagement.336 The relatively modest proposals for recording 
information in an OA consultation do not seem a disproportionate response to the scale of OA as a 
clinical problem.  
The population approach to determination of quality of care as used in this work was in keeping 
with that adopted by the QOF. This uses process and surrogate or intermediate outcome indicators, 
measured at the level of the patient, to make payments to general practice on the basis of 
aggregated level of care achieved in the registered practice population and is used as a means of 
assessment of general practice, such as by the Care Quality Commission.337 It was also consistent 
with that suggested by Gribben et al. for use in New Zealand primary care, which included 
population-level indicators such as ratios of lower risk drugs to higher risk.338 
Overall, the indicators seem to be feasible for use but there is a need to understand how to make 
clinical engagement with their use more consistent between clinicians as well as within clinicians 
over time.  
 OA coding as an aspect of quality of care 
One aspect of the medical-technical quality of care is the making of a correct diagnosis,40,41,339 and 
the recording of adequate information in the health record.340 By extension, one might also argue 
that the recording of a correct diagnosis is also an aspect of technical quality of care and this would 
be consistent with the first NICE OA quality standard about making a diagnosis of OA.334 The 
potential benefits to the patient lie in provision of adequate information about the condition – 
which requires a working diagnosis to be made – and for sufficient continuity of information 
between clinicians.341 There would also be potential benefits to clinicians (information continuity, 
again) and to public health and health care commissioning (for planning and service evaluation 
purposes, consistent with the need identified by Brand et al.342). Clinical audit depends on adequate 
information about the proportion of eligible people receiving care or their outcomes, which again 
requires sufficiently precise recording of diagnoses to enable this. This would be comparable to 
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QOF102 for long term conditions such as diabetes, the care of which has been found to benefit from 
a structured approach as described by Brennan.343 
There was no evidence that the template changed practice regarding the recording of a diagnosis 
of OA or joint pain. The diagnostic misclassification work has indicated that there is a need to 
improve coding of clinical OA. Restriction of the definition of OA to a formal diagnosis is too specific, 
with cases missed. On the other hand, the joint pain diagnoses used were too sensitive, with 
misclassification again, resulting in non-OA cases being included. A refined definition of clinical OA 
from diagnostic codes is needed, potentially excluding joint pain codes relating to the ankle/foot, 
wrist/hand and unspecified sites. Coding training and feedback, such as used in the inception of 
CiPCA,22 may assist with diagnostic coding.  
 Quality improvement in OA 
The association of prescribing patterns and some known risk factors for OA suggests that clinicians 
may have been more willing to treat people with clinical OA people pharmacologically if they fit the 
stereotype of a patient with OA. If so, increased education might be expected to help with 
management of clinical OA in a wider sense. Association between increased odds of many 
prescriptions and older age, coupled with reduced odds of referral to secondary care, may 
represent an appropriate desire at the level of either the clinician or patient to manage symptoms 
with analgesia rather than surgery, but it is also possible that this could have reflected inappropriate 
reduced access to effective secondary care treatments on ground of age.  
The association of odds of referral with prior X-ray use suggests that clinicians selected patients for 
referral on the basis of radiographic reports: this may represent a desire for clinical certainty prior 
to referral, symptom severity as a confounding factor, or an attempt to ration care. Given the 
association of template-derived indicator achievement with X-ray use within 14 days after a clinical 
OA consultation, it is possible that, for some patients, clinicians undertook a more in-depth 
approach to assessment and management of clinical OA, including the use of radiographic 
assessment even though this is not a recommended investigation. If the triggers for this more 
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thorough approach could be identified, it is possible that the higher level of quality might be 
achievable even with reduced used of X-rays, through appropriate clinician education and 
development. 
Had the intention been to implement the template as a quality improvement tool for OA in its own 
right, additional strategies could usefully have been considered such as additional training, 
customisation, and educational outreach. This approach would be more consistent with that 
adopted in the JIGAW implementations of the MOSAICS work, discussed under section 9.4, 
Proposals for implementation. Nevertheless, the template had a small-to-moderate effect on 
prescribing behaviours for the relatively safe pharmacological options. The model OA consultation 
was associated with increased use of written information and advice as well as physiotherapy 
referral and it is plausible that a template that instead acted more formally as a prompt to refer 
people might be capable of a similar effect. 
The reason for a lack of identified change in other aspects of care for OA after the model OA 
consultation training may have been due to various factors including baseline variation in recorded 
quality of care and high levels of baseline achievement in some indicators. The Good Life with 
osteoArthritis in Denmark (GLA:D) programme, which has some similarities with the MOSAICS 
model consultation, is reported344 [abstract] to have resulted in reduced levels of paracetamol, 
NSAIDs, or opioids after 3 months. A stepped care programme in the Netherlands (Beating 
osteoARThritis [BART]345) demonstrated high levels of use of most of the first-tier interventions, 
other than glucosamine, after two years of the programme (education 82%, lifestyle advice 73%, 
paracetamol 83%); exercise (a second tier intervention) was used by 63% of patients after two 
years.346 No control group was reported for either of these studies. It is not clear whether such 
success might be transferrable to a UK context but it would be consistent with the possibility that 
the lack of change in other indicators in the MOSAICS trial was due to other factors beyond lack of 
benefit. However, a previous UK general practice-based trial of a self-management programme for 
OA (involving a guidebook and up to six sessions of advice on self-management)347 did not show 
any effect on pain, function or contact with primary care, though there was an improvement in 
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anxiety and self-efficacy. There remains a need to identify how to translate the best evidence on 
treatments for OA into routine clinical practice.  
Potential targets for quality improvement initiatives are indicated by increased odds of 
achievement of relevant indicators with an OA diagnosis, multiple clinical OA consultation, and an 
index consultation with a clinician who conducted more than the median number of index 
consultations. The making of a diagnosis of OA where appropriate is regarded as intrinsically 
important as evidence by its inclusion in the NICE quality standards. It is not known whether the 
diagnosis itself prompts clinicians to adhere more closely to recommended management strategies, 
or whether the diagnosis and improved management are both associated with unobserved 
variables (confounders) in this study. It seems plausible that encouraging clinicians to make and 
record an accurate diagnosis of OA may prompt better guideline adherence as well as act as a basis 
for clinical audit. Multiple consultation associated with better indicator achievement was 
unsurprising, though it is not clear if this reflects only greater opportunity to treat, a more 
consumerist patient philosophy, or greater disease severity. Given that OA is known to be 
marginalised in consultations,62 greater opportunity to manage it proactively might be beneficial, 
possibly through a structured chronic disease review in combination with other relevant conditions 
(for example, linked with cardio-metabolic conditions that would also benefit from a focus on 
weight and exercise). The link with clinician index consultation count would warrant further 
exploration. It is possible that some clinicians have either a low OA workload, or that OA 
consultations with those clinicians go frequently uncoded and are less concordant with guidelines. 
Feedback and education, possibly coupled with structured patient recall systems, may improve care 
for these clinicians’ patients. Given the associations between greater morbidity levels (higher drug 
chapter counts) and reduced odds of recorded pain and function assessment and exercise advice, 
it is possible that a greater emphasis on non-pharmacological management may help rebalance 
assessment and management to be more consistent with the NICE guidelines. 
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 Quality indicators as trial outcomes 
A potentially important aspect of quality indicators as trial outcomes, such as in cluster trials, is the 
ability to use larger samples of patients and the reduction of the potential for selection bias in trial 
recruitment. Attrition during the trial would also be less likely as the outcomes depend on data 
collected through routine clinical contacts. The indicators demonstrated some capability to 
discriminate between the intervention and control trial arms, relating to the provision of written 
information and physiotherapy referral. Lack of discrimination on the basis of other indicators may 
have been related to the variation in baseline performance between trial arms.  
Where there is a strong link between aspects of care suitable for quality indicators and relevant 
trial outcomes, it seems that their use as outcome measures in place of other more traditional 
measures may be appropriate. In a study protocol for a cluster trial of implementation of 
international OA treatment guidelines,348 Østerås et al. have specified the use of patient self-
reported OA quality indicators (which were not dissimilar to those used in MOSAICS) as the primary 
outcome. However, the most feasible indicators would be those that can be measured through the 
routine medical record, since bespoke recording systems appear to have some effect on clinical 
practice that may make determination of the effects of another intervention more complex (by 
inflating baseline achievement and apparently weakening any independent effect of another 
intervention). As discussed in Chapter Three, section 3.8, a smartphone application to facilitate 
writing a patient’s own data to the EHR would be one way to facilitate this.  
9.4 Proposals for implementation 
From the systematic review, a need for structured implementation of the quality indicators had 
need identified. The indicators derived from this review have been used in the development of 
patient-reported OA quality indicators.349 
I had originally envisaged that the result of the research work would be a good candidate for a 
future iteration of the QOF,170 especially supplemented by the work to define clinical OA in general 
practice records. However, there have been major criticisms of the QOF as a vehicle for delivering 
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improved care in general practice350-352 and, with the reducing number of points available for quality 
work contained within the QOF,170 this now seems a less feasible strategy for implementation.  
For OA, the core aspects of management overlap heavily with those for other conditions (education, 
exercise, and weight loss). With the increasingly recognised and burgeoning public health problems 
of inactivity and obesity,353 there is a need across morbidities to promote interventions that tackle 
these problems. It is the role of NICE and commissioners of health and public health services to 
determine which interventions are clinically and cost-effective and for clinicians to participate 
appropriately in signposting to or delivering these: quality indicators can play a useful role in 
recording which patients with a capacity to benefit have been referred and facilitating peer-
referencing and audit.  
Since the publication of the systematic review paper107 and the paper that describes the effect of 
the template on recorded quality of care,99 other routes to implementation have opened. The NICE 
(2014) OA management guidelines reference the systematic review findings as one example of 
research impact. There is a substantial overlap between the quality indicators that resulted from 
the systematic review in Chapter Two and the NICE Quality Standards for the care of OA,334 relating 
to assessment of pain and function, exercise, weight loss, and use of core interventions before 
referral for consideration of surgery. One of the NICE-endorsed resources to support the OA quality 
standards is the template described in Chapter Three, section 3.4.†† The extent of update of the 
NICE OA quality standards in primary care is not known. NICE maintains a list of uptake data354 and 
as at 08/09/2016, OA did not appear in the list of uptake data. However, for many of the other 
clinical conditions, the level of uptake is unclear (due to missing data) or suboptimal.  
The findings of the research into the effects of the template as described in Chapter Seven, coupled 
with OA as a traditionally neglected condition in general practice and its status as a condition 
causing substantial secondary care expenditure, have been enough for all but one MOSAICS 
 
††For more information about the template as a NICE-endorsed resource, see 
https://www.nice.org.uk/guidance/qs87/resources/endorsed-resources-the-osteoarthritis-etemplate-
552602701 [accessed 25/08/2016] 
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practices to wish to continue with the use of the template. Additionally, a local Clinical 
Commissioning Group (CCG) has developed a Local Enhanced Service for GPs in fifteen pilot 
practices to participate in improving care for OA, based on (i) model OA consultation training and 
support materials (ii) use of the indicators and (iii) template with an associated programme of data 
collection with audit and reflection. This local roll-out of the model OA consultation with template 
is referred to as Joint Implementation of Guidelines for oSteoArthritis in the West Midlands 
(JIGSAW). 
Internationally, Professor Dziedzic has led a modification of JIGSAW, referred to as JIGSAW-E, which 
has been granted funding from the European Union via the European Institute of Innovation and 
Technology‡‡ (EIT-Health) to collaborate on the implementation of a similar system of enhanced OA 
care in Denmark, the Netherlands, Norway, and Portugal. This will include local adaptations of the 
template to prompt and record OA care. The candidate is a member of the JIGSAW and JIGSAW-E 
teams, advising on template implementation and evaluation.  
9.5 Research implications 
Quality indicators have an established use in medical audit and quality improvement programmes 
as a means of testing the success of other quality improvement initiatives rather than a means of 
quality improvement in their own right. The extent to which their use causes an improvement in 
quality of care independently of other initiatives is unclear.  
Variation in quality of care is a priority for policy makers who see unwarranted variation as an 
indication of a need for quality improvement as well as a cause of excess expenditure; reminder 
systems have been identified as one intervention to reduce variation.355 The extent of baseline 
variation seen in this analysis implies that much work remains to be done in identifying and reducing 
variation in quality of care. The template-derived indicators were associated with a relatively 
substantial degree of variation explained at the level of the clinician, by unobserved factors. There 
 
‡‡For further information about the work of EIT-Health, see https://eit.europa.eu/eit-community/eit-health 
[accessed 24/08/2016] 
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is also a need to improve adherence to guidelines more generally, for example in the use of X-rays, 
since their use is unnecessary for diagnosis and their use in management decisions is also not 
recommended due to poor linkage between symptoms and radiographic changes.  
Further work is needed to understand how well recorded quality indicators reflect the actual level 
of quality of care delivered, and that experienced by the patient. Also, the reduced frequency of 
template completion in the trial period suggests that the template may not be durable as a means 
of measuring and changing clinician behaviour (with respect to prescribing and weight recording, 
as noted in Chapter Seven). The causes for this reduction should be investigated in further work to 
determine whether there are adjustments that maintain the usefulness of the template as a clinical 
prompt and as a means for collecting data for subsequent clinical audit. 
Given the known problems with pharmacological management of OA (drug effectiveness and side 
effects,139,356 and the lack of disease-modifying agents357), it is disappointing that there was not 
more of a recorded focus on the non-pharmacological management of OA. Strategies known to be 
potentially effective (exercise, predominantly, supplemented with the other core interventions of 
education and weight loss where appropriate) have been shown not to be consistently 
recommended and recorded within the primary care record. Continued efforts to identify effective 
implementation of non-pharmacological management strategies within primary care are needed.  
9.6 Conclusion 
Despite the availability of suitable quality indicators for OA in general practice, only a limited range 
of aspects of quality of care can be measured through routinely-recorded information. This suggests 
that the longstanding arguments for better data quality and quantity to enable assessment of the 
quality of care have yet to make an impact in OA care.  
Although there is variation in recorded quality of care between clinicians, templates such as that 
used in this study hold promise for enhancement of the routine EMR to facilitate the primary care 
of OA though information continuity and to form the basis of medical audit and other quality 
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improvement initiatives that require continuous data collection. Data collected in this way is 
capable of detecting change in aspects of OA care over time. 
In the future, two particular aspects of quality should be explored further: the variation between 
clinicians in recorded care and engagement with quality improvement initiatives needs to be 
understood and reduced, and the link between quality of care as recorded in the medical record 
and experienced by patients requires further investigation.  
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[ggc3((jjj'VXU`'aXg(\aWXk'Tfck6b5*)+.
+- ;T`cUX__ KE% ;Tage\__ B8' ;bafXafhf `Xg[bWf \a ceXfVe\U\aZ eXfXTeV[' / )FDH 3C<LG
7C@L +))*4+/3.#*-'
+. ?XeTXWgf E8P% KX_U`Taa @&C% G__XafV[_TXZXe ?' ;e\g\VT_ TcceT\fT_ bY V_\a\VT_
cXeYbe`TaVX `XTfheXf \a ?Xe`Tal' .HN / 4O<F -@<FNC )<L@ +)),4*.302'
+/ ETef[T__ EF% K[X^X__X H?% EV?_laa =8% @N <F' ;Ta [XT_g[ VTeX dhT_\gl \aW\VTgbef UX
geTafYXeeXW UXgjXXa Vbhage\Xf6 4O<F 6<A -@<FNC )<L@ +)),4*+31#*+'
+0 Ob__Xef[X\` @% @Xe`Xaf J% @h_fV[Xe E% @N <F' ;_\a\VT_ \aW\VTgbef3 WXiX_bc`Xag TaW
Tcc_\VTg\baf' 1@NC / 0@? +))04/.3*.#++'
+1 9bXef E% 9ebb^f H% KgeTaW ;N% @N <F' L[X GE=J8;L !_gXe Ybe GhgVb`X EXTfheXf \a
J[Xh`Tgb_bZl' / 5C@OG<NIF *2214+.3*21#2'
+2 CXee =% 8fV[ K% @T`\_gba =% @N <F' 4O<FDNS IA ><L@ AIL B@H@L<F G@?D><F >IH?DNDIHM& <
L@PD@Q IA NC@ FDN@L<NOL@ <H? KO<FDNS DH?D><NILM' KTagT Eba\VT% ;83 J8F< @XT_g[%
+)))'
,) EV?_laa =% 8fV[ K% 8WT`f B% @N <F' L[X dhT_\gl bY [XT_g[ VTeX WX_\iXeXW gb TWh_gf \a
g[X Ma\gXW KgTgXf' 1@Q +HBF / 0@? +)),4,-13+/,.'
,* 8fV[ K% EV?_laa =% @bZTa E% @N <F' ;b`cTe\fba bY IhT_\gl bY ;TeX Ybe HTg\Xagf \a
g[X NXgXeTaf @XT_g[ 8W`\a\fgeTg\ba TaW HTg\Xagf \a T FTg\baT_ KT`c_X' 'HH .HN@LH
0@? +))-4*-*32,1'
,+ ETVDXTa ;' IhT_\gl \aW\VTgbef Ybe g[X `TaTZX`Xag bY bfgXbTeg[e\g\f \a ih_aXeTU_X
X_WXef' 'HH .HN@LH 0@? +))*4*,.30**'
,, K[X^X__X H% ETVDXTa ;% Ebegba K% @N <F' 8ffXff\aZ ;TeX bY Nh_aXeTU_X =_WXef3 EXg[bWf
Ybe <XiX_bc\aZ IhT_\gl AaW\VTgbef' 'HH .HN@LH 0@? +))*4*,.#1 HTeg +$3/-0'
,- OXaZXe F% Kb_b`ba <% Jbg[ ;% @N <F' L[X IhT_\gl bY EXW\VT_ ;TeX Hebi\WXW gb
Nh_aXeTU_X ;b``ha\gl&<jX__\aZ G_WXe HTg\Xagf' 'HH .HN@LH 0@? +)),4*,230-)'
,. ;[bWbf[ B% Kb_b`ba <% Jbg[ ;% @N <F' L[X dhT_\gl bY `XW\VT_ VTeX cebi\WXW gb
ih_aXeTU_X b_WXe cTg\Xagf j\g[ V[eba\V cT\a' / 'G ,@LD<NL 6I> +))-4.+30./'
,/ @\ZTf[\ L% K[X^X__X H% Kb_b`ba <% @N <F' L[X IhT_\gl bY H[Te`TVb_bZ\V ;TeX Ybe
Nh_aXeTU_X G_WXe HTg\Xagf' 'HH .HN@LH 0@? +))-4*-)30*-'
,0 @\ZTf[\ L% K[X^X__X H% 8WT`f B% @N <F' IhT_\gl bY ;TeX Af 8ffbV\TgXW j\g[ Khei\iT_ \a
Nh_aXeTU_X G_WXe HTg\Xagf' 'HH .HN@LH 0@? +)).4*-,3+0-'
,1 ?Tam <% ;[TaZ B% Jbg[ ;% @N <F' IhT_\gl bY bfgXbTeg[e\g\f VTeX Ybe
Vb``ha\gl&WjX__\aZ b_WXe TWh_gf' 'LNCLDNDM 5C@OG +))/4..3+-*'
,2 ETVDXTa ;% Dbh\X J% K[X^X__X H% @N <F' ;b`cTe\fba bY TW`\a\fgeTg\iX WTgT TaW
`XW\VT_ eXVbeWf gb `XTfheX g[X dhT_\gl bY `XW\VT_ VTeX cebi\WXW gb ih_aXeTU_X b_WXe
cTg\Xagf' 0@? )<L@ +))/4--3*-*'
-) pfgXeqf F% ?TeeTgg 8% ?ebg_X E% @N <F' HTg\Xag&eXcbegXW dhT_\gl bY VTeX Ybe
bfgXbTeg[e\g\f3 WXiX_bc`Xag TaW gXfg\aZ bY g[X bfgXbTeg[e\g\f dhT_\gl \aW\VTgbe
dhXfg\baaT\eX' 'LNCLDNDM )<L@ 5@M +)*,4/.3*)-,#.*'
-* KgXX_ F% EX_mXe <% K[X^X__X H% @N <F' <XiX_bc\aZ dhT_\gl \aW\VTgbef Ybe b_WXe
TWh_gf3 geTafYXe Yeb` g[X MK8 gb g[X MC \f YXTf\U_X' 4O<F 6<A -@<FNC )<L@
+))-4*,3+/)'
-+ KT_\UT <% Kb_b`ba <% JhUXafgX\a D% @N <F' IhT_\gl \aW\VTgbef Ybe g[X `TaTZX`Xag bY
`XW\VT_ VbaW\g\baf \a ahef\aZ [b`X eXf\WXagf' / 'G 0@? *DL 'MMI> +)).4/3K,/'
-, ;TWbZTa E% KV[aX__X B% 8_&KT``TeeT\ F% @N <F' 8 fgTaWTeW\mXW dhT_\gl TffXff`Xag
flfgX` gb XiT_hTgX cT\a WXgXVg\ba TaW `TaTZX`Xag \a g[X ahef\aZ [b`X' / 'G
0@? *DL 'MMI> +)).4/3*'
-- R\aZ`baW <K% KT_\UT <% O\_UXe C@% @N <F' EXTfhe\aZ g[X dhT_\gl bY VTeX cebi\WXW gb
WhT__l Xaeb__XW `XW\VTeX TaW `XW\VT\W UXaX!V\Te\Xf _\i\aZ \a ahef\aZ [b`Xf' 0@?
)<L@ +))24-03.,/'
-. K`\g[ C% Kbe\Tab L% 9bT_ B' 9e\XY Vb``ha\VTg\ba3 FTg\baT_ dhT_\gl&bY&VTeX fgTaWTeWf
\a [b`X&UTfXW ce\`Tel VTeX' 'HH .HN@LH 0@? +))04*-/3*11'
-/ OXaZXe F% Jbg[ ;% K[X^X__X H% @N <F' AagebWhVg\ba gb g[X 8ffXff\aZ ;TeX bY
Nh_aXeTU_X =_WXef&, dhT_\gl \aW\VTgbe `XTfheX`Xag fXg' / 'G ,@LD<NL 6I> +))04
..3K+-0'
-0 8;GN= AaiXfg\ZTgbef' 8ffXff\aZ ;TeX bY Nh_aXeTU_X =_WXef$,3 IhT_\gl AaW\VTgbef'
/ 'G ,@LD<NL 6I> +))04..#Khcc_ +$3K-/-'
-1 ETVDXTa ;% HXaV[Tem B% KTTZ C' IhT_\gl \aW\VTgbef Ybe g[X VTeX bY bfgXbTeg[e\g\f \a
ih_aXeTU_X X_WXef' / 'G ,@LD<NL 6I> +))04..#Khcc_ +$3K,1,'
-2 ETef[T__ E% ;T`cUX__ K% @TV^Xe B% @N <F' XWf' 4O<FDNS DH?D><NILM AIL B@H@L<F JL<>ND>@'
DbaWba3 JKE HeXff% +))+'
.) C\e^ K% ;T`cUX__ K% CXaaX__&OXUU K% @N <F' 8ffXff\aZ g[X dhT_\gl bY VTeX bY `h_g\c_X
VbaW\g\baf \a ZXaXeT_ ceTVg\VX3 ceTVg\VT_ TaW `Xg[bWb_bZ\VT_ cebU_X`f' 4O<F 6<A
-@<FNC )<L@ +)),4*+3-+*'
.* ETVDXTa ;% KTTZ CK% Kb_b`ba <% @N <F' EXTfhe\aZ dhT_\gl \a Teg[e\g\f VTeX3 `Xg[bWf
Ybe WXiX_bc\aZ g[X 8eg[e\g\f >bhaWTg\ba"f dhT_\gl \aW\VTgbe fXg' 'LNCLDNDM 5C@OG
+))-4.*3*2,'
.+ HXaV[Tem B% ETVDXTa ;' EXTfhe\aZ dhT_\gl \a Teg[e\g\f VTeX3 g[X 8eg[e\g\f
>bhaWTg\ba"f IhT_\gl AaW\VTgbe fXg Ybe bfgXbTeg[e\g\f' 'LNCLDNDM 5C@OG +))-4.*3.,1'
., D\ D% KTleX =% CbcXV B% @N <F' IhT_\gl bY abac[Te`TVb_bZ\VT_ VTeX \a g[X Vb``ha\gl
Ybe cXbc_X j\g[ ^aXX TaW [\c bfgXbTeg[e\g\f' / 5C@OG<NIF +)**4,13++,)'
.- 8`Xe\VTa 8VTWX`l bY Geg[bcTXW\V KheZXbaf% H[lf\V\Ta ;bafbeg\h` Ybe HXeYbe`TaVX
A`cebiX`Xag' GfgXbTeg[e\g\f3 H[lf\V\Ta HXeYbe`TaVX EXTfheX`Xag KXg' +))/' [ggc3((
jjj'TTbf'beZ(eXfXTeV[(Vb``\ggXX(Xi\WXaVX(H;HASEXTfheXfSGfgXbTeg[e\g\f'cWY
.. =MEMK;'aXg' @XT_g[ VTeX dhT_\gl \aW\VTgbef Ybe G8' +)*+' [ggc3((jjj'Xh`hfV'aXg(
jbe^cTV^TZXfSjc/'VY`
./ @\ZZ\af BHL% ?eXXa K' XWf' )I>CL<H@ -<H?=IIE AIL 6SMN@G<ND> 5@PD@QM IA .HN@LP@HNDIHM
8@LMDIH %!#!" 9OJ?<N@? 0<L>C $"##;' L[X ;bV[eTaX ;b__TUbeTg\ba% +)**'
.0 @bhfX bY ;b``baf ;b``\ggXX bY HhU_\V 8VVbhagf' *@J<LNG@HN IA -@<FNC&
3L@M>LD=DHB >IMNM DH JLDG<LS ><L@' DbaWba3 L[X KgTg\baXel GY!VX D\`\gXW% +))0'
.1 F@K =`c_blXef' IhT_\gl " GhgVb`Xf >eT`Xjbe^' +)*,' [ggc3((jjj'a[fX`c_blXef'
beZ(HTl8aW;bageTVgf(?XaXeT_EXW\VT_KXei\VXf;bageTVg(IG>(HTZXf(IhT_\glGhgVb`Xf
>eT`Xjbe^'Tfck
+HEJE?=H =J@ ALE@AIEKHKCE?=H NAOA=N?D
-21 =WjTeWf BB% @N <F' 'HH 5C@OG *DM +)*.4'&3-2)#-21' Wb\3*)'**,/(Taae[Xh`W\f&+)*,&+),2*,
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Ih_]_dWb Whj_Yb[
D[HSPZ^ VM JHXL MVX B42 ZOL LMMLJZ VM H WVPUZ&VM&JHXL
JVUY[SZHZPVU XLJVXKPUN ZLTWSHZL
>VOU >' 8K]HXKY)% ?LS\PU C' >VXKHU)% ;LVXNL CLHZ)% >VOU 5LKYVU)%
CLZLX E' 6XVMZ)% 8SHPUL A' <H^) HUK ?X^YPH F' 7_PLK_PJ)
4IYZXHJZ
BIQLJZP\L' N^[ W_ci e\ j^_i ijkZo m[h[ je Z[j[hc_d[ j^[ \[Wi_X_b_jo e\ _djheZkY_d] W Yecfkj[h_p[Z j[cfbWj[
\eh _Z[dj_\o_d] gkWb_jo e\ YWh[ Zkh_d] Wd I; YedikbjWj_ed' Z[iYh_X[ gkWb_jo e\ I; YWh[ _d fhWYj_Y[i _d m^_Y^
j^[ j[cfbWj[ mWi _djheZkY[Z WdZ Wii[ii j^[ [\\[Yj e\ j^[ j[cfbWj[ ed hekj_d[bo h[YehZ[Z Yb_d_Y_Wd X[^Wl(
_ekh _d j^ei[ fhWYj_Y[i)
ALZOVKY' ; Yecfkj[h_p[Z j[cfbWj[ je Wii_ij j^[ h[YehZ_d] e\ YWh[ _d YedikbjWj_edi \eh fWj_[dji m_j^ I;
mWi _dijWbb[Z _d [_]^j ][d[hWb fhWYj_Y[i) ?b_]_Xb[ fWj_[dji m[h[ j^ei[ "/0 o[Whi e\ W][ Yedikbj_d] \eh
Yb_d_YWb I; Zkh_d] W 1 cedj^ f[h_eZ) N^[ cW_d ekjYec[i m[h[ \h[gk[dYo e\ j[cfbWj[ jh_]][h_d]' WY^_[l[(
c[dj e\ gkWb_jo _dZ_YWjehi Zkh_d] j^[ YedikbjWj_ed $Wii[iic[dj e\ fW_d WdZ \kdYj_ed' Wii[iic[dj \eh \_hij(
b_d[ WdWb][i_Yi' fhel_i_ed e\ _d\ehcWj_ed' [n[hY_i[ WZl_Y[' Yedi_Z[hWj_ed e\ f^oi_ej^[hWfo h[\[hhWb' m[_]^j
beii WZl_Y[% WdZ Y^Wd][ _d hekj_d[bo h[YehZ[Z Yb_d_Y_Wd X[^Wl_ekh $Z_W]deij_Y YeZ_d]' fh[iYh_X_d]' h[\[hhWb'
ki[ e\ hWZ_e]hWf^o' m[_]^j h[YehZi% YecfWh[Z m_j^ j^[ ,- cedj^i fh_eh je j[cfbWj[ _dijWbbWj_ed)
ELY[SZY' N^[ j[cfbWj[ mWi jh_]][h[Z \eh ,2.+ fWj_[dji) ;Y^_[l[c[dj e\ _dZ_YWjehi hWd][Z \hec .1" $\eh
Yedi_Z[hWj_ed e\ f^oi_ej^[hWfo h[\[hhWb% je 1." $\eh fW_d Wii[iic[dj%' m_j^ ikXijWdj_Wb lWh_WX_b_jo X[jm[[d
Yb_d_Y_Wdi) N^[h[ mWi Wd _dYh[Wi[ _d fh[iYh_fj_ed e\ h[Yecc[dZ[Z \_hij(b_d[ WdWb][i_Yi \ebbem_d] j^[ j[c(
fbWj[ _dijWbbWj_ed5 fWhWY[jWceb UeZZi hWj_e $IL% ,)/4 $40" =C ,)--' ,)3-% YecfWh[Z m_j^ fh[(j[cfbWj[V WdZ
jef_YWb HM;C>i UIL ,)40 $40" =C ,)1,' -).0%V)
6VUJS[YPVU' N^_i d[m j[cfbWj[ _i W \[Wi_Xb[ jeeb \eh YWfjkh_d] ZWjW Zkh_d] I; YedikbjWj_edi je W_Z Wi(
i[iic[dj e\ gkWb_jo e\ YWh[) Cj mWi WiieY_Wj[Z m_j^ i_]d_\_YWdj _cfhel[c[dji _d h[Yecc[dZ[Z YWh[
fheY[ii[i) Bem[l[h' ijhWj[]_[i Wh[ d[[Z[Z je [dikh[ Yedi_ij[dj WffheWY^[i X[jm[[d Yb_d_Y_Wdi)
GXPHS XLNPYZXHZPVU' ^jjf5**mmm)Yedjhebb[Z(jh_Wbi)Yec*CML=NH+143/1,2*ceiW_Yi)
?L^ ]VXKY2 eij[eWhj^h_j_i' fh_cWho YWh[' gkWb_jo _dZ_YWjeh' h[c_dZ[h ioij[ci' c[Z_YWb h[YehZ ioij[ci'
Yecfkj[h_p[Z)
=UZXVK[JZPVU
I; _i W b[WZ_d] YWki[ e\ Z_iWX_b_jo5 j^[ AbeXWb <khZ[d e\
>_i[Wi[ -+,+ hWda[Z I; ,,j^ _d j^[ ]beXWb YWki[i e\
o[Whi b_l[Z m_j^ Z_iWX_b_jo U,V) ; h[Y[dj h[l_[m e\ j^[ OEri
^[Wbj^ f[h\ehcWdY[ YedYbkZ[Z j^Wj q_dj[hl[dj_edi Wh[
WlW_bWXb[ \eh ckiYkbeia[b[jWb Z_iehZ[hi' Xkj je m^Wj
[nj[dj j^[ ^[Wbj^ ioij[c _i Z[b_l[h_d] _i kdYb[Whr U-V)
Ak_Z[b_d[i h[Yecc[dZ W hWd][ e\ [l_Z[dY[(XWi[Z jh[Wj(
c[dj efj_edi \eh I; U.!3V' WdZ o[j ?khef[Wd WdZ ej^[h
ikhl[oi ^Wl[ Z[cedijhWj[Z ikXefj_cWb cWdW][c[dj
YecfWh[Z m_j^ ]k_Z[b_d[ h[Yecc[dZWj_edi' _dYbkZ_d]
kdZ[hki[ e\ ded(f^WhcWYebe]_YWb c[Wikh[i' _dYbkZ_d]
[n[hY_i[ WdZ m[_]^j beii' WdZ ikXefj_cWb f^WhcWYe(
be]_YWb cWdW][c[dj U4!,.V) Geij ^[Wbj^ YWh[ YedjWYji
\eh I; eYYkh m_j^_d fh_cWho YWh[) Cd j^[ OE' /" e\
WZkbji W][Z "/0 o[Whi Yedikbj \eh Z_W]dei[Z I; [WY^
o[Wh' m_j^ j^[ fh[lWb[dY[ h_i_d] m_j^ W][ U,/V) N^_i [gkWj[i
je ceh[ j^Wd W c_bb_ed f[efb[ _d j^[ OE Yedikbj_d] fh_cWho
YWh[ \eh I; _d W o[Wh' WdZ 3)20 c_bb_ed f[efb[ _d j^[ OE
^Wl[ iek]^j jh[Wjc[dj \eh I; U,0V) ;bj^ek]^ j^[h[ Wh[ de
,;hj^h_j_i L[i[WhY^ OE Jh_cWho =Wh[ =[djh[' L[i[WhY^ Cdij_jkj[ \eh
Jh_cWho =Wh[ WdZ B[Wbj^ MY_[dY[i' E[[b[ Od_l[hi_jo' OE
=ehh[ifedZ[dY[ je5 De^d D) ?ZmWhZi' ;hj^h_j_i L[i[WhY^ OE Jh_cWho
=Wh[ =[djh[' L[i[WhY^ Cdij_jkj[ \eh Jh_cWho =Wh[ MY_[dY[i' E[[b[
Od_l[hi_jo' E[[b[ MN0 0<A' OE) ?(cW_b5 `)`)[ZmWhZi9a[[b[)WY)ka
MkXc_jj[Z -- DWdkWho -+,/6 h[l_i[Z l[hi_ed WYY[fj[Z -, ;k]kij -+,/
" N^[ ;kj^eh -+,/) JkXb_i^[Z Xo In\ehZ Od_l[hi_jo Jh[ii ed X[^Wb\ e\ j^[ <h_j_i^ MeY_[jo \eh L^[kcWjebe]o)
N^_i _i Wd If[d ;YY[ii Whj_Yb[ Z_ijh_Xkj[Z kdZ[h j^[ j[hci e\ j^[ =h[Wj_l[ =eccedi ;jjh_Xkj_ed Hed(=ecc[hY_Wb F_Y[di[ $^jjf5**Yh[Wj_l[Yeccedi)eh]*b_Y[di[i*Xo(dY*/)+*%' m^_Y^ f[hc_ji ded(Yecc[hY_Wb h[(ki['
Z_ijh_Xkj_ed' WdZ h[fheZkYj_ed _d Wdo c[Z_kc' fhel_Z[Z j^[ eh_]_dWb meha _i fhef[hbo Y_j[Z) @eh Yecc[hY_Wb h[(ki[' fb[Wi[ YedjWYj `ekhdWbi)f[hc_ii_edi9ekf)Yec
)%#+'"*(&($,
L^[kcWjebe]o -+,060/53//!30.
Ze_5,+),+4.*h^[kcWjebe]o*a[k/,,
;ZlWdY[ ;YY[ii fkXb_YWj_ed -+ IYjeX[h -+,/
=
F
CH
C=
;
F
M
=
C?
H
=
?
W]h[[Z X[dY^cWhai \eh f[h\ehcWdY[' j^[h[ _i W
h[Ye]d_p[Z d[[Z je _cfhel[ cWdo Wif[Yji e\ fh_cWho
YWh[ \eh I; U,1V)
KkWb_jo e\ YWh[ _d ][d[hWb fhWYj_Y[ _i ][d[hWbbo Wii[ii[Z
ki_d] fheY[ii e\ YWh[ c[Wikh[i U,2V) @eh I;' j^[i[ YekbZ
h[bWj[ je fWj_[dj Wii[iic[dj' _dl[ij_]Wj_ed' _d\ehcWj_ed
fhel_i_ed' f^WhcWYebe]_YWb WdZ ded(f^WhcWYebe]_YWb
cWdW][c[dj WdZ h[\[hhWb U,3V) N^[ _dZ_YWjehi ceij \[Wi(
_Xbo _cfb[c[dj[Z Z[f[dZ ed fh[iYh_X_d] ZWjW' m^_Y^ _d
j^[ OE _i ][d[hWbbo [b[Yjhed_YWbbo h[YehZ[Z WdZ [Wi_bo
WkZ_j[Z) N^[h[ Wh[ Z_\\_Ykbj_[i m_j^ hekj_d[ ki[ e\ ej^[h
fej[dj_Wb _dZ_YWjehi Zk[ je fheXb[ci m_j^ _Z[dj_\_YWj_ed e\
j^ei[ h[Y[_l_d] j^[ YWh[ fheY[ii $dkc[hWjeh% WdZ j^ei[
[b_]_Xb[ \eh ikY^ YWh[ $Z[dec_dWjeh%) @eh [nWcfb[' j^[
d[[Z \eh WdZ ki[ e\ _dl[ij_]Wj_edi WdZ h[\[hhWb Wh[ dej
Yedi_ij[djbo m[bb(YWfjkh[Z Xo j^[ fh_cWho YWh[ [b[Yjhed_Y
h[YehZ)
=ecfkj[h_p[Z j[cfbWj[i eh fe_dj(e\(YWh[ h[c_dZ[hi
^Wl[ X[[d i^emd je ^Wl[ icWbb je ceZ[hWj[ [\\[Yji _d
_cfhel_d] j^[ gkWb_jo e\ YedikbjWj_edi U,4!--V) N^_i cWo
X[ Zk[ fWhjbo je X[jj[h h[YehZ_d]' Xkj _j ^Wi Wbie X[[d
Wjjh_Xkj[Z je _cfhel[Z fheY[ii[i e\ YWh[ U,4V) ; jh[dZ
^Wi X[[d _Z[dj_\_[Z jemWhZ ]h[Wj[h [\\[Yji \eh h[c_dZ[hi
j^Wj h[gk_h[ Wd WYj_l[ h[ifedi[ \hec j^[ Yb_d_Y_Wd U--V)
Ib_l[h U-.V Z[iYh_X[Z W j[cfbWj[ \eh j^[ ckbj_Z_iY_fb_dWho
Wii[iic[dj e\ I; WdZ L;' j^ek]^ j^[h[ _i W bWYa e\ [l_(
Z[dY[ je Z[iYh_X[ j^[ _cfb[c[djWj_ed WdZ [\\[Yj e\ Yec(
fkj[h j[cfbWj[i _d j^[ cWdW][c[dj e\ I;)
N^[ eX`[Yj_l[i e\ j^_i ijkZo m[h[' j^hek]^ W del[b _c(
fb[c[djWj_ed e\ iec[ e\ j^[ fh_dY_fb[i e\ Yecfkj[h_p[Z
j[cfbWj[i' je Z[j[hc_d[ j^[ \[Wi_X_b_jo e\ _djheZkY_d]
ikY^ W j[cfbWj[ \eh _Z[dj_\_YWj_ed e\ gkWb_jo e\ YWh[
Zkh_d] Wd I; YedikbjWj_ed' Z[iYh_X[ gkWb_jo e\ YWh[ \eh
I; YedikbjWj_edi _d fhWYj_Y[i _d m^_Y^ j^[ j[cfbWj[ mWi
_djheZkY[Z WdZ Wii[ii j^[ [\\[Yj e\ j^[ j[cfbWj[ ed Yb_d(
_Y_Wd X[^Wl_ekh' _dYbkZ_d] f^WhcWYebe]_YWb WdZ iec[
ded(f^WhcWYebe]_YWb Wif[Yji e\ cWdW][c[dj)
ALZOVKY
N^_i ijkZo mWi _d jme fWhji) N^[ \_hij mWi Wd Wii[iic[dj
e\ gkWb_jo e\ YWh[ \eh I; _d fh_cWho YWh[ ki_d] ZWjW Yeb(
b[Yj[Z j^hek]^ W d[m fe_dj(e\(YWh[ YedikbjWj_ed h[YehZ_d]
j[cfbWj[ el[h W 1 cedj^ f[h_eZ) N^[ i[YedZ mWi W
X[\eh[(WdZ(W\j[h ijkZo ki_d] hekj_d[bo h[YehZ[Z cWdW][(
c[dj WYj_edi Wi W c[Wdi je [ij_cWj[ j^[ [\\[Yj e\ j^[
j[cfbWj[ ed j^[ cWdW][c[dj e\ I; _d fh_cWho YWh[) N^[
ijkZo mWi d[ij[Z m_j^_d W m_Z[h h[i[WhY^ fhe]hWcc[ Uj^[
GWdW][c[dj e\ Iij[eWhj^h_j_i _d =edikbjWj_edi
$GIM;C=M% ijkZoV Z[i_]d[Z je _dl[ij_]Wj[ [\\[Yj_l[ mWoi
je _cfb[c[dj dWj_edWb ]k_Z[b_d[i \eh fh_cWho YWh[ jh[Wj(
c[dj e\ I; U.V)
N^[ ijkZo mWi i[j _d [_]^j ][d[hWb fhWYj_Y[i m_j^ lWb_(
ZWj[Z ZWjW gkWb_jo _d j^[ Q[ij G_ZbWdZi WdZ Hehj^ Q[ij e\
?d]bWdZ j^Wj lWh_[Z _d j^[ i_p[ e\ j^[ fWj_[dj fefkbWj_ed'
Yb_d_YWb ijW\\_d]' khXWd_pWj_ed WdZ beYWb Z[fh_lWj_ed U-/V)
N^[ fhWYj_Y[i h[Y[_l[Z \kdZ_d] \eh WZZ_j_edWb Yeiji e\ fWh(
j_Y_fWj_ed' Z[f[dZ[dj kfed j^[_h [nf[Yj[Z YedikbjWj_ed
fh[lWb[dY[ \eh I; Xkj dej kfed ijkZo f[h\ehcWdY[)
; Yecfkj[h_p[Z j[cfbWj[ je h[YehZ cWdW][c[dj Zkh_d]
Wd I; YedikbjWj_ed \eh ki[ _d ][d[hWb fhWYj_Y[i mWi Z[(
l[bef[Z $ikffb[c[djWho @_]) M,' WlW_bWXb[ Wj
%+)4.&30-0*6 Idb_d[%) N^[ Yedj[dj e\ j^[ j[cfbWj[ mWi
Z[j[hc_d[Z \hec W ioij[cWj_Y h[l_[m e\ gkWb_jo _dZ_YWjehi
\eh j^[ fh_cWho YWh[ e\ I; U,3V) N^[ gkWb_jo _dZ_YWjehi
h[bWj[Z je Wif[Yji e\ I; cWdW][c[dj kdb_a[bo je X[ YWf(
jkh[Z _d c[Z_YWb h[YehZi WdZ h[\b[Yj[Z Wif[Yji e\ j^[ OE
HWj_edWb Cdij_jkj[ e\ B[Wbj^ WdZ =Wh[ ?nY[bb[dY[ $HC=?%
-++3 ]k_Z[b_d[i \eh j^[ cWdW][c[dj e\ I; U.V) N^[ _dZ_(
YWjehi Wh[ i^emd _d NWXb[ ,' je][j^[h m_j^ fh[Z[j[hc_d[Z
h[ifedi[ efj_edi WdZ Yh_j[h_W \eh WY^_[l[c[dj) N^[ j[c(
fbWj[ Wbie \WY_b_jWj[Z j^[ [djho e\ m[_]^j c[Wikh[c[dji je
YWbYkbWj[ <GC) =b_d_Y_Wdi YekbZ [dj[h ZWjW Yedj[cfehWd(
[ekibo j^hek]^ekj W YedikbjWj_ed eh Yecfb[j[ j^[ j[c(
fbWj[ Wj j^[ YedikbjWj_ed [dZ) N^[ Yb_d_Y_Wd YekbZ h[YehZ
[djh_[i \eh Wbb j^[ j[cfbWj[' \eh i[b[Yj[Z fWhji eh XofWii
j^[ [dj_h[ j[cfbWj[)
N^[ j[cfbWj[ mWi jh_]][h[Z Xo [djho e\ Wd I; YeZ[' eh
i[b[Yj[Z `e_dj fW_d YeZ[i Yedi_Z[h[Z je h[fh[i[dj W meha(
_d] Z_W]dei_i e\ I;' \eh fWj_[dji "/0 o[Whi e\ W][ Yed(
ikbj_d] Wj j^[ fhWYj_Y[' Xo j[b[f^ed[ eh Xo ^ec[ l_i_j _d j^[
1 cedj^i W\j[h j[cfbWj[ _dijWbbWj_ed) Cd OE fh_cWho YWh['
cehX_Z_j_[i Wh[ [dj[h[Z ki_d] j^[ L[WZ ioij[c e\ YeZ_d])
Ikh fh[l_eki meha Z[cedijhWj[Z j^Wj Yb_d_Y_Wdi ki[ L[WZ
YeZ[i _d #40" e\ Wbb YedikbjWj_edi U-/V) L[b[lWdj `e_dj
fW_d YeZ[i \hec j^[ L[WZ ^_[hWhY^o m[h[ Z[j[hc_d[Z Xo
W fWd[b e\ i_n ][d[hWb fhWYj_j_ed[hi $AJi% m_j^ Wd _dj[h[ij _d
ckiYkbeia[b[jWb YedZ_j_edi) N^[ j[cfbWj[ mWi j[ij[Z \eh
fhWYj_YWb_jo _d jme ded(ijkZo fhWYj_Y[i fh_eh je j^[ ijkZo)
NhW_d_d] mWi fhel_Z[Z je Wbb Yb_d_Y_Wdi _d j^[ fWhj_Y_fWj_d]
fhWYj_Y[i Wj j^[ j_c[ e\ j[cfbWj[ _dijWbbWj_ed $Dkd[!;k]kij
-+,,%) N^_i Yedi_ij[Z e\ W c[[j_d] X[jm[[d Wd WYWZ[c_Y
AJ \hec j^[ ijkZo j[Wc WdZ j^[ AJi WdZ fhWYj_Y[ dkhi[i
_d j^[ ijkZo fhWYj_Y[i) ;bj^ek]^ j^[ m_Z[h GIM;C=M ijkZo
Yedj[nj mWi [nfbW_d[Z je fhWYj_Y[i' j^_i mWi W Xh_[\ ][d(
[hWb el[hl_[m edbo WdZ j^[h[ mWi de _dYbki_ed e\ I; cWd(
W][c[dj WZl_Y[ eh jhW_d_d]) Cd eh_[djWj_d] Yb_d_Y_Wdi je j^[
j[cfbWj[' j^[h[ mWi Wd [cf^Wi_i ed hekj_d[ I; cWdW][(
c[dj WdZ ed h[ijh_Yj_d] ki[ e\ j^[ j[cfbWj[ je _cfhel[
h[YehZ_d] e\ Wif[Yji e\ j^Wj hekj_d[ Yb_d_YWb fhWYj_Y[ j^Wj
m[h[ Yedi_Z[h[Z h[b[lWdj Xo j^[ Yb_d_Y_Wdi) Cj mWi cWZ[
Yb[Wh j^Wj Yb_d_Y_Wdi YekbZ \_bb _d edbo j^ei[ Wif[Yji Yed(
i_Z[h[Z Wffhefh_Wj[ WdZ j^Wj j^[ m^eb[ j[cfbWj[ YekbZ X[
XofWii[Z _\ dej Yedi_Z[h[Z h[b[lWdj \eh W fWhj_YkbWh fW(
j_[dj) ; fWf[h Yefo e\ j^[ ib_Z[ fh[i[djWj_ed WdZ ikffb[(
c[djWho [nfbWdWjeho >P> m[h[ fhel_Z[Z \eh \kjkh[
h[\[h[dY[ WdZ je \WY_b_jWj[ W YWiYWZ[ e\ jhW_d_d] je ej^[h
j[Wc c[cX[hi _\ h[gk_h[Z) N^[i[ ikffb[c[djWho cWj[h_Wbi
m[h[ Yed\_d[Z je [nfbWdWj_ed e\ j^[ ki[ e\ j^[ j[cfbWj[ Wi
W h[YehZ_d] jeeb) H[_j^[h fhWYj_Y[i deh Yb_d_Y_Wdi m[h[ fhe(
l_Z[Z m_j^ Yef_[i e\ j^[ HC=? I; cWdW][c[dj ]k_ZWdY['
deh m[h[ j^[i[ fh[i[dj[Z eh ej^[hm_i[ h[_d\ehY[Z) ;\j[h .
cedj^i e\ ki[' Wd _dj[h_c WdWboi_i e\ j[cfbWj[ ZWjW mWi
kdZ[hjWa[d je [dikh[ j^Wj j^[ j[cfbWj[ mWi jh_]][h_d] Wi
[nf[Yj[Z WdZ j^Wj WiieY_Wj[Z ZWjW m[h[ YWfjkh[Z)
@[[ZXWYa i[ii_edi X[jm[[d j^[ fhWYj_Y[i WdZ _dl[ij_]W(
jehi m[h[ ^[bZ W\j[h j^[ _dj[h_c WdWboi_i' Xkj de Y^Wd][i
m[h[ cWZ[ je j^[ j[cfbWj[) N^[ \h[gk[dYo e\ j[cfbWj[
mmm)h^[kcWjebe]o)en\ehZ`ekhdWbi)eh] 0,-
4 JVUY[SZHZPVU ZLTWSHZL MVX B4
jh_]][h_d] mWi ki[Z Wi Wd _dZ_YWjeh e\ j^[ \[Wi_X_b_jo e\
j[cfbWj[ ki[)
>WjW [dj[h[Z j^hek]^ j^[ j[cfbWj[ Zkh_d] j^[ 1 cedj^i
W\j[h _dijWbbWj_ed m[h[ ki[Z je Wii[ii WY^_[l[c[dj e\
gkWb_jo _dZ_YWjehi \eh j^[ YWh[ e\ I; _d Wbb fWj_[dji m^ei[
YedikbjWj_ed jh_]][h[Z j^[ I; j[cfbWj[) Q[ WiY[hjW_d[Z
m^[j^[h [WY^ _dZ_YWjeh ed j^[ j[cfbWj[ ^WZ X[[d
WY^_[l[Z \eh W fWj_[dj Wj Wdo j_c[ Zkh_d] j^[ 1 cedj^i)
N^[ m[_]^j WZl_Y[ _dZ_YWjeh mWi edbo Wii[ii[Z _d el[h(
m[_]^j fWj_[dji $m_j^ W ceij h[Y[dj <GC h[YehZ _d j^[ fh[(
l_eki . o[Whi e\ "-0 a]*c-%) Q[ _Z[dj_\_[Z j^[ \_hij $_dZ[n%
Yb_d_Y_Wd je [dj[h W h[b[lWdj I; eh `e_dj fW_d YeZ[ \eh [WY^
fWj_[dj Zkh_d] j^[ 1 cedj^ eXi[hlWj_ed f[h_eZ)
=^Wd][i _d Yb_d_Y_Wd X[^Wl_ekh m[h[ Wii[ii[Z i[fWh(
Wj[bo \hec j^[ j[cfbWj[(Yebb[Yj[Z _d\ehcWj_ed) Q[ ki[Z
WdWboi_i e\ cWdW][c[dj WYj_edi' m^_Y^ Wh[ hekj_d[bo h[(
YehZ[Z ekji_Z[ e\ j^[ j[cfbWj[ $i[[ X[bem%' [dWXb_d] W
X[\eh[(WdZ(W\j[h j[cfbWj[ _dijWbbWj_ed YecfWh_ied e\
cWdW][c[dj) Lekj_d[bo h[YehZ[Z c[Z_YWb h[YehZi ZWjW
h[bWj_d] je cWdW][c[dj WYj_edi \eh I; m[h[ [njhWYj[Z
\eh Wbb [b_]_Xb[ fWj_[dji m_j^ Wd I; Z_W]dei_i YeZ[ eh i[(
b[Yj[Z `e_dj fW_d YeZ[ h[YehZ[Z _d W YedikbjWj_ed Zkh_d]
j^h[[ j_c[ f[h_eZi5 $_% ,- je 1 cedj^i fh_eh je j[cfbWj[
_dijWbbWj_ed $f[h_eZ ,%' $__% j^[ 1 cedj^i fh_eh je
j[cfbWj[ _dijWbbWj_ed $f[h_eZ -% WdZ $___% j^[ 1 cedj^i
W\j[h j[cfbWj[ _dijWbbWj_ed $f[h_eZ .%) N^_i Wbbem[Z Yb_d_Y_Wd
X[^Wl_ekh _d f[h_eZ . $feij(_dijWbbWj_ed% je X[ YecfWh[Z
m_j^ W f[h_eZ e\ [gk_lWb[dj b[d]j^ _cc[Z_Wj[bo fh[(
_dijWbbWj_ed $f[h_eZ -%' WdZ m_j^ j^[ _Z[dj_YWb YWb[dZWh
f[h_eZ _d j^[ fh[l_eki o[Wh $f[h_eZ ,%)
GWdW][c[dj WYj_edi \eh I; _dYbkZ[Z m[_]^j h[YehZi'
fh[iYh_fj_ed ZWjW' ki[ e\ hWZ_e]hWf^i WdZ h[\[hhWbi' Wbb
_Z[dj_\_[Z \hec j^[ [b[Yjhed_Y c[Z_YWb h[YehZi m_j^_d ,/
ZWoi e\ Wd I; eh `e_dj fW_d YedikbjWj_ed) Jh[iYh_fj_edi
\eh fWhWY[jWceb' jef_YWb HM;C>i' ef_e_Zi WdZ ehWb
HM;C>i m[h[ _Z[dj_\_[Z) Jh[iYh_fj_ed ZWjW m[h[
G45@8 ) KkWb_jo _dZ_YWjehi _dYbkZ[Z _d j^[ j[cfbWj[' h[ifedi[ efj_edi WdZ Yh_j[h_W \eh WY^_[l[c[dj
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He [djho eh dej j^_i j_c[
P[hXWb edbo
Hej Wffhefh_Wj[
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eh dej d[Y[iiWho eh dej Wffhefh_Wj[
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P[hXWb edbo
Hej d[Y[iiWho
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=edi_Z[hWj_ed e\
f^oi_ej^[hWfo h[\[hhWb
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Wffhefh_Wj[
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Hej d[Y[iiWho
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WCd j^ei[ m_j^ W h[YehZ[Z <GC "-0 _d j^[ fh[l_eki . o[Whi)
0,. mmm)h^[kcWjebe]o)en\ehZ`ekhdWbi)eh]
>VOU >' 8K]HXKY #' "$'
_dZ[f[dZ[dj e\ j^[ j[cfbWj[ Xkj j^[ j[cfbWj[ YedjW_d[Z W
fhecfj je Yb_d_Y_Wdi h[]WhZ_d] fWhWY[jWceb WdZ jef_YWb
HM;C>i) Cd j^ei[ m^e m[h[ fh[iYh_X[Z ehWb HM;C>i' m[
Z[j[hc_d[Z m^[j^[h j^[ fWj_[dj ^WZ X[[d fh[iYh_X[Z W
fhejed fkcf _d^_X_jeh) Q[ _Z[dj_\_[Z h[YehZi e\ m[_]^j eh
<GC' h[b[lWdj h[\[hhWbi $h^[kcWjebe]o' ehj^efW[Z_Yi' fW_d
Yb_d_Y' f^oi_ej^[hWfo' eYYkfWj_edWb j^[hWf_ij' [n[hY_i[ eh
m[_]^j beii fhe]hWcc[% WdZ h[b[lWdj R(hWoi $ad[[' ^_f'
^WdZ eh \eej%) ;i j^[ j[cfbWj[ YekbZ Wbie fhecfj Yb_d_Y_Wdi
je Yedi_Z[h f^oi_ej^[hWfo h[\[hhWb' m[ Wii[ii[Z j^_i i[f(
WhWj[bo WdZ `e_djbo m_j^ ej^[h h[\[hhWbi) C\ W fWj_[dj Yed(
ikbj[Z ceh[ j^Wd edY[ \eh I; eh `e_dj fW_d Zkh_d] W
f[h_eZ' j^[o m[h[ Yekdj[Z _d j^[ Z[dec_dWjeh edbo edY[
Xkj m[h[ h[YehZ[Z Wi ^Wl_d] h[Y[_l[Z W cWdW][c[dj
WYj_ed $j^[ dkc[hWjeh% _\ j^[o ^WZ h[Y[_l[Z _j m_j^_d ,/
ZWoi e\ Wdo [b_]_Xb[ YedikbjWj_ed)
?j^_YWb WffhelWb ^Wi X[[d ]hWdj[Z \eh j^_i ijkZo UHehj^
Q[ij , L[i[WhY^ ?j^_Yi =ecc_jj[[ $=^[i^_h[%' h[\[h[dY[
de) ,+*B,+,2*21V)
MjWj_ij_YWb WdWboi_i
MjWX_b_jo _d YedikbjWj_ed fh[lWb[dY[ e\ h[YehZ[Z I; WdZ
`e_dj fW_d X[\eh[ WdZ W\j[h j[cfbWj[ _dijWbbWj_ed mWi Wi(
i[ii[Z je [dikh[ j^[ j[cfbWj[ Z_Z dej Wbj[h cehX_Z_jo h[(
YehZ_d] ^WX_ji) N^[ \[Wi_X_b_jo e\ ki_d] j^[ j[cfbWj[ mWi
Wii[ii[Z Xo m^[j^[h _j ikYY[ii\kbbo \_h[Z ed [djho e\ W
h[b[lWdj YeZ[' ^em e\j[d Wd [djho mWi cWZ[ W\j[h _j ^WZ
\_h[Z WdZ j^[ [nj[dj e\ lWh_WX_b_jo _d Yecfb[j_ed X[jm[[d
Yb_d_Y_Wdi)
@eh [WY^ j[cfbWj[ _dZ_YWjeh j^[ f[hY[djW][ e\ fWj_[dji
m_j^ h[YehZ[Z WY^_[l[c[dj Zkh_d] j^[ 1 cedj^ f[h_eZ
W\j[h _dijWbbWj_ed mWi Z[j[hc_d[Z Wbed] m_j^ _ji 40" =C'
WYYekdj_d] \eh Ybkij[h_d] Xo fhWYj_Y[) Q[ Z[j[hc_d[Z j^[
f[hY[djW][ e\ fWj_[dji m_j^ Wj b[Wij ed[ _dZ_YWjeh WY^_[l[Z
WdZ m_j^ Wbb _dZ_YWjehi WY^_[l[Z) @eh j^ei[ m_j^ W h[YehZ e\
X[_d] el[hm[_]^j' j^[h[ m[h[ W cWn_ckc e\ [_]^j _dZ_YW(
jehi' ej^[hm_i[ j^[h[ m[h[ i[l[d $[nYbkZ_d] m[_]^j beii
WZl_Y[%) ;Y^_[l[c[dj e\ _dZ_YWjehi mWi ijhWj_\_[Z _d jme
mWoi5 $_% Xo m^[j^[h j^[ fWj_[dj mWi Yedikbj_d] \eh W
d[m [f_ieZ[ $Z[\_d[Z Wi de h[YehZ[Z YedikbjWj_ed \eh
I; eh `e_dj fW_d _d j^[ ,- cedj^i fh_eh je j[cfbWj[ _dijWb(
bWj_ed% WdZ $__% Xo m^[j^[h j^[ fWj_[dj ^WZ X[[d ]_l[d Wd
I; eh W `e_dj fW_d bWX[b) ;iieY_Wj_edi X[jm[[d h[Y[_l_d] Wd
I; hWj^[h j^Wd W `e_dj fW_d bWX[b WdZ _dZ_YWjeh WY^_[l[(
c[dj m[h[ Wii[ii[Z j^hek]^ ckbj_b[l[b be]_ij_Y h[]h[i(
i_ed' WYYekdj_d] \eh Ybkij[h_d] m_j^_d Yb_d_Y_Wd WdZ
WZ`kij_d] \eh fhWYj_Y[) M_c_bWh WdWboi_i Wii[ii[Z WiieY_(
Wj_edi e\ W d[m [f_ieZ[ m_j^ _dZ_YWjeh WY^_[l[c[dj) N^[
WdWboi_i mWi h[f[Wj[Z \eh j^ei[ fWj_[dji m_j^ Wj b[Wij ed[
h[YehZ[Z [djho _d j^[ j[cfbWj[' ed j^[ fh[c_i[ j^Wj Wdo
j[cfbWj[ [djho _cfb_[i j^Wj fWj_[dji m[h[ ceh[ b_a[bo je X[
Yedi_Z[h[Z Xo j^[ Yb_d_Y_Wd Wi ^Wl_d] I;)
N^[ cedj^bo f[hY[djW][ e\ YedikbjWj_edi \eh I; WdZ
`e_dj fW_d j^Wj ^WZ [WY^ cWdW][c[dj WYj_ed h[YehZ[Z
mWi fbejj[Z je Wii[ii jh[dZi el[h j^[ ,3 cedj^i) N^[d
j^[ f[hY[djW][ e\ fWj_[dji m_j^ j^[ h[YehZ[Z cWdW][c[dj
WYj_ed mWi YecfWh[Z X[jm[[d j^[ j^h[[ 1 cedj^ j_c[
f[h_eZi) Gkbj_b[l[b be]_ij_Y h[]h[ii_ed mWi ki[Z je jWa[
_dje WYYekdj Ybkij[h_d] e\ fWj_[dji m_j^_d Yb_d_Y_Wd)
L[ikbji Wh[ fh[i[dj[Z Wi ILi m_j^ 40" =Ci' ki_d] f[h_eZ
, Wi j^[ h[\[h[dY[ YWj[]eho WdZ WZ`kij[Z \eh fWj_[dj W]['
][dZ[h' ckbj_fb[ I; YedikbjWj_edi _d j^[ iWc[ f[h_eZ'
m^[j^[h j^[ fWj_[dj h[Y[_l[Z Wd I; eh `e_dj fW_d bWX[b
WdZ fhWYj_Y[) ;bb ckbj_b[l[b ceZ[bi m[h[ [ij_cWj[Z ki_d]
_j[hWj_l[ ][d[hWb_p[Z b[Wij igkWh[i m_j^ i[YedZ(ehZ[h
f[dWb_p[Z gkWi_(b_a[b_^eeZ Wffhen_cWj_ed) MN;N; l[hi_ed
,-), $MjWjW=ehf' =ebb[][ MjWj_ed' NR' OM;%' GFm_H l[h(
i_ed -)-1 $=[djh[ \eh Gkbj_b[l[b GeZ[bb_d] AhWZkWj[ MY^eeb
e\ ?ZkYWj_ed' Od_l[hi_jo e\ <h_ijeb' <h_ijeb' OE% WdZ j^[
MN;N; YeccWdZ hkdcbm_d m[h[ ki[Z \eh j^[ WdWboi[i
U-0' -1V)
ELY[SZY
Cd j^[ 1 cedj^i W\j[h _dijWbbWj_ed' j^[ j[cfbWj[ \_h[Z \eh
,2.+ $4."% e\ j^[ ,30, fWj_[dji m_j^ W h[YehZ[Z I; eh
`e_dj fW_d YeZ[) N^[ j[cfbWj[ \_h[Z edY[ \eh ,-00 fWj_[dji
$2."% WdZ jm_Y[ \eh .-0 fWj_[dji $,4"%' kf je W cWn_ckc
e\ ,+ j_c[i) ; jejWb e\ 31 Yb_d_YWb ijW\\ \_h[Z j^[ j[cfbWj[
m_j^ W c[Z_Wd e\ ,/ fWj_[dji [WY^ $hWd][ ,!3-%) N^[ Yed(
ikbjWj_ed fh[lWb[dY[ hWj[ \eh I; eh `e_dj fW_d \eh WZkbji
W][Z "/0 o[Whi _d j^[ \_hij 1 cedj^i W\j[h j[cfbWj[ _dijWb(
bWj_ed mWi 0/4*,+ +++ $40" =C 0-0' 02/% U-2V' i_c_bWh je
[ij_cWj[i Z[h_l[Z \hec YedikbjWj_ed ZWjW e\ ,- ][d[hWb
fhWYj_Y[i Yedjh_Xkj_d] je ekh beYWb =edikbjWj_edi _d
Jh_cWho =Wh[ ;hY^_l[ YedikbjWj_ed ZWjWXWi[ U-/' -3V
$fhe`[Yj[Z hWj[ 0++*,+ +++% $ikffb[c[djWho NWXb[ M,'
WlW_bWXb[ Wj %+)4.&30-0*6 Idb_d[%)
I\ j^[ ,2.+ fWj_[dji' ,,/2 $11"% fWj_[dji ^WZ Wj b[Wij
ed[ [djho ed j^[ j[cfbWj[' m_j^ ,,/1 UIL 11" $40" =C
0/' 24%V ^Wl_d] Wj b[Wij ed[ _dZ_YWjeh WY^_[l[Z WdZ .0-
$-+"% ^Wl_d] Wbb _dZ_YWjehi WY^_[l[Z $NWXb[ -%) Bem[l[h'
j^_i lWh_[Z ]h[Wjbo Xo _dZ[n Yb_d_Y_Wd5 \eh j^ei[ jh_]][h_d]
j^[ j[cfbWj[ _d #,/ $c[Z_Wd% fWj_[dji' -1" WY^_[l[Z Wj
b[Wij ed[ _dZ_YWjeh \eh #33" e\ j^[_h fWj_[dji) Bem[l[h'
Wdej^[h gkWhj[h \W_b[Z je WY^_[l[ Wdo _dZ_YWjeh \eh ceh[
j^Wd ^Wb\ e\ j^[_h fWj_[dji) JW_d $1."% WdZ \kdYj_ed $1-"%
Wii[iic[dj _dZ_YWjehi m[h[ WY^_[l[Z ceij \h[gk[djbo WdZ
Yedi_Z[hWj_ed e\ f^oi_ej^[hWfo h[\[hhWb j^[ b[Wij $.1"%)
N^[ edbo Z_\\[h[dY[ _d WY^_[l[c[dj e\ _dZ_l_ZkWb _dZ_YWjehi
X[jm[[d d[m [f_ieZ[ WdZ ed]e_d] Yedikbj[hi mWi \eh
Yedi_Z[hWj_ed e\ f^oi_ej^[hWfo h[\[hhWb' m^[h[ W ^_]^[h
f[hY[djW][ e\ ed]e_d] Yedikbj[hi ^WZ [l_Z[dY[ e\
WY^_[l[c[dj $/+" 52 ./"' $ 7 +)++,%) Bem[l[h' fWj_[dji
m_j^ Wd I; hWj^[h j^Wd W `e_dj fW_d bWX[b ^WZ ^_]^[h b[l[bi
e\ h[YehZ[Z WY^_[l[c[dj WYheii j^[ _dZ_YWjehi $Wbb
$ " +)+0%) N^ei[ m_j^ Wd I; bWX[b m[h[ Wbie ceh[ b_a[bo
je WY^_[l[ Wbb _dZ_YWjehi $-3" 52 ,2"' $ " +)++,6 NWXb[ -%)
Q^[d h[ijh_Yj[Z je j^[ ,,/2 fWj_[dji m_j^ Wj b[Wij ed[
j[cfbWj[ [djho' _dZ_YWjeh WY^_[l[c[dj hWd][Z \hec 41"
\eh fW_d Wii[iic[dj je 0/" \eh Yedi_Z[hWj_ed e\ f^oi_e(
j^[hWfo h[\[hhWb $NWXb[ .%6 IL .," $40" =C ,0' /1% e\ fW(
j_[dji ^WZ WY^_[l[c[dj e\ Wbb _dZ_YWjehi) Bem[l[h' m_Z[
lWh_Wj_ed X[jm[[d Yb_d_Y_Wdi h[cW_d[Z) N^[h[ m[h[ Z_\\[h(
[dY[i _d WY^_[l[c[dj X[jm[[d j^ei[ m_j^ Wd I; bWX[b WdZ
`e_dj fW_d \eh \ekh _dZ_YWjehi WdZ \eh WY^_[l[c[dj e\ Wbb
_dZ_YWjehi $.4" 52 -1"' $ " +)++,%)
N^[ 1 cedj^ YedikbjWj_ed fh[lWb[dY[ e\ I; WdZ
`e_dj fW_d WYheii j^[ [_]^j fhWYj_Y[i _dYh[Wi[Z \hec
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>VOU >' 8K]HXKY #' "$'
0--*,+ +++ h[]_ij[h[Z fefkbWj_ed je 0/4*,+ +++ \hec
f[h_eZi , je .' Xkj j^[ cW`eh_jo e\ j^_i _dYh[Wi[ eYYkhh[Z
X[jm[[d f[h_eZi , WdZ - $X[\eh[ j[cfbWj[ _dijWbbWj_ed%
$NWXb[ /%) Id[ fhWYj_Y[ _dYh[Wi[Z fh[lWb[dY[ Xo .." X[(
jm[[d f[h_eZi , WdZ . WdZ Wdej^[h Xo ,3") @ekh fhWY(
j_Y[i _dYh[Wi[Z fh[lWb[dY[ Xo !-" $;ff[dZ_n -%)
=ecfWh_ied X[jm[[d j^[ j^h[[ f[h_eZi i^em[Z de
Y^Wd][ _d j^[ b_a[b_^eeZ e\ h[YehZ_d] Wd I; hWj^[h j^Wd
W `e_dj fW_d bWX[b W\j[h j[cfbWj[ _dijWbbWj_ed Uf[h_eZ . 52 ,5
IL ,)+, $40" =C +)31' ,),3%V' eh _d W][ eh ][dZ[h Z_ijh_(
Xkj_ed e\ fWj_[dji)
; jejWb e\ //,- f[efb[ Yedikbj[Z \eh I; eh `e_dj fW_d
Zkh_d] j^[ j^h[[ f[h_eZi e\ j^[ ijkZo WdZ .0,, $3+"% e\
j^[i[ edbo Yedikbj[Z _d ed[ e\ j^[ j^h[[ f[h_eZi) Cd j^[
lWh_eki f[h_eZi' 4+!4/ Yb_d_Y_Wdi Wj j^[ [_]^j fhWYj_Y[i
iWm W c[Z_Wd e\ ,-!,/ fWj_[dji $hWd][ ,!3-% m_j^ I; eh
`e_dj fW_d)
@_]) , i^emi cedj^bo jh[dZi _d hekj_d[bo h[YehZ[Z cWd(
W][c[dj WYj_edi) N^[ f[hY[djW][ e\ fWj_[dji h[Y[_l_d]
[WY^ WYj_ed Z_Z dej Y^Wd][ X[jm[[d f[h_eZi , WdZ -)
<[jm[[d f[h_eZi - WdZ .' _)[) X[\eh[ WdZ W\j[h j[cfbWj[
_dijWbbWj_ed' j^[h[ mWi W i_]d_\_YWdj Y^Wd][ edbo _d cWd(
W][c[dj WYj_edi' m^_Y^ m[h[ Wbie ikX`[Yj je h[YehZ_d]
fhecfji _d j^[ j[cfbWj[5 IL ,)40 $40" =C ,)1,' -).0%
\eh jef_YWb HM;C> fh[iYh_fj_ed6 IL ,)/4 $40" =C ,)--'
,)3-% \eh fWhWY[jWceb fh[iYh_fj_ed6 IL .).3 $40" =C
-)2.' /),4% \eh W m[_]^j h[YehZ $NWXb[ 0%) N^[ _dYh[Wi[ _d
jef_YWb HM;C> WdZ fWhWY[jWceb fh[iYh_X_d] b[Z je W icWb(
b[h _dYh[Wi[ _d fh[iYh_X_d] e\ Wdo WdWb][i_Y X[jm[[d
f[h_eZi , WdZ . UIL ,).0 $40" =C ,),2' ,)02%V) Bem[l[h'
j^[h[ mWi de _dYh[Wi[ _d f^oi_ej^[hWfo h[\[hhWb hWj[i'
m^_Y^ mWi Wbie fhecfj[Z \eh Yedi_Z[hWj_ed ed j^[
j[cfbWj[)
7PYJ[YYPVU
Ikh ijkZo \ekdZ j^Wj j^[ fh_dY_fb[i e\ W Yecfkj[h_p[Z h[(
YehZ_d] j[cfbWj[ \eh I; YekbZ \[Wi_Xbo X[ _cfb[c[dj[Z)
N^[ ][d[hWb fhWYj_Y[ ijW\\ WYY[fj[Z j^[ j[cfbWj[ Wi fWhj
e\ j^[_h hekj_d[ meha WdZ j^[ j[cfbWj[ jh_]][h[Z ed 4." e\
[nf[Yj[Z eYYWi_edi) GehX_Z_jo YeZ_d] e\ I; WdZ `e_dj
fW_d h[cW_d[Z ijWXb[ W\j[h j^[ j[cfbWj[ mWi _djheZkY[Z'
ik]][ij_d] j^Wj Yb_d_Y_Wdi m[h[ dej Wle_Z_d] j^[ j[cfbWj[
j^hek]^ W Y^Wd][ _d YeZ_d] X[^Wl_ekh) N^_i mWi Yed(
\_hc[Z Xo j^[ eXi[hlWj_ed j^Wj j^[ fhefehj_ed e\ f[efb[
h[YehZ[Z m_j^ Wd I; eh `e_dj fW_d YeZ[ _d j^[ 1 cedj^i
W\j[h j[cfbWj[ _djheZkYj_ed mWi hWj^[h ^_]^[h j^Wd [n(
f[Yj[Z) ;bj^ek]^ j^[h[ mWi lWh_Wj_ed _d j^[ mWo Yb_d_Y_Wdi
Yecfb[j[Z j^[ j[cfbWj[' j^[ X[ij(f[h\ehc_d] Yb_d_Y_Wdi
WY^_[l[Z ^_]^ hWj[i e\ j[cfbWj[ Yecfb[j_ed WdZ gkWb_jo
_dZ_YWjeh WY^_[l[c[dj) N^[ _dYbki_ed e\ fhecfji je Yed(
i_Z[h j^[ h[Yecc[dZ[Z \_hij(b_d[ WdWb][i_Yi $jef_YWb
HM;C>i WdZ fWhWY[jWceb% Wbie b[Z je Wd _dYh[Wi[ _d j^[_h
fh[iYh_X_d])
>[if_j[ lWh_WX_b_jo X[jm[[d Yb_d_Y_Wdi' j^_i ijkZo ^Wi
Z[cedijhWj[Z ]h[Wj[h b[l[bi e\ gkWb_jo WY^_[l[c[dj
ki_d] edbo [b[Yjhed_YWbbo YeZ[Z _d\ehcWj_ed j^Wd fh[l_eki
ijkZ_[i _d OE ][d[hWb fhWYj_Y[' m^_Y^ ki[Z Xej^ [b[Yjhed_Y
WdZ fWf[h h[YehZi) @eh [nWcfb[' WY^_[l[c[dj e\ fW_d
$1."% WdZ \kdYj_ed $1-"% Wii[iic[dj _dZ_YWjehi Yec(
fWh[i \WlekhWXbo m_j^ hWj[i e\ -2" WdZ /." _d
<heWZX[dj )3 &-) U-4V) ;ii[iic[dj e\ _dZ_YWjehi \eh \_hij(
b_d[ WdWb][i_Yi i^em[Z ^_]^[h hWj[i e\ WY^_[l[c[dj j^Wd
fh[l_ekibo h[fehj[Z5 WZl_Y[ WXekj \_hij ki[ e\ fWhWY[jWceb
mWi 01" _d ekh ijkZo YecfWh[Z m_j^ /," _d Mj[[b )3 &-)
WdZ /3" Xo <heWZX[dj )3 &-) U-4' .+V)
B_]^[h b[l[bi e\ gkWb_jo WY^_[l[c[dj m[h[ i^emd m^[d
Wj b[Wij ed[ _j[c _d j^[ h[YehZ_d] j[cfbWj[ mWi Yec(
fb[j[Z) Cj _i \[Wi_Xb[ j^Wj iec[ fWj_[dji ]_l[d W `e_dj fW_d
YeZ[ m[h[ dej Yedi_Z[h[Z Xo j^[ h[YehZ_d] Yb_d_Y_Wd je
^Wl[ I; WdZ ^[dY[ j^[ [dj_h[ j[cfbWj[ mWi ia_ff[Z)
Geh[ j^Wd W gkWhj[h e\ fWj_[dji ]_l[d Wd I; bWX[b Z_Z
dej ^Wl[ Wdo j[cfbWj[ [djho) Cj _i fbWki_Xb[ j^Wj iec[ e\
j^[i[ mekbZ ^Wl[ WY^_[l[Z iec[ _dZ_YWjeh e\ gkWb_jo e\
YWh[' ie j^[ WYjkWb gkWb_jo e\ YWh[ Z[b_l[h[Z cWo X[ ib_]^jbo
^_]^[h j^Wd j^[ h[YehZ[Z b[l[b i^emd) N^[ Z_\\[h[dY[ X[(
jm[[d j^[ WY^_[l[c[dj hWj[i e\ fWj_[dji m_j^ Wd I; bWX[b
WdZ ed[ e\ `e_dj fW_d _i fWhjbo [nfbW_d[Z Xo j^[ `e_dj fW_d
YeZ[ir bWYa e\ if[Y_\_Y_jo \eh I;) Bem[l[h' [l[d _d fW(
j_[dji _d m^ec W j[cfbWj[ [djho ^WZ X[[d cWZ[ $WdZ
j^ki c_]^j X[ Yedi_Z[h[Z je ^Wl[ W meha_d] Z_W]dei_i
e\ I;%' j^[ el[hWbb h[YehZ[Z gkWb_jo e\ YWh[ \eh Z_W]dei[Z
I; mWi X[jj[h j^Wd j^Wj \eh fWj_[dji m_j^ W `e_dj fW_d bWX[b)
N^[h[ cWo X[ W f[hY[_l[Z Z_\\[h[dY[ _d Z_i[Wi[ _d fWj_[dji
m_j^ Wd I; bWX[b' eh _j cWo X[ j^Wj j^ei[ Yb_d_Y_Wdi ceh[
b_a[bo je cWa[ W \ehcWb Z_W]dei_i e\ I; Wh[ Wbie ceh[
b_a[bo je WZ^[h[ je ]k_Z[b_d[i) N^[h[ cWo X[ Wd ehZ[h
[\\[Yj' Wi fW_d WdZ \kdYj_ed Wii[iic[dj m[h[ j^[ jme
ceij Yeccedbo Yecfb[j[Z [djh_[i Wi j^[o m[h[ Wj j^[
ijWhj e\ j^[ j[cfbWj[) Ij^[h _dZ_YWjehi m[h[ b[ii \h[gk[djbo
G45@8 , HkcX[h e\ f[efb[ Yedikbj_d] \eh I; eh `e_dj fW_d f[h ,+ +++ f[efb[ W][Z "/0 o[Whi _d [WY^ 1 cedj^ f[h_eZ
GPTL WLXPVK
B4 WXL\HSLUJL
WLX )( ((( #1-" 6=$
>VPUZ WHPU
WXL\HSLUJL WLX
)( ((( #1-" 6=$
B4 VX QVPUZ WHPU
WXL\HSLUJL WLX
)( ((( #1-" 6=$
1!,- cedj^i X[\eh[ j[cfbWj[ _djheZkY[Z ,2/ $,1,' ,34% .3/ $.1.' /+0% 0-- $/43' 0/2%
+!1 cedj^i X[\eh[ j[cfbWj[ _djheZkY[Z ,4- $,22' -+2% .32 $.11' /+3% 0/- $0,3' 013%
+!1 cedj^i W\j[h j[cfbWj[ _djheZkY[Z ,3- $,13' ,42% .4- $.2,' /,/% 0/4 $0-/' 02/%
=^Wd][W' " 0 - 0
WJ[hY[djW][ Y^Wd][ _d YedikbjWj_ed fh[lWb[dY[ \hec 1!,- cedj^i X[\eh[ j[cfbWj[ je +!1 cedj^i W\j[h j[cfbWj[ _djheZkYj_ed)
mmm)h^[kcWjebe]o)en\ehZ`ekhdWbi)eh] 0,1
4 JVUY[SZHZPVU ZLTWSHZL MVX B4
WY^_[l[Z' m_j^ Yedi_Z[hWj_ed e\ f^oi_ej^[hWfo h[\[hhWb j^[
b[Wij \h[gk[dj)
N^[ j[cfbWj[' m^_Y^ h[c_dZ[Z Yb_d_Y_Wdi je Yedi_Z[h
h[Yecc[dZ[Z \_hij(b_d[ f^WhcWYebe]_YWb WdZ ded(
f^WhcWYebe]_YWb jh[Wjc[dji' h[ikbj[Z _d W ceZ[ij _d(
Yh[Wi[ _d fh[iYh_fj_edi e\ fWhWY[jWceb WdZ jef_YWb
HM;C>i Xkj dej _d f^oi_ej^[hWfo h[\[hhWb hWj[i) N^[h[
mWi de [\\[Yj ed ej^[h _dj[hl[dj_edi5 fh[iYh_fj_ed e\ ef_(
e_Zi' ehWb HM;C>i' fhejed fkcf _d^_X_jehi' h[\[hhWbi _d
][d[hWb eh R(hWo h[gk[iji)
Jh[iYh_fj_edi \eh fWhWY[jWceb _dYh[Wi[Z \hec ,." je
,2" e\ fWj_[dji WdZ jef_YWb HM;C>i _dYh[Wi[Z \hec
,0" je -0") N^[ fhefehj_ed e\ fWj_[dji fh[iYh_X[Z Wdo
WdWb][i_Y _dYh[Wi[Z W\j[h j[cfbWj[ _dijWbbWj_ed) N^_i _d(
Yh[Wi[ _i ]h[Wj[h j^Wd c_]^j X[ [nf[Yj[Z \hec j[cfehWb
jh[dZi Wbed[ U.,V) Hed[ e\ j^[ cWdW][c[dj WYj_edi
_dYh[Wi[Z _d j^[ ,- cedj^i fh_eh je j[cfbWj[ _dijWbbWj_ed'
ik]][ij_d] j^[i[ Y^Wd][i m[h[ dej Zk[ je j[cfehWb \WY(
jehi) M_dY[ gk[ij_edi h[bWj_d] je Wii[iic[dj eh WZl_Y[
WXekj fWhWY[jWceb WdZ jef_YWb HM;C>i Wh[ YedjW_d[Z
m_j^_d j^[ j[cfbWj[' j^[ j[cfbWj[ Wff[Whi je ^Wl[ WYj[Z
Wi W fhecfj \eh f^WhcWYebe]_YWb cWdW][c[dj e\ I;) N^[
^[j[he][d[eki dWjkh[ e\ h[c_dZ[hi' j[cfbWj[i WdZ Z[Y_(
i_ed ikffehj jeebi Wi _dj[hl[dj_edi cWa[i Z_h[Yj YecfWh_(
ied m_j^ ej^[h ijkZ_[i kdh[b_WXb[' Wbj^ek]^ j^[i[
fh[iYh_X_d] Y^Wd][i mekbZ X[ Yedi_ij[dj m_j^ j^[ [\\[Yji
h[fehj[Z _d jme ioij[cWj_Y h[l_[mi e\ Yecfkj[h h[c_dZ[hi
U,4' --V) N^[ cWdW][c[dj e\ i[l[hWb bed](j[hc YedZ_j_edi
^Wi X[[d \ekdZ je X[ _cfhel[Z j^hek]^ j^[ ki[ e\ h[(
c_dZ[hi WdZ j[cfbWj[i' _dYbkZ_d] Wii[iic[dj e\ YWhZ_e(
lWiYkbWh Z_i[Wi[ h_ia U.-V) =ecfkj[h(]k_Z[Z YedikbjWj_edi
^Wl[ Wbie X[[d \ekdZ je _cfhel[ Wif[Yji e\ Y^hed_Y eX(
ijhkYj_l[ fkbcedWho Z_i[Wi[ cWdW][c[dj _d fh_cWho YWh[
U..V) Cd Z_WX[j[i YWh[' Yecfkj[h_p[Z Z[Y_i_ed ikffehj mWi
9=;' ) GWdW][c[dj eYYkhh_d] m_j^_d ,/ ZWoi e\ YedikbjWj_ed \eh I; eh `e_dj fW_d Xo cedj^)
0-( mmm)h^[kcWjebe]o)en\ehZ`ekhdWbi)eh]
>VOU >' 8K]HXKY #' "$'
WiieY_Wj[Z m_j^ _cfhel[Z fheY[ii[i e\ YWh[' Wbj^ek]^ fW(
j_[dj ekjYec[i edbo _cfhel[Z m^[d f[h\ehcWdY[ \[[Z(
XWYa eh YWi[ cWdW][c[dj mWi WZZ[Z je Yecfkj[h_p[Z
Z[Y_i_ed ikffehj U./V)
CdYh[Wi_d] YedY[hd h[]WhZ_d] j^[ iW\[jo e\ fWhWY[jWceb
Wi W \_hij(b_d[ WdWb][i_Y efj_ed' Yekfb[Z m_j^ bed](ijWdZ_d]
YedY[hdi h[]WhZ_d] ehWb HM;C>i WdZ W m_Z[h d[[Z je
h[\ehc I; cWdW][c[dj U,1V' c[Wdi j^Wj j^[h[ _i W fh[ii(
_d] h[gk_h[c[dj \eh ijhWj[]_[i je _cfhel[ fh_cWho YWh[
kfjWa[ e\ ded(f^WhcWYebe]_YWb cWdW][c[dj \eh I;)
Ikh Yecfkj[h_p[Z j[cfbWj[ Ze[i dej h[YehZ W i^_\j _d
fhWYj_Y[ jemWhZi ]h[Wj[h ki[ e\ j^[i[ _dj[hl[dj_edi'
j^ek]^ j^[ [nj[dj je m^_Y^ j^_i _i h[bWj[Z je ijhkYjkhWb eh
fheY[ii \WYjehi eh bWYa e\ kfjWa[ Xo fWj_[dji _i dej
Z[j[hc_d[Z)
N^[ Z_l[hi[ dWjkh[ e\ j^[ fhWYj_Y[i fWhj_Y_fWj_d] _d j^[
ijkZo' _d j[hci e\ ijW\\_d]' fWj_[dj fefkbWj_ed i_p[' khXWd(
_pWj_ed WdZ Z[fh_lWj_ed' ik]][iji j^Wj j^[ h[ikbji i^ekbZ
^Wl[ W ]eeZ b[l[b e\ ][d[hWb_pWX_b_jo je ej^[h OE fhWYj_Y[i)
@khj^[hceh[' j^[ fWhj_Y_fWj_d] fhWYj_Y[i' j^ek]^ h[i[WhY^(
WYj_l[' m[h[ dej i[b[Yj[Z \eh Wdo fWhj_YkbWh Y^WhWYj[h_ij_Yi
X[oedZ j^[ YWfWY_jo je fWhj_Y_fWj[ _d j^[ ijkZo' WdZ
h[Y[_l[Z h[_cXkhi[c[dj edbo je Yel[h j^[_h WZZ_j_edWb
Yeiji WiieY_Wj[Z m_j^ fWhj_Y_fWj_ed)
Ikh ijkZo ^WZ iec[ b_c_jWj_edi) N^[ WdWboi[i Z_Z dej
WYYekdj \eh h[f[Wj[Z l_i_ji Xo fWj_[dji _d ceh[ j^Wd ed[
f[h_eZ) Bem[l[h' m[ \ekdZ j^Wj j^[ cW`eh_jo e\ fWj_[dji Z_Z
dej Yedikbj _d ceh[ j^Wd ed[ f[h_eZ) ; i[di_j_l_jo WdWboi_i
\khj^[h WYYekdj_d] \eh h[f[Wj[Z l_i_ji b[Z je Yedl[h][dY[
fheXb[ci _d j^[ ckbj_b[l[b ceZ[b' Xkj ik]][ij[Z j^Wj j^[
YedYbki_edi mekbZ dej Y^Wd][) Jh[iYh_fj_edi cWo dej \Wbb
m_j^_d j^[ ,/ ZWo f[h_eZ ki[Z \eh WdWboi_i WdZ dej Wbb R(hWoi
WdZ h[\[hhWbi Wh[ [b[Yjhed_YWbbo h[YehZ[Z Xo fhWYj_Y[i)
Bem[l[h' j^[h[ _i de h[Wied je ikif[Yj j^_i _djheZkY[Z
X_Wi _d Wii[iic[dj e\ j^[ j[cfbWj[ [\\[Yj' Wi h[YehZ_d]
c[j^eZi m[h[ kdb_a[bo je ^Wl[ Y^Wd][Z Zkh_d] j^[
ijkZo) Q^[d Yedi_Z[h_d] fheY[ii e\ YWh[ c[Wikh[i'
j^[h[ Wh[ YedY[hdi WXekj j^[ [nj[dj je m^_Y^ _cfhel[(
c[dji _d YWh[ Wi h[YehZ[Z _d j^[ c[Z_YWb h[YehZi h[(
\b[Yj _cfhel[c[dji _d h[YehZ_d] hWj^[h j^Wd j^[
WYjkWb YWh[ Z[b_l[h[Z) Ikh ijkZo ^Wi i^emd i_]d_\_YWdj
_dYh[Wi[i _d j^[ WYjkWb fh[iYh_fj_ed e\ iec[ WdWb][i_Y
fh[iYh_fj_edi)
Q[ YedYbkZ[ j^Wj W h[bWj_l[bo i_cfb[ fe_dj(e\(YWh[ ed(
iYh[[d h[YehZ_d] j[cfbWj[ \eh I; YWd ^[bf WZZh[ii h[(
YehZ_d] Z[\_Y_[dY_[i _d fh_cWho YWh[) Q_j^ m_Z[h kfjWa['
ikY^ W j[cfbWj[ mekbZ X[ W ki[\kb XWi_i \eh WkZ_j_d] Yeh[
I; YWh[) Cd WZZ_j_ed' j^[ j[cfbWj[ Wff[Whi je fhecfj
Y^Wd][i _d i[b[Yj[Z Wif[Yji e\ Yb_d_Y_Wd X[^Wl_ekh)
@kjkh[ h[i[WhY^ W_c[Z Wj cWn_c_p_d] j^[ X[d[\_j \hec
j^_i i^ekbZ \eYki ed j^[ lWh_Wj_ed _d ki[ X[jm[[d Yb_d_Y_Wdi
Wi m[bb _ji Yedjh_Xkj_ed je _cfhel[Z fWj_[dj(b[l[b
ekjYec[i)
EOL[THZVSVN^ RL^ TLYYHNLY
! =ecfkj[h_p[Z j[cfbWj[i \eh I; Wh[ \[Wi_Xb[ _d
fhWYj_Y[ WdZ ^[bf WZZh[ii h[YehZ_d] Z[\_Y_[dY_[i)
! I; h[YehZ_d] j[cfbWj[i Wh[ WiieY_Wj[Z m_j^ Wd _d(
Yh[Wi[ _d j^[ fhefehj_ed e\ fWj_[dji h[Y[_l_d] \_hij(
b_d[ WdWb][i_Yi h[Yecc[dZ[Z Xo [n_ij_d]
]k_Z[b_d[i)
! N^[h[ h[cW_di W d[[Z je _cfhel[ ded(f^WhcWYe(
be]_YWb YWh[ \eh I;)
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4 JVUY[SZHZPVU ZLTWSHZL MVX B4
4JRUV]SLKNLTLUZY
Q[ j^Wda j^[ fWj_[dji WdZ ijW\\ e\ j^[ ][d[hWb fhWYj_Y[i
m^e fWhj_Y_fWj[Z _d j^[ GIM;C=M jh_Wb' Wi m[bb Wi L^_Wd
Bk]^[i' NhWYo Q^_j[^khij' CWd N^ecWi' L[X[YYW @eia[jj
WdZ j^[ ijkZo \WY_b_jWjehi e\ j^[ Jh_cWho =Wh[ L[i[WhY^
H[jmeha' =[djhWb ?d]bWdZ $Hehj^ Mfea[% \eh j^[_h lWbkWXb[
ikffehj) ;kj^eh Yedjh_Xkj_edi5 D)D)?) Z[i_]d[Z j^[ Yec(
fkj[h j[cfbWj[ jeeb WdZ i[b[Yj[Z j^[ _dZ_YWjehi e\ gkWb_jo
e\ YWh[' fhel_Z[Z jhW_d_d] WdZ h[l_[mi e\ j^[ j[cfbWj[ je
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Appendix D. Systematic review appendices (Chapter Two) 
 Data extraction tools for the systematic review 
Appendix D.1.1. Data extraction sheet for quality indicator development studies 
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Data extraction sheet for full-text articles: QI development 
General Info 
Reviewer Choose an item.    Date of extraction    
Study ID      Date of publication    
 
Author               
               
 
Title               
               
 
Source               
               
 
Institution (of              
1st author)              
Study Characteristics 
Population              
               
 
Age (range)      Sex: M  F  Both  Ratio:    
 
Comments 
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Funding/Conflict of Interest 
Is the source of funding clear? Yes  No  
 
 
 
 
Are conflicts of interest transparent/minimised? Yes  No  
 
 
 
Quality Indicator development 
Method of evidence collection, assessment & assimilation  
 Meta-analysis  
 Systematic Review  
 RCTs  
 Epidemiological studies  
 Expert opinion  
 Other (specify)  
 Referenced (specify)  
 
What is the consensus method used in indicator development?  
 RAND Appropriateness  
 Delphi  
 Nominal group  
 Other (specify)  
 Referenced (specify)  
 Not stated  
 
Are numerator & denominator populations clear? - note any limitations, exclusions Yes  No  
 
 
 
 
Is there an identified mechanism for keeping the indicators updated  Yes  No  
especially in response to new evidence 
 
 
 
 
If no updating mechanism stated, have the indicators been produced Yes  No  
sufficiently recently to be considered current? 
 
 
 
[This information will be grouped for families of indicators] 
 
[This information will be grouped for families of indicators] 
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Quality Indicator Data 
For each QI, extract the following: 
In
d
ic
at
o
r 
# Text of indicator Indicator 
clear or 
not, with 
terms 
defined 
where 
needed? 
Structure, 
Process, or 
Outcome- 
based, with 
comments 
Population 
applied to [if 
varies from 
that already 
identified, e.g. 
specified 
exclusions] 
Anticipated health 
benefit (e.g. 
reduced 
gastrointestinal 
bleeding) 
Method of 
measurement 
Is a change to 
routine UK 10 
care 
recording of 
data required 
for indicator 
validity? 
Performance 
thresholds (as per 
audit terms 
Standard and 
Target) if stated, 
with justification 
Outcome Data 
[rate] 
(numerator/ 
denominator)  
Indicator 
grouping (e.g. 
ACOVE/RAND, 
Arthritis 
Foundation) 
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
   
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
   
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
   
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
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Appendix D.1.2. Data extraction sheet for quality indicator implementation studies 
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Data extraction sheet for full-text articles 
General Info 
Reviewer Choose an item.    Date of extraction    
Study ID      Date of publication    
 
Author               
               
 
Title               
               
 
Source               
               
 
Institution (of              
1st author)              
Study Characteristics 
Population              
               
 
Age (range)      Sex: M  F  Both  Ratio:    
 
Comments 
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Funding/Conflict of Interest 
Is the source of funding clear? Yes  No  
 
 
 
 
Are conflicts of interest transparent/minimised? Yes  No  
 
 
 
Quality Indicator Implementation & Testing 
Is the method for indicator selection clear? Yes  No  
 
 
 
 
Is the method for indicator prioritisation clear? Yes  No  
 
 
 
 
Is the rationale for indicator selection clear? Yes  No  
 
 
 
 
Has there been any quality assessment of the indicator by the Yes  No  
implementation group? Comment on degree of rigour of assessment 
 
 
 
 
Have routine data sources been tested? Yes  No  
- and found to yield the necessary data? Yes  No  
- in a manner suitable for our study? Yes  No  
 
 
 
 
Is there evidence of reliability  Yes  No  
(i.e. do repeated data extractions from the same dataset yield the same results?) 
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Is there evidence of quality improvement where the indicators have Yes  No  
been used repeatedly over time on the same population? (External validity)  
 
 
 
 
Is there evidence of the indicators’ sensitivity to change in quality of care? Yes  No  
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Quality Indicator Data 
For each QI, extract the following: 
In
d
ic
at
o
r 
# Text of indicator Indicator 
clear or 
not, with 
terms 
defined 
where 
needed? 
Structure, 
Process, or 
Outcome- 
based, with 
comments 
Population 
applied to [if 
varies from 
that already 
identified, e.g. 
specified 
exclusions] 
Anticipated health 
benefit (e.g. 
reduced 
gastrointestinal 
bleeding) 
Method of 
measurement 
Is a change to 
routine UK 10 
care 
recording of 
data required 
for indicator 
validity? 
Performance 
thresholds (as per 
audit terms 
Standard and 
Target) if stated, 
with justification 
Outcome Data 
[rate] 
(numerator/ 
denominator)  
Indicator 
grouping (e.g. 
ACOVE/RAND, 
Arthritis 
Foundation) 
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
   
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
   
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
   
 
 
 
 
 
 
 Yes  
No  
    Yes  
No  
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 Prior recorded quality indicator achievement 
Indicator K
ir
k 
2
0
0
3
 
M
cG
ly
n
n
 2
0
0
3
 
W
e
n
ge
r 
2
0
0
3
 
A
sc
h
 2
0
0
4
 
C
h
o
d
o
sh
 2
0
0
4
 
H
ig
as
h
i 2
0
0
4
 
C
ad
o
ga
n
 2
0
0
5
 
H
ig
as
h
i 2
0
0
5
 
G
an
z 
2
0
0
6
 
M
ac
le
an
 2
0
0
6
 
St
e
e
l 2
0
0
7
 
B
ro
ad
b
en
t 
2
0
0
8
 
St
e
e
l 2
0
0
8
 
Zi
n
gm
o
n
d
 2
0
0
9
 
Li
 2
0
1
1
 
Ø
st
e
rå
s 
2
0
1
3
 
(p
at
ie
n
t 
se
lf
-
re
p
o
rt
) 
Assessment 
N
o
 in
d
ic
at
o
r-
sp
ec
if
ic
 d
at
a 
p
u
b
lis
h
ed
 
  
Pain - 57.3a 40 80 - - - - 60.6 23 - 30 27 - - - 36 
Function - - - - 41 - - - - 42 - 44 43 - - 6.9b - 29.2c  24 
Weight recording - - - - - - - - - - - - - - - 
X-ray use - - - - - - - - - - - - - - - 
Advice - - - - - - - - - - - - - - - 
Education - - 33 - 36 - - - - - 68.7 29 - 31 30 17.7 - - - 
Education (patient self-report) - - - - - - - - - - - 77.8 - - 19 – 24d 
Exercise - 57.3a - 27 - - - - - - - - - 25.2 49 
Weight loss - - - - - - - - - - - - - 25 34 
NSAID risk advice - - 4 - - - - 4 38.6 - 50.0 14 - 20 17 - - - - 
Non-pharmacological management    
Physio referral/exercise "prescription" - - 0 - 16 - - - 46 16 44 - - 24.8 - - 43 
OT referral - - - - - - - - - - - - - - - 
Weight loss programme - - - - - - - - - - - - - - 5 
Pharmacological management     
Paracetamol first analgesic 45f 57.3a 43 73 - 79 26 43 58.7 45 - 51 48 41.1 - - 46 
Paracetamol maximum dose before alternative - - 33 - - - 37 33 - 03-Jun 5 - - - - 
Topical NSAID - - - - - - - - - - - - - - - 
Oral NSAID 45f - - - - - -  - 58 – 60e 59e - - - 46 
PPI used with oral NSAIDs 45f - 11 - - - - 11 27.4 - - - 26.6 - - 
Opioid/stronger analgesic - - - - - - - - - - - - - - 37 
Capsaicin - - - - - - - - - - - - - - - 
Glucosamine - - - - - - - - - - - - - - - 
Rubefacient - - - - - - - - - - - - - - - 
Referral once nonsurgical treatment failed  45f - 90 - - - - 90 72.7 90 - 95 90 35.8 - - 47 
acomposite of 3 indicators; b nonambulatory; c ambulatory; ddepending on component of education; efor ibuprofen or COX2 as first used oral NSAID; fcomposite of 4 indicators - individual 
indicator pass rates 27 - 100  
Recorded quality achievement in indicator implementation studies identified in the systematic review 
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 Studies excluded from the systematic review 
Author 
[Reference number] Reasons for exclusion 
Abraham, et al. [358] Guideline adherence study 
Alghamdi, et al. 
[359] 
Exercise intervention review 
Allen, et al. [360] Intervention study methods paper 
American College of 
Rheumatology [361] 
No OA-specific indicators 
Arthritis and 
Musculoskeletal 
Alliance [362] 
Standards of care not quality indicators. 
Askari, et al. [363] Systematic review of ACOVE indicators but no additional development or 
implementation 
Barlow [364] Education intervention review 
Baumann, et al. 
[365] 
Patient expectations study 
Bierma-Zeinstra, et 
al. [366] 
Study of GPs management of OA 
Bijlsma [367] Review of OA management, especially analgesia 
Blanda [368] Review of prescribing issues in the elderly 
Bliddal and 
Christensen [369] 
Review of management of OA in the overweight  
Bloodworth [370] Review of opiate prescribing issues 
Boyd, et al. [371] Assessment of guideline applicability in multimorbidity 
Brand [372] Review of evidence into practice for OA hip/knee 
Brand [373] Review of self-management in OA 
Brand and Cox [374] Care pathway development for OA 
Brooks and 
Conaghan [375] 
Editorial 
Brosseau, et al. [376] Guidelines for exercise/ manual therapy 
Cadogan, et al. [377] Pain assessment study 
Chassany, et al. [378] Education intervention study, no qi 
Cieza, et al. [379] Core dataset recommendations  
Conaghan and 
Brooks [380] 
Review of management of OA 
Conrozier, et al. [86] Guideline adherence study 
Cornali, et al. [381] Assessment of OA 
Cox, et al. [382] Intervention review (of COX-2 drugs) 
Curtis and Saag [383] Review of quality improvement – cites indicators but does not additionally 
develop of implement them. 
DeHaan, et al. [84] Guideline adherence study 
Denoeud, et al. [87] Guideline adherence study 
Doherty and 
Dougados [384] 
Review of OA management 
Dominick and Baker 
[385] 
Epidemiology of OA and its treatment 
Dominick, et al. [386] Survey of opioid use 
Dooley and Martin 
[387] 
Education article 
Duran-Barragan and 
Russell [388] 
Editorial 
Emejuaiwe, et al. 
[389] 
Epidemiology of joint replacement 
Escobar, et al. [390] Clinical guideline for criteria for knee replacement  
Feldt [391] Editorial 
Ganz, et al. [392] Intervention study (not using OA indicators) 
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Author 
[Reference number] Reasons for exclusion 
Glazier, et al. [393] Guideline adherence study 
Gogovor, et al. [394] Review of clinical management 
Gordon, et al. [395] Letter 
Gorevic [396] Education article 
Gossec, et al. [397] Clinical guideline for criteria for knee replacement 
Graudins and 
Gazarian [398] 
Survey (of celecoxib use) 
Hall [399] Survey of information provision 
Higashi, et al. [400] Secondary epidemiological analysis (number of morbidities and quality of care) 
Hochberg [105] Narrative review of OA quality indicators but no additional development or 
implementation 
Hochberg, et al. [38] Clinical guidelines 
Holden, et al. [401] Guideline adherence study 
Hollenack, et al. 
[402] 
Review of pain management in elderly patients 
Holman, et al. [403] Letter 
Hunter [404] Review of guidelines. No development or implementation of quality indicators.  
Hunter, et al. [405] Review of quality of OA care, including indicators; no additional development or 
implementation. 
Jansen, et al. [406] Guideline adherence study 
Jawad [407] Guideline adherence study 
Jones and Piterman 
[408] 
Intervention study (education) 
Jordan, et al. [31] Clinical guidelines 
Jordan, et al. [409] Survey of OA treatments 
Kane, et al. [410] Guideline [Health Technology Assessment (joint replacement)] 
Kartal, et al. [411] Survey of prescribing for OA 
Kirkness, et al. [412] Review of OA pain & comorbidity 
Koehn and Esdaile 
[413] 
Review of patient education and self-management.  
Koyama, et al. [414] Survey of patient self-management activities 
Krishnan and Suarez-
Almazor [415] 
Review of evidence-based rheumatology practice – references an indicator set 
but no additional development or implementation 
Labelle, et al. [416] Intervention study (medical education) 
Lai, et al. [417] Intervention study (hyaluronic acid) 
Laine, et al. [418] Guideline adherence study 
Landsberg, et al. 
[419] 
Survey of COX-2 use in secondary care 
Lanza, et al. [420] Clinical guidelines 
Lapane, et al. [421] Epidemiological study (effect of NSAIDs on gastro-protective medication) 
Lee and Katz [422] Education article 
LeLorier, et al. [423] Guideline adherence study (celecoxib) 
Li, et al. [424] Review of treatments. References quality indicators but no additional 
development or implementation.  
LoBuono [425] News/opinion article. No OA quality indicators in referenced reports. 
Maillefert, et al. 
[426] 
Survey of factors influencing joint replacement 
March, et al. [427] Clinical guideline/standards of care 
Marcum, et al. [428] Survey of pain control in OA 
Marks and 
Allegrante [429] 
Guideline adherence study (exercise) 
Mazieres, et al. [430] Guideline adherence study  
McHugh, et al. [431] Qualitative study of quality of care. No quality indicators developed or 
implemented. 
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Author 
[Reference number] Reasons for exclusion 
McHugh, et al. [432] Longitudinal study of quality of care (implementation study). Three indicators of 
quality of care were reported - the source and development not cited.  
McPherson and Reid 
[433] 
Editorial 
Merkle and 
McDonald [434] 
Guideline adherence study (pain management) 
Min, et al. [435] Secondary analysis of data included elsewhere 78 to identify predictors of care; 
no additional development or implementation of quality indicators. 
Min, et al. [276] Secondary analysis of data included elsewhere 78 to identify associations 
between multimorbidity and quality of care; no additional development or 
implementation of quality indicators. 
Mitchell and Hurley 
[436] 
Survey of patient reported management and preferences 
Morewitz [437] Review of developments in care (book) 
Newman and 
Harrington [438] 
Care pathway review (system redesign) 
Oliver [439] Review of a template for multidisciplinary management of OA 
O'Reilly and Doherty 
[440] 
Survey to assess link between knee pain & disability and poor health status & 
psychological distress 
Østerås, et al. [441] Abstract on development of patient self-report quality indicators [excluded as 
abstract only] 
Osterhaus, et al. 
[442] 
Evaluation of new methods of data collection in community pharmacies.  
Pendleton, et al. 
[443] 
Clinical guidelines 
Peter, et al. [444] Abstract on development of quality indicators for physical therapy [excluded as 
abstract only] 
Pitt, et al. [445] Survey of GPs evaluating referral to self-management programmes 
Porcheret, et al. 
[446] 
Care pathway development  
Price-Forbes, et al. 
[447] 
Audit of COX-2 drugs 
Quintana, et al. [448] Development of criteria for total hip replacement. 
Quintana, et al. [449] Survey of patients undergoing hip replacement to evaluate appropriateness 
Quintana, et al. [450] Survey of patients undergoing hip replacement to evaluate appropriateness 
Quintana, et al. [451] Clinical guideline (joint replacement decision tree) 
Reeves, et al. [452] Secondary analysis (of differences in quality indicator aggregation methods) 
Rosemann, et al. 
[453] 
Guideline adherence study  
Saag, et al. [454] Analgesics quality indicators considered too broad for inclusion in this review.  
Saliba, et al. [455] Feasibility assessment of various quality indicators but not those for OA 
Sarzi-Puttini, et al. 
[85] 
Guideline adherence study  
Schilling [456] Review of pain management which references another (included) paper but no 
indicators developed or implemented within this paper. 
Shrank, et al. [138] Analgesics quality indicators considered too broad for inclusion in this review. 
Singh, et al. [457] Review of OA drug treatment 
Solomon, et al. [458] Survey of medical record data, finding that history and examination data as 
recorded were not suitable for use as quality markers.  
Strand [459] Quality indicators for rheumatoid disease not OA 
Strombeck, et al. 
[106] 
Systematic review of quality indicators in OA but no additional development or 
implementation of indicators 
Sturkenboom, et al. 
[460] 
Epidemiological study of gastro-protective strategies in patients receiving 
NSAIDs.  
Vandenberghe, et al. 
[461] 
Comparative study of data sources. Although this does use 5 prescribing 
indicators, we considered this to be a study investigating the use of limited vs. 
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Author 
[Reference number] Reasons for exclusion 
complete datasets from general practice rather than a development or 
implementation of the quality indicators per se. 
Vandenberghe, et al. 
[462] 
Comparative study of data extraction methods 
Webster [463] Editorial 
Wierenga, et al. 
[464] 
Pharmaceutical care quality indicators for hospital in-patients (i.e. secondary 
care not primary care) 
Wilcock, et al. [465] Audit of NSAID prescribing 
Yazdany and 
MacLean [466] 
Review of quality of care but no additional development or implementation of 
indicators 
Zhang, et al. [32] Clinical guidelines 
Zhang, et al. [33] Clinical guidelines 
Zhang, et al. [36] Clinical guidelines 
Zhang, et al. [35] Clinical guidelines 
Zhang, et al. [37] Clinical guidelines 
Zingmond, et al. 
[467] 
No OA quality indicators included in this study of quality of care. 
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 Holistic approach to OA assessment and management indicators and example synthesis 
Development/ 
Implementation 
Author Date Topic Indicator Extracted theme 
Target population Process or outcome Timeframe 
Development Kerr135 2000 Pain & 
function 
assessment 
Providers caring for patients with symptoms of 
OA should document at least one of the 
following at least once in 2 years: a. the location 
of symptoms; b. the presence or absence of 
limitations in daily activities; c. the use and 
effectiveness of treatment modalities. 
Patients with 
symptomatic OA… 
…should be 
assessed for 
symptoms, 
function, and the 
effects of 
treatment… 
…every two 
years. 
Development MacLean134 2001 Pain & 
function 
assessment 
IF a vulnerable elder is diagnosed with 
symptomatic osteoarthritis, THEN his or her 
functional status and the degree of pain should 
be assessed annually BECAUSE this information 
is necessary to direct therapeutic decisions. 
Patients with 
symptomatic OA… 
…should be 
assessed for pain 
and function… 
…annually. 
Development MacLean134 2001 Differential 
diagnosis 
assessment 
IF a vulnerable elder has monoarticular joint pain 
associated with redness, warmth, or swelling 
AND the patient also has an oral temperature 
greater than 38.0 °C and does not have a 
previously established diagnosis of pseudogout 
or gout, THEN a diagnostic aspiration of the 
painfully swollen red joint should be performed 
that day BECAUSE this sign–symptom complex is 
common with joint infection, and it requires 
treatment that is different than that for 
osteoarthritis. 
Patients with a 
possible 
differential 
diagnosis of a 
septic joint… 
…should have a 
joint aspiration… 
…the same day. 
Development MacLean127,128 2004 Examination IF a patient is begun on a drug treatment for 
joint pain, arthritis, or arthralgia, THEN evidence 
that the affected joint was examined should be 
documented 
Patients with joint 
pain who receive 
drug treatment… 
…should have 
documentary 
evidence of a joint 
examination. 
- 
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Development MacLean127,128 2004 Pain 
assessment 
IF a patient is diagnosed with symptomatic 
osteoarthritis of the knee or hip, THEN his or her 
pain should be assessed annually and when new 
to a practice. 
Patients with 
symptomatic OA 
(hip or knee)… 
…should be 
assessed for pain… 
…on practice 
registration and 
annually. 
Development MacLean127,128 2004 Function 
assessment 
IF a patient is diagnosed with symptomatic 
osteoarthritis of the knee or hip, THEN his or her 
functional status should be assessed annually 
and when new to a practice 
Patients with 
symptomatic OA… 
…should be 
assessed for 
function… 
…on practice 
registration and 
annually. 
Development Steel124 2004 Pain & 
function 
assessment 
IF a person aged 65 or older is treated for 
symptomatic osteoarthritis, THEN functional 
status and degree of pain should be assessed at 
least annually 
Patients with 
symptomatic OA… 
…should be 
assessed for pain 
and function… 
…annually. 
Development Saliba133 2005 Examination IF a NH resident has a new joint pain that is 
reported to the primary care provider, THEN the 
affected joint and periarticular structures should 
be examined within 1 month or there should be 
documentation that the problem has resolved.  
Patients with joint 
pain… 
…should have 
documentary 
evidence of a joint 
examination… 
…within four 
weeks of 
identification. 
Development Saliba133 2005 Examination IF a non-OTC drug is newly prescribed to treat 
new joint pain THEN evidence that the affected 
joint was examined should be documented 
within 4 weeks.  
Patients with joint 
pain who receive 
treatment… 
…should have 
documentary 
evidence of a joint 
examination… 
…within four 
weeks of 
prescription of a 
new drug. 
Development Saliba133 2005 Differential 
diagnosis 
assessment 
IF an NH resident has monoarticular joint pain 
associated with redness, warmth, and/or 
swelling, and the patient also has an oral 
temperature ›38⁰C, and does not have a 
previously established diagnosis of gout or 
pseudogout, THEN a diagnostic aspiration of the 
painfully swollen red joint should be performed 
that day 
Patients with a 
possible 
differential 
diagnosis of a 
septic joint… 
…should have a 
joint aspiration… 
…the same day. 
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Development PCPI129 2006 Pain & 
function 
assessment 
Percentage of patient visits for patients aged 21 
years and older with a diagnosis of osteoarthritis 
with assessment for function and pain 
Patients with a 
diagnosis of OA… 
…should be 
assessed for pain 
and function. 
- 
Development PCPI129 2006 Examination Percentage of patients aged 21 years and older 
with a diagnosis of OA for whom a physical 
examination of the involved joint was performed 
during the initial visit 
Patients with joint 
pain… 
…should have 
documentary 
evidence of a joint 
examination… 
…at the initial 
assessment. 
Development MacLean132 2007 Pain 
assessment 
IF a VE has symptomatic OA of the knee or hip, 
THEN pain should be assessed when new to a 
primary care or musculoskeletal disease practice 
and annually [BECAUSE this information should 
direct therapeutic decisions]. 
Patients with 
symptomatic OA 
(hip or knee)… 
…should be 
assessed for pain… 
…on practice 
registration and 
annually. 
Development MacLean132 2007 Function 
assessment 
IF a VE has symptomatic OA of the knee or hip, 
THEN functional status should be assessed when 
new to a primary care or musculoskeletal 
disease practice and annually, BECAUSE this 
information should direct therapeutic decisions. 
Patients with 
symptomatic OA 
(hip or knee)… 
…should be 
assessed for 
function… 
…on practice 
registration and 
annually. 
Development Smith123 2007 Pain & 
function 
assessment 
IF a homebound patient is diagnosed with 
symptomatic osteoarthritis, THEN his or her 
functional status and the degree of pain should 
be assessed at each visit. 
Patients with 
symptomatic OA… 
…should be 
assessed for pain… 
…at each visit. 
Development Smith123 2007 Differential 
diagnosis 
assessment 
IF a homebound patient has monoarticular joint 
pain associated with redness, warmth, or 
swelling AND the patient also has an oral 
temperature greater than 38.0 °C and does not 
have a previously established diagnosis of 
pseudogout or gout, THEN diagnostic aspiration 
of the painfully swollen, red joint should be 
performed that day. 
Patients with a 
possible 
differential 
diagnosis of a 
septic joint… 
…should have a 
joint aspiration… 
…the same day. 
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Development EUMUSC.net125 2012 Pain & 
function 
assessment 
If a patient is diagnosed with symptomatic 
osteoarthritis (OA), then he or she should be 
assessed for pain, functional ability, level of 
physical activity, body mass index (BMI), and 
labor force participation at baseline or when 
experiencing significant pain or functional 
limitation 
Patients with 
symptomatic OA… 
…should be 
assessed for pain, 
function, physical 
activity, BMI, and 
work capability… 
…at diagnosis 
and each 
exacerbation. 
Implementation Wenger78 2003 Pain & 
function 
assessment 
IF a vulnerable elder receives a diagnosis of 
symptomatic osteoarthritis, THEN functional 
status and degree of pain should be assessed 
annually. 
Patients with 
symptomatic OA 
should be 
assessed annually 
for pain and 
function 
  
Implementation Wenger78 2003 Differential 
diagnosis 
assessment 
IF a vulnerable elder has monoarticular joint pain 
associated with redness, warmth, or swelling 
and the patient also has an oral temperature 
greater than 38.0 °C and does not have a 
previously established diagnosis of pseudogout 
or gout, THEN a diagnostic aspiration of the 
painfully swollen red joint should be performed 
that day. 
Patients with a 
possible 
differential 
diagnosis of a 
septic joint… 
…should have a 
joint aspiration… 
…the same day. 
Implementation McGlynn77 2003 Pain & 
function 
assessment 
Providers caring for patients with symptoms of 
OA should document all at least one of the 
following at least once in 2 years: the location of 
symptoms, and/or the presence or absence of 
limitations in daily activities 
Patients with 
symptomatic OA… 
…should be 
assessed for 
symptoms and 
function… 
…every two 
years. 
Implementation Chodosh73 2004 Pain & 
function 
assessment 
IF a vulnerable elder is diagnosed with 
symptomatic osteoarthritis, THEN functional 
status and degree of pain should be assessed 
annually. 
Patients with 
symptomatic OA… 
…should be 
assessed for pain 
and function… 
…annually. 
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Implementation Asch71 2004 Pain & 
function 
assessment 
Providers caring for patients with symptoms of 
osteoarthritis should document all of the 
following at least once in 2 years: the location of 
symptoms and/or the presence or absence of 
limitations in daily activities 
Patients with 
symptomatic OA… 
…should be 
assessed for 
symptoms and 
function… 
…every two 
years. 
Implementation Ganz74 2006 Pain & 
function 
assessment 
IF a person age 75 or older is diagnosed with 
symptomatic osteoarthritis, THEN functional 
status and degree of pain should be assessed 
annually. 
Patients with 
symptomatic OA… 
…should be 
assessed for pain 
and function… 
…annually. 
Implementation Steel68 2007 Pain & 
function 
assessment 
The percentage of patients treated for 
symptomatic osteoarthritis, whose notes contain 
a record that they have been assessed for (1) 
functional status and (2) degree of pain in the 
last year 
Patients with 
symptomatic OA… 
…should be 
assessed for pain 
and function… 
…annually. 
Implementation Broadbent69 2008 Function 
assessment 
The percentage of patients treated for 
symptomatic osteoarthritis, whose notes contain 
a record that they have been assessed for 
functional status in the last year 
Patients with 
symptomatic OA… 
…should be 
assessed for 
function… 
…annually. 
Implementation Broadbent69 2008 Pain 
assessment 
The percentage of patients treated for 
symptomatic osteoarthritis, whose notes contain 
a record that they have been assessed for 
degree of pain in the last year 
Patients with 
symptomatic OA… 
…should be 
assessed for pain … 
…annually. 
Implementation Østerås82 2013 Pain 
assessment 
If you have pain, has it been assessed in the past 
year? 
Patients with 
symptomatic OA… 
…should be 
assessed for pain … 
…annually. 
Implementation Østerås82 2013 Pain 
assessment 
If you have had problems related to daily 
activities, have these problems been assessed by 
health personnel in the past year? 
Patients with 
symptomatic OA… 
…should be 
assessed for 
function… 
…annually. 
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     Synthesised indicators 
Patients with 
symptomatic OA… 
…should be 
assessed for pain … 
…annually. 
Patients with 
symptomatic OA… 
…should be 
assessed for 
function… 
…annually. 
Patients with joint 
pain… 
…should have 
documentary 
evidence of a joint 
examination. 
[not selected for 
inclusion] 
Patients with a 
possible 
differential 
diagnosis of a 
septic joint… 
…should have a 
joint aspiration… 
…the same day. 
[not selected for 
inclusion] 
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Appendix E. Template development studies appendices (Chapter Three)  
 Read codes for assessment of routinely recorded management of OA 
Assessment of pain (Pain assessment, not pain location, codes): 
1D13. C/O: a pain 1M5.. Pattern of pain (+ child codes) 
1DC.. Pain character (+ child codes) 2IA.. O/E - painful sign (+ child codes) 
1M2.. Pain score  
Assessment of function 
Function assessment codes: 39A.. Bathing ability (+ child codes) 
13C.. Mobility - social functioning (+ child codes) 39B.. Walking aid use (+ child codes) 
1DD.. Symptom restricts activity 39D.. Walking distance (+ child codes) 
1P8.. Ability to perform personal care activity (+ 
child codes) 
39E.. Physical disabil.assess score (+ child codes) 
1PA.. Ability to perform activities of everyday life 
(+ child codes) 
39F.. Barthel index 
39... Disability assessment-physical 39G.. Needs help with housework (+ child codes) 
392.. Grooming ability (+ child codes) 39J.. Independent in cooking 
395.. Dressing ability (+ child codes) 39K.. Independent in housework 
396.. Chair/bed transfer (+ child codes) 68O.. Mobility screen 
397.. Toilet dependency (+ child codes) ZV4L0 [V] Poor mobility 
399.. Stairs – ability (+ child codes) ZV4KA [V]Limitation of activities due to disability 
Evidence of education or advice 
679M. Health education – rheumatology 679Z. Health education - subject NOS 
Exercise assessment 
138.. Exercise grading (+ child codes) 8E7.. Physical exercises (+ child codes) 
Exercise advice 
6798. Health ed. – exercise 8CA5. Patient advised re exercise (+ child codes) 
Weight loss advice for people with a BMI ≥25kgm-2 
38F.. Assessment for bariatric surgery  8CV7. Anti-obesity drug therapy commenced  
66C.. Obesity monitoring (+ child codes) 8H4n. Referral to weight management special 
interest general practitioner 
66CH. Weight management plan started 8H5N. Referral to bariatric surgeon  
67I9. Advice about weight 8H76. Refer to dietician (+ child codes) 
8CA4. Patient advised re diet 8HHH. Refer to weight management programme (+ 
child codes) 
8CA40 Patient advised to lose weight 8Hlv. Referral for pre-bariatric surgery assessment  
8Cd7. Advice given about weight management 8IAM. Referral to weight management service 
declined 
8CP4. Discussion about bariatric operative 
procedure 
8IAu. Weight management advice declined 
8CP5. Discussion about weight management 
programme 
9N1yF Seen in bariatric surgery clinic  
8CT5. Anti-obesity drug therapy discontinued  9NS03 Referral to weight management service 
offered 
Evidence of documentation of NSAID risk assessment 
8CD.. Usual warning given  9c0K. Risk information 
9OhB. Non-steroidal anti-inflammatory drug risk 
assessment completed 
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 Initial draft template  
Assessment 
Read code Read term Domain 
1M2 Pain score Pain 
7L1Wz Assessment NOS Function 
13C.. (+child codes) Mobility - social functioning Function 
22A.. (+child codes) O/E – weight Weight (for BMI) 
229.. (+child codes) O/E - height Height (for BMI) 
22K.. (+child codes) Body Mass Index BMI 
C380. (+child codes) Obesity BMI 
138.. (+child codes) Exercise grading Exercise assessment 
68L.. (+child codes) Exercise status screening Exercise assessment 
8I2T. Non-steroidal anti-
inflammatory drugs 
contraindicated 
NSAID risk assessment 
TJ56. Adverse reaction to non-
steroidal anti-inflammatory 
drugs 
NSAID risk assessment 
U6053 [X]Other non-steroidal anti-
inflammatory drugs [NSAID] 
causing adverse effects in 
therapeutic use 
NSAID risk assessment 
Unclear how to include OTC paracetamol/NSAID code – no obvious code 
 
Clinical management 
Read code Read term Domain 
6799. Health ed. – diet Weight advice 
679P. Health education - weight 
management (or system 
default health promotion 
code) 
Weight advice 
67I9. Advice about weight Weight advice 
66C.. Weight monitoring Weight advice 
8B57. Weight reducing diet Weight advice 
8CA40 Patient advised to lose weight Weight advice 
6798. Health ed. – exercise or 
system default 
Exercise advice 
679.. Health education – subject 
(need to specify in free text) 
 
679M. Health education - 
rheumatology (for the 
guidebook?) [? use a 
synonymous created term) 
 
9D1.. MED3 - doctor's statement  
9D2.. MED5 - doctor's special stat.  
 Referral (link to new 
template) 
 
Referrals should link to another template, below. 
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[Prescribing information to be collected for additional information outside of the template] 
Referrals 
Read code Read term Domain 
8BAH. Exercise on prescription Exercise referral/advice 
8CAc. Advised to contact 
physiotherapy triage service 
Exercise referral/advice 
8E... (+child codes) Physiotherapy/remedial 
therapy 
Exercise referral/advice 
8H77. Refer to physiotherapist Exercise referral/advice 
8H7q. Referral for exercise therapy Exercise referral/advice 
8H7s. Referral to physical activity 
programme 
Exercise referral/advice 
8HHc. Referred for exercise 
programme 
Exercise referral/advice 
9NJ3. In-house physio Exercise referral/advice 
9NJ4. In-house physiotherapy - 
domiciliary visit 
Exercise referral/advice 
9NJk. In-house physiotherapy first 
appointment 
Exercise referral/advice 
9NJm. In-house physiotherapy 
follow-up appointment 
Exercise referral/advice 
9N0F. Seen in physiotherapy dept Exercise referral/advice 
8H76. Refer to dietician Weight management referral 
8HHH. Refer to weight management 
programme 
Weight management referral 
8H7J. Refer to occupational therap. OT referral (non-ambulatory 
aids/devices) 
8H7Q. Refer to surgical fitter Podiatry referral (ambulatory 
aids/devices) 
8H7R. Refer to chiropodist Podiatry referral (ambulatory 
aids/devices) 
8H7S. Refer to orthotist Podiatry referral (ambulatory 
aids/devices) 
8H7k. Referral to community-based 
podiatry service 
Podiatry referral (ambulatory 
aids/devices) 
8H7l. Referral to hospital-based 
podiatry service 
Podiatry referral (ambulatory 
aids/devices) 
8H7m. Referral to private state 
registered podiatry service 
Podiatry referral (ambulatory 
aids/devices) 
8H4B. Referred to rheumatologist Secondary care referral 
8H54. Orthopaedic referral Secondary care referral 
8H69. Refer to pain clinic Secondary care referral 
 376 
 Final template created by the CRN staff to the candidate’s specification 
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 Draft MOSAICS OA definition codes with GP consensus exercise results and CiPCA testing outcomes 
Read code 
Separately- 
considered 
child codes 
Number of 
relevant 
child codes Read Term GP1 GP2 GP3 GP4 GP5 GP6 Outcome 
1M0.. 
 
1 Pain in upper limb   Include  Exclude Exclude Include Include Exclude Include 
 1M00. 
 
Pain in elbow Include Exclude Exclude Include Include Exclude Include 
1M1.. 
 
4 Pain in lower limb  Include Exclude Exclude Include Include Exclude Include 
 1M10. 
 
Knee pain Include Exclude Include Include Include Include Include 
 1M11. 
 
Foot pain Include Exclude Include Include Include Possible Include 
 1M12. 
 
Anterior knee pain Include Exclude Include Include Include Exclude Include 
 1M13. 
 
Ankle pain Include Exclude Unsure Include Include Possible Include 
2G26. No 
 
O/E - hands - Heberden's nodes Include Include Include Include Include Include Include 
N05.. (grouped) 98 Osteoarthritis and allied disorders  Include Include Include Include Include Include Include 
N064. (grouped) 31 Transient arthropathy  Exclude Exclude Include Exclude Exclude Exclude Exclude 
N065.  12 Unspecified polyarthropathy or 
polyarthritis  
Exclude Possibly Include Include Exclude Probably Include 
 N065A 
 
Generalised arthritis Include Include Include Include Include Include Include 
N066. (grouped) 10 Unspecified monoarthritis [synonym = 
coxitis] 
Exclude Possibly Include Include Exclude Include Include 
N06y. (grouped) 11 Other specified arthropathy  Exclude Possibly Include Unsure Exclude Exclude Exclude 
N06z. (grouped) 13 Arthropathy NOS  [synonym = arthritis] Include Possibly Include Include Exclude Include Include 
N094. (grouped) 32 Pain in joint – arthralgia  Include Exclude Include Include Include Possible Include 
N095. (grouped) 32 Joint stiffness NEC  Exclude Exclude Include Include Undecided Exclude Exclude 
N096. (grouped) 31 Other joint symptoms [synonyms = joint 
crepitus, musculoskeletal pain - joints] 
Include Exclude Include Include Include Probably Include 
N097. (grouped) 8 Difficulty in walking  Exclude Exclude Include Exclude Include Exclude Exclude 
N099. (grouped) 22 Clicking joint  Exclude Exclude Include Exclude Exclude Exclude Exclude 
           
           
           
           
 382 
Read code 
Separately- 
considered 
child codes 
Number of 
relevant 
child codes Read Term GP1 GP2 GP3 GP4 GP5 GP6 Outcome 
N09A.  1 Patellofemoral disorder  Include Exclude Exclude Unsure Unsure Exclude Exclude  
N09AX 
 
Disorder of patella, unspecified Include Exclude Exclude Exclude Exclude Exclude Exclude 
N09y. (grouped) 11 Other specified joint disorders  Exclude Exclude Exclude Exclude Exclude Probably Exclude 
N09z. (grouped) 11 Joint disorders NOS  Exclude Exclude Exclude Exclude Exclude Possibly Exclude 
N240. (grouped) 8 Rheumatism and fibrositis unspecified  Exclude Exclude Unsure Exclude Exclude Possibly Exclude 
N241. (grouped) 5 Myalgia and myositis unspecified  Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
N245.  8 Pain in limb  Include Exclude Exclude Include Include Exclude Include 
 N2450 
 
Hand pain Include Exclude Unsure Include Include Exclude Include 
 N2451 
 
Foot pain Include Exclude Unsure Include Include Exclude Include 
 N2452 
 
Pain in leg Include Exclude Exclude Exclude Include Exclude Exclude 
 N2453 
 
Pain in arm Include Exclude Exclude Exclude Include Exclude Exclude 
 N2454 
 
Calf pain Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N2455 
 
Axillary pain Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N2456 
 
Tender heel pad Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N2457 
 
Shoulder pain Include Exclude Exclude Exclude Include Exclude Exclude 
N247.  4 Other musculoskeletal limb symptoms  Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N2470 
 
Swelling of limb Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N2471 
 
Leg cramps Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N2472 
 
Cramp Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
 N247z 
 
Musculoskeletal limb symptoms NOS Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
R01z2 No 
 
[D]Musculoskeletal pain Include Exclude Exclude Exclude Exclude Exclude Exclude 
R01zz No  
[D]Nervous or musculoskeletal symptoms 
NOS 
Exclude Exclude Exclude Exclude Exclude Exclude Exclude 
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 CiPCA assessment of Read code triggers for the MOSAICS template 
CODE TERM CODE TERM 
1M10 Knee pain N051A Coxarthrosis resulting from dysplasia, bilateral 
1M11 Foot pain N051B Primary gonarthrosis, bilateral 
1M13 Ankle pain N051E Localised, primary osteoarthritis of toe 
N05 Osteoarthritis and allied disorders N051F Localised, primary osteoarthritis of elbow 
N050 Generalised osteoarthritis - OA N051z Localised, primary osteoarthritis NOS 
N0500 Generalised osteoarthritis of unspecified site N052 Localised, secondary osteoarthritis 
N0501 Generalised osteoarthritis of the hand N0520 Localised, secondary osteoarthritis of unspecified site 
N0502 Generalised osteoarthritis of multiple sites N0521 Localised, secondary osteoarthritis of the shoulder region 
N0503 Bouchard's nodes with arthropathy N0522 Localised, secondary osteoarthritis of the upper arm 
N0504 Primary generalized osteoarthrosis N0523 Localised, secondary osteoarthritis of the forearm 
N0505 Secondary multiple arthrosis N0524 Localised, secondary osteoarthritis of the hand 
N0506 Erosive osteoarthrosis N0525 Localised, secondary osteoarthritis of the pelvic region and thigh 
N0507 Heberden's nodes with arthropathy N0526 Localised, secondary osteoarthritis of the lower leg 
N050z Generalised osteoarthritis NOS N0527 Localised, secondary osteoarthritis of the ankle and foot 
N051 Localised, primary osteoarthritis N0528 Localised, secondary osteoarthritis of other specified site 
N0510 Localised, primary osteoarthritis of unspecified site N0529 Post-traumatic coxarthrosis, bilateral 
N0511 Localised, primary osteoarthritis of the shoulder region N052A Post-traumatic gonarthrosis, bilateral 
N0512 Localised, primary osteoarthritis of the upper arm N052B Post-traumatic arthrosis of first carpometacarpal joints, bilateral 
N0513 Localised, primary osteoarthritis of the forearm N052C Post-traumatic gonarthrosis, unilateral 
N0514 Localised, primary osteoarthritis of the hand N052z Localised, secondary osteoarthritis NOS 
N0515 Localised, primary osteoarthritis of the pelvic region and thigh N053 Localised osteoarthritis, unspecified 
N0516 Localised, primary osteoarthritis of the lower leg N0530 Localised osteoarthritis, unspecified, of unspecified site 
N0517 Localised, primary osteoarthritis of the ankle and foot N0531 Localised osteoarthritis, unspecified, of the shoulder region 
N0518 Localised, primary osteoarthritis of other specified site N0532 Localised osteoarthritis, unspecified, of the upper arm 
N0519 Primary coxarthrosis, bilateral N0533 Localised osteoarthritis, unspecified, of the forearm 
N051C Primary arthrosis of first carpometacarpal joints, bilateral N0534 Localised osteoarthritis, unspecified, of the hand 
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CODE TERM CODE TERM 
N051D Localised, primary osteoarthritis of the wrist N0535 Localised osteoarthritis, unspecified, of the pelvic region and thigh 
N053z Localised osteoarthritis, unspecified, NOS N05z9 Osteoarthritis NOS, of shoulder 
N054 Oligoarticular osteoarthritis, unspecified N05zA Osteoarthritis NOS, of sternoclavicular joint 
N0540 Oligoarticular osteoarthritis, unspecified, of unspecified sites N05zE Osteoarthritis NOS, of wrist 
N0541 Oligoarticular osteoarthritis, unspecified, of the shoulder region N05zF Osteoarthritis NOS, of metacarpophalangeal joint 
N0542 Oligoarticular osteoarthritis, unspecified, of upper arm N05zG Osteoarthritis NOS, of proximal interphalangeal joint of finger 
N0543 Oligoarticular osteoarthritis, unspecified, of forearm N05zH Osteoarthritis NOS, of distal interphalangeal joint of finger 
N0544 Oligoarticular osteoarthritis, unspecified, of hand N05zJ Osteoarthritis NOS, of hip 
N0545 
Oligoarticular osteoarthritis, unspecified, of the pelvic region and 
thigh 
N05zK Osteoarthritis NOS, of sacro-iliac joint 
N0546 Oligoarticular osteoarthritis, unspecified, of lower leg N05zL Osteoarthritis NOS, of knee 
N0547 Oligoarticular osteoarthritis, unspecified, of ankle and foot N05zM Osteoarthritis NOS, of tibio-fibular joint 
N0548 Oligoarticular osteoarthritis, unspecified, of other specified sites N05zN Osteoarthritis NOS, of ankle 
N0549 Oligoarticular osteoarthritis, unspecified, of multiple sites N05zP Osteoarthritis NOS, of subtalar joint 
N054z Osteoarthritis of more than one site, unspecified, NOS N05zQ Osteoarthritis NOS, of talonavicular joint 
N05z Osteoarthritis NOS N05zR Osteoarthritis NOS, of other tarsal joint 
N05z0 Osteoarthritis NOS, of unspecified site N05zS Osteoarthritis NOS, of 1st metatarsophalangeal joint 
N05z1 Osteoarthritis NOS, of shoulder region N05zT Osteoarthritis NOS, of lesser metatarsophalangeal joint 
N05z2 Osteoarthritis NOS, of the upper arm N05zU Osteoarthritis NOS, of interphalangeal joint of toe 
N05z3 Osteoarthritis NOS, of the forearm N05zz Osteoarthritis NOS 
N05z4 Osteoarthritis NOS, of the hand N05zB Osteoarthritis NOS, of acromioclavicular joint 
N05z5 Osteoarthritis NOS, pelvic region/thigh N05zC Osteoarthritis NOS, of elbow 
N05z6 Osteoarthritis NOS, of the lower leg N05zD Osteoarthritis NOS, of distal radio-ulnar joint 
N05z7 Osteoarthritis NOS, of ankle and foot N06z3 Arthropathy NOS-forearm 
N05z8 Osteoarthritis NOS, other specified site N06z4 Arthropathy NOS of the hand 
N0536 Localised osteoarthritis, unspecified, of the lower leg N06z5 Hip arthritis NOS 
N0537 Localised osteoarthritis, unspecified, of the ankle and foot N06z6 Knee arthritis NOS 
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CODE TERM CODE TERM 
N0538 Localised osteoarthritis, unspecified, of other specified site N06z7 Ankle arthritis NOS 
N0539 Arthrosis of first carpometacarpal joint, unspecified N094 Ache in joint 
N0940 Arthralgia - site unspecified N094H Arthralgia of PIP joint of finger 
N0943 Arthralgia - forearm N094K Arthralgia of hip 
N0944 Arthralgia - hand N094M Arthralgia of knee 
N0945 Arthralgia - pelvic/thigh N094P Arthralgia of ankle 
N0946 Arthralgia - lower leg N094T Arthralgia of 1st MTP joint 
N0947 Ankle joint pain N094W Anterior knee pain 
N094F Arthralgia of wrist N2450 Finger pain 
N094G Arthralgia of MCP joint N2451 Foot pain 
Bold text indicates that the code appears in the CiPCA database 2007, italic that it does not 
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 Template joint pain trigger codes (non-N05.. codes): outcome of final MOSAICS team determination of inclusion 
Code Terms Patients (n) Consultations (n) Retention status Reason 
1M00 Elbow pain 9 14 
Exclude Joint not of interest; considerable non-OA pathology 
 Pain in elbow 6 7 
1M10 Knee pain 231 427 Include 
Although this includes lots of non-OA pathology, it has 
usually been included in the RI’s OA work 
1M11 Foot pain 1 1 Include  
1M13 Ankle pain 1 2 Include  
N065 Polyarthropathy NEC 55 94 
Exclude Much non-OA disease 
 Unspecified polyarthropathy 4 6 
N0659 Unsp.polyarthr.-multiple site 3 4 Exclude Small numbers, infrequent definite OA 
N065A Generalised arthritis 14 22 Exclude 
Small numbers, OA pickup low – much possible 
inflammatory disease or spasticity 
N065z Polyarthritis 12 23 Exclude Much possible inflammatory disease 
N066 Unspecified monoarthritis 1 1 Exclude Much possible inflammatory disease 
N0664 Unsp.monoarthr.-hand 1 3 Exclude Infrequently used 
N06z Arthritis 38 53 
Exclude Too nonspecific; some child codes retained 
 Arthropathy NOS 7 10 
N06z0 Arthropathy NOS-site unspecif. 1 2 Exclude Infrequently used 
N06z1 Arthropathy NOS-shoulder 1 1 
Exclude Joint not of interest; much non-OA pathology 
 Shoulder arthritis NOS 7 11 
N06z2 Elbow arthritis NOS 1 1 Exclude Joint not of interest; much non-OA pathology 
N06z3 Arthropathy NOS-forearm 2 4 
Include  
 Wrist arthritis NOS 3 3 
N06z4 Arthropathy NOS of the hand 1 1 
Include 
 
 Arthropathy NOS-hand 2 2  
 Hand arthritis NOS 5 7  
N06z5 Hip arthritis NOS 33 55 Include  
N06z6 Knee arthritis NOS 68 129 Include  
N06z7 Ankle arthritis NOS 4 4 
Include 
 
 Foot arthritis NOS 1 1  
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Code Terms Patients (n) Consultations (n) Retention status Reason 
N06z9 Arthropathy NOS of multiple sites 3 3 Exclude Small numbers, OA pickup low 
N06zA Acute arthritis 2 2 Exclude Small numbers, OA pickup low 
N06zB Chronic arthritis 1 1 Exclude Small numbers, OA pickup low 
N06zz Arthropathy NOS 4 5 Exclude Small numbers, OA pickup low 
N094 Ache in joint 8 10 
Include  
 Pain in joint - arthralgia 39 63 
N0940 Arthralgia - site unspecified 8 9 
Include  
 Arthralgia of unspecified site 1 2 
N0941 Arthralgia - shoulder 64 100 
Exclude Joint not of interest; lots of non-OA pathology  Arthralgia of the shoulder region 61 96 
 Shoulder joint pain 67 134 
N0942 Arthralgia - upper arm 1 2 
Exclude Joint not of interest; lots of non-OA pathology 
 Elbow joint pain 15 22 
N0943 Arthralgia - forearm 1 1 
Include  
 Wrist joint pain 87 125 
N0944 Arthralgia - hand 29 40 
Include 
 
 Arthralgia of the hand 26 41  
 Hand joint pain 13 15  
N0945 Arthralgia - pelvic/thigh 37 61 
Include 
 
 Coxalgia 1 1  
 Hip joint pain 122 184  
N0946 Arthralgia - lower leg 3 4 
Include 
 
 Arthralgia of the lower leg 7 8  
 Knee joint pain 317 460  
N0947 Ankle joint pain 13 19 
Include 
 
 Ankle/foot joint pain 1 1  
 Arthralgia - ankle/foot 31 41  
 Arthralgia of the ankle and foot 6 10  
N0948 Arthralgia - other specified 1 1 Exclude Small numbers, OA pickup low 
N0949 Arthralgia of multiple joints 324 621 Exclude Lots non-OA pathology 
N094A Arthralgia of shoulder 4 4 Exclude Joint not of interest; lots of non-OA pathology 
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Code Terms Patients (n) Consultations (n) Retention status Reason 
N094B Arthralgia - sternoclav joint 3 3 Exclude Joint not of interest; lots of non-OA pathology 
N094C Arthralgia - acromioclav joint 9 11 Exclude Joint not of interest; lots of non-OA pathology 
N094D Arthralgia of elbow 23 31 Exclude Joint not of interest; lots of non-OA pathology 
N094F Arthralgia of wrist 70 111 Include  
N094G Arthralgia of MCP joint 1 1 Include  
N094H Arthralgia of PIP joint of finger 1 2 Include  
N094K Arthralgia of hip 76 118 Include  
 Hip pain 594 955   
N094L Arthralgia of sacro-iliac joint 5 6 Exclude Joint not of interest; lots of non-OA pathology 
N094M Arthralgia of knee 636 970 Include  
N094P Arthralgia of ankle 4 9 Include  
N094T Arthralgia of 1st MTP joint 5 6 Include  
N094W Anterior knee pain 209 316 Include  
N094z Arthralgia NOS 69 108 Exclude Poor OA specificity 
N096 Joint crepitus 2 3 
Exclude Poor OA specificity 
 Musculoskeletal pain - joints 46 108 
N0960 Other joint sympt.-site unspec 1 3 Exclude Poor OA specificity 
N0961 Other joint sympt.-shoulder 1 1 Exclude Joint not of interest; lots of non-OA pathology 
N0964 Other joint symptoms of the hand 1 1 Exclude Only one patient – with a trigger thumb 
N0965 Other joint sympt.-pelv./thigh 1 1 Exclude Poor OA specificity 
N0966 Knee gives way 2 4 Exclude Poor OA specificity 
N096B Other symptoms - sternoclav jt 1 1 Exclude Joint not of interest; lots of non-OA pathology 
N096D Other symptoms - elbow 2 2 Exclude Joint not of interest; lots of non-OA pathology 
N096F Other symptoms - wrist 3 3 Exclude Poor OA specificity 
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Code Terms Patients (n) Consultations (n) Retention status Reason 
N245 Ankle pain 216 333 
Exclude Poor OA specificity 
 Arm pain 114 170 
 Foot pain 190 280 
 Hand pain 74 108 
 Heel pain 110 161 
 Leg pain 243 357 
 Pain in buttock 32 55 
 Pain In Left Leg 41 55 
 Pain in limb 15 23 
 Pain in limb - multiple 1 3 
 Pain In Right Arm 29 49 
 Pain In Right Leg 37 49 
 Shoulder pain 353 624 
 Thigh pain 38 55 
N2450 Finger pain 50 71 
Include 
 
 Hand pain 111 161  
 Thumb pain 54 71  
N2451 Foot pain 417 655 
Include  
 Toe pain 180 259  
Arthralgia trigger codes: retention decision resulting from MOSAICS team discussions after GP assessment and CiPCA usage filter 
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 MOSAICS Template: GP Research Facilitators Meeting 6.4.2011 
Background 
The MOSAICS study aims to investigate the effects of model consultation training and the provision 
of a nurse resource on aspects of primary care of osteoarthritis. In order to understand how care 
changes, we need to be able to compare the intervention practices with controls. Previous evidence 
suggests that either or both of OA care or its recording were not optimal. To disentangle OA care 
provision from its recording, we have designed a computer template to use in consultations to 
capture some of the information that may not routinely be recorded. This template will be 
implemented in both intervention and control arms of the trial.  
Intended template use 
The primary aim of the template is not to alter behaviour, rather to facilitate aspects of care which 
the clinician wishes to record. 
Where a clinical feels the template is not applicable, the template may be ‘escaped’ from - also in 
situations where there are other reasons not to complete it. 
Gaps may be left in the template, though this is not something specifically encouraged.  
The template may be completed with the patient in the room, or potentially once the patient has 
left. The timing of the data entry may affect the responses but this is not a concern. 
The template itself 
Where a clinician wishes to use the template, once it has been triggered it is a question of entering 
the code letter for the selected response to each of the domains, with the exception of the numeric 
value for weight, and the automatic calculation of BMI (assuming a previous height value exists in 
the system). 
The responses are generally quite self-explanatory: 
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PAIN 
A Pain|None 
B Pain|Mild 
C Pain|Moderate 
D Pain|Severe 
A ‘global assessment’ which may be the patient’s own description 
or a clinician’s estimate based on norm references. 
FUNCTION 
A Fn|Not limited 
B Fn|Mild limitation 
C Fn|Moderate limitation 
D Fn|Severe limitation 
Again, a ‘global assessment’ which may be the patient’s own 
description or a clinician’s estimate based on norm references. 
WEIGHT [Numeric value requested] 
BMI [Automatically calculated assuming a previous height record 
exists] 
PARACETAMOL 
A Para|tried full dose 
B Para|advised full dose 
C Para|decline full dose 
D Para|not appropriate 
E Para|unknown 
This provides an opportunity to record a previous trial of 
paracetamol – especially since this can be an over-the-counter use 
which would not otherwise appear in the clinical record.   
Advice to use paracetamol may also be captured for the same 
reason, supporting patient self-management.  
A patient may prefer not to use paracetamol – the reason does 
not have to be recorded – but this fact can be captured here. 
It may be considered clinically inappropriate to use paracetamol 
(e.g. for severe pain where a strong analgesic is considered 
necessary) so this may be identified (again, no reason is needed). 
It may be unknown (e.g. if the patient has left before this aspect of 
the template is completed) and so this option is also provided. 
TOPICAL NSAIDs 
A Top|tried full dose 
B Top|advised full dose 
C Top|declined full dose 
D Top|not appropriate 
E Top|unknown 
This provides an opportunity to record a previous trial of topical 
NSAIDs – since this can be an over-the-counter use which would 
not otherwise appear in the clinical record.   
Advice to use topical NSAIDs may also be captured for the same 
reason, supporting patient self-management. 
A patient may prefer not to use topical NSAIDs – the reason does 
not have to be recorded – but this fact can be captured here. 
It may be considered clinically inappropriate to use topical NSAIDs 
(e.g. for severe pain where a strong analgesic is considered 
necessary) so this may be identified (again, no reason is needed). 
It may be unknown (e.g. if the patient has left before this aspect of 
the template is completed) and so this option is also provided. 
INFORMATION 
A Info|verbal 
B Info|verbal + written 
C Info|not  this time 
D Info|not appropriate 
Provision of information is not always well captured in the record, 
so this provides an opportunity to record the provision of verbal 
advice, or verbal + written (on the basis that it would be unlikely 
to simply hand over a leaflet with no other input). Written advice 
may refer to a variety of system inbuilt leaflets, special pamphlets, 
the OA guidebook, etc.  
The “Not this time” response can be used whenever a consultation 
does not include information giving, leaving open the possibility 
that it has previously been given or may be in the future.  
In some cases it may be considered inappropriate (e.g. in patients 
with advanced dementia) so an active decision to except a patient 
may be captured here.  
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WEIGHT ADVICE 
A Wt|verbal advice 
B Wt|verbal + written 
C Wt|not  this time 
D Wt|not appropriate 
Provision of weight advice is not always well captured in the 
record, so this provides an opportunity to record the provision of 
verbal advice, or verbal + written. Written advice may refer to a 
variety of system inbuilt leaflets, special pamphlets, etc.  
 The “Not this time” response can be used whenever a 
consultation does not include advice on weight management, 
leaving open the possibility that it has previously been given or 
may be in the future.  
In some cases it may be considered inappropriate (e.g. in patients 
who are not overweight, or where they are not able to participate 
in weight management for a reason, not specified) so an active 
decision to except a patient may be captured here. 
EXERCISE & PHYSICAL 
ACTIVITY 
A Ex|verbal advice 
B Ex|verbal + written 
C Ex|not necessary 
D Ex|not  this time 
E Ex|not appropriate 
Similar options are offered for this domain. This provides an 
opportunity to record the provision of verbal advice, or verbal + 
written. Written advice may refer to a variety of system inbuilt 
leaflets, special pamphlets, etc. 
Some patients may already be exercising to a high level – where 
exercise information provision is considered not to be needed 
(superfluous) this may be recorded. 
The “Not this time” response can be used whenever a consultation 
does not include advice on exercise/physical activity, leaving open 
the possibility that it has previously been given or may be in the 
future.  
In some cases it may be considered inappropriate (e.g. in patients 
who are not able to participate for some – unspecified - reason) so 
an active decision to except a patient may be captured here. 
PHYSIOTHERAPY 
REFERRAL 
A PT|offered referral 
B PT|not necessary 
C PT|not this time 
D PT|not appropriate 
Whenever a physiotherapy referral is offered, or a patient is 
advised to contact an open access/triage service such as Physio 
Direct, this is intended to result in the ‘Offered referral’ response.  
Some patients may already be exercising to a high level – where 
physiotherapy referral is considered not to be needed 
(superfluous) this may be recorded. 
The “Not this time” response can be used whenever a consultation 
does not include an offer of a physio referral, leaving open the 
possibility that it has previously been given or may be in the 
future.  
In some cases it may be considered inappropriate (e.g. in patients 
who are not able to participate for some – unspecified - reason) so 
an active decision to except a patient may be captured here. 
Screenshots 
[See Appendix E.3] 
Practicalities 
The template introduction will be preceded by some training (by John Edwards, at the practice, with 
a DVD backup for future reference).  
The template may be used as soon as it is switched on in a practice.  
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There will be the opportunity for a review at 3 months with an exchange of ideas between the 
practice and the study team. 
Questions? 
John Edwards 6.4.2011 
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 Template training DVD script 
“Thank you for agreeing to participate in the Keele MOSAICS Study. We aim to describe aspects of 
osteoarthritis management in general practice, using anonymised data. The best way for us to do 
this is through the analysis of computerised coded information. We hope that you will be willing to 
use a computer template, within EMIS, to record information obtained when consulting with 
patients regarding osteoarthritis.  
“I would like to demonstrate the way in which the template can be used. I hope to show that the 
template is brief, intuitive, and integrates well into a consultation. The template will be triggered 
by a range of problems and codes, which are considered to reflect the possibility of a working 
diagnosis of osteoarthritis.  
“I would like you to imagine a scenario in which a patient presents with foot pain. In this example, 
I propose that the diagnosis in this case is biomechanical pain rather than osteoarthritis. Thus, the 
code 1M11. Foot pain can be entered, which triggers the template as it is a candidate code for a 
working diagnosis of OA. However, in this scenario, it is considered inappropriate to use the 
template and so by pressing the ‘escape’ key, and selecting ‘Yes’ to the exit without filing prompt, 
the usual method for recording information can be used.  
“In a second scenario, a patient consults with knee pain. This is considered to be due to 
osteoarthritis. We enter the code 1M10…. Knee pain, and the template fires. This time, the 
template is completed as it is considered relevant. The same process would be followed if an 
osteoarthritis disease code (N05..) is entered. Information can be recorded against the system 
prompts for each of the domains on the single screen shown. For the example, I will complete the 
template using the topmost option in each domain. 
“Thus for pain, the severity can be recorded against the broad groups offered – ranging from ‘No 
pain’ through ‘Mild’ and ‘Moderate’ to ‘Severe pain’.  
“For recording information on the degree of functional impairment, a summary assessment can be 
coded with options ranging from ‘Not limited’ through ‘Mild’ and ‘Moderate’ to ‘Severe limitation’.  
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“For weight, the numeric value entered will allow the system to calculate BMI automatically if a 
patient’s height has previously been recorded.  
“A previous trial of paracetamol at a dose appropriate to that patient can be recorded, as can advice 
to the patient to try paracetamol up to an appropriate maximal dose. If a patient’s preference is 
not to use paracetamol, this may be coded as “Declined”. If such a trial is not considered to be 
clinically appropriate, the response “Not appropriate” may be used. “Unknown” is also an option, 
if required.  
“The same options are provided for topical anti-inflammatory agents. A previous trial of topical 
anti-inflammatories at a dose appropriate to that patient can be recorded, as can advice to the 
patient to try topical anti-inflammatories up to an appropriate dose. If a patient’s preference is not 
to use topical anti-inflammatories, this may be coded as “Declined”. If such a trial is not considered 
to be clinically appropriate, the response “Not appropriate” may be used. “Unknown” is also an 
option, if required.  
“Provision of information about osteoarthritis may be recorded as ‘Verbal advice’, or ‘Verbal and 
written’. If information is not given in a consultation, that can also be recorded as “Not this time”. 
In some circumstances, information provision may be considered not to be appropriate, and this 
might be noted too.  
“Similarly, advice to the patient about weight management may be recorded as ‘Verbal’ or ‘Verbal 
and written’. If such advice is not given in a consultation, this may be recorded as “Not this time.” 
“It may be that provision of weight advice is considered not to be appropriate and this may also be 
recorded.  
“The same options of ‘Verbal’ or ‘Verbal and written’ are offered for recording advice about 
exercise and physical activity, with the addition of a “Not necessary” category. This may be used if 
a patient is already undertaking exercise and physical activity deemed to be of an appropriate type, 
intensity, and frequency. The other options of ‘Not this time’ and ‘Not appropriate’ remain 
available. 
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“Likewise, physiotherapy referral may be considered and recorded. In this case, it is the offer of a 
referral or advice to contact an open-access or triage service that should trigger the “Offered 
referral” prompt, not only cases in which the referral was accepted. In some cases, Physio referral 
may not be considered necessary, such as in patients who are already well aware of the type of 
exercise to do: this may be recorded as “Not necessary”. If a referral is not offered, or has previously 
been recommended and not reiterated or it is not a current treatment strand, this should be 
recorded as “Not this time”. “Not appropriate” can be used in circumstances where such a referral 
is not a clinically appropriate course of action, such as in someone unable to participate in a 
physiotherapy treatment.  
“At completion of the template, the information can be filed [<Return>] and the record then used 
as normal to record any other information necessary in the usual data entry manner. 
“This has been a quick demonstration of the template. I hope that it has demonstrated a practicable 
way of using it and that you will feel able to complete the template as appropriate in clinical 
practice. You may have additional questions. These are can be put to the Keele Informatics team – 
contact Tracy Whitehurst on 01782 734712, t.whitehurst@cphc.keele.ac.uk” 
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 Mapping of Read codes to sites of disease 
Read code Term Site allocation 
Defined OA or 
joint pain 
Reclassified OA 
‘not OA’ or joint 
pain 
1M10 Knee pain Knee Joint pain OA 
1M11 Foot pain Ankle/foot Joint pain Not OA 
1M13 Ankle pain Ankle/foot Joint pain Not OA 
EGTON279 Painful Right Knee Knee Joint pain OA 
N05 Osteoarthritis+allied disord. Unspecified OA OA 
N05-1 Osteoarthritis Unspecified OA OA 
N050 Generalised osteoarthritis - OA Generalised OA OA 
N0501 Generalised OA-hand Wrist/hand OA OA 
N0501-1 Heberdens' nodes Wrist/hand OA OA 
N0502 Generalised OA-multiple sites Generalised OA OA 
N0502-99 Osteoarthritis -Multiple Joint Multiple OA OA 
N0514 Local.primary OA-hand Wrist/hand OA OA 
N0517 Local.primary OA-ankle/foot Ankle/foot OA OA 
N0519 Primary coxarthrosis bilateral Hip OA OA 
N051E Local prim osteoarth toe Ankle/foot OA OA 
N0536-1 Patellofemoral osteoarthritis Knee OA OA 
N0537 Local.OA unsp.-ankle/foot Ankle/foot OA OA 
N05z Osteoarthritis NOS Unspecified OA OA 
N05z1 Osteoarthritis NOS-shoulder Shoulder OA OA 
N05z1-99 Osteoarthritis -Shoulder Joint Shoulder OA OA 
N05z2-1 Elbow osteoarthritis NOS Elbow OA OA 
N05z3-1 Wrist osteoarthritis NOS Wrist/hand OA OA 
N05z3-99 Osteoarthritis - Wrist Joint Wrist/hand OA OA 
N05z4 Osteoarthritis NOS of the hand Wrist/hand OA OA 
N05z4-1 Finger osteoarthritis NOS Wrist/hand OA OA 
N05z4-2 Thumb osteoarthritis NOS Wrist/hand OA OA 
N05z4-99 Osteoarthritis - Hand Joint Wrist/hand OA OA 
N05z5-1 Hip osteoarthritis NOS Hip OA OA 
N05z5-99 Osteoarthritis - Hip Joint Hip OA OA 
N05z6 Osteoarthritis NOS-lower leg Knee OA OA 
N05z6-1 Knee osteoarthritis NOS Knee OA OA 
N05z6-99 Osteoarthritis - Knee Joint Knee OA OA 
N05z7 Osteoarthritis NOS-ankle/foot Ankle/foot OA OA 
N05z7-1 Ankle osteoarthritis NOS Ankle/foot OA OA 
N05z7-2 Foot osteoarthritis NOS Ankle/foot OA OA 
N05z7-3 Toe osteoarthritis NOS Ankle/foot OA OA 
N05z7-99 Osteoarthritis - Ankle/Foot Ankle/foot OA OA 
N05z8 Osteoarthritis NOS-other spec Unspecified OA OA 
N05z8-99 Osteoarthritis - Other Joint Unspecified OA OA 
N05z9 Osteoarthritis NOS of shoulder Shoulder OA OA 
N05zB OA NOS-acromioclavicular joint Shoulder OA OA 
N05zE Osteoarthritis NOS of wrist Wrist/hand OA OA 
N05zF Osteoarthritis NOS of MCP joint Wrist/hand OA OA 
N05zJ Osteoarthritis NOS of hip Hip OA OA 
N05zL Osteoarthritis NOS of knee Knee OA OA 
N05zS OA NOS-1st MTP joint Ankle/foot OA OA 
N05zz Osteoarthritis NOS Unspecified OA OA 
N06z3-1 Wrist arthritis NOS Wrist/hand Joint pain Not OA 
N06z4 Arthropathy NOS of the hand Wrist/hand Joint pain Not OA 
N06z4-1 Hand arthritis NOS Wrist/hand Joint pain Not OA 
N06z5-1 Hip arthritis NOS Hip Joint pain OA 
N06z6-1 Knee arthritis NOS Knee Joint pain OA 
N06z7-1 Ankle arthritis NOS Ankle/foot Joint pain Not OA 
N06z7-2 Foot arthritis NOS Ankle/foot Joint pain Not OA 
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Read code Term Site allocation 
Defined OA or 
joint pain 
Reclassified OA 
‘not OA’ or joint 
pain 
N094 Pain in joint - arthralgia Unspecified Joint pain OA 
N0940 Arthralgia of unspecified site Unspecified Joint pain OA 
N0943 Arthralgia - forearm Wrist/hand Joint pain Not OA 
N0943-1 Wrist joint pain Wrist/hand Joint pain Not OA 
N0943-99 Wrist Joint Pain Wrist/hand Joint pain Not OA 
N0944 Arthralgia of the hand Wrist/hand Joint pain Not OA 
N0944-1 Hand joint pain Wrist/hand Joint pain Not OA 
N0944-99 Hand Joint Pain Wrist/hand Joint pain Not OA 
N0945 Arthralgia - pelvic/thigh Hip Joint pain OA 
N0945-2 Hip joint pain Hip Joint pain OA 
N0945-99 Hip Joint Pain Hip Joint pain OA 
N0946 Arthralgia - lower leg Knee Joint pain OA 
N0946-1 Knee joint pain Knee Joint pain OA 
N0946-99 Knee Joint Pain Knee Joint pain OA 
N0947 Arthralgia - ankle/foot Ankle/foot Joint pain Not OA 
N0947-1 Ankle joint pain Ankle/foot Joint pain Not OA 
N0947-99 Ankle/Foot Joint Pain Ankle/foot Joint pain Not OA 
N094F Arthralgia of wrist Wrist/hand Joint pain Not OA 
N094F-1 Wrist pain Wrist/hand Joint pain Not OA 
N094G Arthralgia of MCP joint Wrist/hand Joint pain Not OA 
N094H Arthralgia of PIP joint of finger Wrist/hand Joint pain Not OA 
N094K Arthralgia of hip Hip Joint pain OA 
N094K-2 Hip pain Hip Joint pain OA 
N094M Arthralgia of knee Knee Joint pain OA 
N094P Arthralgia of ankle Ankle/foot Joint pain Not OA 
N094T Arthralgia of 1st MTP joint Ankle/foot Joint pain Not OA 
N094W Anterior knee pain Knee Joint pain OA 
N2450 Hand pain Wrist/hand Joint pain Not OA 
N2450-1 Thumb pain Wrist/hand Joint pain Not OA 
N2450-2 Finger pain Wrist/hand Joint pain Not OA 
N2451 Foot pain Ankle/foot Joint pain Not OA 
N2451-1 Toe pain Ankle/foot Joint pain Not OA 
Read codes mapped to site of disease with initial and revised suggestions for use as a definition of 
clinical OA 
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Appendix F. Routinely-recorded quality of care appendices (Chapter Five): Associations of routinely-recorded measures with 
independent variables 
 Assessment processes 
Appendix F.1.1. Weight record 
Weight record within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.26 (0.97,1.63) 1.00 (0.75,1.34) 1.00 (0.74,1.34) 
Sex (reference: female) 1.21 (0.95,1.54) 1.26 (0.98,1.62) 1.25 (0.97,1.61) 
Age 65-74 (reference: 45-64) 1.00 (0.76,1.33) 0.89 (0.66,1.19) 0.89 (0.66,1.20) 
Age 75-84 0.74 (0.53,1.04) 0.64 (0.44,0.93) 0.64 (0.44,0.92) 
Age 85+ 0.32 (0.16,0.64) 0.31 (0.15,0.63) 0.30 (0.15,0.63) 
Hip (reference: knee) 0.82 (0.59,1.14) 0.88 (0.63,1.23) 0.88 (0.62,1.23) 
Ankle/foot 0.72 (0.41,1.25) 0.85 (0.48,1.49) 0.84 (0.47,1.48) 
Wrist/hand 0.87 (0.55,1.38) 1.05 (0.65,1.69) 1.04 (0.64,1.68) 
Unspecified 0.81 (0.44,1.49) 0.91 (0.48,1.71) 0.93 (0.49,1.75) 
Multisite 1.60 (1.12,2.29) 1.22 (0.83,1.79) 1.21 (0.82,1.79) 
BMI 25 to <30 (reference: BMI <25) 1.07 (0.72,1.60) 0.93 (0.62,1.39) 0.94 (0.62,1.41) 
BMI 30+ 1.79 (1.24,2.59) 1.40 (0.96,2.05) 1.42 (0.97,2.09) 
BMI unknown 0.47 (0.30,0.73) 0.41 (0.26,0.64) 0.41 (0.26,0.64) 
5-9 BNF chapters (reference: 0-4) 1.20 (0.90,1.59) 1.05 (0.77,1.42) 1.05 (0.77,1.43) 
10+ BNF chapters 1.43 (1.06,1.93) 1.35 (0.96,1.89) 1.34 (0.96,1.88) 
Multiple consultations in phase 1 (vs. single) 2.52 (1.97,3.23) 2.38 (1.83,3.10) 2.36 (1.81,3.08) 
X-ray, phase 1a (vs. none) 1.68 (1.11,2.52) 1.39 (0.89,2.16) 1.33 (0.86,2.07) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.21 (0.68,2.15) 1.34 (0.74,2.40) 1.41 (0.79,2.53) 
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Weight record within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.37 (0.64,2.96) 1.52 (0.73,3.16) - 
Practice 3 0.46 (0.25,0.86) 0.53 (0.29,0.97) - 
Practice 4 1.22 (0.74,2.01) 1.59 (0.98,2.60) - 
Practice 5 1.25 (0.73,2.15) 1.29 (0.77,2.17) - 
Practice 6 2.08 (1.03,4.19) 1.88 (0.96,3.67) - 
Practice 7 0.93 (0.53,1.64) 0.93 (0.53,1.64) - 
Practice 8 1.27 (0.61,2.63) 1.04 (0.51,2.14) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between a weight record within 14 days of a consultation for clinical OA in phase 
one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.1.2. X-ray record 
X-ray record within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 0.78 (0.62,0.97) 0.54 (0.41,0.71) 0.54 (0.41,0.71) 
Sex (reference: female) 0.91 (0.74,1.13) 0.88 (0.70,1.10) 0.87 (0.70,1.10) 
Age 65-74 (reference: 45-64) 1.07 (0.84,1.36) 1.15 (0.88,1.51) 1.15 (0.88,1.51) 
Age 75-84 0.99 (0.75,1.31) 1.07 (0.78,1.47) 1.08 (0.78,1.48) 
Age 85+ 0.42 (0.26,0.68) 0.48 (0.28,0.82) 0.49 (0.28,0.83) 
Hip (reference: knee) 1.73 (1.35,2.21) 1.92 (1.46,2.51) 1.92 (1.44,2.55) 
Ankle/foot 0.45 (0.26,0.79) 0.54 (0.31,0.95) 0.54 (0.30,0.95) 
Wrist/hand 0.51 (0.33,0.79) 0.55 (0.35,0.88) 0.55 (0.34,0.88) 
Unspecified 0.29 (0.14,0.61) 0.39 (0.18,0.86) 0.39 (0.18,0.87) 
Multisite 1.20 (0.87,1.65) 1.01 (0.70,1.45) 1.03 (0.72,1.48) 
BMI 25 to <30 (reference: BMI <25) 1.58 (1.11,2.24) 1.61 (1.10,2.34) 1.60 (1.09,2.34) 
BMI 30+ 1.39 (0.99,1.94) 1.26 (0.87,1.81) 1.26 (0.87,1.81) 
BMI unknown 1.13 (0.81,1.59) 1.09 (0.76,1.57) 1.09 (0.76,1.57) 
5-9 BNF chapters (reference: 0-4) 1.05 (0.83,1.33) 0.90 (0.69,1.18) 0.91 (0.69,1.18) 
10+ BNF chapters 0.80 (0.61,1.05) 0.63 (0.46,0.87) 0.64 (0.46,0.89) 
Multiple consultations in phase 1 (vs. single) 4.56 (3.66,5.67) 4.99 (3.95,6.31) 4.96 (3.51,7.00) 
X-ray, phase 1a (vs. none) 2.41 (1.79,3.26) 1.82 (1.30,2.55) 1.78 (1.25,2.53) 
Above the clinician median index consultation count 
(reference: at or below the median) 
0.54 (0.25,1.15) 1.06 (0.69,1.65) 1.04 (0.66,1.64) 
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X-ray record within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.71 (0.38,1.31) 0.90 (0.46,1.78) - 
Practice 3 0.18 (0.11,0.29) 0.12 (0.07,0.21) - 
Practice 4 0.02 (0.00,0.05) 0.01 (0.00,0.05) - 
Practice 5 0.02 (0.01,0.06) 0.01 (0.00,0.05) - 
Practice 6 0.02 (0.00,0.13) 0.01 (0.00,0.08) - 
Practice 7 1.53 (1.05,2.23) 1.42 (0.92,2.19) - 
Practice 8 1.13 (0.67,1.90) 0.83 (0.46,1.50) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between a relevant recorded X-ray within 14 days of a consultation for clinical OA 
in phase one and the independent variables. Adjusted models include all independent variables. 
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 Pharmacological management 
Appendix F.2.1. Paracetamol 
Paracetamol prescription within 14 days of a clinical 
OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 2.21 (1.79,2.73) 1.58 (1.23,2.03) 1.57 (1.22,2.02) 
Sex (reference: female) 0.70 (0.56,0.87) 0.76 (0.60,0.95) 0.76 (0.60,0.96) 
Age 65-74 (reference: 45-64) 2.42 (1.82,3.21) 1.93 (1.44,2.60) 1.94 (1.44,2.60) 
Age 75-84 4.60 (3.48,6.09) 3.29 (2.43,4.45) 3.27 (2.42,4.44) 
Age 85+ 5.43 (3.80,7.78) 3.75 (2.53,5.55) 3.73 (2.52,5.52) 
Hip (reference: knee) 1.48 (1.14,1.90) 1.37 (1.04,1.79) 1.37 (1.05,1.80) 
Ankle/foot 0.43 (0.23,0.78) 0.51 (0.27,0.96) 0.52 (0.28,0.98) 
Wrist/hand 0.49 (0.30,0.82) 0.59 (0.35,1.00) 0.60 (0.35,1.01) 
Unspecified 1.40 (0.87,2.24) 1.22 (0.74,2.03) 1.20 (0.72,1.99) 
Multisite 2.12 (1.57,2.88) 1.19 (0.84,1.66) 1.21 (0.86,1.69) 
BMI 25 to <30 (reference: BMI <25) 1.02 (0.73,1.42) 1.07 (0.75,1.52) 1.05 (0.73,1.50) 
BMI 30+ 1.07 (0.78,1.48) 1.08 (0.76,1.53) 1.07 (0.75,1.52) 
BMI unknown 0.79 (0.57,1.10) 0.93 (0.66,1.32) 0.92 (0.65,1.31) 
5-9 BNF chapters (reference: 0-4) 2.45 (1.90,3.17) 1.62 (1.23,2.13) 1.62 (1.23,2.14) 
10+ BNF chapters 3.79 (2.92,4.93) 2.04 (1.53,2.74) 2.06 (1.53,2.76) 
Multiple consultations in phase 1 (vs. single) 2.14 (1.74,2.63) 1.83 (1.46,2.30) 1.84 (1.46,2.31) 
X-ray, phase 1a (vs. none) 1.36 (0.95,1.96) 0.95 (0.64,1.41) 0.95 (0.64,1.42) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.22 (0.78,1.93) 1.01 (0.62,1.65) 1.04 (0.64,1.69) 
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Paracetamol prescription within 14 days of a clinical 
OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.62 (0.35,1.12) 0.76 (0.41,1.43) - 
Practice 3 0.94 (0.66,1.32) 1.20 (0.82,1.75) - 
Practice 4 0.51 (0.34,0.75) 0.53 (0.35,0.81) - 
Practice 5 0.66 (0.45,0.98) 0.90 (0.59,1.37) - 
Practice 6 0.90 (0.53,1.53) 1.10 (0.62,1.97) - 
Practice 7 0.63 (0.42,0.95) 0.80 (0.51,1.26) - 
Practice 8 0.62 (0.35,1.11) 0.55 (0.29,1.04) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between paracetamol prescription within 14 days of a consultation for clinical OA in 
phase one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.2.2. Topical NSAIDs  
Topical NSAIDs prescription within 14 days of a clinical 
OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.38 (1.12,1.71) 0.97 (0.75,1.24) 0.98 (0.77,1.26) 
Sex (reference: female) 0.67 (0.54,0.82) 0.67 (0.53,0.83) 0.66 (0.53,0.83) 
Age 65-74 (reference: 45-64) 2.47 (1.93,3.17) 2.45 (1.88,3.19) 2.45 (1.88,3.20) 
Age 75-84 2.54 (1.93,3.33) 2.32 (1.72,3.13) 2.33 (1.72,3.14) 
Age 85+ 3.02 (2.08,4.38) 2.71 (1.80,4.07) 2.68 (1.78,4.04) 
Hip (reference: knee) 0.40 (0.30,0.55) 0.34 (0.25,0.47) 0.34 (0.24,0.46) 
Ankle/foot 0.52 (0.32,0.83) 0.53 (0.32,0.88) 0.53 (0.32,0.88) 
Wrist/hand 1.11 (0.79,1.57) 1.27 (0.89,1.82) 1.28 (0.89,1.83) 
Unspecified 0.97 (0.62,1.54) 0.92 (0.56,1.50) 0.91 (0.56,1.49) 
Multisite 1.39 (1.02,1.90) 1.03 (0.73,1.46) 1.02 (0.73,1.44) 
BMI 25 to <30 (reference: BMI <25) 1.15 (0.83,1.62) 1.16 (0.82,1.65) 1.16 (0.82,1.66) 
BMI 30+ 1.09 (0.78,1.51) 1.04 (0.73,1.47) 1.04 (0.73,1.47) 
BMI unknown 1.06 (0.77,1.46) 1.23 (0.87,1.72) 1.23 (0.87,1.73) 
5-9 BNF chapters (reference: 0-4) 1.78 (1.40,2.26) 1.40 (1.08,1.82) 1.41 (1.09,1.83) 
10+ BNF chapters 2.44 (1.90,3.12) 1.82 (1.37,2.41) 1.83 (1.38,2.43) 
Multiple consultations in phase 1 (vs. single) 1.71 (1.40,2.09) 1.59 (1.27,1.98) 1.59 (1.27,1.99) 
X-ray, phase 1a (vs. none) 0.96 (0.65,1.43) 1.00 (0.66,1.53) 0.99 (0.65,1.52) 
Above the clinician median index consultation count 
(reference: at or below the median) 
0.95 (0.59,1.54) 0.75 (0.44,1.25) 0.77 (0.46,1.30) 
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Topical NSAIDs prescription within 14 days of a clinical 
OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 3.47 (1.52,7.94) 4.61 (1.87,11.4) - 
Practice 3 1.09 (0.64,1.86) 1.20 (0.67,2.14) - 
Practice 4 1.14 (0.65,1.99) 1.21 (0.66,2.24) - 
Practice 5 2.17 (1.23,3.82) 2.59 (1.39,4.83) - 
Practice 6 0.71 (0.28,1.78) 0.74 (0.28,1.99) - 
Practice 7 0.70 (0.38,1.28) 0.68 (0.35,1.32) - 
Practice 8 2.47 (1.25,4.88) 2.56 (1.19,5.51) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between topical NSAID prescription within 14 days of a consultation for clinical OA 
in phase one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.2.3. Paracetamol or topical NSAIDs 
Paracetamol or topical NSAID prescription within 14 
days of a clinical OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.85 (1.56,2.20) 1.27 (1.03,1.55) 1.29 (1.05,1.58) 
Sex (reference: female) 0.63 (0.53,0.75) 0.65 (0.54,0.78) 0.65 (0.54,0.78) 
Age 65-74 (reference: 45-64) 2.57 (2.09,3.17) 2.29 (1.84,2.85) 2.28 (1.83,2.84) 
Age 75-84 3.78 (3.03,4.72) 3.04 (2.39,3.88) 3.03 (2.38,3.86) 
Age 85+ 4.76 (3.51,6.47) 3.75 (2.69,5.23) 3.69 (2.65,5.15) 
Hip (reference: knee) 0.81 (0.66,1.01) 0.69 (0.55,0.87) 0.68 (0.54,0.86) 
Ankle/foot 0.47 (0.32,0.71) 0.51 (0.34,0.79) 0.52 (0.34,0.80) 
Wrist/hand 0.85 (0.63,1.16) 0.99 (0.71,1.37) 0.99 (0.72,1.37) 
Unspecified 1.35 (0.93,1.95) 1.22 (0.81,1.83) 1.20 (0.80,1.80) 
Multisite 1.77 (1.37,2.29) 1.14 (0.85,1.52) 1.13 (0.84,1.51) 
BMI 25 to <30 (reference: BMI <25) 1.06 (0.81,1.39) 1.10 (0.83,1.47) 1.10 (0.83,1.47) 
BMI 30+ 1.10 (0.85,1.42) 1.09 (0.82,1.44) 1.09 (0.82,1.44) 
BMI unknown 0.87 (0.67,1.13) 1.04 (0.79,1.38) 1.04 (0.79,1.37) 
5-9 BNF chapters (reference: 0-4) 2.18 (1.79,2.65) 1.53 (1.24,1.89) 1.54 (1.24,1.90) 
10+ BNF chapters 3.45 (2.81,4.25) 2.11 (1.67,2.67) 2.13 (1.68,2.68) 
Multiple consultations in phase 1 (vs. single) 1.88 (1.60,2.22) 1.69 (1.41,2.03) 1.69 (1.41,2.03) 
X-ray, phase 1a (vs. none) 1.16 (0.85,1.57) 1.00 (0.71,1.40) 0.99 (0.71,1.39) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.06 (0.73,1.53) 0.85 (0.56,1.28) 0.88 (0.58,1.32) 
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Paracetamol or topical NSAID prescription within 14 
days of a clinical OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.75 (0.95,3.23) 2.27 (1.15,4.51) - 
Practice 3 0.92 (0.63,1.36) 1.10 (0.72,1.70) - 
Practice 4 0.76 (0.51,1.13) 0.78 (0.49,1.23) - 
Practice 5 1.32 (0.87,2.00) 1.76 (1.09,2.82) - 
Practice 6 0.87 (0.47,1.61) 0.98 (0.49,1.94) - 
Practice 7 0.65 (0.42,1.00) 0.71 (0.44,1.15) - 
Practice 8 1.47 (0.86,2.50) 1.48 (0.81,2.72) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between paracetamol or topical NSAID prescription within 14 days of a consultation 
for clinical OA in phase one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.2.4. Opioids 
Opioids prescription within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 2.06 (1.75,2.43) 1.44 (1.19,1.75) 1.46 (1.20,1.77) 
Sex (reference: female) 0.82 (0.70,0.95) 0.88 (0.74,1.04) 0.88 (0.74,1.05) 
Age 65-74 (reference: 45-64) 1.69 (1.40,2.03) 1.38 (1.13,1.70) 1.39 (1.13,1.70) 
Age 75-84 1.90 (1.54,2.33) 1.33 (1.05,1.69) 1.32 (1.04,1.68) 
Age 85+ 2.43 (1.81,3.26) 1.72 (1.24,2.39) 1.71 (1.23,2.38) 
Hip (reference: knee) 1.33 (1.10,1.61) 1.36 (1.11,1.68) 1.36 (1.11,1.68) 
Ankle/foot 0.36 (0.24,0.55) 0.43 (0.28,0.65) 0.42 (0.27,0.64) 
Wrist/hand 0.46 (0.33,0.63) 0.56 (0.39,0.79) 0.56 (0.40,0.79) 
Unspecified 1.26 (0.88,1.81) 1.20 (0.81,1.80) 1.20 (0.80,1.79) 
Multisite 2.17 (1.69,2.78) 1.13 (0.86,1.49) 1.12 (0.85,1.48) 
BMI 25 to <30 (reference: BMI <25) 1.03 (0.79,1.33) 1.00 (0.76,1.33) 1.00 (0.75,1.32) 
BMI 30+ 1.64 (1.28,2.09) 1.44 (1.10,1.89) 1.44 (1.10,1.89) 
BMI unknown 0.93 (0.73,1.19) 1.02 (0.78,1.34) 1.01 (0.77,1.33) 
5-9 BNF chapters (reference: 0-4) 2.09 (1.74,2.50) 1.62 (1.32,1.98) 1.63 (1.34,2.00) 
10+ BNF chapters 3.67 (3.01,4.48) 2.66 (2.13,3.34) 2.72 (2.17,3.41) 
Multiple consultations in phase 1 (vs. single) 3.40 (2.90,3.98) 3.05 (2.57,3.63) 3.07 (2.58,3.65) 
X-ray, phase 1a (vs. none) 1.63 (1.23,2.15) 1.04 (0.76,1.42) 1.04 (0.76,1.43) 
Above the clinician median index consultation count 
(reference: at or below the median) 
0.68 (0.49,0.94) 0.71 (0.50,1.01) 0.68 (0.48,0.98) 
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Opioids prescription within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.89 (1.23,2.91) 2.42 (1.45,4.06) - 
Practice 3 0.83 (0.62,1.11) 0.97 (0.69,1.37) - 
Practice 4 0.59 (0.43,0.79) 0.66 (0.46,0.94) - 
Practice 5 0.71 (0.52,0.97) 0.95 (0.65,1.38) - 
Practice 6 1.32 (0.86,2.03) 1.45 (0.87,2.44) - 
Practice 7 1.52 (1.13,2.05) 1.81 (1.26,2.60) - 
Practice 8 1.37 (0.90,2.07) 1.13 (0.69,1.85) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between opioid prescription within 14 days of a consultation for clinical OA in phase 
one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.2.5. Oral NSAIDs 
Oral NSAIDs prescription within 14 days of a clinical 
OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.16 (0.95,1.43) 1.03 (0.81,1.31) 1.03 (0.81,1.31) 
Sex (reference: female) 1.13 (0.93,1.37) 1.10 (0.90,1.35) 1.10 (0.90,1.35) 
Age 65-74 (reference: 45-64) 0.62 (0.49,0.78) 0.62 (0.49,0.79) 0.62 (0.48,0.79) 
Age 75-84 0.45 (0.34,0.61) 0.46 (0.34,0.62) 0.46 (0.33,0.62) 
Age 85+ 0.22 (0.13,0.39) 0.22 (0.12,0.39) 0.22 (0.12,0.39) 
Hip (reference: knee) 0.95 (0.74,1.21) 1.06 (0.82,1.38) 1.06 (0.82,1.38) 
Ankle/foot 0.87 (0.57,1.35) 1.01 (0.65,1.58) 1.01 (0.64,1.58) 
Wrist/hand 0.92 (0.64,1.33) 1.10 (0.75,1.60) 1.09 (0.74,1.60) 
Unspecified 1.14 (0.72,1.78) 1.36 (0.85,2.19) 1.38 (0.85,2.22) 
Multisite 1.55 (1.15,2.08) 1.24 (0.89,1.72) 1.24 (0.89,1.72) 
BMI 25 to <30 (reference: BMI <25) 1.32 (0.94,1.85) 1.26 (0.89,1.79) 1.26 (0.89,1.80) 
BMI 30+ 1.31 (0.94,1.81) 1.14 (0.81,1.61) 1.14 (0.81,1.61) 
BMI unknown 1.51 (1.10,2.07) 1.33 (0.96,1.85) 1.33 (0.96,1.86) 
5-9 BNF chapters (reference: 0-4) 0.87 (0.70,1.08) 0.99 (0.78,1.26) 1.00 (0.78,1.27) 
10+ BNF chapters 0.59 (0.45,0.77) 0.73 (0.54,0.98) 0.73 (0.54,0.99) 
Multiple consultations in phase 1 (vs. single) 2.56 (2.11,3.11) 2.61 (2.12,3.22) 2.62 (2.12,3.24) 
X-ray, phase 1a (vs. none) 1.80 (1.31,2.47) 1.38 (0.97,1.96) 1.38 (0.97,1.97) 
Above the clinician median index consultation count 
(reference: at or below the median) 
0.95 (0.60,1.50) 0.90 (0.58,1.41) 0.93 (0.59,1.47) 
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Oral NSAIDs prescription within 14 days of a clinical 
OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.83 (0.39,1.80) 0.90 (0.42,1.92) - 
Practice 3 1.22 (0.78,1.90) 1.19 (0.76,1.85) - 
Practice 4 0.75 (0.46,1.23) 0.87 (0.54,1.42) - 
Practice 5 0.37 (0.21,0.67) 0.35 (0.20,0.63) - 
Practice 6 0.89 (0.43,1.86) 0.91 (0.44,1.89) - 
Practice 7 0.34 (0.19,0.62) 0.29 (0.16,0.52) - 
Practice 8 0.68 (0.34,1.35) 0.59 (0.29,1.17) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between oral NSAID prescription within 14 days of a consultation for clinical OA in 
phase one and the independent variables. Adjusted models include all independent variables. 
 
 413 
Appendix F.2.6. Oral NSAIDs in the presence of a recorded relative contraindication 
Oral NSAIDs prescription within 14 days of a clinical 
OA consultation with relative contraindication, phase 
1 
Two level models 
Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.36 (1.00,1.85) 1.18 (0.82,1.69) 1.19 (0.83,1.71) 
Sex (reference: female) 1.11 (0.83,1.50) 1.14 (0.83,1.55) 1.13 (0.83,1.55) 
Age 65-74 (reference: 45-64) 0.54 (0.38,0.77) 0.53 (0.37,0.76) 0.52 (0.36,0.76) 
Age 75-84 0.41 (0.27,0.61) 0.37 (0.24,0.56) 0.37 (0.24,0.57) 
Age 85+ 0.33 (0.17,0.64) 0.29 (0.15,0.58) 0.29 (0.15,0.58) 
Hip (reference: knee) 0.94 (0.64,1.39) 1.03 (0.69,1.53) 1.02 (0.68,1.53) 
Ankle/foot 1.11 (0.60,2.05) 1.29 (0.69,2.41) 1.29 (0.68,2.43) 
Wrist/hand 1.00 (0.56,1.77) 1.23 (0.68,2.21) 1.22 (0.67,2.21) 
Unspecified 0.99 (0.44,2.20) 1.24 (0.54,2.86) 1.21 (0.52,2.80) 
Multisite 1.72 (1.13,2.62) 1.37 (0.86,2.17) 1.37 (0.86,2.18) 
BMI 25 to <30 (reference: BMI <25) 1.62 (0.96,2.74) 1.49 (0.88,2.55) 1.51 (0.88,2.59) 
BMI 30+ 1.62 (0.98,2.68) 1.28 (0.76,2.16) 1.27 (0.75,2.16) 
BMI unknown 1.39 (0.80,2.42) 1.18 (0.67,2.08) 1.20 (0.68,2.12) 
5-9 BNF chapters (reference: 0-4) 0.95 (0.67,1.35) 1.09 (0.75,1.59) 1.11 (0.76,1.61) 
10+ BNF chapters 0.91 (0.63,1.32) 1.10 (0.73,1.64) 1.10 (0.73,1.66) 
Multiple consultations in phase 1 (vs. single) 2.24 (1.66,3.02) 2.00 (1.44,2.76) 2.03 (1.46,2.81) 
X-ray, phase 1a (vs. none) 2.16 (1.39,3.36) 1.60 (0.99,2.60) 1.60 (0.99,2.61) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.16 (0.59,2.26) 1.06 (0.55,2.05) 1.09 (0.56,2.14) 
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Oral NSAIDs prescription within 14 days of a clinical 
OA consultation with relative contraindication, phase 
1 
Two level models 
Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.57 (0.23,1.45) 0.67 (0.26,1.71) - 
Practice 3 1.64 (1.03,2.61) 1.78 (1.09,2.89) - 
Practice 4 0.66 (0.35,1.24) 0.83 (0.43,1.58) - 
Practice 5 0.41 (0.21,0.81) 0.44 (0.23,0.87) - 
Practice 6 1.24 (0.63,2.43) 1.27 (0.63,2.55) - 
Practice 7 0.25 (0.11,0.55) 0.24 (0.10,0.55) - 
Practice 8 0.76 (0.36,1.63) 0.74 (0.34,1.61) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between oral NSAID prescription in the presence of a relative comorbidity 
contraindication, within 14 days of a consultation for clinical OA in phase one and the independent variables. Adjusted 
models include all independent variables. 
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Appendix F.2.7. PPIs (in those prescribed oral NSAIDs) 
PPI prescription within 14 days of a clinical OA 
consultation, phase 1 (in those prescribed an oral 
NSAID) 
Two level models 
Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.34 (0.93,1.93) 1.06 (0.67,1.68) 1.11 (0.71,1.75) 
Sex (reference: female) 0.72 (0.50,1.04) 0.71 (0.48,1.05) 0.74 (0.50,1.09) 
Age 65-74 (reference: 45-64) 2.02 (1.32,3.10) 2.11 (1.33,3.35) 2.17 (1.37,3.45) 
Age 75-84 2.64 (1.55,4.49) 2.16 (1.19,3.90) 2.08 (1.15,3.77) 
Age 85+ 12.1 (3.22,45.7) 9.66 (2.35,39.6) 10.9 (2.63,44.8) 
Hip (reference: knee) 1.22 (0.77,1.93) 1.10 (0.66,1.86) 1.13 (0.67,1.89) 
Ankle/foot 1.18 (0.52,2.66) 1.23 (0.51,2.97) 1.32 (0.55,3.15) 
Wrist/hand 0.80 (0.38,1.66) 0.87 (0.40,1.92) 0.88 (0.40,1.93) 
Unspecified 1.24 (0.55,2.82) 0.97 (0.39,2.41) 0.93 (0.38,2.28) 
Multisite 1.03 (0.61,1.75) 0.65 (0.35,1.21) 0.61 (0.33,1.12) 
BMI 25 to <30 (reference: BMI <25) 1.27 (0.67,2.42) 1.35 (0.67,2.70) 1.34 (0.67,2.68) 
BMI 30+ 1.25 (0.67,2.33) 1.43 (0.71,2.86) 1.47 (0.74,2.94) 
BMI unknown 1.08 (0.58,1.98) 1.41 (0.72,2.75) 1.52 (0.78,2.96) 
5-9 BNF chapters (reference: 0-4) 1.81 (1.19,2.73) 1.33 (0.84,2.11) 1.29 (0.82,2.05) 
10+ BNF chapters 3.66 (2.21,6.08) 3.11 (1.75,5.55) 3.21 (1.81,5.69) 
Multiple consultations in phase 1 (vs. single) 1.69 (1.17,2.44) 1.73 (1.14,2.63) 1.84 (1.22,2.79) 
X-ray, phase 1* (vs. none) 1.45 (0.85,2.48) 1.28 (0.68,2.42) 1.20 (0.64,2.26) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.01 (0.50,2.04) 1.03 (0.47,2.29) 0.93 (0.43,2.03) 
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PPI prescription within 14 days of a clinical OA 
consultation, phase 1 (in those prescribed an oral 
NSAID) 
Two level models 
Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.44 (0.16,1.23) 0.56 (0.18,1.77) - 
Practice 3 0.98 (0.57,1.70) 0.88 (0.47,1.65) - 
Practice 4 0.72 (0.39,1.35) 0.77 (0.38,1.58) - 
Practice 5 2.31 (1.06,5.07) 2.19 (0.91,5.28) - 
Practice 6 0.88 (0.35,2.21) 0.86 (0.30,2.46) - 
Practice 7 2.50 (1.06,5.88) 2.90 (1.11,7.55) - 
Practice 8 1.01 (0.41,2.49) 0.92 (0.34,2.54) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between PPI prescription within 14 days of a consultation for clinical OA in phase 
one and the independent variables. Adjusted models include all independent variables. 
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 Referral management 
Appendix F.3.1. Physiotherapy referral 
Physiotherapy referral within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 0.81 (0.59,1.11) 0.51 (0.35,0.75) 0.52 (0.35,0.76) 
Sex (reference: female) 0.92 (0.68,1.24) 0.87 (0.64,1.18) 0.87 (0.64,1.19) 
Age 65-74 (reference: 45-64) 0.78 (0.55,1.11) 0.85 (0.58,1.23) 0.84 (0.58,1.23) 
Age 75-84 0.73 (0.48,1.09) 0.81 (0.52,1.28) 0.81 (0.51,1.27) 
Age 85+ 0.47 (0.24,0.93) 0.52 (0.25,1.07) 0.52 (0.25,1.06) 
Hip (reference: knee) 0.97 (0.68,1.40) 0.99 (0.68,1.44) 0.99 (0.68,1.45) 
Ankle/foot 0.21 (0.07,0.68) 0.24 (0.07,0.79) 0.24 (0.07,0.79) 
Wrist/hand 0.47 (0.24,0.93) 0.48 (0.24,0.97) 0.49 (0.24,0.97) 
Unspecified 0.20 (0.05,0.82) 0.30 (0.07,1.28) 0.30 (0.07,1.28) 
Multisite 1.37 (0.91,2.08) 1.40 (0.88,2.21) 1.39 (0.88,2.20) 
BMI 25 to <30 (reference: BMI <25) 0.71 (0.44,1.13) 0.68 (0.42,1.11) 0.68 (0.42,1.11) 
BMI 30+ 0.86 (0.55,1.33) 0.75 (0.47,1.20) 0.75 (0.47,1.19) 
BMI unknown 0.78 (0.50,1.22) 0.70 (0.44,1.11) 0.70 (0.44,1.11) 
5-9 BNF chapters (reference: 0-4) 0.83 (0.59,1.17) 0.82 (0.56,1.19) 0.83 (0.57,1.20) 
10+ BNF chapters 0.81 (0.55,1.19) 0.79 (0.51,1.22) 0.80 (0.51,1.24) 
Multiple consultations in phase 1 (vs. single) 2.86 (2.11,3.86) 2.75 (2.00,3.79) 2.75 (2.00,3.79) 
X-ray, phase 1a (vs. none) 2.18 (1.44,3.31) 1.78 (1.14,2.79) 1.79 (1.14,2.81) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.04 (0.47,2.28) 1.23 (0.64,2.34) 1.22 (0.63,2.36) 
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Physiotherapy referral within 14 days of a clinical OA 
consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.62 (0.29,1.30) 0.75 (0.35,1.61) - 
Practice 3 0.18 (0.09,0.35) 0.16 (0.08,0.32) - 
Practice 4 0.01 (0.00,0.10) 0.02 (0.00,0.11) - 
Practice 5 0.00 (0.00,0.00) 0.00 (0.00,0.00) - 
Practice 6 0.52 (0.24,1.12) 0.48 (0.21,1.06) - 
Practice 7 0.46 (0.26,0.79) 0.40 (0.22,0.71) - 
Practice 8 0.09 (0.02,0.37) 0.07 (0.02,0.32) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between physiotherapy referral within 14 days of a consultation for clinical OA in 
phase one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.3.2. All primary care referrals 
All primary care team referrals within 14 days of a 
clinical OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 0.77 (0.56,1.05) 0.44 (0.31,0.64) 0.44 (0.30,0.64) 
Sex (reference: female) 0.87 (0.65,1.17) 0.85 (0.63,1.14) 0.85 (0.63,1.16) 
Age 65-74 (reference: 45-64) 0.77 (0.54,1.09) 0.81 (0.56,1.16) 0.80 (0.56,1.16) 
Age 75-84 0.74 (0.50,1.10) 0.81 (0.53,1.24) 0.80 (0.51,1.24) 
Age 85+ 0.63 (0.35,1.15) 0.67 (0.36,1.26) 0.67 (0.35,1.27) 
Hip (reference: knee) 0.97 (0.67,1.40) 0.96 (0.67,1.40) 0.97 (0.66,1.42) 
Ankle/foot 0.25 (0.09,0.76) 0.29 (0.10,0.84) 0.29 (0.10,0.86) 
Wrist/hand 0.88 (0.51,1.51) 0.94 (0.55,1.63) 0.95 (0.54,1.67) 
Unspecified 0.69 (0.30,1.60) 1.12 (0.48,2.62) 1.12 (0.46,2.71) 
Multisite 1.61 (1.08,2.40) 1.62 (1.05,2.51) 1.63 (1.04,2.54) 
BMI 25 to <30 (reference: BMI <25) 0.69 (0.44,1.09) 0.70 (0.45,1.11) 0.69 (0.43,1.11) 
BMI 30+ 0.85 (0.56,1.30) 0.77 (0.50,1.19) 0.77 (0.49,1.20) 
BMI unknown 0.67 (0.44,1.04) 0.64 (0.41,0.99) 0.63 (0.40,0.99) 
5-9 BNF chapters (reference: 0-4) 0.86 (0.61,1.20) 0.85 (0.59,1.22) 0.85 (0.59,1.23) 
10+ BNF chapters 0.99 (0.69,1.42) 0.94 (0.62,1.41) 0.95 (0.62,1.44) 
Multiple consultations in phase 1 (vs. single) 3.18 (2.36,4.28) 3.07 (2.26,4.15) 3.12 (2.27,4.28) 
X-ray, phase 1a (vs. none) 2.28 (1.52,3.43) 1.95 (1.27,3.01) 2.01 (1.29,3.12) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.13 (0.50,2.53) 1.03 (0.57,1.86) 1.05 (0.56,1.97) 
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All primary care team referrals within 14 days of a 
clinical OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.58 (0.28,1.22) 0.65 (0.30,1.44) - 
Practice 3 0.15 (0.08,0.31) 0.14 (0.07,0.28) - 
Practice 4 0.05 (0.02,0.14) 0.05 (0.02,0.15) - 
Practice 5 0.04 (0.01,0.14) 0.04 (0.01,0.14) - 
Practice 6 0.56 (0.27,1.17) 0.48 (0.22,1.06) - 
Practice 7 0.52 (0.31,0.87) 0.41 (0.23,0.72) - 
Practice 8 0.15 (0.05,0.46) 0.12 (0.04,0.38) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between any referral to a primary care team member within 14 days of a 
consultation for clinical OA in phase one and the independent variables. Adjusted models include all independent variables. 
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Appendix F.3.3. All secondary care referrals 
All secondary care team (specialist) referrals within 14 
days of a clinical OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.50 (1.24,1.82) 1.31 (1.04,1.64) 1.30 (1.04,1.63) 
Sex (reference: female) 1.18 (0.98,1.42) 1.18 (0.97,1.44) 1.18 (0.97,1.44) 
Age 65-74 (reference: 45-64) 0.99 (0.80,1.22) 0.92 (0.72,1.16) 0.91 (0.72,1.16) 
Age 75-84 0.67 (0.51,0.87) 0.59 (0.44,0.79) 0.59 (0.44,0.79) 
Age 85+ 0.39 (0.25,0.63) 0.34 (0.20,0.55) 0.34 (0.21,0.56) 
Hip (reference: knee) 0.94 (0.75,1.19) 1.01 (0.80,1.29) 1.02 (0.80,1.30) 
Ankle/foot 0.29 (0.17,0.51) 0.36 (0.20,0.64) 0.35 (0.20,0.63) 
Wrist/hand 0.39 (0.25,0.60) 0.48 (0.31,0.76) 0.48 (0.30,0.75) 
Unspecified 0.24 (0.12,0.48) 0.23 (0.11,0.47) 0.24 (0.12,0.49) 
Multisite 1.23 (0.92,1.64) 0.78 (0.57,1.07) 0.78 (0.57,1.07) 
BMI 25 to <30 (reference: BMI <25) 1.49 (1.08,2.07) 1.35 (0.95,1.90) 1.35 (0.96,1.90) 
BMI 30+ 1.57 (1.14,2.16) 1.23 (0.88,1.73) 1.24 (0.89,1.74) 
BMI unknown 1.29 (0.94,1.77) 1.15 (0.83,1.61) 1.15 (0.82,1.60) 
5-9 BNF chapters (reference: 0-4) 1.10 (0.89,1.36) 1.04 (0.82,1.32) 1.04 (0.82,1.32) 
10+ BNF chapters 0.93 (0.73,1.18) 0.98 (0.74,1.30) 0.98 (0.74,1.29) 
Multiple consultations in phase 1 (vs. single) 3.46 (2.85,4.19) 3.24 (2.64,3.98) 3.22 (2.62,3.96) 
X-ray, phase 1a (vs. none) 2.54 (1.89,3.43) 1.67 (1.19,2.33) 1.66 (1.19,2.31) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.18 (0.79,1.77) 1.25 (0.82,1.92) 1.26 (0.82,1.93) 
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All secondary care team (specialist) referrals within 14 
days of a clinical OA consultation, phase 1 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.76 (0.43,1.33) 0.93 (0.52,1.65) - 
Practice 3 0.64 (0.44,0.93) 0.71 (0.48,1.04) - 
Practice 4 1.16 (0.83,1.61) 1.67 (1.18,2.36) - 
Practice 5 0.64 (0.43,0.95) 0.71 (0.47,1.07) - 
Practice 6 1.16 (0.69,1.93) 1.33 (0.78,2.27) - 
Practice 7 0.97 (0.67,1.40) 1.11 (0.75,1.65) - 
Practice 8 1.07 (0.65,1.77) 0.90 (0.53,1.53) - 
arecorded relevant X-ray in phase 1 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between any referral to a secondary care speciality within 14 days of a consultation 
for clinical OA in phase one and the independent variables. Adjusted models include all independent variables.
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Appendix G. Template-derived quality of care appendices (Chapter Six) 
 Template triggering patterns 
The descriptive epidemiological characteristics of patients triggering versus not triggering the 
template are shown below. Non-triggering of the template occurred in all practices but was most 
frequent in practice 4 and to a lesser extent in practices 3 and 7. There was no substantial 
difference between males and females or between age bands.  
 Template triggered n (%) Template not triggered n (%) 
Total 1730 (93.5) 121 (6.5) 
Diagnosis   
Joint pain 95 (7.7) 1142 (92.3) 
OA 26 (4.2) 588 (95.8) 
Sex   
M 711 (93.4) 50 (6.6) 
F 1019 (93.5) 71 (6.5) 
Age band   
45-64 819 (92.9) 63 (7.1) 
65-74 443 (94.3) 27 (5.7) 
75-84 351 (94.1) 22 (5.9) 
85+ 117 (92.9) 9 (7.1) 
Practice   
1 612 (97.9%) 13 (2.1%) 
2 93 (98.9%) 1 (1.1%) 
3 220 (89.8%) 25 (10.2%) 
4 202 (81.8%) 45 (18.2%) 
5 231 (93.5%) 16 (6.5%) 
6 96 (99.0%) 1 (1.0%) 
7 163 (90.6%) 17 (9.4%) 
8 113 (97.4%) 3 (2.6%) 
Characteristics and practices of patients triggering or not triggering the recording template in phase 
2 
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 Template-derived quality indicators - multilevel models 
Appendix G.2.1. Pain assessment 
Pain assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.33 (1.02,1.73) 1.26 (0.93,1.72) 1.26 (0.93,1.72) 
Sex (reference: female) 1.12 (0.88,1.42) 1.09 (0.84,1.41) 1.09 (0.84,1.41) 
Age 65-74 (reference: 45-64) 1.20 (0.90,1.61) 1.21 (0.87,1.67) 1.21 (0.87,1.67) 
Age 75-84 1.33 (0.97,1.82) 1.46 (1.02,2.10) 1.46 (1.02,2.10) 
Age 85+ 1.07 (0.66,1.74) 1.35 (0.78,2.35) 1.35 (0.77,2.35) 
Hip (reference: knee) 0.89 (0.66,1.22) 0.92 (0.66,1.27) 0.91 (0.66,1.27) 
Ankle/foot 0.33 (0.20,0.52) 0.40 (0.24,0.66) 0.40 (0.24,0.66) 
Wrist/hand 0.69 (0.45,1.06) 0.83 (0.53,1.29) 0.83 (0.53,1.30) 
Unspecified 0.61 (0.37,1.02) 0.67 (0.39,1.15) 0.67 (0.39,1.16) 
Multisite 1.08 (0.67,1.74) 0.66 (0.39,1.12) 0.66 (0.39,1.12) 
BMI 25 to <30 (reference: BMI <25) 1.27 (0.89,1.81) 1.31 (0.90,1.91) 1.30 (0.90,1.90) 
BMI 30+ 1.24 (0.88,1.76) 1.35 (0.93,1.98) 1.35 (0.93,1.97) 
BMI unknown 0.72 (0.50,1.06) 0.67 (0.45,1.00) 0.67 (0.45,1.00) 
5-9 BNF chapters (reference: 0-4) 1.18 (0.87,1.60) 0.90 (0.64,1.26) 0.90 (0.65,1.27) 
10+ BNF chapters 0.91 (0.68,1.22) 0.58 (0.41,0.84) 0.59 (0.41,0.84) 
Multiple consultations in phase 2 (vs. single) 2.85 (2.16,3.76) 3.03 (2.24,4.11) 3.00 (2.21,4.08) 
X-ray, phase 2a (vs. none) 1.26 (0.72,2.22) 1.04 (0.57,1.91) 1.07 (0.59,1.96) 
Above the clinician median index consultation count 
(reference: at or below the median) 
2.54 (1.14,5.64) 2.42 (1.11,5.27) 2.60 (1.15,5.86) 
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Pain assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.34 (0.04,2.73) 1.49 (0.16,13.4) - 
Practice 3 0.54 (0.05,6.40) 0.48 (0.17,1.33) - 
Practice 4 0.04 (0.00,0.34) 0.22 (0.06,0.78) - 
Practice 5 0.12 (0.01,1.02) 0.08 (0.02,0.30) - 
Practice 6 0.18 (0.02,1.29) 1.20 (0.20,7.29) - 
Practice 7 0.85 (0.05,13.9) 0.70 (0.21,2.29) - 
Practice 8 0.47 (0.07,3.25) 2.31 (0.34,15.6) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-recorded pain assessment in phase two and the independent 
variables. Adjusted models include all independent variables. 
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Appendix G.2.2. Function assessment 
Function assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.30 (1.00,1.68) 1.15 (0.85,1.56) 1.15 (0.85,1.56) 
Sex (reference: female) 1.05 (0.83,1.33) 1.01 (0.78,1.30) 1.01 (0.78,1.30) 
Age 65-74 (reference: 45-64) 1.29 (0.97,1.71) 1.32 (0.96,1.82) 1.32 (0.96,1.82) 
Age 75-84 1.27 (0.94,1.72) 1.40 (0.98,1.99) 1.40 (0.98,2.00) 
Age 85+ 0.98 (0.61,1.57) 1.16 (0.67,1.98) 1.16 (0.67,1.99) 
Hip (reference: knee) 0.84 (0.62,1.14) 0.84 (0.61,1.16) 0.84 (0.61,1.16) 
Ankle/foot 0.30 (0.19,0.48) 0.35 (0.21,0.57) 0.35 (0.21,0.58) 
Wrist/hand 0.76 (0.49,1.15) 0.90 (0.58,1.41) 0.91 (0.58,1.42) 
Unspecified 0.51 (0.31,0.84) 0.56 (0.33,0.95) 0.56 (0.33,0.96) 
Multisite 1.39 (0.86,2.27) 0.91 (0.53,1.55) 0.91 (0.53,1.56) 
BMI 25 to <30 (reference: BMI <25) 1.26 (0.89,1.78) 1.31 (0.91,1.90) 1.31 (0.90,1.89) 
BMI 30+ 1.21 (0.86,1.70) 1.29 (0.89,1.88) 1.30 (0.89,1.88) 
BMI unknown 0.65 (0.45,0.94) 0.59 (0.40,0.88) 0.59 (0.40,0.87) 
5-9 BNF chapters (reference: 0-4) 1.00 (0.74,1.35) 0.72 (0.52,1.01) 0.73 (0.52,1.01) 
10+ BNF chapters 0.91 (0.68,1.21) 0.58 (0.41,0.83) 0.58 (0.41,0.83) 
Multiple consultations in phase 2 (vs. single) 3.04 (2.31,4.00) 3.11 (2.31,4.19) 3.11 (2.31,4.20) 
X-ray, phase 2a (vs. none) 1.53 (0.87,2.67) 1.37 (0.75,2.49) 1.41 (0.77,2.57) 
Above the clinician median index consultation count 
(reference: at or below the median) 
3.30 (1.57,6.97) 3.28 (1.58,6.82) 3.58 (1.66,7.73) 
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Function assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.40 (0.06,2.79) 1.94 (0.24,15.5) - 
Practice 3 0.72 (0.07,7.43) 0.48 (0.18,1.24) - 
Practice 4 0.05 (0.01,0.39) 0.29 (0.09,0.93) - 
Practice 5 0.15 (0.02,1.09) 0.11 (0.03,0.38) - 
Practice 6 0.17 (0.03,1.08) 1.66 (0.30,9.22) - 
Practice 7 1.21 (0.09,17.0) 0.86 (0.28,2.60) - 
Practice 8 0.48 (0.08,2.87) 2.40 (0.41,14.0) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-recorded function assessment in phase two and the independent 
variables. Adjusted models include all independent variables. 
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Appendix G.2.3. Weight record within 14 days of a clinical OA consultation 
Weight record within 14 days of a clinical OA 
consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.05 (0.81,1.37) 0.95 (0.70,1.30) 0.97 (0.71,1.32) 
Sex (reference: female) 1.20 (0.93,1.53) 1.27 (0.98,1.65) 1.27 (0.97,1.65) 
Age 65-74 (reference: 45-64) 1.22 (0.91,1.63) 1.12 (0.82,1.55) 1.12 (0.81,1.55) 
Age 75-84 0.90 (0.64,1.25) 0.90 (0.62,1.30) 0.89 (0.61,1.30) 
Age 85+ 0.53 (0.30,0.93) 0.58 (0.31,1.09) 0.58 (0.31,1.08) 
Hip (reference: knee) 0.99 (0.72,1.36) 1.06 (0.75,1.48) 1.06 (0.75,1.49) 
Ankle/foot 0.81 (0.49,1.35) 0.97 (0.57,1.65) 0.97 (0.56,1.65) 
Wrist/hand 0.64 (0.40,1.05) 0.69 (0.41,1.14) 0.68 (0.41,1.13) 
Unspecified 0.98 (0.58,1.65) 1.19 (0.68,2.08) 1.20 (0.69,2.11) 
Multisite 1.36 (0.87,2.14) 1.34 (0.82,2.20) 1.34 (0.81,2.20) 
BMI 25 to <30 (reference: BMI <25) 0.84 (0.59,1.18) 0.78 (0.54,1.11) 0.77 (0.53,1.10) 
BMI 30+ 1.17 (0.83,1.64) 1.09 (0.76,1.56) 1.08 (0.75,1.55) 
BMI unknown 0.30 (0.18,0.48) 0.26 (0.16,0.42) 0.25 (0.15,0.42) 
5-9 BNF chapters (reference: 0-4) 1.46 (1.07,1.99) 1.28 (0.90,1.80) 1.29 (0.91,1.83) 
10+ BNF chapters 0.94 (0.69,1.29) 0.77 (0.53,1.12) 0.78 (0.53,1.13) 
Multiple consultations in phase 2 (vs. single) 2.02 (1.55,2.62) 2.13 (1.61,2.82) 2.12 (1.60,2.82) 
X-ray, phase 2a (vs. none) 1.22 (0.86,1.73) 0.88 (0.49,1.56) 0.89 (0.50,1.59) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.07 (0.63,1.81) 1.31 (0.69,2.46) 1.47 (0.76,2.86) 
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Weight record within 14 days of a clinical OA 
consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.54 (0.79,3.01) 1.94 (0.50,7.53) - 
Practice 3 1.84 (0.48,7.03) 0.35 (0.15,0.79) - 
Practice 4 0.32 (0.14,0.71) 0.95 (0.39,2.33) - 
Practice 5 0.97 (0.40,2.33) 0.30 (0.12,0.77) - 
Practice 6 0.34 (0.13,0.85) 0.93 (0.27,3.22) - 
Practice 7 1.21 (0.36,4.08) 0.22 (0.08,0.60) - 
Practice 8 0.26 (0.10,0.71) 1.52 (0.45,5.14) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between weight record within 14 days of a clinical OA consultation in phase two and 
the independent variables. Adjusted models include all independent variables. 
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Appendix G.2.4. Assessment of paracetamol use 
Paracetamol assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.50 (1.18,1.92) 1.32 (0.99,1.76) 1.33 (1.00,1.77) 
Sex (reference: female) 0.90 (0.72,1.13) 0.90 (0.71,1.14) 0.90 (0.71,1.15) 
Age 65-74 (reference: 45-64) 1.69 (1.28,2.22) 1.63 (1.20,2.22) 1.65 (1.22,2.25) 
Age 75-84 1.60 (1.19,2.15) 1.62 (1.15,2.27) 1.64 (1.16,2.30) 
Age 85+ 1.55 (0.98,2.45) 1.70 (1.02,2.83) 1.72 (1.03,2.88) 
Hip (reference: knee) 1.07 (0.80,1.43) 1.03 (0.76,1.39) 1.03 (0.75,1.39) 
Ankle/foot 0.37 (0.23,0.58) 0.44 (0.27,0.71) 0.44 (0.27,0.71) 
Wrist/hand 0.61 (0.41,0.91) 0.72 (0.47,1.10) 0.71 (0.47,1.10) 
Unspecified 0.64 (0.39,1.03) 0.61 (0.37,1.03) 0.62 (0.37,1.03) 
Multisite 1.28 (0.81,2.00) 0.73 (0.44,1.19) 0.72 (0.44,1.19) 
BMI 25 to <30 (reference: BMI <25) 1.09 (0.78,1.51) 1.09 (0.77,1.54) 1.08 (0.76,1.54) 
BMI 30+ 1.04 (0.75,1.44) 1.08 (0.76,1.54) 1.08 (0.76,1.54) 
BMI unknown 0.62 (0.44,0.89) 0.61 (0.42,0.89) 0.60 (0.41,0.87) 
5-9 BNF chapters (reference: 0-4) 1.48 (1.11,1.96) 1.08 (0.79,1.48) 1.09 (0.79,1.48) 
10+ BNF chapters 1.23 (0.93,1.61) 0.72 (0.51,1.01) 0.72 (0.51,1.01) 
Multiple consultations in phase 2 (vs. single) 2.90 (2.24,3.75) 2.98 (2.26,3.94) 3.02 (2.28,3.99) 
X-ray, phase 2a (vs. none) 1.59 (0.93,2.71) 1.33 (0.76,2.35) 1.38 (0.78,2.43) 
Above the clinician median index consultation count 
(reference: at or below the median) 
3.37 (1.70,6.67) 3.18 (1.66,6.08) 3.41 (1.70,6.84) 
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Paracetamol assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.73 (0.14,3.72) 0.60 (0.12,3.02) - 
Practice 3 0.35 (0.16,0.80) 0.48 (0.21,1.13) - 
Practice 4 0.40 (0.14,1.10) 0.36 (0.13,0.99) - 
Practice 5 0.15 (0.05,0.42) 0.16 (0.06,0.46) - 
Practice 6 2.42 (0.53,11.0) 2.87 (0.63,13.1) - 
Practice 7 0.66 (0.26,1.69) 0.69 (0.27,1.79) - 
Practice 8 3.35 (0.69,16.4) 3.40 (0.72,16.0) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-derived assessment of paracetamol use in phase two and the 
independent variables. Adjusted models include all independent variables. 
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Appendix G.2.5. Assessment of topical NSAID use 
Topical NSAID assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.47 (1.14,1.90) 1.36 (1.01,1.83) 1.36 (1.01,1.83) 
Sex (reference: female) 0.93 (0.73,1.17) 0.87 (0.68,1.12) 0.87 (0.68,1.12) 
Age 65-74 (reference: 45-64) 1.37 (1.04,1.82) 1.38 (1.01,1.88) 1.38 (1.01,1.88) 
Age 75-84 1.38 (1.02,1.87) 1.50 (1.06,2.13) 1.50 (1.06,2.13) 
Age 85+ 1.00 (0.62,1.62) 1.22 (0.71,2.10) 1.23 (0.72,2.10) 
Hip (reference: knee) 0.69 (0.51,0.92) 0.68 (0.50,0.93) 0.68 (0.50,0.93) 
Ankle/foot 0.46 (0.29,0.74) 0.56 (0.34,0.93) 0.56 (0.34,0.93) 
Wrist/hand 0.71 (0.47,1.07) 0.86 (0.55,1.34) 0.86 (0.55,1.34) 
Unspecified 0.44 (0.26,0.73) 0.43 (0.25,0.75) 0.43 (0.25,0.75) 
Multisite 1.51 (0.95,2.41) 0.93 (0.56,1.54) 0.93 (0.56,1.55) 
BMI 25 to <30 (reference: BMI <25) 1.50 (1.07,2.10) 1.48 (1.04,2.12) 1.47 (1.03,2.10) 
BMI 30+ 1.65 (1.18,2.31) 1.71 (1.19,2.45) 1.69 (1.18,2.43) 
BMI unknown 0.88 (0.60,1.28) 0.83 (0.56,1.23) 0.82 (0.55,1.21) 
5-9 BNF chapters (reference: 0-4) 1.36 (1.02,1.82) 1.01 (0.73,1.39) 1.01 (0.74,1.40) 
10+ BNF chapters 1.12 (0.84,1.49) 0.69 (0.48,0.97) 0.69 (0.49,0.98) 
Multiple consultations in phase 2 (vs. single) 2.73 (2.10,3.54) 2.75 (2.08,3.65) 2.75 (2.07,3.64) 
X-ray, phase 2a (vs. none) 1.14 (0.67,1.92) 1.03 (0.58,1.82) 1.05 (0.60,1.86) 
Above the clinician median index consultation count 
(reference: at or below the median) 
3.14 (1.43,6.92) 2.87 (1.28,6.45) 3.25 (1.41,7.49) 
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Topical NSAID assessment, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.86 (0.11,6.47) 0.68 (0.08,5.54) - 
Practice 3 0.18 (0.06,0.49) 0.22 (0.07,0.65) - 
Practice 4 0.44 (0.13,1.50) 0.41 (0.11,1.47) - 
Practice 5 0.15 (0.04,0.53) 0.15 (0.04,0.57) - 
Practice 6 1.40 (0.26,7.56) 1.53 (0.25,9.27) - 
Practice 7 0.49 (0.15,1.53) 0.48 (0.14,1.60) - 
Practice 8 0.80 (0.13,4.77) 0.81 (0.12,5.45) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-derived assessment of topical NSAID use in phase two and the 
independent variables. Adjusted models include all independent variables. 
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Appendix G.2.6. Provision of education or information 
Education provision, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.68 (1.30,2.15) 1.60 (1.19,2.14) 1.61 (1.20,2.16) 
Sex (reference: female) 1.04 (0.83,1.31) 1.01 (0.79,1.29) 1.01 (0.79,1.29) 
Age 65-74 (reference: 45-64) 1.45 (1.10,1.91) 1.47 (1.08,2.01) 1.48 (1.09,2.01) 
Age 75-84 1.25 (0.93,1.68) 1.30 (0.92,1.83) 1.30 (0.92,1.83) 
Age 85+ 1.15 (0.73,1.83) 1.36 (0.81,2.31) 1.36 (0.80,2.30) 
Hip (reference: knee) 0.81 (0.61,1.09) 0.81 (0.59,1.10) 0.80 (0.59,1.09) 
Ankle/foot 0.39 (0.24,0.62) 0.47 (0.29,0.78) 0.47 (0.29,0.78) 
Wrist/hand 0.64 (0.42,0.97) 0.79 (0.51,1.22) 0.78 (0.50,1.22) 
Unspecified 0.47 (0.28,0.78) 0.43 (0.25,0.74) 0.43 (0.25,0.74) 
Multisite 1.31 (0.84,2.05) 0.74 (0.46,1.21) 0.73 (0.45,1.20) 
BMI 25 to <30 (reference: BMI <25) 1.35 (0.97,1.89) 1.34 (0.94,1.90) 1.33 (0.94,1.90) 
BMI 30+ 1.37 (0.99,1.90) 1.39 (0.97,1.97) 1.39 (0.97,1.98) 
BMI unknown 0.87 (0.60,1.25) 0.82 (0.56,1.21) 0.81 (0.55,1.20) 
5-9 BNF chapters (reference: 0-4) 1.18 (0.88,1.57) 0.88 (0.64,1.20) 0.88 (0.64,1.21) 
10+ BNF chapters 1.02 (0.77,1.35) 0.64 (0.45,0.90) 0.64 (0.45,0.90) 
Multiple consultations in phase 2 (vs. single) 2.83 (2.19,3.66) 2.87 (2.18,3.77) 2.88 (2.18,3.82) 
X-ray, phase 2a (vs. none) 1.34 (0.79,2.25) 1.06 (0.61,1.85) 1.07 (0.61,1.88) 
Above the clinician median index consultation count 
(reference: at or below the median) 
3.94 (1.80,8.62) 3.16 (1.54,6.48) 3.47 (1.62,7.43) 
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Education provision, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.63 (0.27,9.87) 1.40 (0.22,8.75) - 
Practice 3 0.12 (0.05,0.30) 0.14 (0.05,0.37) - 
Practice 4 0.39 (0.13,1.13) 0.36 (0.12,1.09) - 
Practice 5 0.10 (0.03,0.32) 0.10 (0.03,0.33) - 
Practice 6 1.80 (0.40,8.17) 2.14 (0.45,10.2) - 
Practice 7 0.38 (0.14,1.02) 0.39 (0.14,1.08) - 
Practice 8 1.89 (0.40,8.93) 2.07 (0.42,10.2) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-derived education provision achievement in phase 2 and the 
independent variables. Adjusted models include all independent variables. 
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Appendix G.2.7. Provision of exercise advice 
Exercise advice provision, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.66 (1.30,2.12) 1.56 (1.18,2.08) 1.58 (1.19,2.11) 
Sex (reference: female) 1.08 (0.87,1.36) 1.04 (0.82,1.32) 1.04 (0.82,1.32) 
Age 65-74 (reference: 45-64) 1.40 (1.06,1.84) 1.36 (1.01,1.83) 1.37 (1.01,1.85) 
Age 75-84 1.09 (0.81,1.46) 1.06 (0.76,1.48) 1.06 (0.76,1.49) 
Age 85+ 0.71 (0.45,1.13) 0.74 (0.44,1.24) 0.74 (0.44,1.24) 
Hip (reference: knee) 0.78 (0.59,1.04) 0.79 (0.58,1.06) 0.78 (0.58,1.06) 
Ankle/foot 0.40 (0.25,0.64) 0.46 (0.28,0.74) 0.46 (0.28,0.75) 
Wrist/hand 0.40 (0.26,0.61) 0.45 (0.29,0.69) 0.44 (0.28,0.69) 
Unspecified 0.58 (0.35,0.94) 0.53 (0.32,0.89) 0.53 (0.31,0.89) 
Multisite 1.33 (0.85,2.07) 0.90 (0.55,1.46) 0.89 (0.54,1.45) 
BMI 25 to <30 (reference: BMI <25) 1.40 (1.01,1.95) 1.31 (0.93,1.85) 1.31 (0.93,1.85) 
BMI 30+ 1.41 (1.02,1.95) 1.29 (0.91,1.82) 1.30 (0.92,1.84) 
BMI unknown 0.77 (0.54,1.11) 0.67 (0.46,0.98) 0.66 (0.45,0.97) 
5-9 BNF chapters (reference: 0-4) 1.14 (0.86,1.50) 0.88 (0.64,1.20) 0.88 (0.65,1.20) 
10+ BNF chapters 0.93 (0.71,1.23) 0.65 (0.47,0.91) 0.65 (0.47,0.92) 
Multiple consultations in phase 2 (vs. single) 2.24 (1.75,2.87) 2.20 (1.69,2.86) 2.21 (1.70,2.89) 
X-ray, phase 2a (vs. none) 1.45 (0.87,2.44) 1.15 (0.66,2.00) 1.17 (0.67,2.04) 
Above the clinician median index consultation count 
(reference: at or below the median) 
3.00 (1.50,6.03) 2.43 (1.28,4.59) 2.65 (1.34,5.25) 
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Exercise advice provision, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.57 (0.32,7.80) 1.40 (0.28,7.05) - 
Practice 3 0.18 (0.08,0.40) 0.22 (0.09,0.50) - 
Practice 4 0.40 (0.15,1.05) 0.40 (0.15,1.07) - 
Practice 5 0.14 (0.05,0.38) 0.14 (0.05,0.40) - 
Practice 6 1.94 (0.49,7.72) 2.17 (0.53,8.87) - 
Practice 7 0.46 (0.19,1.12) 0.49 (0.20,1.23) - 
Practice 8 2.49 (0.60,10.4) 2.61 (0.62,10.9) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-derived exercise advice provision achievement in phase 2 and the 
independent variables. Adjusted models include all independent variables. 
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Appendix G.2.8. Provision of weight loss advice 
Weight loss advice provision, phase 2  
[in those patients known to be overweight] 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.46 (1.06,2.01) 1.29 (0.91,1.85) 1.31 (0.92,1.88) 
Sex (reference: female) 0.95 (0.71,1.28) 0.96 (0.70,1.30) 0.95 (0.70,1.29) 
Age 65-74 (reference: 45-64) 1.12 (0.80,1.57) 1.21 (0.83,1.76) 1.21 (0.83,1.76) 
Age 75-84 0.93 (0.63,1.38) 0.99 (0.63,1.53) 0.99 (0.63,1.54) 
Age 85+ 0.78 (0.38,1.61) 0.77 (0.36,1.68) 0.78 (0.36,1.69) 
Hip (reference: knee) 0.79 (0.54,1.18) 0.78 (0.52,1.18) 0.79 (0.52,1.18) 
Ankle/foot 0.46 (0.25,0.83) 0.54 (0.29,1.01) 0.53 (0.28,1.01) 
Wrist/hand 0.46 (0.26,0.81) 0.52 (0.29,0.94) 0.51 (0.28,0.93) 
Unspecified 0.63 (0.33,1.22) 0.60 (0.31,1.19) 0.61 (0.31,1.20) 
Multisite 1.16 (0.65,2.07) 0.82 (0.44,1.51) 0.80 (0.43,1.49) 
BMI 30+(reference: BMI 25.0-29.9) 1.32 (0.98,1.77) 1.29 (0.94,1.76) 1.30 (0.95,1.77) 
5-9 BNF chapters (reference: 0-4) 0.94 (0.63,1.40) 0.79 (0.52,1.22) 0.80 (0.52,1.23) 
10+ BNF chapters 0.91 (0.62,1.33) 0.71 (0.45,1.11) 0.72 (0.46,1.13) 
Multiple consultations in phase 2 (vs. single) 2.02 (1.47,2.78) 2.00 (1.42,2.80) 1.99 (1.41,2.80) 
X-ray, phase 2a (vs. none) 1.55 (0.80,3.01) 1.32 (0.66,2.66) 1.35 (0.67,2.73) 
Above the clinician median index consultation count 
(reference: at or below the median) 
2.67 (1.23,5.79) 1.99 (0.99,3.96) 2.13 (1.02,4.41) 
Practice 2 (reference: Practice 1) 2.70 (0.62,11.8) 2.55 (0.53,12.4) - 
Practice 3 0.24 (0.10,0.56) 0.24 (0.10,0.60) - 
Practice 4 0.46 (0.18,1.16) 0.45 (0.17,1.19) - 
Practice 5 0.10 (0.04,0.29) 0.10 (0.03,0.30) - 
Practice 6 2.87 (0.77,10.6) 3.02 (0.76,12.0) - 
Practice 7 0.26 (0.11,0.66) 0.28 (0.11,0.75) - 
Practice 8 2.81 (0.75,10.6) 2.95 (0.73,11.9) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-derived weight loss advice provision achievement (in people 
known to be overweight) in phase 2 and the independent variables. Adjusted models include all independent variables. 
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Appendix G.2.9. Consideration of physiotherapy referral 
Physiotherapy consideration, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.38 (1.08,1.77) 1.34 (1.01,1.78) 1.36 (1.02,1.80) 
Sex (reference: female) 1.09 (0.87,1.37) 1.12 (0.89,1.42) 1.12 (0.88,1.43) 
Age 65-74 (reference: 45-64) 0.82 (0.62,1.07) 0.80 (0.59,1.07) 0.79 (0.58,1.07) 
Age 75-84 1.08 (0.80,1.45) 1.06 (0.76,1.48) 1.05 (0.75,1.47) 
Age 85+ 1.01 (0.64,1.60) 1.02 (0.62,1.69) 1.02 (0.62,1.69) 
Hip (reference: knee) 0.95 (0.71,1.27) 0.97 (0.72,1.30) 0.96 (0.71,1.30) 
Ankle/foot 0.63 (0.39,1.02) 0.79 (0.48,1.31) 0.79 (0.47,1.30) 
Wrist/hand 0.93 (0.61,1.41) 1.10 (0.71,1.69) 1.09 (0.71,1.69) 
Unspecified 0.49 (0.29,0.85) 0.50 (0.28,0.88) 0.49 (0.28,0.88) 
Multisite 1.49 (0.98,2.25) 1.05 (0.67,1.65) 1.05 (0.67,1.65) 
BMI 25 to <30 (reference: BMI <25) 0.97 (0.70,1.34) 0.93 (0.66,1.31) 0.93 (0.66,1.30) 
BMI 30+ 1.08 (0.78,1.49) 1.03 (0.73,1.46) 1.04 (0.73,1.46) 
BMI unknown 0.86 (0.60,1.24) 0.76 (0.52,1.12) 0.76 (0.52,1.11) 
5-9 BNF chapters (reference: 0-4) 1.04 (0.78,1.38) 0.96 (0.70,1.31) 0.96 (0.71,1.31) 
10+ BNF chapters 1.02 (0.77,1.35) 0.86 (0.62,1.21) 0.87 (0.62,1.21) 
Multiple consultations in phase 2 (vs. single) 2.21 (1.74,2.82) 2.20 (1.71,2.84) 2.22 (1.72,2.87) 
X-ray, phase 2a (vs. none) 1.49 (0.92,2.42) 1.26 (0.76,2.12) 1.29 (0.77,2.17) 
Above the clinician median index consultation count 
(reference: at or below the median) 
2.77 (1.44,5.34) 2.49 (1.32,4.73) 2.70 (1.38,5.25) 
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Physiotherapy consideration, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.39 (0.32,5.98) 1.20 (0.27,5.32) - 
Practice 3 0.29 (0.14,0.62) 0.35 (0.16,0.76) - 
Practice 4 0.40 (0.16,0.98) 0.42 (0.17,1.06) - 
Practice 5 0.10 (0.04,0.28) 0.10 (0.03,0.29) - 
Practice 6 0.83 (0.24,2.88) 0.88 (0.24,3.28) - 
Practice 7 0.53 (0.23,1.23) 0.56 (0.23,1.34) - 
Practice 8 0.58 (0.16,2.04) 0.53 (0.14,2.02) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between template-derived physiotherapy consideration achievement in phase 2 and 
the independent variables. Adjusted models include all independent variables. 
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Appendix G.2.10. Achievement of all eight template-derived indicators 
Achievement of all eight template-derived indicators, 
phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.98 (1.47,2.67) 1.84 (1.30,2.60) 1.86 (1.31,2.65) 
Sex (reference: female) 1.07 (0.81,1.41) 1.13 (0.84,1.51) 1.13 (0.84,1.52) 
Age 65-74 (reference: 45-64) 1.01 (0.72,1.42) 0.94 (0.65,1.35) 0.93 (0.64,1.36) 
Age 75-84 1.29 (0.89,1.86) 1.15 (0.76,1.74) 1.16 (0.76,1.76) 
Age 85+ 0.95 (0.53,1.68) 0.78 (0.41,1.47) 0.77 (0.40,1.48) 
Hip (reference: knee) 0.93 (0.64,1.33) 0.94 (0.65,1.38) 0.94 (0.64,1.38) 
Ankle/foot 0.76 (0.42,1.37) 0.96 (0.51,1.79) 0.96 (0.51,1.80) 
Wrist/hand 0.75 (0.44,1.29) 0.92 (0.52,1.61) 0.91 (0.52,1.61) 
Unspecified 0.81 (0.42,1.54) 0.69 (0.35,1.37) 0.70 (0.35,1.39) 
Multisite 1.75 (1.10,2.80) 1.11 (0.67,1.83) 1.10 (0.67,1.83) 
BMI 25 to <30 (reference: BMI <25) 0.90 (0.61,1.34) 0.81 (0.53,1.22) 0.80 (0.53,1.22) 
BMI 30+ 0.96 (0.64,1.43) 0.83 (0.54,1.27) 0.83 (0.54,1.27) 
BMI unknown 0.90 (0.57,1.42) 0.80 (0.50,1.29) 0.80 (0.49,1.28) 
5-9 BNF chapters (reference: 0-4) 1.07 (0.75,1.53) 0.95 (0.64,1.40) 0.95 (0.64,1.41) 
10+ BNF chapters 1.17 (0.83,1.66) 0.95 (0.62,1.44) 0.95 (0.62,1.46) 
Multiple consultations in phase 2 (vs. single) 2.21 (1.64,2.98) 2.14 (1.56,2.92) 2.17 (1.58,2.98) 
X-ray, phase 2a (vs. none) 1.69 (0.98,2.92) 1.28 (0.72,2.29) 1.31 (0.73,2.35) 
Above the clinician median index consultation count 
(reference: at or below the median) 
2.98 (1.21,7.32) 2.37 (1.04,5.42) 2.55 (1.05,6.20) 
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Achievement of all eight template-derived indicators, 
phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.37 (0.07,1.88) 0.32 (0.06,1.71) - 
Practice 3 0.17 (0.06,0.45) 0.20 (0.07,0.56) - 
Practice 4 0.32 (0.11,0.90) 0.34 (0.12,1.01) - 
Practice 5 0.10 (0.03,0.35) 0.11 (0.03,0.39) - 
Practice 6 1.45 (0.38,5.51) 1.87 (0.45,7.77) - 
Practice 7 0.22 (0.07,0.65) 0.25 (0.08,0.79) - 
Practice 8 0.73 (0.18,2.93) 0.65 (0.15,2.93) - 
arecorded relevant X-ray in phase 2 prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between all eight template-derived indicator (excludes weight measurement) 
achievement in phase 2 and the independent variables. Adjusted models include all independent variables. 
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Appendix G.2.11. Achievement of all eight template indicators in people referred on 
Achievement of all eight template indicators in people 
referred for further care, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.84 (0.93,3.65) 1.47 (0.63,3.43) 1.46 (0.63,3.39) 
Sex (reference: female) 0.96 (0.51,1.82) 0.77 (0.37,1.59) 0.79 (0.38,1.64) 
Age 65-74 (reference: 45-64) 0.95 (0.44,2.06) 0.81 (0.32,2.05) 0.79 (0.31,2.00) 
Age 75-84 1.16 (0.45,2.99) 0.80 (0.26,2.47) 0.78 (0.25,2.43) 
Age 85+ 2.28 (0.42,12.28) 1.16 (0.14,9.71) 1.22 (0.14,10.4) 
Hip (reference: knee) 1.09 (0.47,2.54) 0.94 (0.37,2.40) 0.92 (0.36,2.36) 
Ankle/foot 0.98 (0.13,7.36) 1.15 (0.13,10.13) 1.34 (0.15,11.9) 
Wrist/hand 0.42 (0.07,2.53) 0.39 (0.05,2.88) 0.38 (0.05,2.76) 
Unspecified 0.40 (0.03,5.13) 1.13 (0.07,17.16) 1.04 (0.07,15.2) 
Multisite 2.19 (0.78,6.16) 1.53 (0.46,5.10) 1.31 (0.40,4.34) 
BMI 25 to <30 (reference: BMI <25) 1.51 (0.56,4.11) 1.09 (0.35,3.39) 1.16 (0.37,3.64) 
BMI 30+ 1.02 (0.36,2.87) 0.87 (0.27,2.77) 0.91 (0.29,2.92) 
BMI unknown 0.78 (0.26,2.39) 0.70 (0.21,2.40) 0.71 (0.21,2.45) 
5-9 BNF chapters (reference: 0-4) 1.14 (0.52,2.48) 0.88 (0.35,2.20) 0.89 (0.36,2.22) 
10+ BNF chapters 1.60 (0.72,3.56) 1.19 (0.39,3.68) 1.18 (0.38,3.63) 
Multiple consultations in phase 2 (vs. single) 4.40 (2.14,9.06) 4.45 (2.04,9.70) 4.38 (1.96,9.81) 
X-ray, phase 2a (vs. none) 2.73 (0.96,7.74) 2.49 (0.77,8.05) 2.48 (0.75,8.24) 
Above the clinician median index consultation count 
(reference: at or below the median) 
3.54 (0.56,22.4) 5.02 (0.88,28.5) 4.95 (0.76,32.1) 
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Achievement of all eight template indicators in people 
referred for further care, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.14 (0.00,4.64) 0.07 (0.00,4.33) - 
Practice 3 0.29 (0.06,1.37) 0.30 (0.05,1.85) - 
Practice 4 0.05 (0.00,0.89) 0.04 (0.00,1.09) - 
Practice 5 0.15 (0.01,1.87) 0.08 (0.00,1.49) - 
Practice 6 7.19 (1.05,49.4) 7.77 (0.85,71.1) - 
Practice 7 0.19 (0.03,1.03) 0.18 (0.03,1.34) - 
Practice 8 2.09 (0.25,17.7) 1.51 (0.13,17.0) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95%CI) between all eight template-derived indicators (excludes weight measurement) 
achievement in phase 2 (in people referred for further care) and the independent variables. Adjusted models include all 
independent variables. 
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 Pharmacological management - multilevel models 
Appendix G.3.1. Recorded paracetamol prescription 
Recorded paracetamol prescription within 14 days of a 
clinical OA consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.89 (1.44,2.48) 1.39 (1.00,1.92) 1.40 (1.01,1.93) 
Sex (reference: female) 0.78 (0.60,1.02) 0.87 (0.66,1.16) 0.88 (0.66,1.18) 
Age 65-74 (reference: 45-64) 2.09 (1.48,2.94) 1.54 (1.07,2.22) 1.55 (1.08,2.24) 
Age 75-84 3.55 (2.53,4.99) 2.50 (1.72,3.63) 2.52 (1.73,3.68) 
Age 85+ 5.13 (3.22,8.17) 3.48 (2.06,5.87) 3.54 (2.09,5.99) 
Hip (reference: knee) 1.23 (0.89,1.70) 1.16 (0.83,1.64) 1.15 (0.81,1.63) 
Ankle/foot 0.60 (0.33,1.09) 0.77 (0.41,1.44) 0.75 (0.40,1.42) 
Wrist/hand 0.59 (0.34,1.03) 0.71 (0.40,1.27) 0.70 (0.39,1.26) 
Unspecified 1.10 (0.63,1.91) 0.90 (0.49,1.65) 0.87 (0.47,1.60) 
Multisite 1.55 (0.98,2.47) 0.83 (0.49,1.39) 0.83 (0.49,1.40) 
BMI 25 to <30 (reference: BMI <25) 0.84 (0.57,1.23) 0.74 (0.49,1.11) 0.74 (0.49,1.13) 
BMI 30+ 1.16 (0.80,1.69) 1.20 (0.80,1.80) 1.19 (0.79,1.79) 
BMI unknown 0.79 (0.51,1.21) 0.87 (0.55,1.37) 0.87 (0.54,1.38) 
5-9 BNF chapters (reference: 0-4) 3.59 (2.30,5.62) 2.72 (1.70,4.35) 2.72 (1.69,4.38) 
10+ BNF chapters 5.75 (3.74,8.84) 3.32 (2.06,5.35) 3.32 (2.05,5.38) 
Multiple consultations in phase 2 (vs. single) 2.06 (1.58,2.69) 1.98 (1.48,2.64) 1.98 (1.48,2.64) 
X-ray, phase 2a (vs. none) 1.29 (0.74,2.25) 1.17 (0.63,2.16) 1.15 (0.62,2.13) 
Above the clinician median index consultation count 
(reference: at or below the median) 
0.99 (0.62,1.60) 0.97 (0.59,1.59) 0.92 (0.55,1.56) 
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Recorded paracetamol prescription within 14 days of a 
clinical OA consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.88 (0.40,1.96) 0.92 (0.37,2.28) - 
Practice 3 1.41 (0.88,2.26) 1.94 (1.13,3.31) - 
Practice 4 0.62 (0.35,1.11) 0.65 (0.34,1.24) - 
Practice 5 1.02 (0.60,1.72) 1.21 (0.66,2.22) - 
Practice 6 1.63 (0.79,3.34) 2.31 (1.01,5.27) - 
Practice 7 0.44 (0.23,0.87) 0.50 (0.24,1.05) - 
Practice 8 0.58 (0.26,1.31) 0.49 (0.20,1.20) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95% CI) between recorded prescription for paracetamol within 14 days of a clinical OA 
consultation in phase two and the independent variables. Adjusted models include all independent variables. 
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Appendix G.3.2. Recorded topical NSAID prescription 
Recorded topical NSAID prescription within 14 days of 
a clinical OA consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.37 (1.06,1.76) 0.92 (0.68,1.26) 0.94 (0.69,1.28) 
Sex (reference: female) 0.76 (0.60,0.96) 0.80 (0.62,1.03) 0.79 (0.61,1.02) 
Age 65-74 (reference: 45-64) 2.35 (1.73,3.20) 2.08 (1.46,2.96) 1.74 (1.27,2.39) 
Age 75-84 3.79 (2.42,5.93) 3.46 (2.08,5.77) 2.02 (1.42,2.87) 
Age 85+ 1.37 (1.06,1.76) 0.92 (0.68,1.26) 3.34 (2.01,5.55) 
Hip (reference: knee) 0.43 (0.31,0.61) 0.36 (0.25,0.52) 0.37 (0.26,0.53) 
Ankle/foot 0.37 (0.21,0.65) 0.38 (0.21,0.68) 0.39 (0.22,0.70) 
Wrist/hand 1.00 (0.67,1.50) 1.16 (0.76,1.79) 1.15 (0.75,1.77) 
Unspecified 0.73 (0.44,1.22) 0.67 (0.38,1.15) 0.66 (0.38,1.15) 
Multisite 1.32 (0.87,2.02) 0.93 (0.58,1.48) 0.90 (0.56,1.45) 
BMI 25 to <30 (reference: BMI <25) 1.09 (0.77,1.53) 1.00 (0.70,1.45) 1.00 (0.69,1.44) 
BMI 30+ 1.28 (0.92,1.80) 1.25 (0.87,1.81) 1.24 (0.86,1.79) 
BMI unknown 0.67 (0.44,1.00) 0.75 (0.49,1.16) 0.73 (0.48,1.13) 
5-9 BNF chapters (reference: 0-4) 2.46 (1.75,3.46) 1.89 (1.31,2.72) 1.89 (1.31,2.73) 
10+ BNF chapters 3.49 (2.51,4.86) 2.17 (1.48,3.18) 2.19 (1.49,3.21) 
Multiple consultations in phase 2 (vs. single) 1.92 (1.50,2.45) 1.84 (1.41,2.40) 1.83 (1.40,2.39) 
X-ray, phase 2a (vs. none) 0.96 (0.56,1.64) 1.10 (0.60,2.00) 1.08 (0.60,1.96) 
Above the clinician median index consultation count 
(reference: at or below the median) 
1.39 (0.82,2.33) 1.23 (0.70,2.14) 1.38 (0.78,2.42) 
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Recorded topical NSAID prescription within 14 days of 
a clinical OA consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 1.69 (0.59,4.85) 1.82 (0.56,5.90) - 
Practice 3 0.42 (0.22,0.82) 0.45 (0.22,0.93) - 
Practice 4 0.95 (0.47,1.91) 0.95 (0.44,2.06) - 
Practice 5 1.21 (0.62,2.36) 1.42 (0.67,3.01) - 
Practice 6 1.69 (0.65,4.40) 1.70 (0.59,4.95) - 
Practice 7 0.80 (0.40,1.61) 0.83 (0.38,1.81) - 
Practice 8 1.00 (0.37,2.68) 0.92 (0.31,2.75) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95% CI) between recorded prescription for topical NSAIDs within 14 days of a clinical OA 
consultation in phase two and the independent variables. Adjusted models include all independent variables. 
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 Referral management - multilevel models 
Appendix G.4.1. Recorded physiotherapy referral 
Recorded physiotherapy referral within 14 days of a 
clinical OA consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
OA diagnosis (reference: joint pain) 1.02 (0.65,1.58) 1.08 (0.65,1.79) 1.04 (0.62,1.76) 
Sex (reference: female) 1.59 (1.06,2.36) 1.46 (0.97,2.19) 1.47 (0.96,2.25) 
Age 65-74 (reference: 45-64) 0.69 (0.41,1.16) 0.76 (0.44,1.30) 0.75 (0.43,1.32) 
Age 75-84 1.01 (0.60,1.71) 1.06 (0.59,1.87) 1.07 (0.59,1.93) 
Age 85+ 0.80 (0.35,1.83) 0.87 (0.36,2.12) 0.88 (0.35,2.21) 
Hip (reference: knee) 0.74 (0.45,1.21) 0.75 (0.45,1.24) 0.74 (0.44,1.25) 
Ankle/foot 0.18 (0.04,0.81) 0.23 (0.05,1.03) 0.22 (0.05,1.09) 
Wrist/hand 0.20 (0.06,0.69) 0.23 (0.07,0.80) 0.23 (0.06,0.83) 
Unspecified 0.20 (0.04,0.91) 0.26 (0.06,1.20) 0.26 (0.05,1.27) 
Multisite 0.56 (0.26,1.22) 0.45 (0.20,1.02) 0.45 (0.20,1.05) 
BMI 25 to <30 (reference: BMI <25) 1.20 (0.67,2.17) 1.00 (0.55,1.82) 1.02 (0.54,1.90) 
BMI 30+ 1.15 (0.63,2.08) 0.99 (0.54,1.84) 1.00 (0.53,1.90) 
BMI unknown 0.95 (0.48,1.86) 0.78 (0.40,1.55) 0.77 (0.38,1.57) 
5-9 BNF chapters (reference: 0-4) 0.97 (0.59,1.60) 0.91 (0.54,1.54) 0.91 (0.53,1.58) 
10+ BNF chapters 0.86 (0.52,1.40) 0.86 (0.47,1.54) 0.85 (0.46,1.57) 
Multiple consultations in phase 2 (vs. single) 2.50 (1.68,3.74) 2.35 (1.56,3.53) 2.39 (1.56,3.66) 
X-ray, phase 2a (vs. none) 2.24 (1.11,4.52) 1.87 (0.90,3.89) 1.98 (0.93,4.21) 
Above the clinician median index consultation count 
(reference: at or below the median) 
0.99 (0.45,2.20) 1.00 (0.49,2.03) 0.98 (0.46,2.10) 
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Recorded physiotherapy referral within 14 days of a 
clinical OA consultation, phase 2 
Two level models Three level model 
(adjusted) Unadjusted Adjusted 
Practice 2 (reference: Practice 1) 0.44 (0.13,1.49) 0.44 (0.12,1.57) - 
Practice 3 0.48 (0.23,1.02) 0.49 (0.22,1.06) - 
Practice 4 0.12 (0.03,0.44) 0.13 (0.03,0.51) - 
Practice 5 0.04 (0.00,0.30) 0.04 (0.00,0.32) - 
Practice 6 1.67 (0.67,4.18) 1.59 (0.59,4.27) - 
Practice 7 0.83 (0.39,1.77) 0.78 (0.35,1.74) - 
Practice 8 0.22 (0.05,0.90) 0.19 (0.04,0.83) - 
arecorded relevant X-ray in phase two prior to the index clinical OA consultation 
Estimates of associations (OR, 95% CI) between recorded referral to physiotherapy within 14 days of a clinical OA 
consultation in phase two and the independent variables. Adjusted models include all independent variables. 
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Appendix H. Assessment of the effects of the model OA consultation (MOSAICS cluster trial) appendices (Chapter Eight)  
 Adjusted odds of specified outcomes in intervention practices compared to control, trial period  
Outcome measure OR (intervention vs. control arm) (95% CI) 
 Unadjusted two-level modeld Adjusted two-level modeld Adjusted three-level modele 
Assessment    
Pain assessment  2.69 (1.39,5.20) 1.34 (0.54,3.32) 1.34 (0.54,3.32) 
Function assessment  2.71 (1.41,5.22) 1.14 (0.46,2.82) 1.14 (0.46,2.82) 
Weight record  1.78 (1.07,2.97) 1.15 (0.66,2.03) 1.54 (0.64,3.71) 
X-ray recorded  3.43 (1.68,7.00) 0.43 (0.09,1.99) 0.65 (0.03,12.5) 
Core interventions    
OA information provision  2.97 (1.52,5.80) 1.31 (0.56,3.03) 1.31 (0.56,3.03) 
    Written OA information  25.7 (8.89,74.4)  23.2 (7.10,75.8)  29.5 (7.41,118)  
Exercise advice provision  2.63 (1.45,4.77) 1.50 (0.68,3.29) 1.50 (0.68,3.29) 
    Written exercise advice  27.6 (8.57,89.1)  21.4 (6.69,68.8)  25.5 (7.10,91.7) 
Weight loss advice provisiona  3.08 (1.52,6.24) 1.39 (0.66,2.96) 1.39 (0.66,2.96) 
    Written weight loss adviceab  24.8 (5.47,113)   23.5 (4.61,120)   28.8 (4.58,181)  
Non-pharmacological management 
Consideration of physiotherapy referralb  2.17 (1.18,3.97) 1.41 (0.56,3.57) 1.41 (0.56,3.56) 
Physiotherapy referral made  7.66 (3.07,19.1)  5.50 (2.13,14.2)  5.50 (2.13,14.2) 
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Outcome measure OR (intervention vs. control arm) (95% CI) 
 Unadjusted two-level modeld Adjusted two-level modeld Adjusted three-level modele 
Pharmacological management    
Consideration of paracetamol use  2.69 (1.49,4.86) 1.42 (0.67,3.04) 1.42 (0.67,3.04) 
Paracetamol prescribed  1.77 (1.32,2.39)  1.58 (1.14,2.20)  1.58 (1.14,2.20) 
Consideration of topical NSAID use  2.00 (1.14,3.53) 0.91 (0.43,1.92) 0.91 (0.43,1.92) 
Topical NSAID prescribed  1.46 (1.01,2.10) 1.13 (0.75,1.70) 1.13 (0.75,1.70) 
Oral NSAID prescribed 1.26 (0.99,1.60) 0.79 (0.53,1.16) 0.79 (0.53,1.16) 
Oral NSAID prescribed in the presence of a relative comorbid 
contraindication 
0.74 (0.41,1.33) 0.74 (0.42,1.32) 0.74 (0.42,1.31) 
Gastroprotection prescribed (PPI)c 0.90 (0.60,1.35) 0.96 (0.50,1.82) 0.80 (0.35,1.81) 
Opioid prescribed 1.05 (0.62,1.78) 0.85 (0.66,1.09) 0.85 (0.66,1.09) 
Adjusted for OA or joint pain code, sex, age band, site of disease, BMI status, morbidity load (BNF chapter count), multiple clinical OA consultation, staff member index 
consultation count dichotomy, and practice pre-trial achievement; ain those known to be overweight at time of index consultation; bPQL1 model; cdenominator: those 
prescribed oral NSAIDs; dpatients within clinicians; epatients within clinicians within practices 
Intention-to-treat analysis: comparison of two-level unadjusted and adjusted model, and three-level model OR. 
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 Adjusted odds of specified outcomes in intervention practices compared to control, restriction to patients triggering template  
Outcome measure 
Number of patients with 
outcome n (%) Odds of outcome (intervention vs. control arm) (95% CI) 
 
Intervention 
arm Control arm 
Unadjusted two-level 
modeld 
Adjusted two-level 
modeld 
Adjusted three-level 
modele 
Adjusted two-level 
modeld in new 
consultersf only 
(n=1205) 
Total 1053 751     
Assessment       
Pain assessment 612 (58.1) 317 (42.2) 2.57 (1.33,4.97) 1.37 (0.55,3.45) 1.38 (0.54,3.51) 0.79 (0.29,2.14) 
Function assessment 606 (57.5) 307 (40.9) 2.60 (1.35,5.02) 1.17 (0.46,2.93) 1.17 (0.46,2.93) 0.68 (0.24,1.88) 
Weight record 301 (28.6) 136 (18.1) 1.73 (1.04,2.89) 1.17 (0.65,2.08) 1.58 (0.64,3.89) 0.92 (0.52,1.65) 
X-ray recorded 154 (14.6) 43 (5.7) 3.32 (1.57,7.04) 0.38 (0.08,1.80) 0.58 (0.03,12.8) 0.30 (0.07,1.36) 
Core interventions       
OA information provision 549 (52.1) 267 (35.6) 2.84 (1.47,5.47) 1.34 (0.58,3.13) 1.34 (0.58,3.13) 0.78 (0.32,1.90) 
 Written OA information 292 (27.7) 12 (1.6) 25.0 (8.75,71.5)  24.2 (7.33,80.1)  32.3 (7.70,135).  26.5 (7.19,97.8) 
Exercise advice provision 522 (49.6) 245 (32.6) 2.51 (1.40,4.50) 1.56 (0.71,3.46) 1.56 (0.71,3.46) 0.93 (0.43,2.02) 
 Written exercise advice 230 (21.8) 7 (0.9) 26.8 (8.42,85.2)  21.9 (6.79,70.4)  26.9 (7.25,99.6)  11.9 (4.19,33.8) 
Weight loss advice provisiona 327 (47.3) 130 (29.0) 2.77 (1.37,5.60) 1.37 (0.64,2.94) 1.37 (0.64,2.94) 0.93 (0.42,2.06) 
 Written weight loss adviceab 99 (14.3) 2 (0.4) 30.2 (4.16,219)  34.3 (4.05,291).  28.6 (4.61,178).  13.1 (2.34,73.5) 
Non-pharmacological management       
Consideration of physiotherapy 
referral 
94 (8.9) 65 (8.7) 2.04 (1.11,3.73) 1.41 (0.55,3.59) 1.41 (0.55,3.58) 0.98 (0.38,2.51) 
Physiotherapy referral made 107 (10.2) 19 (2.5) 7.09 (2.88,17.4)  5.44 (2.15,13.8)  5.44 (2.14,13.8)  5.78 (1.77,18.9) 
      (con’t) 
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Outcome measure 
Number of patients with 
outcome n (%) Odds of outcome (intervention vs. control arm) (95% CI) 
 
Intervention 
arm Control arm 
Unadjusted two-level 
modeld 
Adjusted two-level 
modeld 
Adjusted three-level 
modele 
Adjusted two-level 
modeld in new 
consultersf only 
(n=1205) 
Pharmacological management       
Consideration of paracetamol use 549 (52.1) 282 (37.5) 2.54 (1.41,4.56) 1.43 (0.67,3.07) 1.43 (0.67,3.07) 0.97 (0.43,2.21) 
Paracetamol prescribed 236 (22.4) 107 (14.2) 1.81 (1.34,2.45)  1.69 (1.20,2.37)  1.69 (1.20,2.37)  1.78 (1.13,2.78) 
Consideration of topical NSAID use 496 (47.1) 274 (36.5) 1.88 (1.07,3.31) 0.93 (0.44,1.99) 0.93 (0.44,1.99) 0.55 (0.24,1.25) 
Topical NSAID prescribed 312 (29.6) 167 (22.2) 1.45 (1.00,2.10) 1.15 (0.77,1.72) 1.15 (0.77,1.72) 1.01 (0.62,1.64) 
Oral NSAID prescribed 173 (16.4) 124 (16.5) 0.88 (0.58,1.35) 0.78 (0.52,1.16) 0.78 (0.52,1.16) 1.07 (0.67,1.71) 
Oral NSAID prescribed in the presence 
of a relative comorbid 
contraindication 
52 (12.4) 40 (15.7) 0.75 (0.41,1.37) 0.75 (0.41,1.35) 0.75 (0.41,1.35) 0.99 (0.50,1.93) 
Gastroprotection prescribed (PPI)c 68 (39.3) 46 (37.1) 1.02 (0.59,1.78) 1.01 (0.52,1.97) 0.82 (0.35,1.96) 1.69 (0.48,5.95) 
Opioid prescribed 353 (33.5) 208 (27.7) 1.27 (0.99,1.63) 0.88 (0.68,1.14) 0.88 (0.68,1.14) 0.91 (0.66,1.24) 
Adjusted for OA or joint pain code, sex, age band, site of disease, BMI status, morbidity load (BNF chapter count), multiple clinical OA consultation, staff member index 
consultation count dichotomy, and practice pre-trial achievement ain those known to be overweight at time of index consultation bPQL1 model; cdenominator: those prescribed 
oral NSAIDs; dpatients within clinicians epatients within clinicians within practices fnew consulters defined as first clinical OA consultation since the introduction of the template 
and with at least 365 days since any previous OA or joint pain consultation 
Odds of outcome in intervention practices compared to control, trial period (95% CI) in patients for whom the template was recorded as triggering.  
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 Adjusted odds of specified outcomes in intervention practices compared to control, restriction to patients with at least one template 
entry  
Outcome measure 
Number of patients with outcome 
n (%) Odds of outcome (intervention vs. control arm) (95% CI) 
 
Intervention arm Control arm 
Unadjusted two-level 
modelf Adjusted two-level modelf Adjusted three-level modelg 
Total 630 328    
Assessment      
Pain assessmentab 612 (97.1) 317 (96.6) 1.60 (0.54,4.68) 1.37 (0.33,5.73) 1.37 (0.33,5.73) 
Function assessmentab 606 (96.2) 307 (93.6) 1.97 (0.70,5.50) 1.97 (0.70,5.50) 1.85 (0.71,4.83) 
Weight record 275 (43.7) 91 (27.7) 1.78 (0.97,3.27) 1.17 (0.59,2.31) 1.59 (0.55,4.64) 
X-ray recorded 116 (18.4) 24 (7.3) 2.82 (1.21,6.56) 0.43 (0.06,3.01) 0.49 (0.01,16.2) 
Core interventions      
OA information provision 549 (87.1) 267 (81.4) 2.21 (1.03,4.74) 1.34 (0.57,3.12) 1.34 (0.57,3.12) 
 Written OA information 292 (46.3) 12 (3.7) 25.3 (9.50,67.6)  24.5 (8.29,72.6)  29.5 (8.52,102). 
Exercise advice provision 522 (82.9) 245 (74.7) 1.94 (1.02,3.66) 1.92 (0.90,4.09) 1.92 (0.90,4.09) 
 Written exercise advice 230 (36.5) 7 (2.1) 27.5 (8.50,89.2)  21.8 (6.81,69.6)  23.5 (6.94,79.5) 
Weight loss advice provisionc 327 (74.5) 130 (64.0) 2.01 (0.95,4.24) 1.02 (0.45,2.30) 1.02 (0.45,2.30) 
 Written weight loss advicec 99 (22.6) 2 (1.0) 20.0 (4.23,94.7)  17.6 (3.28,94.0)  17.6 (3.29,94.0) 
Non-pharmacological management      
Consideration of physiotherapy referral 94 (14.9) 65 (19.8) 1.33 (0.71,2.47) 0.77 (0.38,1.59) 0.77 (0.38,1.59) 
Physiotherapy referral maded 68 (108) 13 (4.0) 5.28 (2.07,13.5)  4.87 (1.83,12.9)  4.87 (1.83,12.9) 
     (con’t) 
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Outcome measure 
Number of patients with outcome 
n (%) Odds of outcome (intervention vs. control arm) (95% CI) 
 
Intervention arm Control arm 
Unadjusted two-level 
modelf Adjusted two-level modelf Adjusted three-level modelg 
Pharmacological management      
Consideration of paracetamol use 549 (87.1) 282 (86.0) 2.89 (1.21,6.92) 1.91 (0.77,4.75) 1.91 (0.77,4.75) 
Paracetamol prescribed 163 (25.9) 53 (16.2) 1.97 (1.24,3.12)  1.76 (1.06,2.92)  1.76 (1.06,2.92) 
Consideration of topical NSAID use 496 (78.7) 274 (83.5) 1.19 (0.54,2.60) 1.17 (0.48,2.81) 0.95 (0.32,2.83) 
Topical NSAID prescribed 211 (33.5) 90 (27.4) 1.27 (0.74,2.20) 1.09 (0.62,1.92) 1.09 (0.62,1.92) 
Oral NSAID prescribed 102 (16.2) 55 (16.8) 0.90 (0.54,1.47) 0.65 (0.39,1.09) 0.60 (0.33,1.08) 
Oral NSAID prescribed in the presence of 
a relative comorbid contraindication 
30 (11.7) 14 (11.4) 1.05 (0.41,2.64) 0.86 (0.30,2.49) 0.86 (0.30,2.49) 
Gastroprotection prescribed (PPI)e 46 (45.1) 23 (41.8) 1.08 (0.55,2.15) 1.50 (0.35,6.52) 0.81 (0.11,6.27) 
Opioid prescribed 227 (36.0) 97 (29.6) 1.33 (0.91,1.94) 0.88 (0.62,1.25) 0.88 (0.62,1.25) 
Adjusted for diagnostic group, sex, age band, site of disease, BMI status, total morbidity, multiple clinical OA consultation s, consultation with a clinician holding more than the 
median number of index consultations and practice pre-trial achievement except aadjusted for diagnostic group, sex, age, practice pre-trial achievement; bMQL1 model; cin people 
known to be overweight at the index consultation; dPQL1 model; edenominator: those prescribed oral NSAIDs; fpatients within clinicians; gpatients within clinicians within practices 
Odds of outcome in intervention practices compared to control, trial period (95% CI) in patients with at least one recorded template entry 
 
